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SUMMARY 
Asthma is a chronic inflammatory disease of the airways characterised by early and late asthmatic 
responses (EAR & LAR) to allergen, airways hyperresponsiveness (AHR) to inhaled spasmogens, 
airway inflammation and airway oedema. Viral infections and lipopolysaccharide (LPS) from bacteria 
and environmental sources contribute to exacerbations of asthma and the development of 
insensitivity to corticosteroids. Complete insensitivity to oral corticosteroids is rare and most 
patients lie on a continuum of steroid responsiveness. This thesis aimed to examine the effect of 
viral infection and LPS in a guinea-pig model of asthma and determine the sensitivity to inhaled and 
systemic corticosteroids.  
Sensitised guinea-pigs challenged with ovalbumin displayed EAR, LAR, AHR to histamine, airways 
inflammation and airway oedema. Inoculation of guinea-pigs with parainfluenza-3 virus alone 
induced AHR to histamine and airway inflammation. However this response was not consistent. 
Inhaled LPS alone induced an immediate bronchoconstriction, AHR, airway inflammation and 
oedema and goblet cell hyperplasia. LPS co-administered with ovalbumin exacerbated the allergen 
response by lengthening the EAR, prolonging the bronchoconstrictor response to histamine, 
increasing airway inflammation and oedema and goblet cell hyperplasia.  
In guinea-pigs challenged with ovalbumin alone, treatment with inhaled fluticasone propionate (FP) 
and inhaled and systemic dexamethasone decreased the LAR, abolished AHR, airway inflammation 
and oedema. Responses to LPS alone were not reduced by inhaled dexamethasone or FP but 
partially reduced by systemic dexamethasone. Ovalbumin and LPS combined responses were 
insensitive to inhaled corticosteroids, except lavage fluid protein. These responses were partially 
sensitive to systemic dexamethasone, with the prolonged EAR, inflammation and airway oedema all 
reduced.  
The data in this thesis suggests that LPS inhalation exacerbates ovalbumin-induced functional and 
inflammatory responses rendering them insensitive to inhaled corticosteroids but partially sensitive 
to systemic corticosteroids. Thus, the experimental combination of ovalbumin with LPS might 
represent a useful preclinical model of corticosteroid-insensitive airway inflammation. 
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1.1 DEFINITION 
The current operational definition of asthma by the National Asthma Education and 
Prevention Program Expert Panel Report 3 (2007) is  
“Asthma is a chronic inflammatory disorder of the airways in which many cells and 
cellular elements play a role: in particular, mast cells, eosinophils, neutrophils (especially 
in sudden onset, fatal exacerbations, occupational asthma, and patients who smoke), T 
lymphocytes, macrophages, and epithelial cells. In susceptible individuals, this 
inflammation causes recurrent episodes of coughing (particularly at night or early in the 
morning), wheezing, breathlessness, and chest tightness. These episodes are usually 
associated with widespread but variable airflow obstruction that is often reversible 
either spontaneously or with treatment” from Busse, (2007) 
Maintaining a precise definition that includes all aspects of the disease remains 
problematic. One particular problem in asthma’s definition stems from the overlap 
between symptoms of other respiratory conditions such as COPD. In particular, airways 
hyperresponsiveness is one of the key characteristics of asthma but is absent in some 
patients, despite clear evidence of other asthma symptoms. It is also present in some 
individuals without other significant respiratory symptoms (Pattemore et al, 1990). 
There are also wide differences in the reversibility of airway obstruction, especially in 
asthmatics that smoke or work in polluted environments (Barnes et al, 1998). 
Accordingly, diagnosis is not always clear cut and the re-assessment of symptom 
histories can lead to re-classification of diagnosis from asthma. 
1.2 PREVALENCE 
Asthma has seen a growing diagnosis/prevalence over the last 50 years, especially in the 
western world, with an estimated 300 million people worldwide now suffering from the 
affliction (ISAAC, 1998). Approximately 180,000 deaths across the world annually are 
asthma related. In the UK alone an estimated 5.1 million people have asthma costing 
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the NHS £2.5 billion (Holgate et al, 2008). The exact reasons for increased incidence of 
asthma are unknown but factors such as genetic background, early life infection and the 
adoption of a western lifestyle are all implicated. More recently, disturbances in the 
bacterial community of the lungs have been implicated (Hilty et al, 2009).  
1.3 ASTHMA SUBTYPES 
Both the environment and genetic factors are likely to lead to the creation of a 
phenotypically heterogeneous disease with numerous aetiologies (Barnes et al, 1998). 
Many forms of asthma such as childhood asthma, aspirin sensitive asthma, chronic 
respiratory infection related asthma, occupational asthma and severe asthma have been 
described in the past but often overlap in definition and do not consider more than one 
symptom. More recent attempts to classify asthma subtypes have used multiple factors 
to designate subgroups (Moore et al, 2008).  
The first distinction between asthma subtypes can be made based on the presence of 
atopy. 70% of asthmatics are atopic and demonstrate increased circulating levels of IgE 
antibodies to specific allergens; although these allergens may not be the driving force 
behind the condition in all cases. The other 30% of asthmatics are non-atopic, with an 
onset commonly in the forties and an association with intolerance to non-steroidal anti-
inflammatory drugs (Botturi et al, 2011). Further distinctions can be made on the basis 
of independent factors including clinical markers (Body mass index and age of onset), 
lung function (Forced expiratory volume in 1 second, FEV1), inflammatory markers 
(eosinophils and neutrophils) and treatment use (frequency and type) (Rosi et al, 1999; 
Moore et al, 2008). Severe asthmatics are one such subgroup and demonstrate high 
numbers of eosinophils, more FEV1 variability and a higher risk of tracheal intubation 
during exacerbation. The presence of high neutrophil counts and increased resistance to 
steroid therapy is also observed in some individuals (Leung & Bloom, 2003).  
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The term ‘asthma’ in the context of this thesis will refer to atopic, IgE-related asthma. 
Eosinophil dominant inflammation is also a key characteristic but not an exclusive term 
as the presence of neutrophils is often observed in severe asthma, particularly at times 
of exacerbation (in't Veen et al, 1999). IgE-mediated asthma is characterised by 
hypersensitivity to allergens such as pollen and house dust mites, and in experimental 
animals to ovalbumin from egg whites. Hypersensitivity to an allergen results from initial 
sensitisation and subsequent allergen re-encounter which triggers the effector phase.  
1.4 ASTHMA PATHOLOGY 
1.4.1 ALLERGEN SENSITISATION 
In asthma, the sensitisation process begins with the inhalation of allergen and its active 
uptake by antigen presenting cells (APCs) such as macrophages and dendritic cells. The 
antigen is internalised, then proteolysed into peptide for incorporation into major 
histocompatibility complex (MHC) class II at the cell membrane. Following this, APCs 
migrate to local lymph nodes or lymph mucosa and present antigen to T and B 
lymphocytes (Lambrecht & Hammad, 2011). Depending on the presence of certain co-
stimulatory molecules such as OX40L, these cells then become active or undergo 
apoptosis. T lymphocyte differentiation requires IL-2. Whether lymphocytes become the 
Th1 or Th2 type is dependent on the presence of IL-12 or IL-4 respectively. In allergen 
sensitisation Th2 cells predominate (Galli et al, 2008). These cells secrete IL-4 and IL-13, 
which drive immunoglobulin class switching to IgE (Geha et al, 2003). IL-4 is also able to 
increase the expression of the high affinity IgE receptor (FcεRI) on mast cells and 
basophils. Monovalent binding of IgE to the high affinity IgE receptor (FcεRI) results in 
receptor priming for degranulation upon further exposure to the same allergen (Gould 
& Sutton, 2008).  
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1.4.1.1 ENHANCEMENT OF SENSITISATION 
Several factors contribute to an enhancement of allergic sensitisation. The first is the 
breakdown of the airway epithelial barrier which in asthmatics has leaky tight junctions 
which facilitate penetration of allergens (Xiao et al, 2011). This problem is further 
augmented by intrinsic properties of allergens such as house dust mite and cockroach 
extract which can disrupt the epithelial barrier and trigger the release of danger signals. 
Pollutants, viruses, ozone, LPS and tobacco smoke can also augment allergen 
sensitisation. The second factor is the enhancement of dendritic cell maturation and 
activation. Pattern recognition receptors on dendritic cells recognise pathogen 
associated molecular patterns (PAMPs) such as those on LPS and single stranded 
(ss)RNA. Danger associated molecular patterns (DAMPs) such as those on ATP are also 
recognized. These enhance dendritic cell maturation, allergen sampling and the 
production of co-stimulatory molecules via mediators such as TSLP, IL-33 and IL-25, 
which are secreted by airway epithelial cells in response to pathogens (Holgate, 2012).
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Figure 1: Simplified diagram of allergic sensitisation in the airways. Antigen presenting cells such 
as dendritic cells capture allergen, internalise it and process it to the cell surface. This along with 
co-stimulatory molecules promotes the differentiation of T helper (Th) cells into Th2 cells which 
stimulate the production of immonoglubulin E (IgE) from B lymphocytes. IgE binds to the surface 
of mast cells in the airways.  Figure adapted and redrawn from Galli et al, 2008. 
1.4.2 EFFECTOR PHASE 
The effector phase results from re-exposure to an allergen to which an individual is 
sensitised. This phase can be divided into 2 distinct categories; that of the early 
asthmatic response (EAR) and the late asthmatic response (LAR). The EAR occurs within 
minutes of allergen exposure and is mediated by IgE crosslinking on the surface of mast 
cells (Gould & Sutton, 2008). Crosslinking triggers a complex intracellular cascade of 
signalling molecules leading to mast cell degranulation and the secretion of three 
classes of active products. The first set of mast cell products are those stored in 
cytoplasmic granules prior to degranulation and include biogenic amines (e.g. 
Th naïve Th2
B 
cell
IgE
Mast cell
Dendritic 
cell
Allergen
IL-4
Airwayepithelium
Local lymph node
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histamine), serglycin proteoglycans (e.g. heparin and chondroitin sulphate), serine 
proteases (e.g. chymases, trypases and carboxypeptidases) and other granule associated 
products like TNF-α and vascular endothelial growth factor A (VEGFA). The second class 
of mast cell product are lipid mediators and include prostaglandins, leukotrienes, 
cysteinyl leukotrienes and platelet activating factor (PAF). The third class of mast cell 
products is cytokines, chemokines and the growth factors (Bradding et al, 2006). The 1st 
two classes of product act within the duration of the EAR and are responsible for 
physiological changes including vasodilation, increased vascular permeability (causing 
tissue swelling), contraction of bronchial smooth muscle (causing airflow obstruction) 
and increased mucus secretion (contributing to airflow obstruction in the lower 
airways). Sneezing, coughing and itching can also be evoked by stimulation of 
nociceptors on sensory nerves. These effects are shown in Figure 2.  
The LAR develops 6-9 hours after allergen exposure. This phase is characterised by the 
recruitment, activation and migration of eosinophils, lymphocytes, neutrophils and 
macrophages into the lamina propria, epithelium and the airway lumen (Galli et al, 
2008). The cytokines, chemokines and growth factors produced during the EAR drive 
this process and allow for further release of mediators from these cells and further 
bronchoconstriction. 
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Figure 2: Diagram of the main processes during the early asthmatic response (EAR) evoked by an 
allergen. Allergen enters the airway and binds with high affinity IgE receptors on mast cells 
resulting in degranulation. Mast cell degranulation products increased leukocyte recruitment, 
increased vascular permeability, vasodilatation, bronchoconstriction and increased mucus 
production Based on Galli et al, 2008. 
1.4.3 INFLAMMATION 
Inflammation of the lungs is one of the key hallmarks of asthma and is observed across 
the entire spectrum of disease severity (Laitinen et al, 1996). The extent of inflammation 
has also been shown to correlate with disease severity, suggesting inflammation may be 
important in the pathogenesis of the disease (Barnes, 1996). The relationship between 
inflammation and the clinical symptoms of asthma is complex, with inflammation likely 
contributing to them both directly and indirectly. The inflammatory infiltrate consists of 
Chapter 1 
 
  9 
numerous cell types both from the innate and adaptive branches of the immune system. 
Discussed below are the aspects of the various cell types.  
1.4.3.1 EOSINOPHILS 
Eosinophils are the predominant cell type during the late asthmatic response to 
allergens, with their numbers peaking 24 hours after allergen challenge (Smith & 
Broadley, 2007; Toward & Broadley, 2004). Eosinophils are found in the lungs of those 
even with mild asthma. An association between eosinophil activation and asthma 
severity and bronchial responsiveness exists (Bousquet et al, 1990; Bradley et al, 1991). 
Eosinophils release many biological products including eicosanoids, oxygen free radicals, 
Th2 cytokines, growth factors and toxic granule products which contribute to 
contraction of smooth muscle, airways hyperresponsiveness (AHR) and increased 
vascular permeability (Bousquet et al, 2000). Granule products such as major basic 
protein (MBP), eosinophil cationic protein (ECP) and eosinophil derived neurotoxin 
(EDN) contribute directly to the development of AHR and epithelial shredding (Gleich et 
al, 1993). Other products such as growth factors, metalloproteases and elastase are 
involved in fibrosis and tissue remodelling (Bousquet et al, 2000).  
1.4.3.2 MAST CELLS 
Mast cells play a key role in both sensitisation to an allergen and also in the effector 
phase of asthma. Mast cell numbers are 2-6 times higher in the bronchial lavage fluid of 
asthmatics compared to non-asthmatics (Hamid et al, 2003). Mast cells are commonly 
found in their degranulated state in both stable asthma and following allergen exposure 
(Bousquet et al, 2000). Their cytoplasmic granules contain products including tryptase, 
prostaglandin (PG)-D2, histamine, cysteinyl leukotrienes (Cys-LT), which when released 
can elicit bronchoconstriction, mucus secretion, and oedema (Broide et al, 1991). Other 
products such as chymase may contribute to increased collagen deposition (Kofford et 
al, 1997). Mast cells also produce heparin, which has biological activities including 
modulation of wound healing and cell proliferation and differentiation (Bousquet et al, 
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2000). Heparin is also thought to have an anti-inflammatory role by binding and 
inhibiting chemokines; in addition to inhibiting the effects of several eosinophil-specific 
granule proteins such as major basic protein (MBP) (Diamant and Page, 2000). 
1.4.3.3 MACROPHAGES 
Macrophages are derived from monocytes and are the most commonly found 
inflammatory cell type in asthma (Hamid et al, 2003). Macrophages seem to have a dual 
role in asthma in both increasing and decreasing inflammation. Classical activation of 
macrophages by cytokines such as interferon-γ (IFN-γ), IL-1β, IL-6, IL-12 and tumour 
necrosis factor (TNF)-α lead to differentiation into M1 macrophages, which are efficient 
at phagocytosis and pathogen clearance. They also release cytokines, growth factors 
and chemoattractants directly and indirectly via epithelial cells and fibroblasts. Factors 
such as CCL2 (MCP-1) and CCL5 (RANTES) attract eosinophils and further macrophages 
(Barnes, 1996). In the presence of Th2 cytokines such as IL-4, macrophages can 
differentiate into M2 macrophages with anti-inflammatory actions such as IL-10 
production. Macrophages can also suppress inflammation by decreasing lymphocyte 
activity. However, this effect may be impaired following allergen exposure (Hamid et al, 
2003). M2 macrophages can also become a source of IL-13 and worsen asthma 
increasing AHR and mucus production (Byers & Holtzman, 2011).    
1.4.3.4 NEUTROPHILS 
Neutrophils are important in severe cases of asthma along with asthma exacerbations 
where their numbers are significantly elevated compared to milder forms of the disease. 
(Taha et al, 2001; Douwes et al, 2002). Neutrophils are also implicated in the pathology 
of steroid insensitive asthma (Monteseirín, 2009). Neutrophils may also play a role in 
milder forms of asthma, having been implicated in the early asthmatic response. In 
patients that died within 2 hours of an asthma attack, neutrophil numbers were found 
to be significantly elevated as compared to individuals that died from slow-onset fatal 
asthma (Sur et al, 1993). Neutrophil numbers are also found raised in animal models, 
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peaking only 2 hours after allergen challenge (Toward & Broadley, 2004). Neutrophils 
are able to produce a wide range of substances including metalloproteinases, elastase, 
lactoferrin, myeloperoxidase and reactive oxygen species (ROS). These have the 
capability to increase inflammation and increase the extent of tissue damage 
(Monteseirín, 2009).    
1.4.3.5 LYMPHOCYTES 
Lymphocytes play an indispensable role in the asthmatic inflammatory response. B 
lymphocyte’s main role is in the secretion of IgE antibodies. T lymphocytes can be 
broadly divided on the presence of the cell surface marker CD4 or CD8. CD8+ cells are 
generally cytotoxic (TC) cells and are more rarely found in asthmatics. CD4+ cells are 
normally T helper (Th) cells and the predominant T lymphocyte type observed in asthma 
(Corrigan et al, 1995). The activation of CD4+ lymphocytes has been shown to correlate 
with eosinophil number and bronchial responsiveness (Robinson et al, 1993). Several 
subtypes of Th cells exist including Th1, Th2, Th17, and Th9. These cells differ in their 
cell surface markers, cytokine secretion pattern and role in the disease. Classically Th2 
cells, secreting IL-4, IL-5 and IL-13 have been identified as the main Th cell type in the 
mediation of allergic airway inflammation (Galli et al, 2008). T regulatory (Treg) cells 
may be important in suppressing the persistent inflammation. Other innate-like T cells 
such as the natural killer and γδ cells may also have roles. A detailed analysis of specific 
lymphocyte sub-populations is beyond the scope of this thesis. Table 1 contains an 
overview of the main roles of T lymphocytes in asthma and their cytokine mediators. 
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Cell Type Cytokines secreted Role in Asthma 
CD8+ T cell IFN-γ, IL-4, IL-13 AHR, eosinophilia, viral 
exacerbation? 
Th1 cell IFN-γ Exacerbations? 
Th2 cell IL-4, IL-5, IL-13 IgE production, 
eosinophilia, AHR, mucus 
Th17 cell IL-17 Neutrophilia, steroid 
insensitivity? 
Th9 cell IL-9 IgE production, mucus, 
mast cell recruitment 
T-reg cell IL-10, TGF-β Suppression of 
inflammatory response 
Natural killer cell IFN-γ, IL-13 eosinophilia, AHR, IgE 
production, 
γδ T cell IL-4, IL-17 Subtypes respectively 
suppress and promote AHR 
Table 1: An overview of the different T lymphocyte sub-populations, their role in asthma and 
cytokine mediators secreted.  
1.4.3.6 INFLAMMATORY CYTOKINES 
Cytokines, chemokines and other inflammatory mediators play a central role in 
coordinating the actions of inflammatory cells and promoting the functional changes 
seen in asthma. Table 2 shows some of the main mediators involved in asthma. Of 
particular importance are the Th2 cytokines, IL-4, IL-5 and IL-13, cytokines triggered by 
toll like receptor signaling such as TNF-α and IL-8. Th17 cytokines such as IL-17 are also 
important and have been implicated in steroid insensitivity.  
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Cytokine Effect in asthma Mechanism 
T helper cell cytokines (Th2, Th9, Th1, Th17) 
IL-4 ↑ disease ↑ IgE, Th2 cells 
IL-5 ↑ disease ↑ eosinophils 
IL-9 ↑ disease ↑ mast cells 
IL-13 ↑ disease ↑ IgE, AHR 
IL-12 ↓ disease ↑ Th1 cells 
IL-17 ↑ disease ↑ neutrophils 
IL-18 ↑ disease ↑ IFN-γ release 
IFN-γ ↓ disease ↓  Th2 cells 
Pro-inflammatory and innate cytokines 
IL-1β, IL-6 ↑ disease ↑ inflammation 
TNF-α ↑ severe disease ↑ inflammation 
TSLP, IL-25, IL-33 ↑ disease ↑ Th2 cells, dendritic cell 
maturation 
Growth factors and anti-inflammatory 
EGF ↑ disease ↑ mucus secretion 
GM-CSF ↑ disease ↑ eosinophils,  neutrophils  
TGF-β ↑ severe disease ↑ fibrosis, ↓ inflammation 
IL-10 ↓ disease ↓ inflammation 
Table 2: Table showing the some of the main inflammatory cytokines involved in asthma. IL = 
Interleukin; IFN = Interferon; EGF = TNF = Tumour necrosis factor; TSLP = Thymic stromal 
lumphopoietin; Epidermal growth factor; GM-CSF = Granulocyte-macrophage colony stimulating 
factor; TGF = Transforming growth factor. Adapted from Barnes, 2008 
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1.4.4 AIRWAY HYPERRESPONSIVENESS 
Airway hyperresponsiveness (AHR) is an increased response to a bronchoconstrictor 
stimulus of natural or pharmacological origin. AHR is an essential component of asthma 
and is a requirement for diagnosis. However, the presence alone of AHR is not an 
indicator of asthma as it can also be present in asymptomatic people and sufferers of 
other respiratory diseases like COPD (Woolcock et al, 1987). The AHR seen in asthmatics 
can be episodic, persistent or both (Cockcroft & Davis, 2006). On this basis it has been 
suggested that AHR can be divided into 2 subtypes, persistent and variable. Persistent 
AHR which is thought to be associated with airway remodelling is often seen in chronic 
asthma. Variable AHR is more commonly associated with acute inflammation. 
Bronchoconstrictive agents can be divided into those that act directly or indirectly on 
airway smooth muscle. Direct stimuli include histamine and methacholine which act on 
H1 and muscarnic receptors respectively and are used clinically for diagnosis. Other 
direct acting stimuli not used clinically, include cysteinyl leukotrienes, thromboxanes, 
and prostaglandins (O'Byrne et al, 2009). Indirect stimuli include adenosine 
monophosphate (AMP) and allergens, but also stimuli that alter the physical 
environment including cold air, exercise, hypertonic saline, mannitol and voluntary 
hyperventilation. These agents cause the release of bronchoconstrictor mediators from 
inflammatory cells, which then act on the smooth muscle (O'Byrne et al, 2009). 
Clinically, AHR is measured using bronchial provocation tests such as FEV1 following the 
inhalation of a direct stimulus like methacholine. Both asthmatics and non-asthmatics 
are able to respond to these stimuli, although the dose required in asthmatics is far 
lower. AHR is expressed as provocative dose (PD) of the stimuli causing a 20% reduction 
in FEV1.  
AHR constitutes two distinct components: airway hypersensitivity and airway 
hyperreactivity and increased maximum response (Figure 3). Airway hypersensitivity is a 
decrease in the threshold dose of the bronchoconstrictor stimulus required to elicit 
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bronchoconstriction of the airways. Graphically, this is represented as a leftward shift in 
the dose-response curve to bronchoconstrictor stimulus from one in non-asthmatics. 
Airway hyperreactivity is a greater degree of closure in the airways in response to 
bronchoconstrictor stimuli. Graphically it is represented by an increased gradient in the 
slope of a dose-response curve (O'Connor et al, 1999). An increase in the maximum 
response is graphically represented as a greater degree of bronchoconstriction before 
the response plateaus. These changes are more pronounced in severe asthmatics 
compared to milder forms of the disease. The mechanisms behind these components of 
AHR may be different. Airway hypersensitivity has been linked to epithelial disruption 
and changes in the neuronal regulation of the airways. Airway hyperreactivity has been 
linked to changes in the structure in the lung including smooth muscle hyperplasia 
(Sterk & Bel, 1989.) 
The causes of AHR are still unclear. Variable AHR demonstrates a link between airways 
inflammation and the LAR (Meijer et al, 1999). Many inflammatory cells and mediators 
have been suggested as being important in the development of AHR. In particular, 
eosinophils have been implicated. However, treatment with an anti-IL-5 antibody does 
not reduce AHR despite reducing eosinophilia, suggesting eosinophils are not essential 
in this process (Lekie et al, 2000). Other inflammatory cells such as CD4+ and CD8+ T 
cells and the cytokine IL-13 have also been investigated for a potential role but a 
definitive answer as to what in the inflammatory milieu is responsible for AHR is still 
unknown (Cockcroft & Davis, 2006). On the other hand persistent AHR seems to be 
more clearly related to the consequences of airway remodelling including increased 
airway smooth muscle mass (Rennard, 1996). 
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Figure 3: Graphically demonstrates the three components of airways hyperresponsiveness 
(AHR) to a bronchoconstrictor stimuli. Hyperreactivity (red), hypersensitivity (green), increased 
maximum response (orange) and normal response (blue). PC20 expressed as the provocative 
concentration of the bronchoconstrictive agent required to cause a 20% reduction in forced 
expiratory volume in 1 second (FEV1). Redrawn from Lotvall et al, 1998 and Sterk & Bel, 1989. 
1.4.5 AIRWAY REMODELLING 
Airway remodeling is typically seen in chronic cases of asthma and is related to the 
severity of the disease (Rennard, 1996). More recently, it has been suggested that 
airway remodelling can occur in parallel and/or may be required for persistent 
inflammation (Galli et al, 2008). Several structural changes are observed in the disease. 
Increased vascularity and detachment of the epithelium, the latter leads to exposure of 
epithelial nerves and increase their exposure to irritant stimuli (Sumi & Hamid, 2007; 
Laitinen et al, 1987). Subepithelial fibrosis is also observed as a result of increased 
collagen and fibronectin deposition in the lamina reticularis (Roche et al, 1989). Elastic 
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fibres, which give the lungs their elastic recoil, are often found fragmented and tangled, 
although the number of fibres appears unchanged (Bousquet et al, 1996). These two 
changes make the lungs less compliant and can reduce the maximum improvement in 
lung function with therapy. An increase in smooth muscle mass is also observed in 
asthmatic airways and can be as much as 2-4 times that seen in normal subjects. This 
increase is thought to result from both hyperplasia and hypertrophy (Bousquet et al, 
2000).  
Mucus in the lungs is secreted by mucus glands and goblet cells distributed 
throughout the airways. An increased mucus production is one of the hallmarks of 
asthma and is attributable to increased goblet cell number, along with hyperplasia of 
the submucosal glands (Aikawa et al, 1992; Bousquet et al, 2000). The excessive mucus 
in asthma can lead to mucus plugging in both the central and peripheral airways and is a 
frequent contributor to fatal asthma (Andoh et al, 1992). A decrease in mucociliary 
clearance may also contribute to this effect (Pavia et al, 1985). The increase in mucus 
production has been atrributed to cytokines such as IL-4, IL-9 and IL-11, which can 
increase the expression of the mucus genes, MUC2 and MUC5AC (Temann et al, 1997). 
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1.5 ASTHMA EXACERBATIONS 
Asthma exacerbations are acute or sub-acute episodes of worsening symptoms such as 
wheezing, chest tightness, cough and shortness of breath. Underlying this is an increase 
in airflow obstruction due to smooth muscle contraction, mucus obstruction of the 
airway lumen and oedema (Hogg, 1997). Mucus in particular seems to be prominent, as 
emphasised by its finding in fatal cases of asthma. Cases of near fatal asthma are often 
associated with segmental lung collapse due to mucus plugging (Kuyper et al, 2003). 
Clinically, exacerbations can be measured as a further decrease in expiratory airflow by 
spirometry and peak flow from pre-exacerbation values (Busse, 2007).  
Asthma exacerbations can be divided into two types. The first are severe exacerbations, 
which require urgent action on the part of the patient and physician to prevent a life 
threatening outcome. The second are moderate exacerbations which are troublesome 
to the patient, require prompt change in treatment but are not life threatening (Reddel 
et al, 2009). It is the former that lead to hospitalisations and represent a significant 
economic burden in the developed world. The number of asthma sufferers that have an 
exacerbation requiring hospital treatment is a relatively small percent of the total 
population  of asthmatics (20%) but accounts for about 80% of the total direct costs 
(Rodrigo et al, 2004). The incidence of asthma exacerbations is similar across all age 
groups and races, when socioeconomic factors are taken into consideration. The 
occurrence of exacerbations increases in obese individuals and the presence of female 
sex hormones (Dougherty & Fahy, 2009).  
Asthma exacerbations can become self reinforcing, further increasing the risk of 
recurrent future exacerbations, independent of socioeconomic factors. (Miller et al, 
2007). A particular group of patients which have an ‘exacerbation prone’ phenotype has 
been identified. They are typically characterised by irreversible airflow limitation, 
psychological dysfunction, chronic sinusitis and intolerance to non-steroidal anti-
inflammatory medications (Koga et al, 2006). Asthma exacerbations may also have long 
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term effects on the lung. The exacerbation prone phenotype is associated with an 
accelerated loss of lung function, over asthmatics with a relatively stable form of the 
disease (Bai et al, 2007). This may be due to the increased inflammatory burden during 
an exacerbation, in addition to the activation of alternative inflammatory pathways 
(Holgate, 2007).  
1.6.1 CAUSES OF EXACERBATION 
Factors that contribute to the exacerbation of asthma include occupational exposures 
(cleaning products, grains, flours), hormones, drugs (NSAIDs, β-blockers), stress, 
exercise, air pollutants (diesel particulates) and bacterial infections (chlamydia 
pneumonia) and high doses of allergens (pollen, dust mites, animal dander). However, 
the most common cause is viral infection (Nicholson et al, 1993). Lipopolysaccharide  
(LPS) from gram-negative bacteria, which is also found ubiquitously in the environment, 
is also recognised as an important contributor to asthma exacerbations (Douwes et al, 
2006).   
1.6.1.1 VIRAL EXACERBATIONS OF ASTHMA 
Viruses are main cause of asthma exacerbations in both adults and children (Busse et al, 
2010). The importance of viruses in asthma exacerbations is well demonstrated by the 
higher rates of asthma mortality during the winter, coinciding with higher rates of 
influenza at that time of year (McCoy et al, 2005). Varying levels of virus detection have 
been made during asthma exacerbations. Using PCR techniques, viral detection rates in 
asthma patients have been recorded to be as low as 57%, to as high as 85% (Nicholson 
et al, 1993; Johnston et al, 1995). Common viral infections found during exacerbation 
include rhinovirus (RV), coronaviruses, influenza, parainfluenza and respiratory syncytial 
virus (RSV) (Atmar et al, 1998). The most commonly detected virus is RV; being reported 
in 65% of cases (Nicholson et al, 1993). Parainfluenza viruses (PIV) are also commonly 
found and thus represent a relevant human pathogen in asthma exacerbations. Viral 
exacerbations of asthma are described in more detail in chapter 4.    
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1.6.1.2 LIPOPOLYSACCHARIDE-INDUCED EXACERBATIONS OF ASTHMA 
LPS is found in the cell wall of gram-negative bacteria and also ubiquitously in the 
environment. A range of studies in humans and animal models have demonstrated that 
LPS also contributes to asthma exacerbations. Correlations between wheezing episodes 
and LPS exposure in humans have been demonstrated (Douwes et al, 2006). 
Additionally, correlations between the concentration of LPS in the domestic 
environment and severity rating of asthma exist (Michel et al, 1996). In animal models 
an increase in allergen-induced inflammation and decreased lung function with LPS has 
been demonstrated (Delayre-Orthez et al, 2004; Murakami et al, 2006). LPS-induced 
exacerbations of asthma are described in more detail in chapter 5.  
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1.6 TREATMENTS 
Treatments for asthma can be broadly divided in to those that provide symptomatic 
relief and those that target the underlying inflammation of the disease. The former 
include bronchodilators such as β2 adrenoreceptor agonists, muscarinic receptor 
antagonists and phosphodiesterase 4 (PDE4) inhibitors which relax airway smooth 
muscle and reduce bronchoconstriction. Anti-inflammatory therapies indicated in the 
treatment of asthma include leukotriene antagonists, PDE4 inhibitors, anti-IgE 
monoclonal antibodies and corticosteroids. The Global strategy for asthma management 
and prevention (GINA) outlines in its 2008 executive summary the 5 step treatment 
program indicated in the treatment of asthma across a range of disease severity 
(Bateman et al, 2008) (see Figure 4). The general principles of treatment are the use of a 
short acting β2 agonist as a reliever in all patients and a gradual introduction of longer 
acting β2 agonists and inhaled corticosteroids if symptomatic control is not achieved.   
 
Figure 4: A schematic of the treatment steps taken in the management of asthma. Treatment is 
taken to the next step if symptomatic control is not achieved. Step 1 introduces short acting β2 
agonists. Step 2 adds a low dose inhaled corticosteroids (ICS). Step 4 adds long acting β2 agonist 
(LABA). Step 3 either increases the dose of ICS or adds an additional therapy such as 
theophylline, anti-leukotriene or anti-cholinergic. Step 5 trials anti-IgE therapy or 
immunosuppresants and periodic oral corticosteroid (OCS) use. Adapted and redrawn from 
Bateman et al, 2008 
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1.6.1 Β2 ADRENORECEPTOR AGONISTS  
β2 adrenoreceptor agonists are the frontline bronchodilator used in the treatment of 
asthma. Both short and long acting β2 agonists (LABA) are available and differ in their 
use according to their pharmacological properties. Short acting β2 agonists such as 
salbutamol have a short duration of action but work rapidly so are used for symptomatic 
control when required, especially during exacerbations. Longer acting β2 agonists such 
as salmeterol have a longer duration of action and are used in long term control of 
symptoms. Additionally, several ultra-LABA are currently in development and indicated 
for once daily dosing. Controversy still exists regarding the safety of long acting β2 
agonists despite recent systematic reviews (Cates et al, 2012). Both classes of drug work 
on the β2 adrenergic receptor, which is the predominant subtype in the lungs. Binding of 
the β2 agonist to its receptor activates intra-cellular adenylate cyclase, which increases 
the production of cyclic adenosine monophosphate (cAMP). cAMP then acts via a 
variety of mechanisms to promote relaxation of smooth muscle. In addition, they may 
be able to prevent the inflammatory cell mediator release, inhibit cholinergic 
transmission, reduce vascular permeability and increase mucocilliary clearance (Barnes 
et al, 1998).  
1.6.2 ANTI-CHOLINERGIC DRUGS 
Anti-cholinergic drugs such as atropine have been established as bronchodilators for 
several centuries but have a wide range of side effects. They work by blocking the 
actions of the parasympathetic nervous system on the contraction of smooth muscle 
and mucus production in the airways (Barnes, 1989). More recently drugs which are 
selective for the muscarinic receptor subtypes of the parasympathetic nervous system 
have been developed. Ipratropium bromide is a non-selective muscarinic receptor 
antagonist, blocking the M1, M2 and M3 receptors (Barnes et al, 1998). However, the 
blocking of the M2 receptor on pre-synaptic cholinergic terminals is undesirable as it 
would enhance transmitter release and oppose the benefits from blocking the post-
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junctional M3 receptors on airway smooth muscle. M3 receptor specific antagonists 
would be of clinical benefit but have been hard to develop (Maesen et al, 1993). 
1.6.3 PHOSPHODIESTEREASE (PDE) INHIBITORS AND THEOPHYLLINE 
Phosphodiesterease (PDE) inhibitors such as theophylline have been used to treat 
asthma for over a century. The PDE4 isoform of the enzyme is found predominantly in 
inflammatory cells and airway smooth muscle. It is involved in the breakdown of cAMP 
to the inactive substance adenosine monophosphate (AMP). Inhibition of PDE will cause 
cAMP levels to increase and the inhibition of inflammatory cells (Boswell-Smith et al, 
2006).  
Clinically, theophylline is able to significantly improve asthmatic symptoms 
(Evans et al, 1997). However, the extent of PDE4 inhibition at therapeutically relevant 
concentrations is low suggesting an alternative mechanism of action (Polson et al, 
1978). One alternative mechanism suggested is antagonism of adenosine receptors. 
Adenosine causes bronchoconstriction in asthmatics by promoting the release of 
leukotrienes and histamine (Björck et al, 1992). These effects are prevented by 
therapeutic concentrations of theophylline (Cushley et al, 1984). Theophylline also 
seems to have some anti-inflammatory effects such as inhibition of the LAR and the 
activation of HDAC-2 which decreases pro-inflammatory gene transcription (Pauwels et 
al, 1985; Jaffar et al, 1996). The drug may also be able to attenuate inflammatory cell 
mediator release and lower the oxidative burden of the lung, potentially being useful in 
treating exacerbations (Nielson et al, 1988). The negative side effect profile of 
theophylline compared to β2 agonists has given the drug limited usage. More selective 
PDE4 inhibitors including roflumilast and cilomilast have been approved for use in 
severe exacerbations of COPD. Clinical studies in asthma have suggested that these 
drugs may also be beneficial in the treatment of asthma (Boswell-Smith et al, 2006). 
1.6.4 CYSTEINYL LEUKOTRIENES  
Chapter 1 
 
  24 
Cysteinyl leukotrienes (Cys-LTs) are arachidonic acid derived inflammatory mediators. 
Their effects include bronchoconstriction, inflammatory cell recruitment and mucus 
hypersecretion (Riccioni et al, 2007). Montelukast, an anti-cysteinyl leukotriene drug has 
both bronchodilator and anti-inflammatory effects and works by antagonising the 
receptor of leukotriene D4: the Cysteinyl Leukotriene 1 receptor. These receptors are 
found on mast cells and can prevent release of histamine and development of the EAR 
(Taylor et al, 1991). Montelukast is also able to attenuate symptoms of the late phase 
such as mucus hypersecretion and eosinophil recruitment (Barnes et al, 1998). These 
drugs have not proved to be as successful as inhaled corticosteroids in corticosteroid-
sensitive asthma in controlling symptoms and consequently are used as 3rd line therapy.  
1.6.5 CORTICOSTEROIDS 
Corticosteroids continue to be the mainstay treatment in long term control of asthma. 
They are mainly given as an inhaled preparation due to their decreased systemic side 
effect profile compared to oral preparations. Oral preparations are reserved for treating 
severe asthma exacerbations and patients with inhaled corticosteroid insensitivity. They 
also have wide ranging effects on both functional and inflammatory components of 
asthma. Corticosteroids are able to suppress numerous inflammatory cell types 
including eosinophils, lymphocytes and mediators (Underwood et al, 1997, Krouwels et 
al, 1996; Barnes et al, 1998A). Corticosteroids act via the glucocorticoid receptor (GR), 
which translocates to the nucleus and both suppresses pro-inflammatory and increases 
anti-inflammatory gene transcription (Marwick et al, 2007). A more detailed overview of 
inhaled and systemic corticosteroids including their mechanisms can be found in 
chapter 6 and 7 respectively.  
 
 
Chapter 1 
 
  25 
1.6.6 NEW AND FUTURE THERAPIES 
The most recent anti-asthma drug to be approved is the anti-IgE monoclonal antibody, 
omalizumab. Currently, issues such as certain patients demonstrating lack of symptom 
improvement and the cost of the therapy have prevented wider adoption of the 
treatment. Other treatments based on blocking key cytokines in the allergic response 
such as IL-4, IL-5, IL-9 and IL-13 are at various stages of clinical and pre-clinical 
development (Barnes, 2010). So far these have shown mixed results and may indicate 
the need to better understand the various mechanisms that underlie different forms of 
asthma. 
1.6.7 TREATMENT OF ASTHMA EXACERBATIONS 
Corticosteroids have been shown to be the most protective in the reduction of 
exacerbations, decreasing their occurrence by 55% when compared with short acting β2 
agonist or placebo (Sin et al, 2004). They also seem to be able to reduce AHR, which is 
likely to contribute to better exacerbation control (Sont et al, 1999). Despite this, 
asthma exacerbations continued to be under treated. One problem in the treatment of 
asthma exacerbations is the poor compliance with inhaled drug treatment within the 
asthmatic population. Due to this, treatment is often only begun when the symptoms of 
an asthma exacerbation have emerged and treatment is less effective. The effectiveness 
of corticosteroids during exacerbations remains under debate. In particular, the 
effectiveness of corticosteroids in reducing viral-induced exacerbation remains 
controversial, despite an extensive Cochrane review that found that inhaled 
corticosteroids are an effective strategy in dealing with respiratory viral infection (Zhang 
et al, 2007; McKean & Ducharme, 2000). The mechanism behind this may be an 
enhancement of innate immunity and epithelial defense, and also reduction in Th2 pro-
inflammatory cytokine production, which is weakly anti-viral (Zhang et al, 2007). In 
animal models, viral exacerbations have been shown to be refractory to inhaled 
corticosteroids (Singam et al, 2006) LPS-induced exacerbations of asthma have also 
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been shown to be partially refractory to even systemic corticosteroids (Komlosi et al, 
2006). Alternative strategies to treat asthma exacerbations are also under investigation. 
Exogenous interferon-β has been shown to have both anti-viral and anti-inflammatory 
properties in vitro on primary bronchial epithelia cells from asthmatics (Cakebread et al, 
2011). Thus this may represent an alternative and/or complimentary strategy to 
corticosteroids for treating viral specific asthma exacerbations.  
1.7 STEROID INSENSITIVITY 
Approximately 5% of asthmatics have been found to be unresponsive to inhaled 
corticosteroid treatment and show decreased responsiveness to oral corticosteroid 
treatment. This is termed steroid insensitivity. Relatively few people are completely 
resistant to oral steroids (Ito et al, 2006). Steroids are a front line treatment for 
controlling asthma and few alternative anti-inflammatory therapies exist. Therefore, 
patients that are unresponsive to steroid treatment are more likely to have poorly 
controlled asthma and present considerable management and economic problems. The 
underlying mechanisms of steroid insensitivity in asthma are largely unknown, although 
several pieces of evidence have suggested possible causes including a decrease in the 
activity of a group of enzymes called the histone deacetylases, which suppress pro-
inflammatory gene transcription (Ito et al, 2006).  New animal models that reflect 
human steroid insensitivity in asthma are required. These will enable the development 
of novel therapeutics to directly treat patients or to restore normal steroid response, 
allowing for better symptom control. A more detailed discussion of steroid insensitivity 
can be found in chapter 6 and 7.  
1.8 ANIMAL MODELS 
Animals are used to model diseases and test the efficacy of new drugs. However, since 
asthma is a complex disease, no one animal model can represent the heterogeneity of 
the human condition. Animals do not develop asthma spontaneously but some 
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demonstrate diseases akin to human asthma including cats, dogs, sheep and horses 
although their pathogenesis may be vastly different (Kurucz & Szelenyi, 2006). As a 
result, the majority of models of asthma are created through allergen sensitisation and 
subsequent allergen challenge. A variety of different allergens have been used in these 
models including ovalbumin (Ova), cockroach extract, ragweed, Aspergillus fumigatus 
and house dust mite (Smith & Broadley, 2007; Canning & Chou, 2008). 
A discussion of Ova allergen challenge models can be found in chapter 3. A discussion of 
viral and LPS induced asthma exacerbation models can be found in chapter 4 and 5 
respectively. A discussion of inhaled and systemic corticosteroid insensitivity models can 
be found in chapters 6 and 7 respectively. Many different animals have been used as 
models for asthma including monkeys, dogs, mice and guinea-pigs. Guinea-pigs in 
particular have been the most commonly used small animal species in preclinical testing 
for asthma (Canning & Chou, 2008). Although guinea-pigs have offered vital insight into 
processes such as immediate hypersensitivity reactions and the actions of histamine, 
their value as an animal model must be carefully considered.  
1.8.1 GUINEA-PIG MODELS 
Guinea-pigs offer several advantages over larger species such as sheep in modelling 
asthma. They are relatively cheap; so that using them is fairly cost effective. Like other 
rodents they are small and therefore easy to handle. Unlike other rodents many aspects 
of the guinea-pig lung physiology and anatomy is similar to humans (Ressmeyer et al, 
2006). As in humans, guinea-pigs have a pseudo-stratified epithelium lining the trachea, 
a similar bronchi structure, vagal innervation of the epithelial and sub epithelial spaces, 
goblet cell and mucus glands that are both neuronally and locally regulated and smooth 
muscle of similar anatomical location and functional properties (Canning & Chou, 2008). 
Importantly, the pharmacology of receptors including responses to airway smooth 
muscle relaxants and contractile agonists are nearly identical to humans, with a few 
exceptions (Muccitelli et al, 1987). In addition, in both humans and guinea-pigs the EAR 
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is mediated by histamine and leukotrienes from mast cells, whereas in species such as 
mice and rats, mast cells contain 5-HT (Lamm et al, 1984; Roquet et al, 1997). Finally, 
the docile nature of guinea-pigs makes the use of anaesthetic unnecessary for accurate 
measurements of airway function.  
The use of guinea-pigs does have several disadvantages. There exists in guinea-pigs an 
axonal reflex that results in the local release of tachykinins and the induction of 
bronchospasm, mucus secretion, inflammatory cell recruitment, vascular engorgement 
and plasma extravasation. It appears that this reflex does not exist in humans and thus 
serves as a drawback of the guinea-pig model (Barnes, 2001). It should also be noted 
that in humans the main antibody involved in type 1 hypersensitivity reactions is IgE 
whereas in guinea-pigs it is IgG (Regal, 1987). Guinea-pigs have seen decreased use as 
models for asthma due to a lack of available biochemical and molecular biological 
reagents. Guinea-pigs also have a more uncharacterised genome as compared to mice 
and thus genetic manipulation is more difficult (Canning & Chou, 2008). However, the 
advantages of guinea-pigs as models of asthma outweigh the disadvantages and they 
continue to be a useful tool in drug discovery and modelling.  
Ultimately, no animal model can seek to represent the full human asthmatic condition 
due to its heterogeneous nature, its complex causes and underlying mechanisms. 
Criticism that animal models fail to replicate the full human condition represent a 
misunderstanding of the use of animal models (Holmes et al, 2011). Animal models are 
best applied to recreating certain aspects of asthma and having their mechanisms 
shown as relevant in humans.  
1.8.2 USE OF WHOLE BODY PLETHYSMOGRAPHY 
Whole body plethysmography allows for conscious measurement of lung function over a 
prolonged period. This enables measurement of both the early and late asthmatic 
responses in the same animal, along with measurement of other asthma characteristics 
such as AHR and cellular inflammation at a separate time point. This technique has been 
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successfully employed to measure early and late asthmatic responses in a range of 
studies (Johnson & Broadley, 1999; Underwood et al, 1995, Evan et al, 2011). The 
disadvantage of this method is that it does not allow for direct measurement of 
bronchoconstriction in specific airways, along with a direct measurement of airway 
resistance and compliance. Whole body plethysmography does overcome the issues 
with using anaesthetic, as required for invasive measurement of lung function. 
Anaesthetic can interfere with the vagal reflex in the lung which can be important in 
bronchoconstrictor responses (Toward & Broadley, 2004). 
1.9 AIMS 
The overall aims of this thesis are: 
 Establish an acute allergen challenge model of asthma demonstrating an early 
and late asthmatic responses, airways hyperresponsiveness and airway 
inflammation. 
 Establish a model of asthma exacerbation demonstrating a worsening of the 
parameters observed above using live virus, viral mimetic or lipopolysaccharide. 
Also to establish the effect of these agents alone. 
 Establish the inhaled and systemic corticosteroid sensitivity of experimental 
asthma, asthma exacerbation models and virus/LPS alone.  
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A complete list of the materials, equipment and solutions used in this thesis and 
their suppliers is available in Appendix 1. Figures in this thesis were produced using 
“Servier Medical Art" (www.servier.com).  
2.1 IN VIVO METHODS 
2.1.1 ANIMAL HUSBANDRY 
Male Dunkin-Hartley guinea-pigs, 200-300g were purchased from Harlan Ltd, UK or 
Charles River, Germany. On arrival guinea-pigs were given one week to acclimatise 
with their new surroundings before commencement of experiments. Guinea-pigs 
were housed in pathogen free conditions; with environmental enrichment in the 
form of cardboard tubes and hay. The housing room conditions were: twelve hour 
light/dark cycles, at 50% humidity and room temperature of 20°C±2°C. All guinea-
pigs were given food and water ad-libitum. All procedures were carried out in 
accordance with Home office licence conditions and legislation covering animal 
husbandry and severity limits.  
2.1.2 MEASUREMENT OF LUNG FUNCTION 
Guinea-pig airway function was measured using non-invasive double chamber 
plethysmography supplied by Buxco systems Ltd. During respiration, an exchange of 
air between the airways of the animal and the surrounding environment 
(plethysmography chamber) takes place. This exchange is induced by changes in the 
volume of the small airways and alveoli of the lungs. During inspiration the volume 
of the lungs increases, resulting in a decrease in the airway pressure. Air then travels 
down its pressure gradient resulting in reduction in the volume of air of the 
surrounding environment. The opposite process takes place during expiration. The 
plethysmograph allows the difference between the rate of change of thoracic 
displacement volume and the nasal flow to be measured when the chamber is kept 
at a constant temperature.  
Chapter 2 
 
32 
 
The chamber is split into both a nasal and thoracic sections, separated by a neck seal 
and monitored by separate transducers. This allows thoracic and nasal flows to be 
compared. The difference in pressure between the alveoli and the nose or mouth, 
when divided by the airflow between them produces a measure of airway resistance 
(Raw). The reciprocal of Raw, airway conductance (Gaw), is considered a better 
measurement of airway function as it accounts for change in lung tissue tension and 
transpulmonary pressure. Gaw is influenced by changes in the thoracic gas volume 
(TGV), as occur in the alveoli and therefore a further correction is required. The value 
produced is termed specific airway conductance (sGaw) (Griffiths-Johnson et al, 1988) 
(Figure 1). The greater the resistance in airway, the greater the time delay between 
the nasal and thoracic flows, which consequently alters sGaw. A fuller description of 
the measurement of lung function can be found in Appendix 2. 
 
Gaw = 1/ Raw 
sGaw = Gaw/TGV 
Figure 1: Equation used to calculate specific airway conductance (sGaw) from airway 
resistance (Raw). Airway conductance (Gaw), Thoracic gas volume (TGV).  
 
Guinea-pigs were placed in a double chamber plethysmograph and prevented from 
moving their bodies by use of a neck restraint (Figure 2). The restraint also serves the 
function of separating the nasal and thoracic compartments of the chamber and 
makes them both airtight. Air temperature and gas percentages were kept constant 
by use of a bias flow supply unit. Box pressure changes in both compartments were 
measured by pressure transducers. The pre-amplified output is converted to 
waveforms by Finepoint software (Buxco system Ltd). An example of the waveform 
is given in Figure 3. The software is also able to derive sGaw based on the inputs it 
receives. Readings are taken every 2 seconds and at least 20 breaths are recorded 
during any time point measurement. For calculation of sGaw at a particular time 
point, 15 values are taken at random and the average is calculated. 
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Prior to the commencement of lung function measurements, all guinea-pigs were 
acclimatised to being restrained in plethysmograph chambers for at least 20 minutes 
on two separate occasions. This reduces movement related signal ‘noise’ during 
measurements. It also reduces animal stress during subsequent restraint, reducing 
the interference of stress-related hormones such as cortisol and adrenaline on 
allergen responses. 
 
 
Figure 2: Diagram of double chamber plethysmograph used for measurement of specific 
airway conductance (sGaw) in conscious, restrained guinea-pigs. Airflow is measured by aid 
of pnuemotachograph and pressure changes by transducer. The difference in these values is 
captured using the pre-amplifiers and specific airway conductance (sGaw) calculated using 
Finepoint software.  
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Figure 3:  A trace of the waveform data produced from double chamber plethysmography. 
Thoracic flow (blue) and nasal flow (red) are both represented as near overlapping 
waveforms. Taken from (Lomask, 2005). 
2.1.3 OVALBUMIN AND COMBINED OVALBUMIN AND LPS PROTOCOLS 
2.1.3.1 SENSITISATION 
Guinea-pigs were sensitised by 3 bilateral intra-peritoneal (I.p) injections (day 1, 4 
and 7) of ovalbumin (Ova, 150ug) and aluminium hydroxide (100mg) in 1ml of 
normal saline, unless otherwise stated. All further procedures commenced on day 
15. This method of sensitisation is modified from Smith and Broadley, 2007 and is 
described in more detail in chapter 3.  
2.1.3.2 ACUTE OVALBUMIN CHALLENGE PROTOCOL 
Modifications were made to this protocol and are described in chapter 3. This 
description represents the final protocol developed and used in all subsequent 
experiments. Airways hyper-responsiveness (AHR) was determined by histamine 
inhalation, both pre- and post-saline or Ova challenge on day 15 and 22 respectively 
(described in more detail in section 2.1.6). Guinea-pigs were exposed to inhaled 
ovalbumin (0.03% w/v) or saline challenge on day 21. Exposure was performed in a 
Perspex exposure chamber (15x30x15cm) using a DeVilbiss nebuliser, delivered at a 
rate of 0.3ml/min and at an air pressure of 20 ib p.s.i. Guinea-pigs were exposed for 
an hour or until they appeared distressed, in which case exposure was considered 
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complete. Lung function was subsequently measured over 12 hours (described in 
more detail in section 2.1.5). Further to histamine inhalation on day 22, guinea-pigs 
were sacrificed and bronchoalveolar lavage (BAL) performed (described in more 
detail in section 2.2.1). Using the fluid returned from the lungs, total and differential 
cell counts were performed. Figure 4 shows the acute protocol. 
 
Figure 4: A diagram of the acute ovalbumin protocol. Ova: Ovalbumin; BAL: bronchoalveolar 
lavage 
2.1.3.3 OVALBUMIN AND LPS CO-ADMINISTRATION PROTOCOL 
Variations of this protocol were used in chapter 5 and 6. This description refers to 
the protocol using 2 LPS exposures used in chapter 5-8. Airways hyperresponsiveness 
(AHR) was determined by histamine inhalation both pre- and post-saline or Ova 
challenge on day 15 and 22 respectively (described in more detail in section 2.1.6). 
Guinea-pigs were exposed to inhaled LPS (30μg/ml) 48 hours before Ova challenge 
and both LPS (30μg/ml) and Ova (0.03% w/v) co-administered on day 21. Exposures 
were performed for an hour using the same equipment mentioned in section 2.1.3.2. 
Lung function was subsequently measured over 12 hours (described in more detail in 
section 2.1.5). Following the second histamine inhalation on day 22, guinea-pigs 
were sacrificed and bronchoalveolar lavage performed (described in more detail in 
section 2.2.1). Using the fluid returned from the lungs, total and differential cell 
counts were performed. Figure 5 shows a diagram of this protocol. 
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Figure 5: Diagram of LPS and Ova co-exposure protocol. Guinea-pigs were exposed to saline 
or LPS (30μg/ml) on day 19 and both Ova and LPS co-administered on day 21.  
2.1.4 LPS EXPOSURE PROTOCOL 
Guinea-pigs were exposed to inhaled histamine both pre and post- LPS exposure on 
days 1 and 8 respectively of the protocol to determine the presence of AHR 
(described in more detail in section 2.1.6).  Guinea-pigs were exposed to saline or 
LPS (30μg/ml) on day 5 and 7 of the protocol. Exposures were performed for an hour 
using the same equipment mentioned in section 2.1.3.2. Lung function was 
determined for 12 hours after the 2nd LPS or saline exposure to determine the 
presence of a bronchoconstriction as described in section 2.1.5. Bronchoalveolar 
lavage was performed on day 8, following histamine inhalation and sacrifice. Total 
and differential cell counts were performed to determine airways inflammation.   
 
Figure 6: Diagram of the LPS alone exposure protocol. Guinea-pigs are exposed to 30μg/ml 
of LPS on day 5 and 7.   
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2.1.5 RECORDING LUNG FUNCTION  
Lung function was measured by the use of sGaw immediately following saline, Ova 
or LPS challenge. Values for sGaw were taken hourly for 12 hours and every 15 
minutes during the first hour of measurements. A final measurement was also taken 
24 hours post-challenge. sGaw was expressed as a percentage of the baseline 
reading, taken before saline, Ova or 2nd LPS challenge. A negative percentage change 
in baseline value represents a bronchoconstriction, whereas a positive change in 
percentage represents a bronchorelaxation. In ovalbumin challenged animals early 
and late asthmatic responses (EAR and LAR, respectively) which are characterised by 
distinct bronchoconstrictions, were determined. The EAR occurs within the first hour 
but can take as long as 6 hours to fully return to baseline. Therefore, to account for 
any individual differences between guinea-pigs the peak value between 0-6 hours is 
considered to represent the EAR. The LAR starts from about 6 hours onwards and 
shows considerable temporal variation between animals. Therefore the peak value 
between 6-12 hours is considered to represent a LAR.  
2.1.6 MEASUREMENT OF AIRWAYS HYPERRESPONSIVENESS 
The development of airway hyperresponsiveness (AHR) following Ova, LPS or saline 
challenge was determined by measuring the response to the bronchoconstrictor 
agent histamine using plethysmography. Histamine was delivered to the guinea-pigs 
by the use of a Buxco nebuliser chamber, which directly feeds into the nasal 
chamber of the plethysmograph (Figure 7). The rate of gas flow into this chamber is 
dependent on the total of the bias flow units suction vs the rate of the nebuliser 
control units extraction. The nebuliser control unit was set to extract histamine from 
the nebulisation chamber at a rate of 2 litres per minute (LPM), per chamber, which 
when subtracted from the bias flow extraction rate of 2.5LPM per chamber results in 
a flow of histamine from the nebuliser chamber to the nasal chamber of the 
plethysmograph of 0.5 LPM per chamber. Nebulisation of histamine took place over 
the first two minutes, with a 10% duty setting per chamber i.e. 1.2 seconds out of 
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every 6 seconds spent nebulising. The third minute included a 1 minute drying 
period which removes excess aerosolised histamine from the nebulisation chamber.  
 
Figure 7: A diagram of double chamber plethysmograph with nebuliser unit for performing 
assessment of the bronchoconstrictor response to aerosolised histamine. Solutions are 
added to the nebuliser, aerosolised into the chamber below and sucked into the nasal 
portion of the plethysmograph chamber where the guinea-pig inhales it. Aerosolised 
histamine is removed from the chamber by the bias flow unit. Specific airway conductance 
(sGaw) values are derived an from both the nasal and the thoracic portions of the 
plethysmograph chamber by the transducers finepoint software.  
 
A concentration of histamine that evokes minimal bronchoconstriction in naïve 
guinea-pigs was determined by dose-response curve (Figure 8). The effect of 
different nebulisation regimes on histamine response was also determined (Figure 
9). From these studies a histamine concentration of 0.3mM, 2 minutes nebulisation + 
1 minute drying, 10% duty cycle per chamber was chosen. This protocol produces a 
small bronchoconstriction in naïve guinea-pigs which ensures that a failure to see 
AHR to histamine is not due to the dose of histamine being too low.
Nebuliser
Bias Flow
Aerosolised
Histamine
Pneumotachograph
Transducer
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Figure 8: A dose-response curve to histamine performed in naïve guinea-pigs. Settings used 
were 1 minute nebulisation, 1 minute drying. Net flow to each chamber was 0.5LPM 
(2.5LPM from bias flow against 2LPM extraction from neubliser control unit), 20% duty per 
chamber.  
 
 
Figure 9: The effect of altering the nebulisation period and duty cycle on the 
bronchoconstrictor response to 2 different doses of histamine. Neb: nebulisation time, Duty: 
duty cycle for duration of nebulisation, per chamber. 
 
To determine the bronchoconstrictor response to histamine, a 1 minute baseline 
value of lung function is recorded using sGaw and all other values recorded are taken 
as a percentage of this. Further sGaw values are recorded at time points 0, 5 and 10 
minutes post histamine exposure. A decrease in sGaw following histamine exposure 
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represents a bronchoconstriction, suggestive of AHR. In each protocol, histamine 
challenges were performed both pre- and 24 hours post-Ova or LPS challenge. Pre-
Ova or saline histamine exposures were used to determine individual guinea-pigs 
sensitivity to histamine prior to Ova challenge. A direct comparison between the pre- 
and post-Ova, LPS or saline responses accommodates for group to group variation in 
responsiveness to histamine. 
2.1.7 DRUG ADMINISTRATION 
The effect of inhaled (fluticasone propionate and dexamethasone) and systemic 
corticosteroid (dexamethasone) were used on various acute asthma models of 
asthma throughout this thesis. Drugs were all administered for 6 consecutive days 
before lavage, to reflect the clinical situation where corticosteroids treatment is 
underway before asthma exacerbation. On days of Ova or LPS challenge, 
corticosteroid treatment was administered 30 minutes prior to subsequent 
challenge. The dosing regimen used for each drug is described in Table 1.  
Drug Administration Daily Doses Vehicle Frequency 
Fluticasone 
propionate 
Inhaled 
(nebulised) 15 
minutes 
0.05, 0.1, 0.5 
and 1mg/ml 
30% ethanol 
30% DMSO 
40% saline 
Split into 2x 
daily dose, 6 
hours apart 
Dexamethasone 
21-phosphate 
disodium salt 
Inhaled 
(nebulised) 15 
minutes 
4 & 20mg/kg 25% DMSO 
75% Saline 
Once daily 
Dexamethasone 
21-phosphate 
disodium salt 
Intra-peritoneal 5, 10 & 
20mg/kg 
25% DMSO 
75% Saline 
Once daily 
Table 1: A list of the compounds used throughout this thesis. 
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The corticosteroid vehicle selected was chosen to minimise side effects whilst fully 
dissolving the drug. Previous work with dexamethasone used 50% DMSO and 50% 
saline as a vehicle (Toward & Broadley, 2004). This was reduced to 25% DMSO to 
reduce local irritation at the site of injection and potential anti-inflammatory actions. 
This fully solubilised dexamethasone at even the highest concentrations used for 
both inhaled and intra-peritoneal routes. The vehicle for fluticasone propionate 
included ethanol due to issues with solubility in DMSO and saline alone. This mix has 
been shown to have minimal effects on Ova and histamine responses (Nevin & 
Broadley, 2004).  
Drugs administered by inhalation were delivered for 15 minutes in a Perspex 
exposure chamber (15x30x15cm) using a DeVilbiss nebuliser delivered at a rate of 
0.3ml/min and at an air pressure of 20 ib p.s.i. Fluticasone propionate was 
administered twice daily to reflect its clinical administration and according to a 
protocol already shown to be effective on Ova-induced allergic and functional 
responses (unpublished data). Dexamethasone was administered once daily due to 
its long biological half life of 36-54 hours, in spite of its short plasma half life (3.5-4.5 
hours) in humans (Sparrow & Geelhoed, 2006).  
Drug doses selected were based on previous work and dose-response relationships 
performed in this thesis. Previous work with inhaled fluticasone propionate has 
found that 0.5mg/ml is a dose effective at reducing Ova induced LAR, AHR and 
airway inflammation (Evans et al, 2012). Similarly, an intra-peritoneal injection of 
20mg/kg dexamethasone has been shown effective at reducing the same 
parameters (Toward & Broadley, 2004). Dexamethasone is not commonly given by 
the inhaled route and consequently there are no studies using it in guinea-pigs on 
which to estimate an effective dose. The dose used was extrapolated from one 
effective in mice (Jungsuwadee et al, 2004), relative to intra-peritoneal mouse doses 
reported in the literature (Komlósi et al, 2006; Korideck & Peterson, 2009). From this 
a ratio (5:1) between effective intra-peritoneal and inhaled doses was determined 
and used to calculate an inhaled dose for guinea-pigs.  
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2.2 EX VIVO METHODS 
2.2.1 MEASURING AIRWAY INFLAMMATION 
At 24 hours post-Ova exposure and following final histamine challenge, guinea-pigs 
were sacrificed by an intra-peritoneal overdose of sodium pentobarbitone (euthatal 
400mg/kg).  Death was confirmed by the absence of neural reflexes and heartbeat. 
Guinea-pigs were then bled via severance of the carotid artery. An incision into the 
neck was made and subsequently an intravenous 7-9FG (trachea size-dependent) 
cannula was inserted into the trachea. Dissection was then performed to excise the 
lungs. Subsequently, the right lung, consisting of 4 lobes was clamped off. 
Bronchoaleveolar lavage (BAL) was performed on the non-clamped left lung using 
normal saline (0.5ml per 100g of guinea-pig weight) instilled through the cannula for 
3 minutes. This process was then repeated and the 2 volumes of lavage return fluid 
combined. The largest of the right lobes was stored in 10% buffered formaldehyde 
for later histology. The smallest lobe had its wet weight measured and was 
subsequently dried overnight in an oven at 40oC. The remaining two lobes were 
stored at -80oc for future protein or RNA analysis.  
To measure cellular influx, both total and differential cell counts were 
performed on BAL fluid. The total number of cells (per ml of lavage fluid) was 
counted using a Neubauer haemocytometer under a light microscope at 40x 
magnification. Cell counts were performed using undiluted BAL fluid. Lavage fluid 
returns were consistent across experiments. 100µl of lavage solution was pipetted 
under a coverslip placed on top of the haemocytometer, evenly distributed by the 
aid of capillary action. 2 grids of 25 squares are present on the haemocytometer, 
with the number of cells in 5 of these squares being counted each time (always the 
top left, top right, bottom, right, bottom, left and central square). The formula used 
to calculate total cell numbers per ml of BALF is shown in (Figure 10). The resulting 
figure was multiplied by 5 and averaged with the total from the other grid of 25 cells. 
As each of the squares measure 0.04 mm2 and 25 were counted, a figure of number 
Chapter 2 
 
43 
 
of cells per 1 mm2 was established. However, the depth of the chamber is 0.1 mm, 
therefore giving a number of cells per 0.1 mm3. The cell count figure was multiplied 
by 104 to provide a total cell count per ml (1cm3) 
 
 
Figure 10: Formula used to calculate total cell numbers/ml of bronchoalveolar lavage fluid.  
 
Differential cell counts were the second count performed. 100µl of undiluted, 1:5 
diluted or 1:10 diluted BAL fluid stock was centrifuged for 7 minutes at 1000rpm 
onto a glass slide using a cytospin. Slides were subsequently air dried to aid cell 
adhere to the slide. Slides were then stained with 1.5% Leishmans solution in 100% 
methanol for 6 minutes and rinsed in dH20 twice. Slides were air dried overnight. 
Once slides were dry, cells were counted at x100 magnification to determine the 
subpopulations of leukocytes present. The subpopulations of leukocytes counted 
included eosinophils, macrophages, lymphocytes and neutrophils. No mast cells 
were observed. Cell types were differentiated on the basis of their granularity, cell 
size, nucleus shape and stain colouration (Figure 11).  
 
Cells/1mm3= [Average (GC1x5 & GC2x5)] x10
4 
 
GC1= Grid count 1 
GC2= Grid count 2 
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Figure 11: Photographs of the four subtypes of leukocytes, stained with Leishman’s solution, 
counted in a differential count. Adapted from (Gude et al., 1982). 
 
Macrophages are the predominant inflammatory cell in BAL fluid. They are also the 
largest ranging from 15-20μm.  Eosinophils are most easily identified on the basis of 
their bi-lobed nucleus, red/pink staining of granules in the cytoplasm and their 
smaller size (10-14 μm), compared to macrophages. Lymphocytes are mononuclear 
and are the smallest cell type of the 4 (<10 μm). Identification is reliant on the 
presence of a large spherical, darkly stained nucleus, taking up 70-80% of the total 
cell volume. Neutrophils are similar in size to eosinophils but easily distinguished 
from them by the presence of a multi-lobed, blue stained nucleus. The cytoplasm 
also stains a light blue further differentiating the 2 cell types (Gude et al, 1982).  
2.2.2 DETERMINATION OF AIRWAYS OEDEMA 
Initially airway oedema was determined by assessment of the wet vs dry weight of 
the lungs (described in section 2.2.2.1). This technique was used in chapter 4. 
Further studies used total protein content in lavage fluid as an indicator of airway 
oedema. This measure correlates with the wet/dry weight measure and allows for 
clearer determination of differences in oedema.  
2.2.2.1 WET VS DRY WEIGHT OF LUNG 
Wet lung oedema was determined by comparison of lung wet weight with dry 
weight. This was performed as follows. The 3rd largest lobe of the right lung was 
weighed following excision from the guinea-pig and then dried overnight in an oven 
Macrophage Eosinophil Lymphocyte Neutrophil
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at 40ºC. The lobe was again weighed. The difference between the wet and dry 
weight of the lung allows determination of lung water content and consequently 
oedema. However, percentage changes are small and do not allow for differences in 
oedema to be easily seen. Therefore the difference was expressed as a percentage 
of the dry weight according to the following equation: [Airway oedema= ((wet 
weight-dry weight)/dry weight x 100)].  
2.2.2.2 BICINCHONINIC ACID (BCA) PROTEIN ASSAY 
Total protein content was determined in lavage fluid supernatant using a BCA 
protein assay as per the manufacturer’s instructions (Pierce protein biology). This 
was performed as follows. 10µl of a 1:3 dilution of lavage fluid, PBS or protein 
standard (range 2- 0.025mg/ml) was added to 96 well plate. 200µl of BCA working 
reagent (See Appendix A1.3) was added to each well, covered and put on a plate 
shaker for 30 seconds. The plate was then incubated at 37oC for 30mins. The plate 
was then cooled and read at 540nm on a plate reader. Protein content in lavage fluid 
was determined using an 8 point protein standard curve.  
2.2.3 QUANTIFICATION OF CYTOKINE LEVELS USING ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) 
To quantify the changes in cytokine levels ELISAs were performed on lung 
homogenate and lavage fluid. An initial list of cytokines of interest was determined 
and included the Th2 cytokines IL-4, IL-5 and IL-13, the Th1 cytokine IL-12p70 and 
IFN-γ, TNF-α, IL-10, IL-17 and the chemoattractant IL-8. However, due to the limited 
availability of guinea-pig specific kits an attempt at cross-reacting readily available 
mouse and human antibodies was made. The guinea-pig genome has not been fully 
sequenced yet and so antibodies for other species are not routinely screened for 
guinea-pig protein cross-reactivity. Therefore, cross-reactivity between guinea-pigs 
and mouse and human antibodies is unknown  
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2.2.3.1 BIOINFORMATIC ASSESSMENT OF POTENTIAL SPECIES CROSS REACTIVITY 
To maximise the chances of successful cross-reactivity between non-guinea-pig 
antibodies and guinea-pig proteins, an assessment of the protein sequence 
homology between species was made. Using Pubmed, the protein sequences for 
guinea-pig cytokines of interest were obtained. The homology of these guinea-pig 
sequences to other species was assessed using BLAST. The most homologous species 
to the guinea-pig species protein sequence was selected for cross-reactivity 
screening. Table 2 shows a summary of the results. For full sequence data please see 
Appendix 3. 
Cytokine Role Ab used Homology 
IL-4 Th2 differentiation Mouse 54% 
IL-5 Th2 derived, 
eosinophil recruitment and 
activation 
Human 81% 
IL-13 Th2 derived, AHR Human 79% (predicted) 
IL-12 p70 Pro-inflammatory, 
Th1 differentiation 
Human 85% 
IFN-γ Th1 effector cytokine, anti-
intracellualar pathogen 
Human 71% 
IL-17 (a) ‘exacerbation’ linked Human 81% (predicted) 
IL-10 Anti-inflammatory Human 92% 
IL-8 Neutrophil 
chemoattractant 
Human 82% 
TNF-α Pro-inflammatory Guinea pig N/a 
Table 2: Shows function of cytokines assessed, the species with the closet sequence to the 
guinea-pig protein and the percentage homology between the two. 
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Special consideration for the results obtained using the human IL-8 ELISA kit is 
necessary for rodents. In mice and rats, the functional ortholog CXCL1 (KC) is the 
main neutrophil chemoattractant (Mestas J, Hughes, 2004). Unlike other rodents 
used in research, in the guinea-pig it appears that CXCL8 (IL-8) is the main neutrophil 
chemoattractant, as in humans (Lyons et al, 2004; Gorden et al, 2005). Guinea-pig IL-
8 also signals through the same receptors: CXCR1 and CXCR2 as in humans (Catusse 
et al, 2003; Takahashi et al, 2007). In rats and mice CXCR1 is not present. This would 
suggest that a antibody against human IL-8 would be capable of reacting with the 
guinea-pig homologue. 
2.2.3.2 PERFORMING AN ELISA 
Approximately 100mgs of lung lobes snap frozen in liquid nitrogen and stored at -
80°C were homogenised in Precellys tubes containing 1ml of lysis buffer (see 
Appendix 1.3) for 2x 50 seconds in a Precellys tissue homogeniser. The resulting 
homogenate was then spun at 13,000rpm for 15 minutes at 4°C, aliquoted into tubes 
and stored at -80°C until use. Lavage fluid was stored at -80°C until use. ELISA assays 
were performed using Duoset kit reagents supplied by R&D systems, UK. The major 
steps in this process are shown in Figure 12. In all assays a 96 well maxisorb plate 
was coated overnight at 24°C with 100μl of capture antibody. The following day the 
plate was washed 3 times with 400μl phosphate-buffered saline with tween-20 
(PBST) and blotted dry. To prevent non-specific binding, plates were blocked for 90 
minutes at 24°C with 1x reagent diluent (1% BSA in PBS, R&D systems). Plates were 
washed as previously described. 100μl of samples, standards or 1x reagent diluent 
were added in duplicate to wells and incubated for 2 hours at 24°C. A 7 point 
standard curve with 2-fold serial dilutions were used (refer to Table 4 for details for 
specific cytokines). A wash step was performed as above. Next, 100μl of the 
detection antibody was added to each well and incubated for 2 hours at 24°C. A 
wash step was again performed as described above. Next, 100μl of enzyme labelled 
(HRP-Stepavidin, diluted per manufacturer’s instructions) was added to each well 
and incubated for 20 minutes at room temperature, avoiding direct sunlight. A wash 
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step was then performed. 100μl of enzyme substrate (TMB) was added to each well 
and incubated away from direct sunlight at room temperature for 20-40 minutes 
until the standard curve colour had developed sufficiently. 50μl of stop solution 
(H2SO4) was added to each well to stop the reaction and then gently mixed on a 
plate shaker. Optical densities were determined at 450nm using a plate reader. 
Results were calculated from a 7-point standard curve using softmax pro or 
Microsoft excel. Standard curves with R2 values below 0.95 were excluded. Values 
below the lowest point of the standard curve and therefore indistinguishable from 
blanks were given a value of 0. Lung homogenate cytokine levels were adjusted for 
protein content (performed by BCA protein assay) and expressed as weight per mg 
of lung. 
 
Figure 12: Diagram of the major steps in an enzyme-linked immunosorbent assay (ELISA). 
Step 1: the biological sample is added to a plastic well coated with primary antibody. Step 2: 
The secondary antibody is added and binds to the primary-antibody-sample complex. Step 3: 
Strepavidin-Horse radish peroxidase (HRP) is added and binds to the secondary antibody. 
Step 4: The substrate tetramethylbenzene (TMB) is added and is turned from yellow to blue 
by strepavidin-HRP. The more the colour changes the more protein in the sample there is 
present. 
2.2.3.3 INITIAL SCREENING OF ANTIBODY CROSS REACTIVITY. 
Initial screening of antibody cross-reactivity was performed using neat lavage fluid 
and a 1:2 serial dilution of lung homogenate from acute saline or Ova challenged 
guinea-pigs. ELISAs were performed as per the manufacturer’s instructions. 
Cytokine
Primary
Ab
Secondary
Ab
Strepavidin-
HRP
TMB
Colour
change
Step 1 Step 2 Step 3 Step 4
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Antibodies were considered to cross-react if samples produced higher optical density 
values then blank values and fell within the range of the standard curve. Table 3 
shows the results of these studies. Only IL-13, IL-17 and IL-8 antibodies were found 
to cross-react with guinea-pig proteins in lung homogenate. IL-17 and IL-13 were 
detectable in lavage fluid but not reliably so, only occasionally within the range of 
the standard curve. The lack of detection of the other cytokines could be due to lack 
of cross-reactivity or that the time point at which the lavage fluid and lungs were 
sampled was not optimal for specific cytokine detection. Cytokines differ in their 
temporal profile following allergen challenge. In particular, the levels of IL-8 have 
been shown to be lower at 24 hours post-allergen challenge compared to 4 hours 
post (Danahay et al, 1999). 
Cytokine Ab Lung detection Lavage fluid detection 
IL-4 (mouse) 
 
 
IL-5 (human) 
 
 
IL-13 (human) 
 
 
IL-12 p70 (human) 
 
 
IFN-γ (human) 
 
 
IL-17 (a) (human) 
 
 
IL-10 (human) 
 
 
IL-8 (human) 
 
 
TNF-α (guinea-pig) 
  
Table 3: Shows which of the selected antibodies reacted with guinea-pig specific cytokines. 
Cytokines were considered to be detectable if levels were higher then background and fell 
within the standard curve. Lung homogenate was tested via serial dilution to remove protein 
matrix effects. Lavage fluid was tested neat.  
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2.2.3.4 ELISA OPTIMISATION 
Capture and detection antibody concentrations were optimised for IL-8, IL-13, IL-17 
and TNF-α. Grid optimisations using 3 different standard concentrations (+blanks) 
and varying concentrations of both capture and detection antibody were performed. 
Table 4 shows the final assay conditions for each cytokine assessed.  
Cytokine C: Ab 
conc 
C: Ab 
diluent 
D: Ab 
conc 
D: Ab 
diluent 
Standard 
range 
Standard 
diluent 
TNF-α 4ug/ml PBS 4ug/ml 1% BSA in 
PBS 
2000-
32pg/ml 
1% BSA in 
PBS 
IL-8 8ug/ml PBS 30ng/ml 0.1% BSA 
in TBS-T 
2000-
32pg/ml 
0.1% BSA 
in TBS-T 
IL-13 4ug/ml PBS 300ng/ml 1% BSA in 
PBS 
6000-
94pg/ml 
1% BSA in 
PBS 
IL-17 4ug/ml PBS 150ng/ml 1% BSA in 
PBS 
1000-
16pg/ml 
1% BSA in 
PBS 
Table 4: Shows the final ELISA antibody conditions after optimisation. C: Ab: Capture 
antibody, D: Ab detection antibody. 
 
The dilution of lung homogenate used in ELISAs was also optimised by performing 
1:5 serial dilution curves. This is necessary to overcome the interference of matrix 
factors present in lung tissue which can otherwise obscure the differentiation of 
protein concentrations between groups (Lavoie-Lamoureuxa et al, 2010). Figure 13 
shows the results of these dilution curves. From these dilution curves a dilution in 
the linear range was selected: IL-8: 1/5, IL-13: 1/625, IL-17: 1/25, TNFa: 1/625. 
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Figure 13: Shows the relative optical densities of A) IL-8 B) IL-13 C) IL-17 and D) TNF-α in lung homogenate. Lung homogenate from ovalbumin sensitised 
and challenged and LPS challenged guinea-pigs was serially diluted. Background absorbance was subtracted from absolute ODs. Data presented as the 
mean±SEM.  N=3. 
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2.2.3 HISTOLOGICAL ANALYSIS OF LUNGS 
Histological procedures were carried out on the un-lavaged large lobe of the right 
lung.  
2.2.3.1 TISSUE PROCESSING 
Tissues were removed from formaldehyde and sliced transversely, mid-way down 
the lobe, and the flat-edge of the dissected lobe used to obtain two 1-2mm sections. 
Each section was placed into a tissue cassette and stored in fresh phosphate-
buffered (pH7.3) 10% formaldehyde. 
 
Tissue samples were treated via the following protocol, without removal from 
cassettes. 
50% ethanol (1 hour). 
70% ethanol (1 hour). 
90% ethanol (1 hour). 
100% ethanol (1.5 hours). 
100% ethanol (1.5 hours). 
100% ethanol (1.5 hours). 
Chloroform:100% ethanol 50:50 (overnight). 
100% chloroform (1.5 hours). 
100% chloroform (1.5 hours). 
Molten paraffin (2 hours).  
Molten paraffin (2 hours). 
Molten paraffin (2 hours). 
Tissue cassettes were removed from molten paraffin and samples placed into metal 
mounts. The mount was filled with molten paraffin, the tissue cassette backing 
applied under pressure and the set placed onto a cooling block at -20oC for 10 
minutes. Solidified sections were removed from mounts and excess wax trimmed.  
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Using a microtome, 5µm thick sections were obtained, placed immediately onto 
water (40oC), and fixed onto Polysine® slides. Slides were dried overnight at 300C in 
an oven.  
2.2.3.2 HISTOLOGICAL STAINING 
The following protocol was followed for all samples and staining procedures. Stain-
specific procedures are detailed in sections 2.2.3.2.1 and 2.2.3.2.2  
1. Histoclear® (5 minutes). 
2. Histoclear® (5 minutes). 
3. Histoclear® (5 minutes). 
4. 100% ethanol (3 minutes). 
5. 100% ethanol (3 minutes). 
6. 90% ethanol (3 minutes). 
7. 70% ethanol (3 minutes). 
8. Stain-specific procedures (sections 2.2.3.1 and 2.2.3.2). 
9. 70% ethanol (3 minutes). 
10. 90% ethanol (3 minutes). 
11. 100% ethanol (3 minutes). 
12. 100% ethanol (3 minutes). 
13. Histoclear® (5 minutes). 
14. Histoclear® (5 minutes). 
15. Histoclear® (5 minutes). 
16. Air-dry for 24 hours, mounted using Histomount® and a cover-slip placed on 
top. 
Subsequent to this lung sections were analysed using a Leica DMRAZ microscope. 
Images were acquired using a Leica DC500 camera and Leica QWin software. 
2.2.3.2.1 HAEMATOXYLIN AND EOSIN STAINING 
1. Deparaffinise with Histoclear® and rehydrate through graded ethanol (section 
2.2.3.2 points 1-7). 
2. Running tap water (5 minutes) 
Chapter 2 
 
54 
3. Rinse with distilled water. 
4. Mayer’s haematoxylin (2 minutes). 
5. Running tap water (5 minutes) 
6. Rinse with distilled water. 
7. 1x scotts tap water 
8. Running tap water (5 minutes) 
9. Rinse with distilled water. 
10. 1% Eosin Y (90 seconds).  
11. Dehydrate through graded ethanol and clear with Histoclear® (section 2.2.3.2, 
points 9-16). 
A typical photomicrograph obtained with the HE staining procedure is illustrated in 
Figure 14. Haematoxylin & eosin stain allows for assessment of general lung 
morphology. Sections were blinded to prevent experimenter bias. A semi-
quantitative scoring method was used to assess inflammation in and around the 
bronchi. Each sample was scored for the number of cells on the basis of 3 images. 
The scoring system used was 0=normal lung; 1= minor peribronchiolar (PB) 
inflammation, minimal PB inflammation; 2= slight inflammation in PB area; 3= 
moderate PB inflammation; 4= marked PB inflammation and cuffing. Slight loss of 
lung structure (alevoli etc); 5= severe PB inflammation, cufifng and infiltration. Loss 
of lung structure i.e. solid lung (Barends et al., 2004).  
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Figure 14: Haematoxylin and eosin stained section of guinea-pig lung following acute 
ovalbumin challenge (original magnification 200x). A large bronchiole exhibiting notable 
eosinophilia (bar = 30 µm).  
2.2.3.2.2 ALCIAN BLUE/PERIODIC ACID SCHIFF STAIN 
1. Deparaffinise with Histoclear® and rehydrate through graded ethanol (section 
2.2.3.2 points 1-7). 
2. Distilled water (5 minutes) 
3. 1% Alcian blue dissolved in 3% aqueous acetic acid (pH 2.5) (5 minutes) 
4. Running tap water (5 minutes) 
5. Periodic acid (0.5%) (5 minutes) 
6. Running tap water (5 minutes) 
7. Distilled water (5 minutes) 
8. Schiff’s reagent (10 minutes) 
9. Running tap water (10 minutes) 
10. Mayer’s haematoxylin (20 seconds) 
11. Running tap water (5 minutes) 
12. Dehydrate through graded ethanol and clear with Histoclear® (section 2.2.3.2, 
points 9-16). 
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A typical photomicrograph obtained with the Alcian blue/periodic acid Schiff staining 
procedure is illustrated in figure 15. The Alcian blue/ periodic acid Schiff stain allows 
for the identification of mucin and goblet cells. 
  
Figure 15: Alcian blue/periodic acid Schiff stain stained section following acute ovalbumin 
challenge and 2 pre-ovalbumin LPS inhalations (original magnification 200x). A large 
bronchiole exhibiting goblet cell hyperplasia (bar = 30 µm). 
 
To quantify the number of mucin-associated goblet cells in the epithelium by light 
microscopy and using the program image J. First epithelial area was calculated by 
subtracting the lumen area from the total area of the epithelium and lumen 
combined (shown in Figure 16A). Next the number of goblet cells (Ab/PAS positive 
points, stained dark blue and purple and typical goblet cell morphology) were 
counted (Figure 16B). The following formula was applied to calculate the number of 
mucin-associated goblet cells per 10,000 epithelial pixels.  
 
Mucin per 10,000 = (Number of AB/PAS+ points ÷ Epithelial area) x 10000 
 
Lumen
Smooth 
muscle
Epithelium
Goblet cell
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The resulting values allowed for determination of whether goblet cell hyperplasia 
and metaplasia had taken place.  
 
Figure 16: Alcian blue/periodic acid Schiff stain stained section following acute ovalbumin 
challenge and a single pre-ovalbumin LPS inhalation. A) A large bronchiole exhibiting goblet 
cell hyperplasia (original magnification 100x) B) Airway epithelium with numerous goblet 
cells (original magnification 200x); (bar = 30 µm). 
 
2.2.3.2.3 SIRIUS RED STAIN 
1. Deparaffinise with Histoclear® and rehydrate through graded ethanol (section 
2.2.3.2 points 1-7). 
2. Mayer’s haematoxylin (2 minutes). 
3. Running tap water (2 minutes). 
4. Rinse with 100% ethanol. 
5. Sirius red (2 hours). 
6. Running tap water (2 minutes). 
7. Dehydrate through graded ethanol and clear with Histoclear® (section 2.2.3.2, 
points 9-16). 
A typical photomicrograph obtained with the Sirius Red staining procedure is 
illustrated in Figure 17. Sirius red staining allows for the differentiation of eosinophils 
BA
Smooth muscle
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Goblet cell
Goblet cell
Smooth muscle
Lumen
Lumen
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from neutrophils (Mayerholz et al, 2009). For analysis, 3 bronchioles of comparable 
size were selected and each centered within the field of view at a 200x 
magnification. The number of eosinophils was analysed as the number per field of 
view and per bronchiole area. For the latter, bronchiole perimeter was defined by a 
line around the adventitia and all eosinophils within that area counted (Figure 18). 
Counting the number of eosinophils per bronchiole area minimises the confounding 
effect of bronchiole size on eosinophil counts. For counting, eosinophils were 
defined as cells demonstrating a cytoplasm staining an intense red with dark bi-
lobed nuclei. Neutrophils demonstrated less cytoplasmaic staining and different 
nuclear morphology. Investigator blinding was performed to minimise investigator 
bias. 
 
 
Figure 17: Sirius red stained section of guinea-pig lung following acute ovalbumin challenge 
(original magnification 200x). A An artery in close proximity to a heavily eosinophil-
infiltrated bronchiole (bar = 30 µm). B Two eosinophils with clearly-defined bi-lobed nuclei 
(black arrows; bar = 15 µm). C Clearly differentiated eosinophils (black arrows) and 
neutrophils (purple arrows; bar = 15 µm). 
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Figure 18:  Sirius red stained section of guinea-pig lung tissue showing the area defined as 
bronchiole perimeter. Eosinophils within or in contact with the bronchiolar perimeter were 
eligible for counting. 
2.3 STATISTICAL ANALYSIS 
Student’s t-tests were used for the comparison of differences between groups or 
data points. One way analysis of variance (ANOVA) followed by Dunnet post hoc test 
were used when 2 or more groups were being compared to a control group. * 
P<0.05, ** P<0.01, *** P<0.001. Results are plotted as the mean±standard error of 
the mean (SEM). All lung function data were plotted as a percentage of baseline to 
take into account the individual differences in guinea-pig baseline sGaw values. 
Graphs were drawn using GraphPad Prism 5 and results analysed using Graphpad 
Instat 3. 
 
 
Chapter 3 
 
60 
 
 
 
  
CHAPTER 3 
The Optimisation of an Acute Ovalbumin 
Model of Asthma in Guinea-pigs 
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3.1 Introduction 
3.1.1 Ovalbumin models of asthma 
Allergen challenge models of asthma are created through the initial sensitisation to 
an allergen and subsequent re-encounter of the same allergen. A variety of different 
allergens have been used in a range of species including ragweed, cockroach extract, 
Aspergillus fumigatus, house dust mite and ovalbumin (Ova) (Canning & Chou, 2008). 
The most common allergen used is ovalbumin (Ova), especially in guinea-pigs (Smith 
& Broadley, 2007). A variety of different protocols have been used but generally all 
follow a basic structure. Commonly Ova is administered intraperitoneally with an 
adjuvant such as aluminium hydroxide. Animals are then given several weeks to 
develop an immune response. Re-exposure to Ova, generally by the inhaled route 
then triggers the effector phase. The intraperitoneal route of administration in these 
models has been criticised for its lack of relevance to the likely route of allergen 
sensitisation in humans, the respiratory mucosa. This could lead to differences in the 
immune response (Cates et al, 2007). However, no direct comparison between 
models that use intraperitoneal and respiratory mucosa (house dust mite) 
sensitisation have been performed, so currently this is unknown. Protocols involving 
sensitisation by aerosolised Ova exist but they take up to 4 weeks to achieve 
sensitisation (Nabe et al, 1997).  
Aluminium adjuvants exist as many different salts including aluminium phosphate 
and aluminium hydroxide. The latter is the most commonly used in allergy research 
and exists as several different preparations including powders and gels. Differences 
in the amount of other salts including magnesium hydroxide and the method of 
preparation can alter the immunestimulating capabilities of the adjuvants (Lindblad, 
2004). Aluminium hydroxide performs its action as an adjuvant by several 
mechanisms. It forms bonds with Ova when in solution, which then act as a depot for 
the slow release of antigen. This prolongs the time that antigen, antigen presenting 
cells (APC) and lymphocytes have to interact (Gupta et al, 1993). Additionally, 
aluminum hydroxide is reported to increase the efficiency of antigen uptake by APCs 
Chapter 3 
 
62 
 
by aiding the formation of particles of optimal size (< 10 µm) for APCs (Gupta et al, 
1995). Additionally, adjuvant-allergen pairings act as an inflammatory focus for 
immunocompetent cells (Gupta et al, 1995). Aluminium hydroxide has also been 
shown to favour development of Th2 lymphocyte responses (Cooper, 1994). Th2 
responses in asthmatic patients favour the development of early and late asthmatic 
(EAR and LAR respectively) responses. Finally, aluminium hydroxide activates 
complement and aids the development of B cell memory (Gupta et al, 1995). 
3.1.2 Features of acute ovalbumin models of asthma 
Both acute and chronic Ova models of asthma have been developed. Acute models 
of asthma involve either a single or several allergen challenges. Chronic models of 
asthma typically involve at least 8 allergen challenges over several weeks (Evans et 
al, 2012). Both acute and chronic models typically display an EAR, LAR to the final 
allergen challenge, airways hyperresponsiveness (AHR) and airway inflammation. 
Chronic models also display additional features seen in human asthma such as 
airway remodelling (Rennard, 1996). This makes chronic models useful for 
investigating remodelling processes in asthma. The length of time they take to 
develop (typically over 6 weeks) is a drawback for drug screening. Acute models have 
the advantage of reproducing key functional and inflammatory responses in asthma 
while taking less time to develop. Thus, they represent a good starting point for the 
investigation of the effect of viruses and LPS on these features.  
Early and late asthmatic responses are seen in humans following allergen challenge 
(Booij-Noord et al, 1971).  The EAR is an immediate bronchoconstriction to allergen 
and usually resolves within the first couple of hours. The LAR is a delayed 
bronchoconstriction to an allergen and is observed in the majority of asthmatic 
patients. In humans, this is typically seen 4-8 hours after allergen challenge (Galli et 
al, 2008). Airways hyperresponsiveness (AHR) is another key feature of asthma. AHR 
is an increased response to a bronchoconstrictor stimulus such as histamine 
(Cockcroft & Davis, 2006). The final key feature that acute Ova models demonstrate 
is airway inflammation. In particular eosinophils, macrophages and lymphocytes are 
Chapter 3 
 
63 
 
increased in human asthma (Laitinen et al, 1996). Neutrophils are also important; 
especially in more severe forms of the disease (Taha et al, 2001). Airway 
inflammation can be assessed by bronchoalveolar lavage or histological staining of 
lung sections (Walters and Gardiner, 1991; Grootendorst et al, 1997). Dissociation 
between these indices of airway inflammation has been observed making it useful to 
investigate inflammation using both methods (Barends et al, 2004). 
Several groups have demonstrated isolated characteristics such as AHR, EAR and LAR 
in guinea-pig models (Hutson et al, 1990; Danahay et al, 1999). However, not all 
groups have been able reproduce these features. In particular the LAR has proved 
difficult to achieve under a range of different sensitisation conditions (Everitt & 
Moore, 1992; Underwood et al, 1992). Within this laboratory a model demonstrating 
an EAR, LAR, AHR and airway inflammation to Ova challenge in guinea-pig has been 
developed (Evans et al, 2012). However this model has required optimisation on 
several occasions over the years to continue to produce these features. Lewis et al, 
(1996) modified the allergen challenge conditions to stop the need for mepyramine, 
which prevents fatal anaphylaxis. Smith & Broadley, (2007) modified the 
sensitisation conditions because of the loss of key features over time, increasing the 
amount of Ova used and the number of injections given. This restored the EAR, LAR 
and AHR to Ova challenge. In the present study, modifications to both the challenge 
and sensitisation conditions were made to restore EAR, LAR, AHR and airway 
inflammation. That had again waned by the start of this PhD project. 
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3.2 Hypothesis 
Modifications to the ovalbumin sensitisation and challenge protocol will restore 
functional and inflammatory responses in an acute model of asthma 
3.3 Aims and objectives 
The aim of this chapter was to re-establish an acute guinea-pig model of asthma 
displaying an early and late asthmatic responses, airway hyperresponsiveness and 
airway inflammation as demonstrated by Smith & Broadley, (2007) and Evans et al, 
(2012). By producing these features, subsequent work to investigate the effect of 
viruses, LPS and anti-asthma drugs on these characteristics can be performed. 
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3.4 Methods 
These methods are described in more detail in chapter 2.  
3.4.1 Sensitisation 
Guinea pigs (Dunkin-Hartley, male) were sensitised by an bilateral intra-peritoneal 
injection of a solution containing ovalbumin (Ova) and aluminium hydroxide 
(Al(OH)3) in normal saline on days 1 and 5 (protocol 1 and 2) or 1, 4 and 7 (protocol 
3-7). Please refer to Table `1 or details on the amount of Ova and (Al(OH)3) used in 
each protocol. The solution was stirred for 2 hours previous to injection to ensure 
the formation of Ova-aluminium hydroxide complexes. 
3.4.2 Ovalbumin challenge 
Allergic responses were triggered by inhalation of Ova in a Perspex exposure 
chamber using a DeVilbiss nebuliser for 1 hour. Please refer to Table 1 for 
information on the day of Ova challenge and the concentration. 
3.4.3 Acute challenge protocols 
An acute challenge protocol as per Smith & Broadley, (2007) was used initially as 
described below (protocol 1). Subsequently, modifications were made to the 
protocol to produce an EAR, LAR, AHR and total and differential cell numbers. 
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Protocol 
Ova 
Challenge 
Dose 
No. of 
sensitisati
ons 
Ova 
Sensitisation 
dose 
(Al (OH)3) 
sensitisation 
dose 
Injection 
volume 
Challenge 
day 
Protocol 1 * 0.01% 2 100µg/ml 100mg/ml 1ml Day 15 
Protocol 2 0.03% 2 100µg/ml 100mg/ml 1ml Day 15 
Protocol 3 0.03% 3 100µg/ml 100mg/ml 1ml Day 15 
Protocol 4 0.03% 3 150µg/ml 100mg/ml 1ml Day 15 
Protocol 5 0.03% 3 75µg/ml 50mg/ml 2ml Day 15 
Protocol 6 0.03% 3 75µg/ml 75mg/ml 2ml Day 15 
Protocol 7 0.03% 3 150µg/ml 100mg/ml 1ml Day 21 
Table 1:  Variations made to the acute ovalbumin guinea-pig model as established in Smith & 
Broadley, (2007). * Protocol of Smith and Broadley, (2007). Modifications for each protocol 
are shown in red. 
 
3.4.4 Measurement of lung function 
Guinea-pig airway function was measured using non-invasive double chamber 
plethysmography, using specific airway conductance (sGaw) as a measure of airway 
conductance (Griffiths-Johnson et al, 1988). Lung function was recorded following 
Ova challenge, hourly for 12 hours and every 15 minutes during the first hour of 
measurements. A final measurement was also taken 24 hours post-challenge. All 
values from these readings were expressed as a percentage of the baseline reading, 
taken before Ova challenge. A negative percentage change in baseline value 
represents a bronchoconstriction. To account for differences in the timing of allergen 
responses during the early (0-6 hours) and late (6-12 hours) phases, sGaw was also 
expressed as the peak bronchoconstriction during that period (displayed as a 
histogram next to a time course plot) and area under the curve. 
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3.4.5 Measurement of Airways hyperresponsiveness (AHR) 
AHR was determined using whole body plethysmography. This was performed by 
measuring the bronchoconstrictor response to histamine pre- (day 15) and post-Ova 
challenge (24 hours after Ova challenge). Histamine (0.3mM) was delivered to the 
guinea-pigs by the use of a Buxco nebuliser chamber at a rate of 0.5 LPM per, two 
minutes nebulisation, and 1 minute drying period with a 10% duty setting per 
chamber. Lung function was measured before histamine inhalation and at 0, 5 and 
10 minutes post-histamine exposure.  
3.4.6 Measuring Airway Inflammation 
Following final histamine challenge, guinea-pigs were sacrificed by an intra-
peritoneal overdose of sodium pentobarbitone, the lungs excised and lavaged. Total 
and differential cell counts were then performed. 
3.4.7 Histological analysis of lungs 
Lung lobe samples were stored in formaldehyde and 1-2mm bilateral sections cut. 
Samples were dehydrated in increasing concentrations of alcohol and then 
chloroform. Tissue sections were then set into wax blocks using molten paraffin. 
5µm sections were cut using a microtome and fixed to polysine coated slides. Slides 
were stained using the Sirius red staining protocol which allows the identification of 
eosinophils. The number of eosinophils was counted per field of view and per 
bronchiole. Eosinophils within the perimeter of a bronchiole were included in the 
latter. Eosinophils were defined as cells demonstrating a cytoplasm staining an 
intense red with dark bi-lobed nuclei. 
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3.5 Results 
3.5.1 Protocol 1 
Sensitisation: 2 intra-peritoneal injections of 100µg Ova and 100mg Al(OH)3 
Ova challenge: 0.01% Ova or saline 
 
 
Figure 1: The acute ovalbumin protocol for guinea-pigs exposed to saline or Ova protocol 1.  
 
In Ova challenged guinea-pigs a significant bronchoconstriction was observed 
immediately (-45.6± 6.2%), which did not return to saline challenged levels until 2 
hours post-Ova challenge. This bronchoconstriction was the early asthmatic 
response. No further significant differences between saline and Ova challenged 
sGaw values were observed. Therefore no late asthmatic response was observed 
(Figure 2, time-course). A significant increase in the peak bronchoconstriction during 
the EAR was observed in Ova challenged guinea-pigs, as shown by a significant 
decrease in sGaw compared to saline challenged guinea pigs (-45.6±6.2 compared 
with 2.0±2.6 respectively). No significant difference in the peak sGaw values was 
seen between 6-12 hours (Figure 2, histogram). Throughout the total time course, 
Ova challenged guinea-pigs demonstrated significantly greater area under the curve 
then saline challenged guinea-pigs (97.6±11.1%.hr compared to 10.0±6.1%.hr). This 
1 2       3       4 5 14 15         16
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Al(OH)3 (100mg)
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was also the case for the EAR time points (80.3±9.4%.hr compared to 8.5±5.4%.hr). A 
significant increase in area under the curve (AUC) during the LAR was also seen with 
Ova challenge (17.7±5.0%.hr compared to 1.6±1.0%) (Figure 3). 24 hours after saline 
challenge, guinea-pigs show no significant change in the bronchoconstrictor 
response to histamine compared to before saline challenge (Figure 4A). This was also 
the case for Ova challenged animals (Figure 4B). 
Ova challenge significantly increased total lavage cells (3.2±0.5x106/ml compared to 
saline, 1.6±0.13x106/ml). Eosinophils made up most of this increase (1.3±0.3x106/ml 
compared to saline, 0.05±0.01x106/ml). No changes in any other cell type were 
observed (Figure 5). 
3.5.1.1 Summary 
Guinea-pigs sensitised with 2 injections of 100µg Ova and 100mg aluminium 
hydroxide and subsequently challenged with 0.01% Ova (protocol 1) demonstrated 
an EAR, an increase in total cells and eosinophils in lavage fluid. The protocol did not 
lead to the development of a clear LAR, AHR and increase in macrophages and 
lymphocytes. These results are inconsistent with Smith and Broadley, (2007) and 
Evans et al, (2012). In both studies this protocol induced an EAR, LAR, AHR and 
airway inflammation.  
To restore these features, modifications to the sensitisation and challenge protocol 
were made. Previously, protocol modification has been shown to restore these 
responses (Smith and Broadley, 2007). The first modification made was an increase 
in the allergen challenge concentration from 0.01% to 0.03% Ova, to ensure the full 
allergen response was being triggered. 
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Figure 2: The mean time-course values of sGaw in guinea-pigs sensitised with 2 injections of a suspension of 100µg ovalbumin (Ova) and 100mg aluminium 
hydroxide and challenged with 0.01% Ova or saline. The histogram represents the maximum bronchoconstriction values recorded during early asthmatic 
response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as mean±SEM 
percentage change from baseline. A negative value represents a bronchoconstriction. N=6 (saline), N=5 (Ova); *Significantly different from saline treatment 
p<0.05, *** p<0.001; performed with a two tailed T-test. 
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Figure 3: Area under the curve analysis of bronchoconstrictor responses in guinea-pigs 
sensitised with 2 injections of a suspension of 100µg ovalbumin (Ova) and 100mg aluminium 
hydroxide and challenged with 0.01% Ova or saline. For the purpose of analysis only 
negative peaks were considered and all positive sGaw values were excluded. Total includes 
all negative peaks from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 
hours and late asthmatic response (LAR) includes values from 6-12 hours. Area under the 
curve is measured in %.hour. N=6 (saline), N=5 (Ova).  ***Significantly different from saline 
treatment p<0.001; performed with a two tailed T-test. 
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Figure 4: Response of the airways to nebulised histamine delivered in a plethysmograph 
(0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 minutes, 1 minute drying 
period) in guinea-pigs sensitised with 2 injections of a suspension of 100µg ovalbumin (Ova) 
and 100mg aluminium hydroxide and challenged with A) saline or B) 0.01% Ova. Values were 
recorded 24 hours pre- and post-saline or Ova challenge. Mean changes in sGaw are 
expressed as mean±SEM percentage change from baseline. A negative value represents a 
bronchoconstriction. N=6 (saline), N=5 (Ova); performed with a two tailed T-test. 
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Figure 5: The total cell (A), macrophages (B), eosinophils (C), lymphocytes (D) and 
neutrophils (E) counts in bronchoalveolar fluid in guinea-pigs sensitised with 2 injections of a 
suspension of 100µg ovalbumin (Ova) and 100mg aluminium hydroxide and challenged with 
0.01% Ova or saline. N=6 (saline), N=5 (Ova); **Significantly different from saline treatment 
p<0.01; *** p<0.001; performed with a two tailed T-test. 
Total
0
1
2
3
4 **
Saline Ova P1
N
o
. 
 C
e
lls
 (
x1
0
6
/m
l)
Macrophages
0.0
0.5
1.0
1.5
2.0
2.5
Saline Ova P1
N
o
. 
 C
e
lls
 (
x1
0
6
/m
l)
Eosinophils
0.0
0.5
1.0
1.5
2.0
***
Saline Ova P1
N
o
. 
 C
e
lls
 (
x1
0
6
/m
l)
Lymphocytes
0.000
0.005
0.010
0.015
0.020
Saline Ova P1
N
o
. 
 C
e
lls
 (
x1
0
6
/m
l)
Neutrophils
0.0
0.1
0.2
0.3
0.4
0.5
*
Saline Ova P1
N
o
. 
 C
e
lls
 (
x1
0
6
/m
l)
A
B C
D E
Chapter 3 
 
74 
 
3.5.2 Protocol 2 
Sensitisation: 2 intra-peritoneal injections of 100µg Ova and 100mg Al(OH)3 
Ova challenge: 0.01% (Protocol 1) or 0.03% Ova (protocol 2). 
 
Figure 6: The acute ovalbumin protocol for guinea pigs exposed to Ova protocol 1 or 2. 
 
In both 0.01% and 0.03% Ova challenged guinea-pigs a significant 
bronchoconstriction was observed immediately (-45.6± 6.2% and -60.9±2.1%). No 
significant difference was seen between the times either group took to return to 
baseline levels following Ova challenge. Both these bronchoconstrictions constitute 
the EAR. No further bronchoconstrictions representing the LAR were seen in either 
of the Ova challenged groups (Figure 7, time course). The peak EAR of the 0.03% Ova 
challenged guinea-pigs was significantly increased compared to the 0.01% Ova 
challenged guinea-pigs (-45.6±6.2 and -60.9±2.1% respectively). No significant 
difference in peak sGaw values was seen 6-12 hours post-Ova challenge (Figure 7, 
histogram). Throughout the total time course 0.03% Ova challenged guinea-pigs 
demonstrated significantly greater area under the curve then 0.01% Ova challenged 
guinea-pigs (165.8±15.3%.hr compared to 97.5±9.1%.hr). This was also the case for 
the EAR time point (141.3±6.8%.hr compared to 80.3±7.7%.hr). No difference was 
observed between the two groups at LAR time points (Figure 8) 
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24 hours after 0.03% Ova challenge a significant increase in the immediate 
bronchoconstriction to histamine inhalation compared to the pre-Ova challenge 
sGaw values was observed (-38.5±7.9% compared to -4.1±2.3%). A significant 
bronchoconstriction to histamine was still present 5 minutes post-histamine 
challenge (-2.2±3.1% compared to -18±4.2%). At 10 minutes post-histamine 
exposure sGaw values were no different from pre-Ova challenge values (Figure 9). 
0.03% Ova challenge significantly increased the total cells present in lavage fluid 
(5.3±0.4x106/ml compared to 0.01% Ova, 3.2±0.5x106/ml). Eosinophils were 
significantly elevated (2.0±0.2x106/ml compared to 0.01% Ova, 1.3±0.3x106/ml). No 
changes in any other cell type with Ova challenge were observed (Figure 10). 
3.5.2.1 Summary 
Guinea-pigs sensitised with 2 injections of 100µg Ova and 100mg aluminium 
hydroxide and subsequently challenged with 0.03% Ova (protocol 2) demonstrated 
an EAR, slightly increased in duration, AHR and an increase in total cells, eosinophils 
and macrophages. Thus increasing the allergen challenge concentration 3-fold 
induced AHR and increased airway inflammation.  However, a clear LAR was not 
demonstrated so further modification to the Ova protocol were made. Increasing the 
number of sensitisation injections was shown by Smith & Broadley, 2007 to induce a 
LAR. Therefore the next modification made to the protocol was to increase the 
number of sensitisation injections from 2 to 3.  
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Figure 7: The mean time-course sGaw values in guinea-pigs sensitised with 2 injections of a suspension of 100µg ovalbumin (Ova) and 100mg aluminium 
hydroxide and challenged with 0.01% (protocol 1) or 0.03% Ova (protocol 2). The histogram represents the maximum bronchoconstriction values recorded 
during the early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are 
expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=5 (protocol 1), N=6 (protocol 2) 
*significantly different from protocol 1 p<0.05; performed with a two tailed T-test. 
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Figure 8: Area under the curve analysis of bronchoconstrictor responses in guinea-pigs 
sensitised with 2 injections of a suspension of 100ug ovalbumin (Ova) and 100mg aluminium 
hydroxide and challenged with 0.01% (protocol 1) or 0.03% Ova (protocol 2).  For the 
purpose of analysis only negative peaks were considered and all positive sGaw values were 
excluded. Total includes all negative peaks from 0-24 hours, early asthmatic response (EAR) 
includes values from 0-6 hours) and late asthmatic response (LAR) includes values from 6-12 
hours. Area under the curve is measured in %.hour. N=5 (protocol 1), N=6 (protocol 2) 
***significantly different from protocol 1 p<0.001; performed with a two tailed T-test. 
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Figure 9: Response of the airways to nebulised histamine delivered in a plethysmograph 
(0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 minutes, 1 minute drying 
period) in guinea-pigs sensitised with 2 injections of a suspension of 100ug ovalbumin (Ova) 
and 100mg aluminium hydroxide and challenged with A) 0.01% (protocol 1) or B) 0.03% Ova 
(protocol 2). Values were recorded 24 pre- and post-Ova challenge. Mean changes in sGaw 
are expressed as mean±SEM percentage change from baseline. A negative value represents 
a bronchoconstriction.  N=5 (protocol 1), N=6 (protocol 2) *Significantly different from time 
paired pre-Ova challenge values p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 10: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs sensitised with 2 injections of a suspension 
of 100ug ovalbumin (Ova) and 100mg aluminium hydroxide and challenged with 0.01% 
(protocol 1) or 0.03% Ova (protocol 2). N=5 (protocol 1), N=6 (protocol 2) *Significantly 
different from protocol 1 p<0.05; performed with a two tailed T-test. 
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3.5.3 Protocol 3 
Sensitisation: 3 intra-peritoneal injections of 100µg Ova and 100mg Al(OH)3 
Ova challenge:  0.03% Ova. 
 
Figure 11: The acute ovalbumin protocol for guinea-pigs exposed to Ova protocol 3. 
 
In both guinea-pigs sensitised with protocol 2 & 3 (2 and 3 I.p sensitisation injections 
respectively) and subsequently challenged with Ova a significant bronchoconstriction 
was observed immediately (-60.9±2.15% and -61.9±2.1% respectively). No significant 
difference was observed between the times either group took to return to baseline 
sGaw values following Ova challenge. Both these bronchoconstrictions constitute the 
EAR. No further bronchoconstrictions representing the LAR were seen in either of 
the Ova challenged groups (Figure 12, time course). No significant difference 
between the peak EAR and LAR bronchoconstrictions was seen between groups 
(Figure 12, histogram). No difference in area under the curve was observed between 
the two groups at total, EAR and LAR time points ( 
Figure 13) 
Guinea-pigs sensitised with 3 intra-peritoneal injections of Ova demonstrated a 
significant increase in the bronchoconstrictor response to histamine inhalation 24 
hours after Ova challenge (-28.3±6.0% compared to pre-Ova challenge, -3.9±2.8%). 
This bronchoconstriction to histamine was still present 5 minutes post-exposure (-
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11.8±3.7%) compared to pre-challenge (-2.8±3.7%). At 10 minutes post-histamine 
exposure the guinea-pig sGaw values had recovered to pre-Ova exposure levels. The 
extent of the increased bronchoconstrictor response to histamine was not 
significantly different between groups (Figure 14).  
The addition of a 3rd sensitisation injection did not significantly change total cells or 
any other specific cell populations measured (Figure 15). 
3.5.3.1 Summary 
Guinea-pigs sensitised with 3 injections of 100µg Ova and 100mg aluminium 
hydroxide and subsequently challenged with 0.03% Ova (protocol 3) demonstrated 
an EAR, AHR and airway inflammation. However, a LAR was not observed. Therefore, 
further modifications to Ova protocol were made.  Smith & Broadley, 2007 
demonstrated that an increase in the number of sensitisation injections, increasing 
the Ova concentration in each was can promote a LAR. Therefore the next 
modification made to the protocol was to increase the concentration of Ova in each 
sensitisation injection from 100µg to 150µg/ml.  
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Figure 12: The mean time-course values of sGaw in guinea-pigs sensitised with 2 (protocol 2) or 3 (protocol 3) injections of a suspension of 100µg Ova and 
100mg aluminium hydroxide and challenged with 0.03% Ova. The histogram represents the maximum bronchoconstriction values recorded during the early 
asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as 
mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=6 (protocol 2)’ N=4 (protocol 3; performed with a two 
tailed T-test. 
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Figure 13: Area under the curve analysis of bronchoconstrictor responses in guinea-pigs 
sensitised with 2 (protocol 2) or 3 (protocol 3) injections of a suspension of 100µg Ova and 
100mg aluminium hydroxide and challenged with 0.03% Ova.  For the purpose of analysis 
only negative peaks were considered and all positive sGaw values were excluded. Total 
includes all negative peaks from 0-24 hours, early asthmatic response (EAR) includes values 
from 0-6 hours) and late asthmatic response (LAR) includes values from 6-12 hours. Area 
under the curve is measured in %.hour. N=6 (protocol 2)’ N=4 (protocol 3); performed with a 
two tailed T-test. 
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Figure 14: Response of the airways to nebulised histamine delivered in a plethysmograph 
(0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 minutes, 1 minute drying 
period) in guinea-pigs sensitised with A) 2 (protocol 2) or B) 3 (protocol 3) injections of a 
suspension of 100µg Ova and 100mg aluminium hydroxide and challenged with 0.03% Ova. 
Values were recorded 24 hours pre- and post-Ova challenge. Mean changes in sGaw are 
expressed as mean±SEM percentage change from baseline. A negative value represents a 
bronchoconstriction. N=6 (protocol 2), N=4 (protocol 3); *significantly different from pre-
Ova challenge values p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 15: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs sensitised with 2 (protocol 2) or 3 (protocol 
3) injections of a suspension of 100ug Ova and 100mg aluminium hydroxide and challenged 
with 0.03% Ova. N=6 (protocol 2), N=4 (protocol 3); performed with a two tailed T-test. 
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3.5.4 Protocol 4 
Sensitisation: 3 intra-peritoneal injections of 150µg Ova and 100mg Al(OH)3 
Ova challenge:  0.03% Ova 
 
Figure 16: The acute ovalbumin protocol for guinea-pigs exposed to Ova protocol 4. 
 
Guinea-pigs sensitised with 100µg and 150µg of Ova (protocol 3 & 4 respectively) 
demonstrated a significant bronchoconstriction immediately following Ova challenge 
(-61.9±2.1% and -60.7±4.1%). No significant difference between groups was 
observed during the early phase responses. No significant late phase 
bronchoconstrictions were observed in either group (Figure 17, time course). No 
significant difference in peak early phase bronchoconstrictions was observed 
between groups. No significant late phase bronchoconstriction was observed with an 
increase in the Ova sensitisation dose. (Figure 17, histogram). No significant 
difference in area under the curve was observed between the two groups at total, 
EAR and LAR time points (Figure 18) 
Guinea-pigs sensitised with 150ug of Ova demonstrated a significant 
bronchoconstrictor response to histamine 24 hours after Ova inhalation challenge (-
35.7±8.9% compared to pre-Ova values, -1.4±2.8). A significant bronchoconstriction 
was still present 5 minutes post-histamine challenge (-29.2±6.4% compared to -
0.3±4.5%). At 10 minutes post-histamine exposure guinea-pigs sGaw values were not 
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significantly different from pre-Ova challenge values. No significant difference in the 
post-Ova bronchoconstrictor response to histamine was observed between the 2 
groups (Figure 19). 
Increasing the sensitisation dose of Ova from 100 to 150ug significantly increased 
the total cells present in lavage fluid (8.3±0.9x106/ml compared to 4.8±0.4x106/ml). 
Eosinophils and macrophages were also significantly increased with increased Ova 
during sensitisation (3.9±0.3x106/ml compared to 2.4±0.3x106/ml; 3.5±0.3x106/ml 
compared to, 2.2±0.2x106/ml respectively) (Figure 20).  
3.5.4.1 Summary 
Guinea-pigs sensitised with 3 injections of 150µg Ova and 100mg aluminium 
hydroxide and subsequently challenged with 0.03% Ova (protocol 4) demonstrated 
an EAR, AHR and airway inflammation.  An increase in total cells was observed but 
no LAR. Therefore, further modifications to Ova protocol were made.  To further 
enhance sensitisation to Ova, the concentration of aluminium hydroxide was 
increased to 150mg.  
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Figure 17: The mean time-course values of sGaw in guinea-pigs sensitised with 3 injections of a suspension of 100µg or 150ug ovalbumin (Ova) and 100mgs 
of aluminium hydroxide (protocol 3 & 4 respectively) and challenged with 0.03% Ova. The histogram represents the maximum bronchoconstriction values 
recorded during the early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hour readings. Mean changes in sGaw 
are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=4 (protocol 3), N=5 (protocol 4); 
performed with a two tailed T-test. 
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Figure 18: Area under the curve analysis of bronchoconstrictor responses in guinea-pigs 
sensitised with 3 injections of a suspension of 100µg or 150ug ovalbumin (Ova) and 100mgs 
of aluminium hydroxide (protocol 3 & 4 respectively) and challenged with 0.03% Ova. For 
the purpose of analysis only negative peaks were considered and all positive sGaw values 
were excluded. Total includes all negative peaks from 0-24 hours, early asthmatic response 
(EAR) includes values from 0-6 hours and late asthmatic response (LAR) includes values from 
6-12 hours. Area under the curve is measured in %.hour. N=4 (protocol 3), N=5 (protocol 4); 
performed with a two tailed T-test. 
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Figure 19: Response of the airways to nebulised histamine delivered in a plethysmograph 
(0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 minutes, 1 minute drying 
period) in guinea-pigs sensitised with A) 3 injections of a suspension of 100µg or B) 150ug 
ovalbumin (Ova) and 100mgs of aluminium hydroxide (protocol 3 & 4 respectively) and 
challenged with 0.03% Ova. Values were recorded 24 pre- and post-Ova challenge. Mean 
changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative 
value represents a bronchoconstriction. N=4 (protocol 3), N=5 (protocol 4); **significantly 
different from time paired pre-Ova challenge values p<0.01; performed with a two tailed T-
test. 
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Figure 20: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs sensitised with 3 injections of a suspension 
of 100µg or 150ug ovalbumin (Ova) and 100mgs of aluminium hydroxide (protocol 3 & 4 
respectively) and challenged with 0.03% Ova N=4 (protocol. 3) N=5 (protocol 4); 
*significantly different from protocol 3 p<0.05, ** p<0.01; performed with a two tailed T-
test. 
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3.5.5 Protocol 5 & 6 
Sensitisation: 3 intra-peritoneal injections of 150µg Ova and 100mg or 150mg 
Al(OH)3 in normal saline (protocols 5 & 6 respectively). For protocol 5 and 6, 2mls of 
sensitisation solution was injected bilaterally on days 1, 4 and 7. This prevented 
clogging of the injection syringe due to the increased viscosity of solution. Protocol 5 
was the control for the volume change of the sensitisation solution used in protocol 
6. Increasing the sensitisation solution volume from 1 to 2ml did not significantly 
alter any parameter. These results of the comparison between protocol 4 and 5 can 
be found in Appendix 4.  
Ova challenge:  0.03% Ova 
 
Figure 21: The acute ovalbumin protocol for guinea-pigs exposed to Ova protocol 6. 
 
Guinea-pigs sensitised with 100mg or 150mg of aluminium hydroxide (Protocol 5 & 6 
respectively) demonstrated an immediate bronchoconstriction to Ova (-61.0±5.5% 
and -53.6±4.3%, protocol 5 and 6 respectively). The bronchoconstrictions returned 
to baseline sGaw values 4 hours post-Ova challenge. These bronchoconstrictions 
constitute the EAR. In guinea-pigs sensitised with an increased amount of aluminium 
hydroxide (protocol 6), a second significant bronchoconstriction was observed at 6 
hours (-17.6±4.6%) compared to protocol 5, (-3.8±4.2%). The bronchoconstriction 
returned to baseline sGaw levels by 8 hours. This bronchoconstriction represents a 
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late asthmatic response (Figure 22, time course). Both groups demonstrated similar 
peak EAR. Increasing the sensitisation dose of aluminium hydroxide from 100 to 
150mg significantly increased the peak late phase bronchoconstriction (-17.6±4.6%) 
compared to protocol 5, (-3.8±4.2%) (Figure 22, histogram). No difference in area 
under the curve (AUC) was observed between the two groups at total and EAR time 
points. Although AUC for the late phase showed a trend for an increase this was 
found to be non-significant (Figure 23).  
Guinea pigs sensitised with 150mg of aluminium hydroxide demonstrated a 
significant bronchoconstrictor response to histamine exposure 24 hours post-Ova 
challenge (-37.0±8.1%) compared to pre-Ova challenge, (-5.9±2.1%). A 
bronchoconstriction was still present 5 minutes after histamine exposure (-
19.2±4.7% compared to -9.4±2.2%). 10 minutes after histamine exposure, sGaw 
values  had returned to baseline. No significant difference in the bronchoconstrictor 
response to histamine between groups was observed (Figure 24). 
Increasing the aluminium hydroxide sensitisation dose from 100 to 150mg did not 
significantly increase total cell counts. A significant increase in eosinophils was 
observed (6.9±0.8x106/ml compared to protocol 5, 4.6±0.5x106/ml). Both 
neutrophils and lymphocytes were also significantly elevated (0.15±0.02x106/ml) 
compared to protocol 5 (0.3±0.01x106/ml) (Figure 25). 
3.5.5.1 Summary 
Guinea-pigs sensitised with 3 injections of 150µg Ova and 150mg aluminium 
hydroxide and subsequently challenged with 0.03% Ova (protocol 6) demonstrated 
an EAR, AHR and airway inflammation, with a significant increase in eosinophils, 
lymphocytes and neutrophils. Most importantly, a clear LAR was seen at 6 hours 
post-allergen challenge. This result was further confirmed by the significant increase 
in the peak bronchoconstriction 6-12 hours after Ova challenge. This protocol 
produced all characteristics of asthma desired in an acute model of asthma. Despite 
this, the protocol was found to be unsuitable for further use due to the high dose of 
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aluminum hydroxide and injection volume. The protocol also produced high levels of 
distress to guinea-pigs during Ova challenge. Thus one further modification to the 
protocol was made. The time between the allergen sensitisation and challenge was 
extended from approximately 1 to 2 weeks. 
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Figure 22: The mean time-course values of sGaw in guinea-pigs sensitised with 3 injections of 2ml of a suspension of 150µg Ova and 100mg or 150mg of 
aluminium hydroxide and challenged with 0.03% Ova (protocol 5 and 6 respectively). The histogram represents the maximum bronchoconstriction values 
recorded during the early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hour readings. Mean changes in sGaw 
are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=5; *significantly different from 
protocol 5 p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 23: Area under the curve analysis of bronchoconstrictor responses of in guinea-pigs 
sensitised with 3 injections of 2ml of a suspension of 150µg Ova and 100mg or 150mg of 
aluminium hydroxide and challenged with 0.03% Ova (protocol 5 and 6 respectively). For the 
purpose of analysis only negative peaks were considered and all positive sGaw values were 
excluded. Total includes all negative peaks from 0-24 hours, early asthmatic response (EAR) 
includes values from 0-6 hours and late asthmatic response (LAR) includes values from 6-12 
hours. Area under the curve is measured in %.hour. N=5; performed with a two tailed T-test. 
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Figure 24: Response of the airways to nebulised histamine delivered in a plethysmograph 
(0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 minutes, 1 minute drying 
period) in guinea-pigs sensitised with 3 injections of 2ml of a suspension of A) 150µg Ova 
and 100mg or B) 150mg of aluminium hydroxide and challenged with 0.03% Ova (protocol 5 
and 6 respectively). Values were recorded 24 pre- and post-Ova challenge. Mean changes in 
sGaw are expressed as mean±SEM percentage change from baseline. A negative value 
represents a bronchoconstriction. N=5; **significantly different from time paired pre-Ova 
challenge values ** p<0.01; performed with a two tailed T-test. 
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Figure 25: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs sensitised with 3 injections of 2ml of a 
suspension of 150µg Ova and 100mg or 150mg of aluminium hydroxide and challenged with 
0.03% Ova (protocol 5 and 6 respectively); N=5; *significantly different from protocol 5 
p<0.05, ** p<0.01; performed with a two tailed T-test. 
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3.5.7 Protocol 7 
Sensitisation: 3 intra-peritoneal injections of 150µg Ova and 100mg Al(OH)3 in 1ml 
saline. 
Ova challenge:  0.03% Ova, day 15 (protocol 4) or day 21 (protocol 7) 
 
Figure 26: The acute ovalbumin protocol for guinea-pigs exposed to Ova protocol 7. 
 
Both guinea-pigs challenged on day 15 (-60.7±4.1%) and day 21 (-66.7±4.0%) 
demonstrated a significant bronchoconstriction at 0 minutes post-Ova challenge. In 
guinea-pigs challenged on day 21 the bronchoconstriction to Ova was significantly 
increased at all time points from 45 minutes to 5 hours post-Ova compared to 
guinea-pigs challenged on day 15. In guinea-pigs challenged with Ova on day 21 a 
further bronchoconstriction was observed from 7-9 hours. At 8 and 9 hours this 
bronchoconstriction was significantly increased compared to guinea-pigs challenged 
with Ova on day 15 (-10.7±3.9% compared to 2.0±1.6%; -13.2±7.0% compared to 
7.2±2.2%). This second bronchoconstriction represents a late asthmatic response 
(Figure 26, time course). No significant difference in peak early phase 
bronchoconstrictions was observed between guinea-pigs challenged on day 15 and 
day 21. A significant increase in the peak LAR was observed in guinea pigs challenged 
with Ova on day 21 (-19.9±4.9%) compared to challenge 15, (1.3±2.6%). No 
significant difference in sGaw values was observed 24 hours post-Ova challenge 
(Figure 26, histogram).  
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Figure 28 represents the area under the curve (AUC) analysis for sensitised guinea-
pigs challenged with Ova on day 15 or day 21. A significant increase in the total 
(246±45.9%.hr compared to 86.2±23.7%.hr), EAR (194.2±25.1%.hr compared to 
76.6±18.6%.hr) and LAR (53.1±21.0%.hr compared to 9.6±5.1%.hr) AUC were seen in 
guinea pigs challenged on day 21 compared to day 15.  
Guinea-pigs challenged with Ova day 15 and 21 demonstrated a significant increase 
in the bronchoconstrictor response to histamine, 24 hours post-Ova challenge (-
35.7±8.9% and -53.9.4±11.4%, respectively) compared to pre-Ova challenge (-
10.1±2.4%). In guinea-pigs challenged with Ova on day 15 the bronchoconstriction to 
histamine was not significantly different from pre-Ova sGaw values at 10 minutes. In 
guinea pigs challenged on day 21 a significant bronchoconstriction was still present 
at 10 minutes (-26.7±11.4% compared to 1.6±2.7%) (Figure 29).  
Total cells were not significantly different between groups. Macrophage and 
neutrophils also remained unchanged. Lymphocytes were significantly increased in 
guinea-pigs challenged with Ova on day 21 compared to day 15 (0.37±0.07x106/ml, 
compared to 0.04±0.01x106/ml respectively). Eosinophils were also significantly 
increased (5.5±0.2x106/ml compared to 3.9±0.3x106/ml) (Figure 30). 
3.5.5.1 Summary 
Guinea-pigs sensitised with 3 injections of 100µg Ova and 150mg aluminium 
hydroxide and subsequently challenged with 0.03% Ova on day 21 (protocol 7) 
demonstrated an EAR, LAR, AHR and airway inflammation with a significant increase 
in lymphocytes.  The duration of the EAR increased with the lengthening of the 
sensitisation period. Thus this protocol was able to produce all the required 
characteristics of an acute Ova model. Unlike protocol 6, the allergen challenge was 
well tolerated. On this basis, the protocol was used in all subsequent chapters.  
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Figure 27: The mean time-course values of sGaw in guinea-pigs sensitised with 3 injections of a suspension of 150µg Ova and 100mg aluminium hydroxide 
and challenged with 0.03% Ova on day 15 (protocol 4) or day 21 (protocol 7). The histogram represents the maximum bronchoconstriction values recorded 
during baseline, early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are 
expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction; N=6 *Significantly different to protocol 4 
p<0.05, ** p<0.01; performed with T-test. 
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Figure 28: Area under the curve analysis of bronchoconstrictor response in guinea-pigs 
sensitised with 3 injections of a suspension of 150µg Ova and 100mg aluminium hydroxide 
and challenged with 0.03% Ova on day 15 (protocol 4) or day 21 (protocol 7). For the 
purpose of analysis only negative peaks were considered and all positive sGaw values were 
excluded. Total includes all negative peaks from 0-24 hours, early asthmatic response (EAR) 
includes values from 0-6 hours and late asthmatic response (LAR) includes values from 6-12 
hours. Area under the curve is measured in %.hour. N=6 *Significantly different to protocol 4 
p<0.05; performed with T-test. 
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Figure 29: Response of the airways to nebulised histamine delivered in a plethysmograph 
(0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 minutes, 1 minute drying 
period) in guinea-pigs sensitised with 3 injections of a suspension of 150µg Ova and 100mg 
aluminium hydroxide and challenged with 0.03% Ova on A) day 15 (protocol 4) or B) day 21 
(protocol 7). Values were recorded 24 pre- and post-Ova challenge. Mean changes in sGaw 
are expressed as mean±SEM percentage change from baseline. A negative value represents 
a bronchoconstriction. N=6; *Significantly different from pre-Ova challenge values p<0.05; 
** p<0.01; performed with T-test. 
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Figure 30: The total cell (A), macrophages (B), eosinophils (C), lymphocytes (D) and 
neutrophils (E) counts in bronchoalveolar fluid in guinea-pigs sensitised with 3 injections of a 
suspension of 150µg Ova and 100mg aluminium hydroxide and challenged with 0.03% Ova 
on day 15 (protocol 4) or day 21 (protocol 7). N=6; **significantly different from protocol 4 
p<0.01; *** p<0.001; performed with a two tailed T-test. 
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3.5.7 Tissue eosinophilia 
Figure 31 shows typical photomicrographs for lung sections stained with Sirus red 
(eosinophil stain). Figure 32A shows the number of eosinophils counted per field of 
view. A progressive trend for increased eosinophil numbers was observed with 
cumulative modifications to the Ova sensitisation and challenge protocol. This 
reached significance with protocol 3 (187.4±40.2) compared to saline, (27.0±7.4). 
Protocols 4-7 also significantly increased tissue eosinophilia (173.7±29.1, 180.2±13.0 
and 185.8±20.5 respectively). Figure 32B shows the number of eosinophils per 
bronchiole area. Similar results to eosinophils per field of view were observed. 
Protocol 3-7 all significantly increased tissue eosinophilia compared to saline 
(90.8±5.9, 99.8±5.9, 89.7±15.3, 73.7±8.8 respectively, compared to saline, 9.4±3.4). 
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Figure 31: Guinea-pig lung tissue stained with Sirius red. Sensitisation and challenge varied accordingly A 2 x 100µg Ova/100mg Al(OH)3 with saline 
challenge. B 2 x 100µg Ova/100mg Al(OH)3 with 0.01% Ova challenge (protocol 1). C 2 x 100µg Ova/100mg Al(OH)3 with 0.03% Ova challenge (protocol 2). D 
3 x 100µg Ova/100mg Al(OH)3 with 0.03% Ova challenge (protocol 3). E 3 x 150µg Ova/100mg Al(OH)3 with 0.03% Ova challenge (protocol 4). F 3 x 150µg 
Ova/150mg Al(OH)3 with 0.03% Ova challenge (protocol 6). G 3 x 100µg Ova/100mg Al(OH)3 with 0.03% Ova challenge  on day 21 (protocol 7). Original 
magnification 200x; bar = 50 µm). L: lumen; ASM: airway smooth muscle; E: epithelium. Eosinophils were defined as cells demonstrating a cytoplasm 
staining an intense red with dark bi-lobed nuclei.  
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Figure 32: A) the number of tissue eosinophils (per field of view) and B) (per bronchiole) following varying ovalbumin (Ova) sensitisation and challenge 
protocols. Sal: 2 x 100µg Ova/100mg Al(OH)3 with saline challenge. Protocol 1: 2 x 100µg Ova/100mg Al(OH)3 with 0.01% Ova challenge. Protocol 2: 2 x 
100µg Ova/100mg Al(OH)3 with 0.03% Ova challenge. Protocol 3: 3 x 100µg Ova/100mg Al(OH)3 with 0.03% Ova challenge (protocol 3). Protocol 4 & 5: 3 x 
150µg Ova/100mg Al(OH)3 with 0.03% Ova challenge. Protocol 6: 3 x 150µg Ova/150mg Al(OH)3 with 0.03% Ova challenge. Protocol 7:  3 x 100µg 
Ova/100mg Al(OH)3 with 0.03% Ova challenge  on day 21; N=4-6; **Significantly different to saline  p<0.01; *** p<0.001; performed with one way analysis 
of variance.  
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3.5.8 Results Summary 
Protocol 
EAR LAR AHR Lavage cells Tissue eos 
Saline      
Protocol 1 
 
  Total, eos  
Protocol 2 
 
 
 
Total, eos  
Protocol 3 
 
 
 
Total, eos,  
 
Protocol 4 & 5 
 
 
 
Total, eos, macro 
 
Protocol 6 
   
Total, eos, 
macro, lympho 
 
Protocol 7 
   
Total, eos, 
macro, lympho 
 
Table 2: Shows a summary of the results of ovalbumin protocol modification in guinea-pigs. 
EAR: early asthmatic response; LAR: late asthmatic response; AHR: airways 
hyperresponsiveness; macro: macrophages; eos: eosinophils; lympho: lymphocytes. 
 
Figure 33 demonstrates the variability between guinea-pigs in the timing of the early 
and late asthmatic response to ovalbumin challenge protocol 7. The parallels the 
situation in humans where individuals demonstrate wide differences in the timing 
and duration of early and late responses.  
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Figure 33: The time-course values of sGaw in individual guinea-pigs sensitised with 3 injections of a suspension of 150µg Ova and 100mg aluminium 
hydroxide and challenged with 0.03% Ova on day 21 (protocol 7). Changes in sGaw are expressed as percentage change from baseline. A negative value 
represents a bronchoconstriction. The figure illustrates the individual variability in the early and late asthmatic responses to Ova challenge in guinea-pigs. 
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3.6 Discussion 
This study has shown that by making modifications to the allergen sensitisation and 
challenge conditions, it is possible to induce an early and late asthmatic response, 
AHR and airway inflammation. Sensitisation of guinea-pigs with 2 injections of 100µg 
Ova and 100mg aluminium hydroxide and subsequent Ova challenge on day 15 with 
0.01% Ova (protocol 1) was unable to produce a LAR and AHR. Total cells were 
increased but of the subtypes measured only eosinophils were elevated. Increasing 
the Ova challenge concentration increased the peak of the EAR, induced AHR and 
increased airway inflammation. Increasing the number of sensitisation injections 
resulted in an increase in tissue eosinophilia. Similarly, increasing the Ova 
sensitisation concentration resulted in an increase in total lavage cell counts. Either 
increasing the aluminium hydroxide sensitisation concentration or increasing the 
time between Ova sensitisation and challenge was able to produce a LAR and a full 
inflammatory cell response. The latter modification was better tolerated by guinea-
pigs and thus selected for further work.  
3.6.1 Loss of sensitivity 
There are several possible reasons for the decreased responsiveness over time of 
guinea-pigs to the allergen sensitisation and challenge protocol successfully 
employed by Smith & Broadley, 2007 and Evans et al, 2012.  
Inbreeding which is employed in maintaining the homogeneity of guinea-pig strains 
such as Dunkin-Hartley is one potential cause.  Successive generations of inbreeding 
could lead to an accumulation of certain traits, including decreased activity of the 
immune response. Differences in the various strains of guinea-pigs have been shown 
to significantly alter their immune response to antigen (Ellman et al, 1971; Stone, 
1962). However, given the time frame in which decreased sensitivity to allergen was 
seen (approximately 1 year) it is unlikely that any trait that decreased sensitivity to 
allergen would have sufficient time to become widespread in the suppliers guinea-
pig colony.  
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This loss appears to be unrelated to infection. An intracellular infection could skew 
the T lymphocyte populations in favour of Th1 responses, which do not favour 
allergen sensitisation (Galli et al, 2008). This is unlikely as animals are routinely 
screened for common infections upon arrival from suppliers and none were found. 
The change does not seem to be associated with alterations to the guinea-pig diet or 
environment at both the supplier and animal house in Cardiff. Seasonal changes also 
don’t seem to be a factor as the lack of sensitivity was observed across nearly an 
entire year. 
3.6.2 Model Optimisation 
3.6.2.1 Increasing the ovalbumin challenge concentration 
All guinea-pigs sensitised and challenged with Ova demonstrated an immediate 
bronchoconstriction, indicative of an EAR. Increasing the Ova challenge dose 3-fold 
from 0.01% to 0.03% increased the magnitude of this bronchoconstriction. The EAR 
is mediated by mast cells. Allergen challenge in sensitised animals causes mast cell 
degranulation by the crosslinking of FcεR1 receptors (Gould and Sutton, 2008). 
Degranulation products include histamine, prostaglandins, PAF and leukotrienes 
which cause bronchoconstriction. The increase in bronchoconstriction with 
increasing allergen challenge concentration is possibly a result of either increased 
release of granule products or an increase in the number of mast cells degranulating 
(Dvorak, 2005). A similar increase in the peak EAR bronchoconstriction was seen in 
Smith and Broadley, (2007). This was achieved by increasing the sensitisation 
concentration of Ova 10-fold, indicating that altering sensitisation conditions can 
also increase mast cell degranulation. This was possibly as a result of enhanced 
sensitisation and IgE production (Galli et al, 2008). 
Increasing the Ova challenge concentration also induced AHR. This may be due to 
increased degranulation of mast cells during the EAR. Mast cell products produced 
during the EAR play a role in triggering later events such as lymphocyte activation 
and eosinophil influx. Eosinophils are able to release granule products such as ECP 
which can cause epithelial damage and exposure of underlying sensory nerves, 
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increasing sensitivity to bronchoconstrictor stimuli like histamine (Gleich et al, 1993; 
Laitinen et al, 1987). Concordantly, in the present study eosinophil numbers 
increased along with the development of AHR.  
AHR has been linked to the LAR and also airways inflammation, in particular 
eosinophils (Hargreave et al, 1986). Smith and Broadley, (2007) study supports this 
as AHR was only seen in association with the LAR. In addition, the AHR increased 
with increasing size of the LAR bronchoconstriction. In contrast, in the current study 
dissociation between AHR and the LAR was observed. Dissociation between AHR and 
the LAR has also been observed in humans, although is sometimes due to the 
presence of a hyperresponsive state before allergen challenge (Ward et al, 1987). 
The result in the present study may indicate that alternative mechanisms of AHR 
exist in the model or that higher numbers of eosinophils are required for a LAR.  In 
support of the latter, tissue eosinophilia was not increased with this Ova challenge 
protocol. 
3.6.2.2 Increasing the ovalbumin and aluminum hydroxide sensitisation 
concentrations and number of sensitisation injections 
The general effect of altering the sensitisation conditions was to increase airway 
inflammation. Increasing the number of sensitisation injections from 2 to 3 increased 
the number of tissue eosinophils, whereas increasing the Ova sensitisation 
concentration also increased the total number of lavage fluid cells. Increasing the 
concentration of aluminium hydroxide during sensitisation also produced this effect, 
increasing lavage eosinophils and lymphocytes. This modification also induced the 
development of a LAR.  
These changes are likely the result of increased immune stimulation during 
sensitisation. Increased immune stimulation during sensitisation increases the 
priming of lymphocytes, which produce stronger Th2 responses when re-
encountering an allergen. In accordance with this, increased lymphocyte numbers 
were observed with increased adjuvant. Additionally, eosinophil numbers also 
increased, characteristic of Th2 responses. The adjuvant used, aluminium hydroxide 
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stimulates the immune system during sensitisation via a variety of mechanisms 
including acting as a depot for the slow release of antigen,  optimising allergen size 
for APC uptake, forming an inflammatory focus site and promoting Th2 type 
lymphocyte responses  (Gupta et al, 1993; Gupta et al, 1995; Cooper, 1994). 
Aluminium hydroxide produces these effects in a concentration dependent manner. 
A small amount of adjuvant may be required for antigen absorption but may not 
provide optimal immune stimulation. Jenson and Koch, (1998) showed that there 
needs to be an excess of free adjuvant for these effects. However, there is also a 
maximal concentration at which the adjuvant works. It is speculated that this is 
because only a certain concentration of aluminium hydroxide is necessary for the 
formation of a depot site and stimulation of antigen presenting cells (APC). Beyond 
this the excess crystals may obstruct antigen access by APCs or be toxic to 
macrophages (Munder et al, 1969).  
An increased immune response during sensitisation may also have contributed to 
the development of a LAR. A link between airway inflammation and the LAR is 
known to exist. Asthmatics displaying a LAR and EAR to allergen tend to have higher 
levels of inflammatory infiltrate then asthmatics that only demonstrate an EAR 
(Silvestri et al, 1997). The development of the LAR has been linked specifically to 
increased lymphocyte activity. In humans demonstrating both an EAR and LAR, 
lymphocyte trafficking and IL-5 secretion is increased (Yoshida et al, 2005). 
Eosinophil numbers and activation also increase in asthmatics who demonstrate a 
LAR (Gauvreau et al, 2000). In the present study, the development of a LAR coincided 
with increased lymphocytes and eosinophils. These cells may contribute to this 
delayed bronchoconstriction through the release of substances including PAF, 
leukotrienes and eosinophilic basic proteins (Bradley et al, 1991; Durham and Kay, 
1985).  
3.6.2.3 Increasing the time between allergen sensitisation and challenge 
Increasing the length of time between final sensitisation and allergen challenge 
increased the length of the bronchoconstriction during the EAR. It also increased the 
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number of cells in lavage fluid, especially lymphocytes and eosinophils and produced 
a LAR. This suggests that a longer period between allergen sensitisation and 
challenge is required to generate a full response to allergen. This modification 
restores the gap between sensitisation and challenge to the length of time used in 
this laboratory’s original sensitisation protocol (Lewis et al, 1996). In this protocol, 
one sensitisation injection was given 2 weeks before Ova challenge. Subsequent 
modifications made to the protocol with the addition of a second injection on day 5 
reduced the antibody generation period to 10 days (Smith and Broadley, 2007). The 
addition of 3rd sensitisation injection on day 7 resulted in a further shortening of this 
period to 8 days from the final sensitisation. 
The increase in time between the final allergen sensitisation and challenge likely 
allowed for the development of a fuller immunological response. This response 
involves the production of IgE, which is important in mast cell degranulation. The 
activation of lymphocytes, which act as the orchestras’ of Th2 responses is also 
important (Matsumoto et al, 2002). The generation of a response to sensitisation in 
animal models can take several weeks (Nials & Uddin, 2008). 8 days between 
allergen sensitisation and challenge may not be enough time to produce a full 
response, except when the sensitisation conditions are increased to a certain extent, 
as seen in guinea-pigs sensitised with increased adjuvant concentration. Thus 
extending the length of time between allergen sensitisation and challenge allows 
more time for the development of this response.  
3.6.3 Conclusions 
This study indicates that it is possible to produce an acute Ova model of asthma in 
guinea-pigs displaying a EAR, LAR, AHR and airway inflammation. This model will be 
useful in investigating the effects of virus and LPS on these asthmatic responses.  
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4.1 INTRODUCTION 
4.1.1 VIRAL EXACERBATIONS OF ASTHMA 
Viral infections have been implicated in both exacerbations and the development of 
asthma. How viruses promote the development of asthma is unknown but a range of 
factors including the age of infection and temporal proximity of infection to allergen 
exposure have been implicated (Hansbro et al, 2008). Viruses are also involved in 
asthma exacerbations which are characterised by a worsening of symptoms such as 
wheezing, cough, chest tightness and shortness of breath (Hogg, 1997). Viral 
infections are the leading cause of asthma exacerbations and have been found in the 
lungs of as many as 80% of patients with an asthma exacerbation (Johnston et al, 
1995). Many types of virus have been found including rhinovirus (RV), influenza 
viruses, parainfluenza and respiratory syncytial virus (RSV) (Atmar et al, 1998). RV is 
the most commonly detected virus but parainfluenza viruses (PIV) are also 
frequently found and are the second leading cause of hospitalisation for respiratory 
tract infection in children (Hall, 2001). 
4.1.2 THE EFFECTS OF VIRAL INFECTION ON ASTHMA 
Viral infections in asthmatics induce a range of changes which underlie the 
worsening of clinical symptoms. These changes include increased airway 
hyperresponsiveness (AHR), increased bronchoconstriction to allergen, β-
adrenoreceptor insensitivity, altered neuronal control of the airways and increased 
airway inflammation (Folkerts et al, 1998). Viral infections increase the risk of 
hospitalisation in asthmatics with sensitisation to 1 or more allergens such as house 
dust mite or animal dander. Asthmatics with viral infection but no sensitisation show 
lower rates of hospital admission (Green et al, 2002). This effect is due to synergism 
between allergens and viruses.  
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4.1.2.1 FUNCTIONAL AND STRUCTURAL EFFECTS  
Clinically, AHR is determined by the response to a bronchoconstrictor such as 
histamine or methacholine. Mild asthmatics, inoculated with RV demonstrate an 
increased sensitivity and maximal response to methacholine compared to sham 
infection. These effects persist for 1 week post inoculation (Cheung et al, 1995). 
Changes are also observed in the bronchoconstriction in response to allergen. In 
atopic individuals who only demonstrate an early asthmatic response (EAR) to 
allergen, viral infection increases the likelihood of a late asthmatic response (LAR) 
(Lemanske et al, 1989). This may be due to increases in total and viral specific IgE, 
which facilitate mast cell degranulation (Welliver et al, 1982). One proposed 
mechanisms of these functional effects is a change of the neural control of the 
airways. Several mechanisms have been suggested including an enhancement of 
parasympathetic innervation and decreased activity of non-adrenergic, non-
cholinergic (NANC) neurons. The former constricts the airways and the latter relaxes 
the airways by the release of nitric oxide (Folkerts et al, 1995; Buckner et al, 1985). 
The increased release of neuropeptides, which upregulate leukotriene synthesis and 
mast cell mediator release has also been implicated (Saban et al, 1987).  
Viral infection in asthma can also promote structural changes in the airway. Studies 
of the effects of viral infections have revealed extensive epithelial desquamination, 
thickening of the basement membrane, hylinisation and a distortion of its airway 
structure (Walsh et al, 1961). Mucus plugging is also commonly observed and can 
lead to hyperinflation of the lungs due to air trapping. Viral infection also increases 
the percentages of degranulated mast cells, mucus gland area and numbers of 
neutrophils in the submucosal glands (Carroll et al, 2002). Ciliary function has been 
shown to be decreased in asthmatics following influenza infection and thus may 
serve to facilitate mucus plugging (Camner et al, 1973). In guinea pigs, epithelial 
disruption by parainfluenza-3 leads to significant increases in epithelial permeability 
to allergens and with it, increased allergen exposure (Riedel et al, 1996).  
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4.1.2.2 INNATE IMMUNE RESPONSES  
The innate immune system is the first line of defence against viruses, which are 
recognised by pathogen recognition receptors (PPRs). These receptors are able to 
recognise pathogen associated molecular patterns (PAMPs) that are present on 
viruses. There are several different groups of these receptors including RNA helicases 
and the toll like receptors (TLR). TLRs are predominantly expressed on APCs such as 
dendritic cells and macrophages but are also found on a range of other cell types 
(See and Wark, 2008). Once recognition of a virus has occurred, an anti-viral 
response is mounted which recruits macrophages and neutrophils. Interferons (IFNs) 
are key mediators in this response and induce an anti-viral state in infected cells and 
their neighbours. Interferons are subdivided into two groups: type 1 IFNs include 
IFN-α and IFN-β; type 2 IFNs only include IFN-γ and are only produced during Th1 
adaptive immune responses by CD4+ lymphocytes, CD8+ lymphocytes and natural 
killer cells. The anti-viral activity of IFNs is mediated through the activation of IFN 
stimulated genes (ISG). ISG have a range of effects including negative regulation of 
cell proliferation and inhibition of viral replication (Katze et al, 2002).  
Several changes in the cellular and cytokine profile occur during viral infection in 
asthmatic individuals. The number of neutrophils increase significantly compared 
with asthmatics without infection (Fahy et al, 1995). Respiratory viruses can also 
enhance superoxide responses, chemotaxis and adhesion of neutrophils, which likely 
contribute to a worsening of symptoms (Folkerts et al, 1998). Respiratory infection is 
also able to increase allergen-induced eosinophil recruitment (Calhoun et al, 1994; 
Toward et al, 2005). However, unlike in a non-infected asthmatic where eosinophils 
are the predominant cell type, eosinophil levels can be up to 8x lower than 
neutrophils (Ordonez et al, 2000). Increases are also seen in eosinophil granule 
products including eosinophil cationic protein (ECP), which may contribute to the 
development of AHR (Grünberg et al, 1997). 
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4.1.2.3 ADAPTIVE IMMUNE RESPONSES  
In asthmatics there is a deficiency in the antiviral response, independent of 
corticosteroid use and increases susceptibility to viral infection. Epithelial cells from 
asthmatic airways demonstrate enhanced viral replication and cell lysis. In addition, 
apoptosis which is important in limiting viral replication and the release of 
inflammatory mediators is impaired in the cells of asthmatic subjects. Furthermore, 
production of IFN-β is also reduced in asthmatic airways (Wark et al, 2006). A 
deficient anti-viral defence allows for enhanced viral replication, production of 
inflammatory cytokines and cell damage.  
Asthmatics may demonstrate a deficient anti-viral response for a number of reasons. 
The balance between the two CD4+ subtypes, Th1 and Th2 may be important. Th1 
cells coordinate cytotoxic and antibody responses to viral infection. However, in 
allergic disease a Th2 lymphocyte response predominates and has weak anti-viral 
activity (Moran et al, 1996; Legg et al, 2003). Additionally viruses can also induce Th2 
responses themselves, facilitating their own replication (van Rijt et al, 2005). 
Changes in CD8+ T cells may also contribute to the weak anti-viral immunity. CD8+ T 
cells’ main role during viral infection is the induction of apoptosis of infected cells 
and the secretion of IFN-γ (Cox et al, 2013). However, on a Th2 inflammatory 
background, CD8+ cells switch to a Th2 cytokine secretion pattern, producing IL-4 
and IL-5 (Erard et al, 1993). This phenotypic switch further reduces anti-viral activity 
of CD8+ T cells and contributes to a Th2 polarised response.  
4.1.3 PARAINFLUENZA-3 
4 types of parainfluenza viruses (PIV) are known and are accordingly numbered PIV 
1-4. PIV is an enveloped RNA virus belonging to the family of Paramyxoviridae with 
single stranded, non-segmented negative sense genomes (Voyles, 1993). The basic 
structure of PIV is shown in Figure 1. The envelope glycoproteins consisting of fusion 
protein (F) and hemagglutinin neuraminidase are integral to immunity and 
pathogenesis of these viruses. Like all respiratory viruses, PIV enter and replicate in 
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airway epithelial cells. PIV has an incubation period of 2-8 days, after which it 
replicates in the nasopharyngeal epithelium and 1-3 days later spreads to the lower 
respiratory tract (Hall, 2001).  
Common features of PIV infections in humans are sloughing of the epithelium in the 
small airways, increased mucus secretion, oedema and associated small airway 
obstruction. These manifest themselves in the clinical symptoms of atelectasis, 
hyperinflation and wheezing. Immunological recognition of PIV is mainly via TLR7/8 
(Heil et al, 2004). In guinea-pig models, PIV-3 alone can induce non-specific AHR and 
an increase in airway inflammation (Folkerts et al, 1992b; Toward et al, 2005). 
Within my laboratory, PIV-3 inoculation superimposed on ovalbumin challenge in 
sensitised guinea-pigs has been shown to cause an exacerbation of the responses to 
allergen. In particular, the early asthmatic response to allergen is prolonged and 
merges with the late asthmatic response. Increased airway inflammation, especially 
neutrophils is also seen (Broadley et al, 2008). Studies from this laboratory have 
suggested that this model may be steroid insensitive (Broadley et al, 2009; Broadley 
et al, 2010). This model may serve as a good basis for further investigation into the 
mechanisms of viral exacerbations of asthma and their effect on asthma treatment. 
 
Figure 1: Diagram of the structure of the parainfluenza virus (PIV). Adapted and redrawn 
from Hall, 2001. 
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4.1.3 POLYINOSINIC-POLYCYTIDYLIC ACID (POLY I:C) 
Polyinosinic-polycytidylic acid (Poly I:C) is synthetic double stranded (ds) RNA which 
can mimic certain aspects of viral infection. RNA viruses such as PIV synthesise 
dsRNA during replication, which is recognized by several PAMPs including MDA5 and 
TLR3 (Jiang et al, 2003; Kato et al, 2006). Both signaling pathways are important in 
viral induction of airways inflammation and AHR without a pre-existing allergic 
background (Wang et al, 2011). In particular, signalling through TLR3 creates a local 
cytokine burst which is specific to the cell type and microenvironment, but generally 
consists of type 1 interferons, TNF-α, CCL-2 (MCP-1) and IL-12 (Nicodemus & Berek, 
2010).  
On an allergic background, poly I:C mimics aspects of viral infection and asthma 
exacerbations including increased cellular influx (neutrophils especially), an 
increased Th2 response, AHR and structural remodeling (increased smooth muscle 
mass and goblet cell hyperplasia) in mice and rats (Torres et al, 2010; Takayama et 
al, 2011). The effects of poly I:C in guinea-pigs alone or in parallel with allergen 
challenge have not been investigated. Pilot data from my laboratory suggests that 
poly I:C can induce AHR and invoke a cellular inflammatory response (unpublished). 
Furthermore, the effect of poly I:C on functional allergic responses including the 
early and late asthmatic responses (EAR and LAR respectively) remains to be 
investigated. 
The advantage of using agents such as poly I:C is that they present no risk of 
infection, making them easier to work with. However, agents such as poly I:C are not 
able to replicate themselves so fail to model this aspect of an viral infection.   
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4.2 HYPOTHESIS 
‘PIV-3 infection in sensitised guinea-pigs will exacerbate the functional and 
inflammatory responses to ovalbumin challenge’. 
4.3 AIMS AND OBJECTIVES 
The aim of this chapter was to investigate the functional and inflammatory response 
of PIV-3 and poly I:C in guinea-pigs. Furthermore, the effect of these agents in an 
ovalbumin model of asthma developed in the previous chapter will be determined. 
In particular, the effect of these agents on the early asthmatic response, late 
asthmatic response to Ova challenge, airway hyperresponsiveness, airway oedema 
and airway inflammation will be investigated.   
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4.4 METHODS 
4.4.1 IN VITRO 
4.4.1.1 GENERATION OF PARAINFLUENZA-3 VIRAL TITRES 
BSC-1 cells from African green monkey kidney epithelium were cultured in 75cc 
flasks containing cell media (EMEM, 2mM glutamine, 1% non-essential amino acids 
(NEAA), 10% foetal bovine serum) at 37oc in a CO2 incubator until a confluent 
monolayer formed. At this stage cells were infected with PIV-3 as follows. PIV-3 
stocks were defrosted rapidly from -80oc freezer stocks. BSC-1 culture medium was 
removed from the culture flask, PIV-3 viral stock added and the cells incubated for 5 
minutes at 37oc. BSC-1 culture medium was then re-added and cells returned to the 
incubator. Cells were checked daily for signs of cytopathic effect, when cells start to 
fuse, form multi nucleated bodies (syncytia) and change shape. This first becomes 
visible 24 hours after PIV-3 inculcation and should reach full prominence 2-3 days 
post-inoculation. At this point viral harvest was performed. This was carried out by 
scraping cells from the bottom of the flask, resulting in cell lysis and the release of 
viral particles. Viral media was centrifuged at 1000rpm for 5 minutes at 20oC to 
pellet cell debris, the supernatant aliqouted and subsequently stored at -80oc. Viral 
tire was determined on samples immediately following viral harvest. 
4.4.1.2 DETERMINATION OF VIRAL TITRE 
Viral titre of PIV-3 harvested from BSC-1 cells and the homogenised lungs and lavage 
fluid of PIV-3 infected guinea-pigs (see section 4.4.2 for information on in vivo 
protocols) were determined. Quantitative assessment of viral RNA titres was 
performed in 2 steps, first by isolating and purifying viral nucleic acids and then 
performing reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) 
to convert RNA to cDNA and then amplify it. 
4.4.1.2.1  ISOLATION OF VIRAL RNA 
Lungs required homogenisation before viral nucleic acid isolation. This was 
performed as follows: ~100mg of lung lobe stored on ice was weighed and added to 
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tissue homogeniser tubes (containing microbeads) with 1ml of dPBS. The lung/dPBS 
mixture was homogenised with the use of an automated homogeniser (3x 5 second 
bursts, with 15 second gaps in between).  
  Viral RNA was isolated from lavage fluid, lung and cell media using a high 
pure viral nucleic acid kit supplied by Roche. All reagents in this section were made 
up as per the manufacturer’s instructions and are described in more detail in 
Appendix1.3. Briefly, 200μl of sample (viral media, lung homogenate or lavage fluid) 
was added to sterile, nuclease free tubes, followed by 200μl of working solution 
(50µl Poly A, 2.5ml binding buffer) and 50μl of proteinase K (dissolved in 500μl of 
elution buffer) to digest any remaining protein in the sample. The contents were 
mixed and incubated at 72oC for 10 minutes. Immediately, 100μl of binding buffer 
was added to the sample. Subsequently, the sample was run through a series of filter 
tube centrifugation steps to remove contaminating cellular components. At each 
step the filter tube (containing a glass fibre fleece which binds viral nucleic acid) was 
kept and flow through liquid discarded. Initially the full sample solution was pipetted 
into the upper reservoir of the filter tube. Samples were centrifuged for 1 minute at 
8,000g in between each step. These steps are shown in Figure 2. The flow through 
liquid from the last step contained isolated viral nucleic acid and was stored at -80oC 
until RT-qPCR was carried out. 
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Figure 2: Schematic of the method used to isolate viral nucleic acid from cell culture 
medium, lavage fluid and homogenised lung. 
4.4.1.3 RT-QPCR  
Reverse transcriptase- quantitative polymerase chain reaction (RT-qPCR) was carried 
out to convert viral RNA into cDNA for amplification and quantitative determination 
of viral titres. Conversion of viral RNA into cDNA was carried out using a superscript 
first-strand synthesis system kit supplied by Invitrogen, which is capable of 
converting 1ng-5ng of RNA into 1st strand cDNA.  Samples were defrosted on ice and 
RNA/primer mixtures prepared as described in Table 1. This primer mix provides the 
substrates and catalysts necessary for the production of cDNA from RNA. An RT 
negative control was used to show that cDNA amplification is not due to DNA 
contamination before the reverse transcriptase step. An RT positive control was used 
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to demonstrate a successful reverse transcription step. The RT H20 sample 
demonstrates the purity of RT water.  
Components Sample -RT Control +RT Control RT H20 
<5µg total RNA 8 µl 8µl - - 
Control RNA (50ng/µl) - - 1µl - 
10mM dNTP mix 1µl 1µl 1µl 1µl 
RT primer mix 1µl 1µl 1µl 1µl 
DEPC-treated water - - 7µl 8µl 
Table 1: Reagents used to produce cDNA from RNA for viral samples and controls. dNTP: 
deoxyribonucleotide triphosphate; DEPC : deionised, diethylpyrocarbonate, RT: reverse 
transcription. 
 
RNA/primer mixtures were added to their respective nuclease free, sterile tube and 
run through a series of thermal cycling steps using a thermocycler. The conditions 
used at each step are shown in Figure 3. During step 2, samples were placed on ice 
and a reaction mix containing 2µl of 10x RT buffer, 4µl 25mM MgCl2, 2µl 0.1mM 
dithiothreitol (DTT) and 1µl of RNase out. This mixture aids the work of the 
superscript enzyme and prevents the cleavage of RNA by RNAses. After step 3, 1μl 
(50U) of superscript was added to all tubes except the RT negative control. Following 
the conclusion of thermal cycling, samples were briefly centrifuged and chilled on ice 
for commencement of cDNA amplification. 
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Figure 3: The timing and temperatures used on a thermocycler to convert RNA to cDNA. 
 
cDNA was amplified using q-PCR performed in a thermo light-cycler. Reaction mixes 
were prepared by the addition of 10µl PCR grade water, 4µl of 5x conc master mix 
(both from Roche, Switzerland) and PIV-3/β-actin cDNA primers (Primer design, Ltd). 
To 5µl of DNA template in a chilled capillary tube and centrifuged for 5 seconds at 
700g. Samples were run using the following parameters: 1 pre-incubation cycle at 
95oc for 10mins, 50 amplification cycles at 95ºc for 10 seconds, 60oc for 60 seconds 
and finally a cooling step at 40oc for 30 seconds. The light cycler software calculates 
the individual virus particles per μl which is then converted into virus particles per 
ml. 
 
65C  for 5 min
4C  for 1 min 
25C  for 2 min
25C  for 10 min 
42C for 50 min
70C  for 15 min
4C for 15 min
Add reaction mix
Add superscript
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4.2.2 IN VIVO METHODS 
4.2.2.1 PARAINFLUENZA-3 INFECTION PROTOCOL 
Guinea-pigs (300-400g, male, Dunkin Hartley) were inoculated intranasally with 
125µl per nostril of PIV-3 (1x107-109 viral particles per ml) or media on day 2 and 3. 
The airway response to histamine was tested on days 1 and 7 of the protocol 
(described in more detail in section 4.2.2.5). Bronchoalveolar lavage (BAL) was 
performed on day 7 of the protocol, following post-virus AHR assessment (Figure 4).  
 
 
Figure 4: Diagram of the 7 day PIV-3 protocol. I.n: intra-nasal; BAL: bronchoalveolar lavage. 
 
4.2.2.2 ACUTE OVALBUMIN AND PIV-3 PROTOCOL 
Guinea-pigs (300-400g, male, Duncan Hartley) were sensitised on days 1, 3 and 7 
with 150μg ovalbumin (Ova) and 100mg aluminium hydroxide. The airway response 
to histamine was tested on days 15 and 22 of the protocol (described in more detail 
in section 4.2.2.5). Guinea-pigs were Intranasally administered 125µl per nostril of 
PIV-3 (1x107-109 viral particles per ml) or media on days 17 and 18. The effector 
phase of asthma was elicited on day 21 by challenging sensitised guinea-pigs to 
0.03% Ova for 1 hour in an exposure chamber. Lung function was then measured 
over 12 hours (described in more detail in section 4.2.2.4). 
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Histamine 
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I.n. media/PIV-3
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BAL was performed on day 22 of the protocol, following post-Ova AHR assessment 
(Figure 5). 
 
Figure 5: Diagram of the 22 day ovalbumin (Ova) and PIV-3 protocol. I.n: intra-nasal; BAL: 
bronchoalveolar lavage. 
 
4.2.2.3 POLY I:C PROTOCOL 
Guinea pigs (300-400g, male, Duncan Hartley) were inoculated with poly I:C (125 or 
500μg) intranasally on day 2, 3 and 4. The airway response to histamine was tested 
on days 1 and 5 (described in more detail in section 4.2.2.5). BAL was performed on 
day 5 of the protocol, following post-poly I:C AHR assessment (Figure 6).  
 
 
Figure 6: Diagram of the 5 day Poly I:C protocol. I.n: intra-nasal; BAL: bronchoalveolar 
lavage. 
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4.2.2.4 MEASUREMENT OF LUNG FUNCTION 
Guinea-pig airway function was measured using non-invasive double chamber 
plethysmography, using specific airway conductance (sGaw) as a measure of airway 
conductance (Griffiths-Johnson et al, 1988). In Ova challenged groups, lung function 
was recorded hourly for 12 hours and every 15 minutes during the first hour of 
measurements following Ova challenge. A final measurement was also taken 24 
hours post-challenge. All values from these readings were expressed as a percentage 
of the baseline reading, taken before Ova/poly I:C challenge. A negative percentage 
change in baseline value represents a bronchoconstriction. To account for 
differences in the timing of allergen responses between animal values for the early 
(0-6 hours) and late (6-12 hours) phases were expressed as the peak 
bronchoconstriction during that period (displayed as a histogram next to a time 
course plot) and area under the curve. 
4.2.2.5 MEASUREMENT OF AIRWAYS HYPERRESPONSIVENESS (AHR) 
AHR was determined using whole body plethysmography. This was performed by 
measuring the bronchoconstrictor response to histamine pre- and post-PIV-3/Poly 
I:C exposure. Histamine (0.3mM) was delivered to the guinea-pigs by the use of 
Buxco nebuliser chamber at a rate of 0.5 LPM, two minute nebulisation, and 1 
minute drying period with a 10% duty setting per chamber. Lung function was 
measured just before histamine inhalation and at 0, 5 and 10 minutes post-
histamine exposure.  
4.2.2.6 MEASURING AIRWAY INFLAMMATION 
Following the final histamine inhalation challenge, guinea-pigs were sacrificed by an 
intra-peritoneal overdose of sodium pentobarbitone, the lungs excised and lavaged. 
Total and differential cell counts were then performed. 
4.2.2.7 MEASURING AIRWAY OEDEMA 
Lung oedema was determined by comparison of lung wet weight with dry weight. 
The 3rd largest lobe of the right lung was weighed following excision from the guinea-
pig and then dried overnight in an oven at 40oC. The lobe was again weighed. The 
difference between the wet and dry weight was expressed as a percentage of the dry 
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weight according to the following formula [Airway oedema= ((wet weight-dry 
weight)/dry weight x 100)]. 
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4.5 RESULTS 
4.5.1 THE EFFECT OF PIV-3 ON AIRWAY RESPONSES TO HISTAMINE, LUNG 
OEDEMA AND INFLAMMATORY CELLS. 
 
Intranasal media inoculation did not cause a significant increase in the 
bronchoconstrictor response to histamine. PIV-3 inoculation resulted in a non-
significant immediate increase in the bronchoconstrictor response to histamine, 
reaching significance 5 minutes post-histamine challenge (-25.9±5.7% compared to 
pre-PIV-3 values, -9.5±1.1% respectively). A bronchoconstriction was still present 10 
minutes after the histamine challenge (-25.3±4.3% compared to 0.5±3.0% 
respectively) (Figure 7). 
 
PIV-3 inoculation significantly increased lung oedema compared to media inoculated 
control animals (410±13.2% compared to 317.0±13.4% respectively) (Figure 8). 
 
PIV-3 inoculation resulted in a significant increase in airway inflammation. Total 
lavage cells were significantly increased in PIV-3 treated guinea-pigs compared to 
media (3.5±0.23x106/ml, 1.6±0.27x106/ml respectively). This was also true for 
macrophage numbers (3.04±0.19x106/ml compared to 1.44±0.26x106/ml 
respectively), eosinophil numbers (0.20±0.05x106/ml compared to 0.09±0.02x106/ml 
respectively), neutrophil numbers (0.09±x0.02x106/ml compared to 
0.01±0.003x106/ml respectively) and lymphocyte numbers (0.02±0.06x106/ml 
compared to 0.01±0.004x106/ml respectively) (Figure 9). 
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Figure 7: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs inoculated with 2 intranasal doses of A) PIV-3 (1x107-109 viral particles per ml) or B) media. Values were 
recorded 24 hours pre- and 4 days post- first inoculation. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative 
value represents a bronchoconstriction. N=12 (media), N=5 (PIV-3); *Significantly different from time paired pre-challenge values p<0.05, ** p<0.01; 
performed with a two tailed T-test. 
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Figure 8: Lung oedema in guinea-pigs inoculated with 2 intranasal doses of PIV-3 (1x107-109 
viral particles per ml) or media, 4 days after the initial inoculation. Oedema is expressed as 
((lung wet weight- lung dry weight)/dry weight x100). Lung weight measured following lung 
excision (wet) and overnight drying in an oven at 40oC (dry). N=12 (media), N=5 (PIV-3) 
**Significantly different from time media p<0.01; performed with a two tailed T-test. 
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Figure 9: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil (E) 
counts in bronchoalveolar fluid in guinea-pigs inoculated with 2 intranasal doses of PIV-3 
(1x107-109 viral particles per ml) or media, 4 days after the initial inoculation. N=12 (media), 
N=5 (PIV-3); *significantly different from media p<0.05, ** p<0.01; *** p<0.001; performed 
with a two tailed T-test. 
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4.5.2 THE EFFECT OF PIV-3 ON OVA-INDUCED FUNCTIONAL AND 
INFLAMMATORY RESPONSES 
In both media and PIV-3 treated guinea-pigs a bronchoconstriction was observed at 
0 minutes post-Ova challenge (-58.8±4.0% and –55.1±3.7% respectively). This 
bronchoconstriction was the early asthmatic response. Both groups also displayed 
evidence of a late asthmatic response between 6-12 hours. No significant difference 
was observed between the 2 groups at the 0 minute time point, or during the further 
12 hours of lung function measurement (Figure 10, time course. No significant 
difference between the EAR and LAR peak values was found for media and PIV-3 
inoculated guinea-pigs (Figure 10, histogram). Similarly, no difference in area under 
the curve was observed between the two groups at total, EAR and LAR time points 
(Figure 11).  
Ova challenge with media inoculation produced a significant increase in the 
bronchoconstrictor response to histamine, when compared to sGaw values pre-Ova 
challenge (-20±4.2% compared to 0.6±3.5%). At 5 minutes post-histamine challenge, 
this bronchoconstriction was no longer significantly different from pre-Ova challenge 
values. In guinea-pigs challenged with Ova, inoculated with PIV-3 a significant 
bronchoconstriction was observed at 0 minutes, compared to pre-Ova challenge 
values (-15.5±3.9% compared to 0.6±2.3%). A bronchoconstriction was still present 
at 5 (-16.7±3.2% compared to -3.1±2.6%) and 10 minutes (-20.2±2.9% compared to 
3.1±3.1%) (Figure 12).  
No significant difference in oedema in the two groups was observed (Figure 13). PIV-
3 inoculated guinea-pigs challenged with Ova demonstrated a non-significant trend 
for increased total lavage cell number compared to media inoculated guinea-pigs. 
There was a significant increase in eosinophil numbers, compared to media 
inoculated guinea-pigs (3.8±0.34x106/ml compared to 2.7±0.23x106/ml respectively). 
Neutrophil, macrophage and lymphocyte numbers were unchanged (Figure 14).  
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Figure 10: The mean time-course values of sGaw in ovalbumin (Ova) sensitised guinea-pigs inoculated with 2 intranasal doses of PIV-3 (1x107-109 viral 
particles per ml) or media, 3 days before subsequent inhalation Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage change from 
baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=10 (Ova + media), N=16 (Ova + PIV-3); performed with a two tailed T-
test. 
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Figure 11: Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) inhalation challenge in guinea-pigs inoculated with 2 intranasal doses of PIV-3 (1x107-
109 viral particles per ml) or media. For the purpose of analysis only negative peaks were 
considered and all positive sGaw values were excluded. Total includes all negative peaks 
from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 hours and late 
asthmatic response (LAR) includes values from 6-12 hours. Area under the curve is expressed 
as %.hour; N=10 (Ova + media), N=16 (Ova + PIV-3); performed with a two tailed T-test. 
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Figure 12 Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in ovalbumin (Ova) sensitised guinea-pigs inoculated with A) 2 intranasal doses of PIV-3 (1x107-109 viral particles per ml) or 
B) media, 3 days before subsequent Ova inhalation challenge. Values were recorded 24 hours before the first inoculation and 24 hours post- Ova challenge. 
Mean changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. * Significantly 
different from time paired pre-challenge values; N=10 (Ova + media), N=16 (Ova + PIV-3); performed with a two tailed T-test. 
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Figure 13: Lung oedema in ovalbumin (Ova) sensitised guinea-pigs inoculated with 2 
intranasal doses of PIV-3 (1x107-109 viral particles per ml) or media, 3 days before 
subsequent Ova inhalation challenge. Oedema is expressed as ((lung wet weight- lung dry 
weight)/dry weight x100). Lung weight measured following lung excision (wet) and overnight 
drying in an oven at 40oC (dry). N=10 (Ova + media), N=16 (Ova + PIV-3); performed with a 
two tailed T-test. 
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Figure 14: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in ovalbumin (Ova) sensitised guinea-pigs inoculated with 
2 intranasal doses of PIV-3 (1x107-109 viral particles per ml) or media, 3 days before 
subsequent to Ova inhalation challenge. N=10 (Ova + media), N=16 (Ova + PIV-3); performed 
with a two tailed T-test. 
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4.5.3 A RE-EVALUATION OF THE EFFECT OF PIV-3 ALONE ON AIRWAY LUNG 
FUNCTION AND AIRWAY INFLAMMATION. 
Because PIV-3 failed to enhance the responses to Ova, it was decided to re-examine 
the effects of PIV-3 alone. Media inoculation failed to produce a significant increase 
in bronchoconstriction in response to histamine, when compared to sGaw values 
prior to media inoculation. PIV-3 inoculation also did not change the 
bronchoconstrictor response to histamine (Figure 15). PIV-3 inoculation produced a 
significant increase in oedema when compared to media inoculated animals 
(404.8±10.6% compared to 317.0±13.4%) respectively (Figure 16). PIV-3 inoculation 
did not significantly increase any of the cell types in lavage fluid measured when 
compared to media inoculated guinea-pigs (Figure 17).  
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Figure 15: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs inoculated with 2 intranasal doses of PIV-3 (1x107-109) or media. Values were recorded 24 hours pre- and 4 
days post- first inoculation. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative value represents a 
bronchoconstriction. N=6; performed with a two tailed T-test. 
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Figure 16: lung oedema in guinea-pigs inoculated with 2 intranasal doses of PIV-3 (1x107-109) 
or media, 4 days after the initial inoculation. Oedema is expressed as ((lung wet weight- lung 
dry weight)/dry weight x100). Lung weight measured following lung excision (wet) and 
overnight drying in an oven at 40oC (dry). **Significantly different from media p<0.01; N=6; 
performed with a two tailed T-test. 
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Figure 17: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs inoculated with 2 intranasal doses of PIV-3 
(1x107-109 viral particles per ml) or media, 4 days after the initial inoculation N=6; performed 
with a two tailed T-test. 
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4.5.4 RESULTS OF RT-QPCR ANALYSIS ON LUNG AND LAVAGE FLUID SAMPLES 
Table 2 shows the results of RT-qPCR analysis of lung and lavage samples from PIV-3 
and media inoculated guinea-pigs. Large numbers of viral particle per ml were found 
in guinea-pigs inoculated with PIV-3 in the first experiment in the chapter. In 
subsequent experiments (Ova + PIV-3 and PIV-3 alone (repeat) viral particles per ml 
were considerably reduced. The reference product, β-actin displayed consistent 
levels for both lung and lavage fluid samples.  
 
Per x106/ml of 
PCR product 
Media PIV-3 1st exp PIV-3 2nd exp Ova + PIV-3 
Lung PIV-3 0.023±1.489 62.49± 39.13 0.287±0.108 0.69±0.304 
Lung β-actin 41.25±9.02 43.31±11.06 52.79±27.95 32.46±3.967 
Lavage fluid –
PIV3 
0.018 ±1.244 2.92±  1.58 0.35±0.24 0.45±0.158 
Lavage fluid - 
β-actin 
0.35±0.08 0.38±0.04 0.428±0.1 0.33±0.03 
Table 2: Shows the amount of PCR product recovered from lung and lavage fluid for PIV-3, 
media and PIV-3 and ovalbumin treated guinea-pigs. β-actin represents a reference gene 
product. Data are displayed as PCR product x106 per ml.  
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4.5.5 THE EFFECT OF POLY I:C ON AIRWAY HYPERRESPONSIVENESS TO 
HISTAMINE, LUNG OEDEMA AND INFLAMMATORY CELLS. 
Saline and the lower dose of poly I:C did not significantly increase the 
bronchoconstrictor response to histamine. 500μg of poly I:C (125µg) did not 
significantly increase the immediate response to histamine challenge post-poly I:C 
administration. At 10 minutes post-histamine inhalation a small increase in this 
response was observed (-9.4±2.2% compared to pre-poly I:C, -1.9±1.9%) (Figure 18).  
 
A significant increase in lung oedema was observed in guinea-pigs treated with 
125µg poly I:C compared to saline treated guinea-pigs (512±75% compared to 
313±17%). Although a trend for increased oedema was observed in guinea-pigs 
treated with 500µg poly I:C, this was not significant (Figure 19).  
 
Although total cells were unchanged between all groups, an increase in neutrophils 
in guinea-pigs treated with low dose poly I:C compared to saline was seen 
(0.3±0.13x106 compared to 0.03±0.01x106 respectively). No other significant 
difference in cell numbers was observed (Figure 20).  
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Figure 18: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles with 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs pre-and post-.administration of 3 intranasal doses of A) saline, B) 125μg poly I:C or 500μg poly I:C. Mean 
changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=6 (Saline), N=6 
(125μg poly I:C), N=9 (500μg poly I:C); *significantly different from time paired pre-Ova challenge values p<0.05; performed with a two tailed T-test. 
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Figure 19: Lung oedema in guinea-pigs administered 3 intranasal doses of poly I:C (125μg or 
500μg) or saline. Oedema is expressed as ((lung wet weight- lung dry weight)/dry weight 
x100). Lung weight measured following lung excision (wet) and overnight drying in an oven 
at 40oC (dry). N=6 (Saline), N=6 (125μg poly I:C), N=9 (500μg poly I:C); **Significantly 
different from saline p<0.01; performed with one-way analysis of variance followed by 
Bonferroni post-test. 
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Figure 20: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs administered 3 intranasal doses poly I:C 
(125μg or 500μg) or saline. N=6 (Saline), N=6 (125μg poly I:C), N=9 (500μg poly I:C);  
*Significantly different from saline p<0.05; performed with one-way analysis of variance 
followed by Bonferroni post-test. 
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4.6 DISCUSSION 
4.6.1 EFFECT OF PIV-3 IN GUINEA-PIGS 
PIV-3 infection in guinea-pigs resulted in an increase in the bronchoconstrictor 
response to histamine, airway oedema and airway inflammation. These results are in 
accordance with Toward et al, (2005) and Broadley et al, (2009). Increases in airway 
response to bronchoconstrictor stimulus such as histamine have been reported by 
several other groups and various mechanisms implicated. Folkerts et al, (1995) 
reported that the development of AHR following PIV-3 infection is related to a 
deficiency in nitric oxide. This was prevented by the administration of nitric oxide 
donor compounds. Inflammatory cells have also been implicated in AHR to PIV-3. 
Folkerts et al, (1992A) demonstrated that ex vivo contractility to histamine in 
tracheal spirals increases when incubated with lavage cells from PIV-3 treated 
guinea-pigs, In particular, incubation with eosinophils which increase significantly 
with PIV-3 infection. Treatment with an antibody to IL-5, a key cytokine in eosinophil 
biology is able to abolish AHR (van Oosterhout et al, 1995). In the present study, a 
significant increase in eosinophilia was also observed but also in several other 
inflammatory cells including lymphocytes, neutrophils and macrophages. In vitro, 
macrophages can significantly increase their production of reactive oxygen species 
which can directly cause epithelial damage (Henricks et al, 1993). This can expose 
the sensory nerves, smooth muscle and also remove a source of spasmogen 
metabolisers, promoting AHR (Folkerts & Nijkamp, 1998). Depletion of spamogen 
metabolisers such as diamine oxidase which metabolises histamine may lengthen 
the response to histamine. In the present study a prolonged bronchoconstrictor 
response to histamine was observed suggesting a decrease in diamine oxidase 
activity. Disruption of sensory nerves due to inflammation may also promote AHR. In 
particular, the M2 receptor has been reported to lose its function with PIV-3 
infection, decreasing pre-synaptic feedback inhibition of cholinergic responses 
(Adamko et al, 1999). 
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4.6.2 EFFECT OF PIV-3 IN AN ACUTE OVALBUMIN MODEL OF ASTHMA 
PIV-3 infection superimposed on ovalbumin challenge increased the duration of the 
bronchoconstrictor response to histamine and the number of eosinophils recovered 
in lavage fluid. However, it did not significantly alter the EAR and LAR. Previously in 
this laboratory, this protocol resulted in an increase in the length of the EAR, 
merging with the LAR. This effect is possibly mediated by increased histamine 
release from basophils and mast cells, which is increased by PIV (Graziano et al, 
1989). Alternatively, an increase in the uptake and response to allergens induced by 
viral infection may mediate this effect (Freihorst et al, 1989). Also unlike Broadley et 
al, 2008, no overall increase in total lavage cells and neutrophils was found. An 
increase in neutrophils is commonly reported during viral infection in asthmatics 
(Fahy et al, 1995). Increases in eosinophil numbers have been observed in both 
humans and animal models (Calhoun et al, 1994; Toward et al, 2005). Eosinophil 
numbers may be increased due to CCL11 (eotaxin-1), which is reported to increase 2-
3 days post-PIV-3 infection (Scheerens et al, 1999). Respiratory viruses can also 
promote Th2 lymphocyte development which favours eosinophilic inflammatory 
responses (Openshaw & O’Donnell, 1994). The results of this study were confirmed 
on several repeat studies. The lack of a full exacerbation response to PIV-3 was 
considered to be due to a diminished responsiveness to PIV-3. Therefore the effects 
of PIV-3 alone were re-examined with a new batch of virus. This repeat showed no 
AHR, oedema and airway inflammation. This loss of response was found to be 
associated with decreased viral titres recovered from the lavage fluid and lungs of 
PIV-3 infected animals.  
 
4.6.3 LOSS OF RESPONSE TO PIV-3 
The reasons for a diminished response to PIV-3 are unknown although there are 
several possible explanations. The first is a delivery problem with the intranasal 
method of administration, without anaesthetic. The distribution of fluid deposition 
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between the lungs can differ widely depending on small changes in animal handling 
and the use of anaesthetic (Southam et al, 2002). PIV-3 inoculation was unable to be 
carried out under anaesthetic due to anti-viral effects of common inhaled 
anaesthetics such as isoflorane (Belvisi, 2009). Problems with this route of 
administration are unlikely though as the change in response to PIV-3 occurred with 
the same animal handler, employing the same inoculation method throughout 
experiments. In addition, this route has previously been shown to result in active 
infection under a number of investigators (Toward et al, 2005, Broadley et al, 2008; 
Broadley et al, 2010).  
Another possibility is that the virus had mutated, resulting in it no longer being able 
to infect guinea-pigs. This is also unlikely as several different stocks were tried and 
completely new PIV-3 brought from the health protection agency. Also, viral titres 
remained high (1x107-9.viral particles per ml) throughout the experiments. 
Furthermore, PIV-3 continued to display normal infective and plaque forming ability 
in BSC-1 cells, not suggestive of mutations. 
The third possibility is that a change in the guinea-pig population has occurred. The 
guinea-pig population is known to have a high prevalence of PIV-3 antibodies due to 
endemic infection in some colonies (Blomgvist et al, 2002). PIV-3 infection spreads 
quickly across a colony, making it possible for the widespread development of 
antibodies to parainfluenzas. These antibodies may account for a faster and more 
specific immune response, eliminating PIV-3 quickly and thus preventing the usual 
responses. This is supported by the observation that PIV-3 viral titres measured by 
RT-qPCR in lavage fluid and lungs were lower in experiments where limited or no 
response to PIV-3 was observed. However, this method is not ideal for detecting 
active viral infection, since it does not distinguish between infectious and non-
infectious particles. Determination of the levels of infectious viral particles by cell 
plaque assay would give a better indication of this. Further studies involving the 
detection of PIV-3 specific antibodies in the blood would be required to confirm 
decreased response to PIV-3 due to increased adaptive immunity.  
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4.6.4 EFFECT OF POLY I:C IN GUINEA-PIGS 
The unreliability of PIV-3 infection and failure to produce a full exacerbation of Ova-
induced responses led to the investigation of the TLR-3 agonist poly I:C as a suitable 
alternative exacerbating agent. Lower doses of poly I:C increased airway oedema 
and neutrophils. Higher doses of poly I:C did not produce these effects but did 
slightly increase the bronchoconstrictor response to histamine.  
Previously, in the laboratory 500μg poly I:C administered intranasally for 3 days 
increased inflammatory cell influx, oedema and AHR. Additionally, on an allergic 
background, poly I:C increased cellular influx, Th2 response and AHR in mice and rats 
(Torres et al, 2010; Takayama et al, 2011). It is unknown why the highest dose of 
poly I:C used did not reproduce the effects of previous work. However, this may 
again suggest changes in the guinea-pig population and their response to antigen. 
Another possibility is that a change in poly I:C is responsible. Differences between 
the in vivo responses to various manufacturers of poly I:C have been observed, along 
with differences between poly I:C batches from the same manufacturer (verbal 
communication).  
The failure of PIV-3 infection and Poly I:C to satisfactorily cause exacerbation of Ova-
induced functional and inflammatory responses led to the search for more reliable 
and robust alternative exacerbating agents. The next chapter examines 
lipopolysaccharide (LPS).  
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5.1 INTRODUCTION 
5.1.1 LIPOPOLYSACCARIDE (LPS) AND ENDOTOXIN 
Endotoxin is a lipopolysaccharide (LPS) derived from the outermost cell wall layer of 
gram negative bacteria such as E.coli and H.influenzae. Endotoxin is comprised of 
several structural domains including o-antigen, core phospholipid and Lipid A. The 
structure of LPS is shown in Figure 1. The polysaccharide component carries an 
organism-specific antigen pattern, whereas the lipid component facilitates cell 
adhesion and the stimulation of innate immunity (Liu, 2002). Endotoxin is ubiquitous 
in the environment, in part due to the high temperatures (>100ºC) and length of 
time (>4 hours) it takes to destroy its immune stimulatory capacity. LPS is found in 
grain dust, livestock, textiles, pets, carpeting, milk, tobacco smoke, house dust-mite, 
particulate air pollution and indoor ventilation systems (Medvedev et al, 2000). 
Thus, the airways are constantly exposed to LPS but the response invoked depends 
on a range of factors discussed below. 
 
 
Figure 1: The structure of a gram-negative bacteria cell wall and the 3 components of 
lipopolysaccharide (endotoxin).  
O-antigen
Lipid A
Core phospholipid
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5.1.2 AIRWAY RESPONSE TO LPS 
A typical response to LPS in a susceptible individual includes increased chest 
tightness, chills and fever, dyspnea and myalgia. The pathophysiology underlying 
these symptoms includes an increase in airflow obstruction, oedema, reduced 
alveolar diffusion capacity and airways hyperresponsiveness. An innate and adaptive 
immune response is also evident and is mediated by epithelial cells, alveolar 
macrophages, B and T lymphocytes which release numerous chemokines, cytokines, 
adhesion molecules and inflammatory mediators. Key mediators include TNF-α, IL-
1β, IL-6 and IL-8, the latter of which is important in neutrophil recruitment (reviewed 
in Reed and Milton, 2001). Another cardinal effect of the inflammatory milieu is the 
increased production of mucus. LPS is also a potent inducer of nitric oxide synthase 2 
(NOS2, aka iNOS), which produces nitric oxide and contributes to LPS-induced 
vasodilation (Stuehr &, Marletta, 1984). LPS produces additional effects when 
exposure coincides with IgE-mediated events including increased histamine release 
from mast cells, CCL5 (RANTES) and GM-CSF from fibroblasts (Warren & Holford-
Strevens, 1986; Nonaka et al, 1999). 
 The recognition of LPS and the initiation of a response involves several 
proteins. LPS-binding protein is released locally from the airway epithelium and acts 
as a high affinity transporter, bringing LPS in contact with both soluble and 
membrane bound CD14 (Dentener et al, 2001). The LPS-CD14 complex then 
associates with TLR4 and MD2 on monocyte-macrophages and epithelial cells and 
initiates a signalling cascade which activates nuclear factor- κB (NF-κB) and activator 
protein 1 (AP1). Interferon regulatory factor 3 (IRF3) is also activated via a separate 
pathway independent of NF-κB and can lead to the expression of type-1 interferons 
(Perros et al, 2011). These nuclear factors subsequently translocate to the nucleus to 
initiate transcription of inflammatory cytokines (Medvedev et al, 2000) (Figure 2). 
LPS can also signal through non-NF-κB pathways to induce expression of the anti-
oxidant manganese superoxide dismutase and COX-2 (White et al, 2000; Wadleigh et 
al, 2000). Systemically, exposure to LPS induces tolerance to subsequent doses via 
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suppression of expression and function of signalling intermediates (Medvedev et al, 
2000). LPS tolerance is a compartmentalised phenomenon and in the lungs actually 
primes alveolar macrophages for further exposures. Subsequent LPS exposures 
increase pro-inflammatory signalling (Hoogerwerf et al, 2010; Reino et al, 2012). An 
increased response to LPS may be due to upregulation of TLR4 expression and 
downstream messengers. (Lin et al, 2006; Hoogerwerf et al, 2010).  
Neutrophil accumulation in the airways is mediated by the chemoattractants IL-8 
and MIP-1α and the binding molecules P-selectin and ICAM-1, all of which are 
upregulated by LPS exposure (Kamochi et al, 1999). LPS also decreases the apoptosis 
of neutrophils, prolonging the airways exposure to products such as elastase.  
Neutrophil elastase breaks down lung elastic fibres and encourages the development 
of emphysema (Nolan et al, 1999). Neutrophil elatase also promotes mucus 
secretion which is further augmented by LPS-induced epithelial growth factor (EGF) 
driven proliferation of goblet cells (Harkema et al, 1992; Takeyama et al, 1999). 
Evidence also suggests that LPS can recruit and activate eosinophils depending on 
the dose and section of airway sampled (Medvedev et al, 2000). LPS inhalation 
produces an immediate bronchoconstriction corresponding to a decrease in FEV1 
and increased bronchoconstrictor response to histamine in asthmatic individuals 
(Jagielo et al, 1996; Pauwels et al, 1990). However not all studies have confirmed 
these functional effects, possibly on account of lower doses of LPS being used 
(Nightingale et al, 1999).  
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Figure 2: Simplified diagram of LPS signalling via toll like receptor 4 (TLR4). LPS can signal 
through several different intracellular pathways to increase pro-inflammatory gene 
transcription in the nucleus. TIRAP (Toll/IL-1R domain containing adapter protein); MyD88 
(myeloid differentiation primary response protein 88); IRAK (IL-1 receptor-associated 
kinase); TRAF6 (tumor necrosis factor receptor-associated factor 6); NF-κB (nuclear factor-
kappa B); JNK (c-Jun N-terminal kinase); ERK (extracellular signal-regulated kinase); TRAM 
(TRIF-related adaptor molecule); TRIF (TIR domain-containing adaptor inducing IFN-β). IRF: 
Interferon regulatory factor; Diagram redrawn and adapted from Gribar et al, 2008. 
5.1.3 FACTORS THAT DETERMINE AIRWAY RESPONSE TO LPS IN ASTHMA 
LPS has paradoxically been shown to be both protective and exacerbating in asthma. 
These differences are due to a range of factors including the concentration of LPS, 
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host genetics, the timing of exposure and temporal proximity to other agents such as 
viruses, pollution and allergen. 
5.1.3.1 TIMING 
The timing of LPS exposure is likely key to its dual role as both protective and 
exacerbating in asthma. Early LPS exposure attenuates allergic responses and later 
LPS exposure augments it. A study by Tulic et al, 2000 demonstrated this 
experimentally in rats using an ovalbumin sensitisation and challenge model. Inhaled 
LPS either before or 4 days after ovalbumin sensitisation decreased the sensitisation 
response. Whereas LPS inhalation 1-5 days before ovalbumin challenge increased 
allergic responses 
5.1.3.2 DOSE 
The dose of LPS individuals encounter varies widely. Individuals that experience LPS 
through factories or farms are reported to be exposed to doses’ 100-1000 times 
greater than that of a typical home environment (Liu, 2002). However there are 
many problems with sampling LPS levels due to variability between measurement 
techniques, room to room differences, dust vs airborne LPS, seasonal variability, 
geographical location and other co-factors such as the presence of dogs (Park et al, 
2000). In vitro, low levels of LPS (pg/ml) prime macrophages and neutrophils for Th1 
cytokine production, whereas higher levels (>ng/ml) result in the production of free 
radical generating substances such as nitric oxide. 
5.1.3.3 GENETICS 
Genetic variability is also likely to account for differences in LPS response. In 
particular, polymorphisms in CD14 one of the receptors necessary for LPS response 
has been implicated. Other candidates for genetic variability in LPS response include 
TLR4 and TLR2, both of which recognise gram-negative bacteria cell products 
(reviewed in Doreswamy & Peden, 2010). 
5.1.3.4 ENVIRONMENTAL CO-FACTORS 
Many other factors can alter the response of the airways to LPS including the 
presence of bacterial DNA, viruses and allergens. In particular, allergen and LPS can 
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act synergistically to enhance each other’s effects. Allergen responses are enhanced 
by the presence of LPS (Tsuchiya et al, 2012). Allergen may also be able to enhance 
the effect of LPS by causing plasma extravasations of proteins such as LBP which can 
enhance LPS induced pro-inflammatory signalling (Dubin et al, 1996). Other factors 
such as differences in gastroinstestinal colonisation, antibiotic use, breast feeding, 
pets and ingestion of fermented vegetables have been shown to influence the 
coincidence of atopy (Liu, 2002). 
5.1.4 THE ROLE OF LPS IN ASTHMA  
5.1.4.1 LPS AS AN ASTHMA PROTECTIVE FACTOR 
The protective benefits of LPS are thought to be associated with exposure in early 
life before allergic sensitisation. This is in accordance with the ‘hygiene hypothesis’ 
which suggests that exposure to microbial infections and products such as LPS in 
early life may inhibit the development or pathogenesis of allergic disease (Strachan, 
1989; Schaub et al, 2006). The mechanism of this protection is thought to be via the 
promotion of Th1 lymphocyte responses over allergy promoting Th2 responses 
(Martinez & Holt, 1999). Several studies support the protective benefits of LPS. 
Children raised in rural environments such as farms, where higher levels of 
endotoxin are present are less affected by allergy (von Mutius et al, 2000; Riedler et 
al, 2000). Furthermore, this protective benefit has been shown to have a critical 
period. Reider et al, (2001) showed that children who were exposed to farm milk and 
stables (both having high endotoxin levels) before the age of 1 had a lower incidence 
of asthma and atopy then non-farming children. Farming children exposed between 
1-5 years showed no protective benefit over their non-farming equivalents. In the 
urban setting, houses with lower levels of house dust mite endotoxin inversely 
correlate with an increasing incidence of asthma (Gereda et al, 2000).  
5.1.4.2 LPS AS AN ASTHMA EXACERBATING FACTOR 
LPS has also been implicated in exacerbations asthma. These effects are thought to 
occur in individuals with pre-existing asthma and sensitisation to allergens. A 
correlation between an increased medication use, incidence of wheezing episodes 
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and LPS exposure in asthmatics has been demonstrated (Douwes et al, 2006). The 
concentration of LPS in the domestic environment is also correlated with the severity 
rating of asthma (Michel et al, 1996). Clinically, LPS exposure can cause a persistent 
bronchoconstriction over 5 hours (Michel et al, 1989). Asthmatics bronchoconstrict 
more readily to low doses of LPS (Cavagna et al, 1969). Underlying the clinical 
worsening of symptoms is range of cellular and molecular changes. A significant 
increase in eosinophil and poly mononuclear cell counts is observed following dust 
mite and LPS challenge (Eldridge & Peden, 2000). LPS can modify the response to 
allergen challenge, favouring a late phase response with a greater number of 
neutrophils then seen with allergen alone (Hunt et al, 1994). Associated with 
neutrophilia are increases in cytokines such as IL-8 and IL-17 (Doe et al, 2010). 
However, not all studies have shown these results. A study by Nightingale et al, 2000 
found no increase in airway inflammation or decrease in FEV1 in asthmatic subjects. 
Thus the effects of LPS remain controversial.  
5.1.4 ANIMAL MODELS OF ASTHMA USING LPS 
The role of LPS in asthma has been assessed in several animal models. These models 
can be broadly divided into those that use LPS during the sensitisation phase and 
those that use it during the allergen challenge phase. LPS exposure in rats prior to 
Ova sensitisation and up to 4 days after protects against the development on Ova 
specific IgE and allergic responses to the allergen (Tulic et al, 2000). Another study 
has shown that LPS induced attenuation of allergic responses is associated with a 
decrease in total and Ova-specific IgE (Delayre-Orthez et al, 2004). This process may 
involve IL-12 as anti-IL-12 antibodies administered with LPS, prior to Ova 
sensitisation were able to prevent LPS induced attenuation of allergic responses to 
Ova (Gerhold et al, 2002). These attenuating effects of LPS seem to be dose-
dependent. At higher LPS doses (>100μg) allergic sensitisation is suppressed but at 
lower concentrations (0.1μg) allergic sensitisation is boosted and dependent on the 
presence of LPS (Eisenbarth et al, 2002). More recently the low levels of LPS present 
in house dust mite extract  have been shown as critical for dendritic cell response. 
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The absence of TLR4 on epithelial cells prevents this response via the secretion of IL-
25, IL-33 and CM-CSF and TSLP (Hammad et al, 2009). 
Other animal models have administered LPS around the time of allergen challenge. 
Studies are split between those that have shown an exacerbation and those that 
demonstrate an attenuation of allergic responses. Delayre-Orthez et al, (2004) 
showed that intra-nasal LPS co-administered with Ova in mice produced a dose-
dependent increase in eosinophilia, IL-4, IL-5 and AHR. Tulic et al, (2000) showed an 
increase in Ova-induced neutrophils, eosinophils and IgE with LPS. The LPS-induced 
exacerbation was shown in part to be dependent on mast cells as mast cell deficient 
mice did not demonstrate an increase in IgE, total cells or eosinophlia (Murakami et 
al, 2006). LPS administered 24 hours before Ova challenge has also been 
demonstrated to increase cellular inflammation and nitric oxide levels but reduce IL-
4, IL-13 and AHR (Komlosi et al, 2006). Other studies have shown opposite effects. A 
study by Rodriguez et al, (2003) found that Intra-nasal LPS administered shortly 
before intra-nasal Ova challenge prolonged AHR to methacholine but did not alter 
inflammation, although neutrophils were increased and eosinophils decreased. 
Contrastingly, intravenous LPS administered with intra-nasal Ova challenge 
significantly attenuated inflammation and AHR. Another study has shown that 
guinea-pigs administered Intravenous LPS 24 hours before intra-tracheal Ova 
challenge demonstrate significantly less bronchoconstriction. This was associated 
with partially degranulated mast cells (Vannier et al, 1991). LPS administered after 
Ova inhalation also seems to attenuate allergic responses. LPS administered 18 hours 
after Ova challenge in rats reduced lymphocyte, macrophages, eosinophils and AHR 
(Tulic et al, 2000). The same group showed that the co-administration of a high 
concentration of LPS with Ova decreases AHR, inflammation and oedema (Tulic et al, 
2002). The effect of LPS on goblet cells in asthma models seems uncertain. LPS alone 
causes goblet cell hyperplasia (Harkema & Hotchkiss, 1992). In combination with 
allergen it has been reported to both not change, increase and decrease goblet cell 
numbers depending on the LPS dose (Dong et al, 2009; Tsuchiya et al, 2012).  
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In summary, in animal models of asthma LPS seems to have an attenuating effect on 
allergic responses when administered close to or with sensitisation. The effect of LPS 
administered close to allergen challenge is less clear but it appears that it may act as 
an exacerbating agent if a high dose is administered with the correct timing. These 
differences probably stem from the range of Ova protocols (single vs repeat 
challenge), dose and timing of LPS administration, route of LPS administration 
(systemic vs local), species and even the strain i.e. BALB/C vs C57BL/6 mice used to 
perform these studies. 
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5.2 HYPOTHESIS 
‘A high dose of LPS when administered with or close to allergen challenge, 
subsequent to allergen sensitisation will exacerbate functional and allergic responses 
to the allergen ovalbumin.’ 
5.3 AIMS AND OBJECTIVES 
The aim of this chapter was to use an acute ovalbumin model and exacerbate at 
least one of the following parameters: early asthmatic response, late asthmatic 
response, airways hyperresponsiveness to histamine, airways inflammation and 
oedema using LPS inhalation. Since data from other animal models suggests that LPS 
exposure close to sensitisation attenuates allergic responses, whereas exposure near 
allergen challenge may exacerbate allergic responses, the latter time point was 
chosen. However, the specific timing of LPS exposure in relation to allergen 
challenge has not been examined in a single study so several LPS exposure time 
points were assessed. A high dose of LPS was selected as both human and animal 
studies suggest that exacerbations of asthma are more likely than with lower doses. 
The effect of single or multiple LPS challenges on responses to allergen challenge 
have not been examined so the present study will assess this. This study will also be 
the first to examine the effect of LPS on both early and late asthmatic responses to 
allergen challenge, along with the more commonly measured airways 
hyperresponsiveness and airway inflammation. The effect of LPS alone was 
examined as a comparison to its effects on allergen challenge. IL-8 and IL-17 levels 
were investigated as both are implicated in neutrophilia. IL-13 was used to 
investigate changes to Th2 responses. Lung histology was assessed to investigate 
changes in airway inflammation and goblet cell numbers.  
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5.4 METHODS 
Methods describing the measurement of lung function, AHR, airway oedema, airway 
inflammation, cytokine levels and lung histology can be found in more detail in 
chapter 2.  
5.4.1 OVALBUMIN PROTOCOLS 
5.4.1.1 SENSITISATION 
Guinea-pigs (200-300g, Dunkin-Hartley, male) were sensitised by a bilateral intra-
peritoneal injection of a solution containing 150µg ovalbumin (Ova) and 100mg 
aluminium hydroxide (Al(OH)3) in normal saline on days 1, 4 and 7. 
5.4.1.2 LPS PRE-ACUTE OVALBUMIN EXPOSURE PROTOCOL 
Sensitised guinea-pigs were exposed to inhaled saline or LPS (30μg/ml) both 72 and 
24 hours before Ova challenge for 1 hour in a Perspex box. On day 21 guinea-pigs 
were exposed to Ova (0.03%) for one hour. The bronchoconstrictor response to 
histamine was assessed on day 15 and day 22. Figure 3 shows a diagram of this 
protocol.  
 
 
Figure 3: Diagram of the pre-ovalbumin (Ova) challenge LPS exposure protocol. Guinea-pigs 
were challenged with saline or LPS (30μg/ml) both 24 and 72 hours pre-Ova exposure. 
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5.4.1.3 LPS AND ACUTE OVALBUMIN CO-EXPOSURE PROTOCOL 
Sensitised guinea-pigs were exposed to inhaled saline or LPS (30μg/ml) 48 hours 
before Ova challenge in an exposure chamber and both LPS (30μg/ml) and Ova 
(0.03%) co-administered on day 21. The bronchoconstrictor response to histamine 
was assessed on day 15 and day 22. Figure 4 shows a diagram of this protocol. 
 
 
Figure 4: Diagram of LPS and Ova co-exposure protocol. Guinea-pigs were exposed to saline 
or LPS (30μg/ml) on day 19 and both Ova and LPS co-administered on day 21.  
5.4.2 LPS EXPOSURE PROTOCOL 
Non-sensitised guinea-pigs were exposed to saline or LPS (30μg/ml) on day 5 and 7 
of the protocol. The bronchoconstrictor response to histamine was assessed on day 
1 and day 8. Figure 5 shows a diagram of this protocol.  
 
Figure 5: Diagram of the LPS alone exposure protocol. Guinea-pigs were exposed to 30μg/ml 
of LPS on day 5 and 7.   
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5.4.3 MEASUREMENT OF LUNG FUNCTION 
Lung function was measured by whole body plethysmography following final saline, 
Ova, LPS or Ova and LPS exposure in all protocols. Lung function was recorded hourly 
for 12 hours and every 15 minutes during the first hour of measurements. A final 
measurement was also taken 24 hours post-final challenge. All values from these 
readings were expressed as a percentage of the baseline reading, taken before the 
final challenge. A negative percentage change in baseline value represents a 
bronchoconstriction. In Ova protocols early (0-6 hours) and late (6-12 hours) phases 
were expressed as the peak bronchoconstriction during that period (displayed as a 
histogram next to a time course plot) and area under the curve. The duration of the 
early phase was expressed as the time taken to recover to 50% of peak early phase 
bronchoconstriction values.  In the LPS only protocol lung function was measured for 
12 hours after the second LPS exposure. The peak bronchoconstriction during this 
period was expressed on a histogram next to the time course plot.  
5.4.4 MEASUREMENT OF AIRWAYS HYPERRESPONSIVENESS  
AHR was determined using whole body plethysmography. This was performed by 
measuring the bronchoconstrictor response to histamine before and 24 hours post-
final saline, Ova, LPS or Ova and LPS exposure challenge. Histamine (0.3mM) was 
delivered to the guinea-pigs by the use of a Buxco nebuliser chamber and lung 
function was measured just before histamine inhalation and at 0, 5 and 10 minutes 
post histamine exposure. The peak bronchoconstriction during this period was 
expressed on a histogram. 
5.4.5 MEASURING AIRWAYS INFLAMMATION 
Following post-saline/Ova/LPS/Ova and LPS histamine challenge guinea-pigs were 
sacrificed by an intra-peritoneal overdose of sodium pentobarbitone, the lungs 
excised and lavaged. Total and differential cell counts were then performed as 
described in chapter 2.  
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5.4.6 QUANTIFICATION OF CYTOKINE LEVELS USING ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) 
Levels of IL-8, IL-17 and IL-13 were measured in diluted homogenised lung samples 
using ELISA supplied by R&D systems. Cytokine levels were adjusted for total lung 
protein and expressed as weight per mg of lung as described in section 2.2.3.2. 
5.4.7 ASSESSMENT OF AIRWAY OEDEMA 
Protein content in lavage fluid was determined as a measure of airway oedema by 
BCA protein assay as per the manufacturer’s instructions (Pierce protein biology).  
5.4.8 HISTOLOGICAL ANALYSIS OF LUNGS 
Lung lobe samples were stored in formaldehyde and 1-2mm bilateral sections cut. 
Samples were dehydrated in increasing concentrations of alcohol and then 
chloroform. Tissue sections were then set into wax blocks using molten paraffin. 
5µm sections were cut using a microtome and fixed to polysine coated slides. Slides 
were stained with haematoxylin and eosin or Alcian blue/periodic acid Schiff stain 
(Ab/PAS). Haematoxylin and eosin staining allows for assessment of general lung 
morphology and inflammation. Semi-quantitative assessment of airway 
inflammation was performed using a scoring method. 0=normal lung; 1= minor 
peribronchiolar (PB) inflammatory cell infiltration; 2= slight inflammatory cell 
infiltration in PB area; 3= moderate PB inflammatory cell infiltration; 4= marked PB 
inflammatory cell infiltration and cuffing. Slight loss of lung structure (alevoli etc); 5= 
severe PB inflammatory cell infiltration, cuffing and infiltration. Loss of lung structure 
i.e. solid lung. Ab/PAS staining allowed assessment of goblet cell numbers in airway 
epithelium using Image J software. 
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5.5 RESULTS 
5.5.1 PRE-ACUTE OVA LPS EXPOSURE 
Figure 6 represents the mean time course changes in sGaw in guinea-pigs exposed to 
inhaled saline or LPS 72 hours and 24 hours pre-ovalbumin (Ova) challenge. All 3 
groups demonstrated an EAR but this was attenuated in guinea-pigs treated with LPS 
24 hour pre-Ova (-25.0±6.6%) and 72 and 24 hours pre-Ova (-12.5±11.4%) compared 
to saline (-72.2±2.0%) at 0 minutes. Both LPS treated groups maintained significantly 
attenuated bronchoconstrictions compared to saline treatment until 3 hours post-
Ova challenge. Whereas in saline treated animals sGaw values had returned to 
baseline by about 6 hours (-10.0±5.5%), the bronchoconstriction in both LPS treated 
guinea-pigs remained relatively constant across the first 6 hours. Evidence of a LAR 
was seen in saline treated guinea-pigs at 8 and 9 hours (-13.3±3.7% and -20±5.5%, 
respectively). A well defined LAR in both LPS treated groups was not seen although 
bronchoconstrictions were present in both guinea-pigs treated with LPS 24 hours 
pre-Ova (-10.9±4%) and LPS 72 and 24 hours pre-Ova (-15.7±7.0%) at 9 hours. These 
bronchoconstrictions were resolved at 12 hours post-Ova challenge in both saline (-
5.8±6.2%) and LPS 24 hours pre-Ova (-4.4±5.5%) treated guinea-pigs. Animals 
treated with LPS twice still had a clear bronchoconstriction present at this same time 
point (-20±6.6%).  
The peak early phase response of guinea-pigs treated with LPS 24 hours (-34.4±4.6%) 
and LPS 72 and 24 hours (-25.2±27.7%) pre-Ova was significantly attenuated 
compared to saline treated animals (-73.5±1.9%). No significant difference in peak 
late asthmatic responses between groups was observed. Although there was a trend 
for guinea-pigs treated with LPS twice to demonstrate a bronchoconstriction at 24 
hours post-Ova challenge, this did not reach significance (Figure 6, histogram). 
Guinea-pigs treated once or twice with LPS demonstrated significantly lower early 
phase area under the curve compared to those treated with saline (124±18.3%.hr 
and 100.7±51.9%.hr compared to 249.8±11.8%.hr respectively). No significant 
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differences were found in LAR area under the curve (Figure 7). No difference 
between the duration of the EAR between groups was observed (Figure 8).  
 
Ova challenge with saline treatment produced a significant increase in immediate 
bronchoconstriction to histamine, when compared to the sGaw values prior to Ova-
challenge (-24.1±7.7% compared to 0.6±3.2%). The bronchoconstriction was no 
longer significant 5 minutes post-histamine challenge. Guinea-pigs challenged with 
Ova and treated with LPS once also demonstrated an increased response to 
histamine at 0 minutes post-Ova challenge (-12.9±4.7% compared to -0.18±1.1%), 
which returned to baseline sGaw values after 5 minutes. No change in the response 
to histamine was seen in guinea-pigs challenged with Ova and treated with LPS 
twice; the AHR to Ova was eliminated by LPS (Figure 9). 
 
No difference in lavage protein levels was found between groups (Figure 10). A trend 
for an increase in total cell numbers was seen with Ova challenge and treatment 
with 1 dose of LPS, although this failed to reach significance. Ova challenge with 2 
doses of LPS significantly increased total cell numbers (18.3±3.5x106/ml compared to 
saline, 8.9±0.4x106/ml respectively). In particular macrophages (7.7±x1.0x106 /ml 
compared with saline, 4.2±0.19x106/ml) and neutrophils (6.1±1.5x106/ml compared 
with saline, 0.6±0.05x106/ml) were increased. Neutrophils were also increased in the 
lavage fluid of guinea-pigs treated with LPS once (5.2±0.8x106/ml). All other cell 
types remained unchanged (Figure 11).  
 
IL-8 levels in lung increased in guinea-pigs treated with Ova and LPS once compared 
to other groups where IL-8 was not detectable. IL-13 levels increased significantly in 
guinea-pigs challenged with Ova compared to sensitised guinea-pigs challenged with 
saline (6.2±0.8ng/mg compared to 1.4±0.5ng/ml). LPS exposure did not significantly 
change IL-13 levels. IL-17 levels were not significantly increased in Ova challenged 
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guinea-pigs. Exposure to LPS once significantly increased IL-17 compared to 
sensitised, saline challenged guinea-pigs (126.1±19.7pg/ml compared to 
61.8±3.2pg/ml respectively). LPS exposure twice did not significantly change IL-17 
levels (Figure 12).  
 
Figure 13 shows lung sections stained with haematoxylin and eosin for general 
morphology of the bronchioles. Guinea-pigs challenged with Ova show increased 
inflammatory cell numbers in the peribronchiolar area. Treatment with LPS did not 
alter the inflammatory cell presence. Figure 14 presents the mean pathology scores 
for the number of inflammatory cells in the peribronchiolar area in these guinea-
pigs.  Ovalbumin challenge with saline pre-treatment significantly increases mean 
pathology score compared to saline challenge (2.64±0.34 compared to 0.58±0.19). 
LPS treatment 72 hours pre-Ova challenge also significantly increases the mean 
pathology score (2.29±0.5 compared to saline challenge, 0.58±0.19) but not 
significantly more than Ova alone. 2 pre-Ova LPS challenges did not significantly 
increase the mean pathology score, despite demonstrating a trend, probably due to 
the low N.  
 
Figure 15 shows the lung sections stained with Alcian blue/ periodic acid to reveal 
mucus containing goblet cells. Guinea-pigs challenged with Ova showed an increase 
in the number of goblet cells. Treatment with LPS further increased the number of 
goblet cells. Figure 16 presents the number of mucin associated-goblet cells per 
10,000 pixels of epithelium. Single saline or LPS exposure 24 hours pre-Ova challenge 
increased the number of goblet cells, although not significantly. Treatment with LPS 
72 and 24 hours pre-Ova challenge increased goblet cells significantly compared to 
saline challenge (769.8±154.3 compared to 182.4±65.2). 
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Figure 6: The mean time-course values of sGaw in ovalbumin (Ova) sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 72 hours and 
24 hours pre-Ova challenge. The histogram represents the maximum bronchoconstriction values recorded during the early asthmatic response (EAR) (0-6 
hours), late asthmatic response (LAR) (6-12 hours) and the 24 hours reading. Mean changes in sGaw are expressed as mean±SEM percentage change from 
baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=6 (saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 (LPS/LPS/Ova). 
*Significantly different from saline treatment p<0.05, ** p<0.01; *** p<0.001; # single LPS significantly different from saline treatment p<0.05; performed 
with one-way analysis of variance followed by Bonferroni post-test. 
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Figure 7: Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) challenge in guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 72 hours 
and 24 hours pre-Ova challenge. For the purpose of analysis only negative peaks were 
considered and all positive sGaw values were excluded. Total includes all negative peaks 
from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 hours and late 
asthmatic response (LAR) includes values from 6-12 hours. Area under the curve is expressed 
as %.hour. N=6 (saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 (LPS/LPS/Ova). **Significantly 
different from saline treatment p<0.01; performed with one-way analysis of variance 
followed by Bonferroni post-test 
 
Figure 8: Analysis of the time taken for early asthmatic responses (EAR) to recover to 50% of 
peak bronchoconstriction values in guinea-pigs treated with either saline or 30μg/ml LPS for 
1 hour, 72 hours and 24 hours pre-Ova challenge. Results are expressed as mean±SEM; N=6 
(saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 (LPS/LPS/Ova); performed with one-way 
analysis of variance followed by Bonferroni post-test 
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Figure 9: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5 LPS per chamber over 2 minutes, 
1 minute drying period) in ovalbumin (Ova) sensitised guinea-pigs treated with either A) saline or 30μg/ml LPS for 1 hour B) 24 hours pre-Ova, C) 72 hours 
and 24 hours pre-Ova challenge. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM 
percentage change from baseline.  A negative value represents a bronchoconstriction. N=6 (saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 (LPS/LPS/Ova). 
*Significantly different from time paired pre-Ova challenge values p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 10:  Total lavage fluid protein in ovalbumin (Ova) sensitised guinea-pigs treated with 
either saline or 30μg/ml LPS for 1 hour, 72 hours and 24 hours pre-Ova challenge. Protein 
content determined by BCA protein assay. Results are expressed as mean±SEM; N=6 
(saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 (LPS/LPS/Ova); performed with one-way 
analysis of variance followed by Bonferroni post-test 
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Figure 11: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in ovalbumin (Ova) sensitised guinea-pigs treated with 
either saline or 30μg/ml LPS for 1 hour, 72 hours and 24 hours pre-Ova challenge. Results 
are expressed as mean±SEM; N=6 (saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 
(LPS/LPS/Ova).  *Significantly different from saline treatment p<0.05, ** p<0.01; *** 
p<0.001; performed with one-way analysis of variance followed by Bonferroni post-test. 
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Figure 12: The concentration of A) IL-8 B) IL-13 C) IL-17 in the lungs of ovalbumin (Ova) 
sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 72 hours and 24 
hours pre-Ova challenge or saline challenge alone. Results are expressed as mean±SEM; N=6 
(saline/saline/Ova), N=8 (saline/LPS/Ova), N=4 (LPS/LPS/Ova). *Significantly different from 
sensitised/saline p<0.05, ** p<0.01; *** p<0.001; performed with one-way analysis of 
variance followed by Bonferroni post-test.  
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Figure 13: Bronchiolar changes in ovalbumin (Ova) sensitised guinea-pigs exposed to A) 
saline or B) Ova C) 30μg/ml LPS for 1 hour, 24 hours pre-Ova challenge D) 30μg/ml LPS, 72 
hours and 24 hours pre-Ova challenge. L: lumen; ASM: airway smooth muscle; E: epithelium, 
IC: inflammatory cell. Stained with haematoxylin and eosin. Original magnification 100x (bar 
= 25 µm). 
 
Figure 14: The mean pathology score of the peribronchiolar area in ovalbumin (Ova) 
sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 72 hours and 24 
hours pre-Ova challenge. Results are expressed as mean±SEM; N=6 Sen/saline (sensitised, 
exposed to saline), (saline/saline/Ova), (saline/LPS/Ova), N=4 (LPS/LPS/Ova). *Significantly 
different from sensitised/saline treated group treatment p<0.05, ** p<0.01; performed with 
one-way analysis of variance followed by Bonferroni post-test.  
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Figure 15: Bronchiolar changes in ovalbumin (Ova) sensitised guinea-pigs exposed to A) 
saline or B) Ova C) 30μg/ml LPS for 1 hour, 24 hours pre-Ova challenge D) 30μg/ml LPS, 72 
hours and 24 hours pre-Ova challenge. L: lumen; ASM: airway smooth muscle; E: epithelium; 
G: goblet cell; Stained with alcian blue/periodic acid Schiff stain Original magnification 200x 
(bar = 50 µm). 
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Figure 16: The number of mucin–associated goblet cells per 10,000 epithelial pixels in 
ovalbumin (Ova) sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 
72 hours and 24 hours pre-Ova challenge or saline challenge alone. Results are expressed as 
mean±SEM; N=6 Sen/saline (sensitised, exposed to saline), (saline/saline/Ova), 
(saline/LPS/Ova), N=4 (LPS/LPS/Ova). *Significantly different from sensitised/saline treated 
group treatment p<0.05, performed with one-way analysis of variance followed by 
Bonferroni post-test.  
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5.5.2 ACUTE OVA AND LPS CO-EXPOSURE 
Figure 17 represents the mean time course changes in sGaw in ovalbumin (Ova) 
challenged guinea-pigs exposed to inhaled saline (saline/Ova), or LPS co-
administered with Ova (Saline/LPS+Ova) or LPS 48 hours before Ova challenge and 
co-administered with Ova (LPS/LPS+Ova). All three groups demonstrated an 
immediate bronchoconstriction, similar in degree; with LPS inhalation once (-
47.5±9.5%), LPS inhalation twice (-52.1±11.6%) and saline inhalation (-60.1±3.4%). 
Guinea-pigs co-administered LPS with Ova but receiving saline pre-treatment 
showed a similar recovery from EAR bronchoconstriction to Ova challenged animals. 
Guinea-pigs exposed to LPS twice demonstrated a slower recovery from EAR 
bronchoconstriction, being significantly more bronchoconstricted at 5 hours (-
37.3±7.6%) compared to saline (-9.7±2.8%). All 3 groups demonstrated late 
asthmatic responses. A LAR was seen in both guinea-pigs exposed to saline (-
14.9±4.4%) and LPS once (-36.6±8.8%) at 8 and 7 hours respectively. A delayed LAR 
at 10 hours (-18.3±2.9) was observed in guinea-pigs that inhaled LPS twice.  
 
The peak EAR responses to Ova were not altered by LPS treatment. LPS treated 
animals demonstrated a trend for an increase in the peak LAR but this did not reach 
statistical significance (Figure 17). No significant differences between total, EAR or 
LAR area under the curve were found between groups (Figure 18). LPS co-
administered with Ova increased the duration of the EAR, which reached significance 
when LPS was both co-administered with Ova and given 48 hours before (4.8±0.6h 
compared to saline, 2.3±0.7h) (Figure 19).  
 
Guinea-pigs challenged with only Ova demonstrated a bronchoconstriction to 
histamine at 0 minutes (-21.6±4.6 compared to pre-Ova, 0.7±4.0%) which returned 
to baseline sGaw values by 5 minutes. Ova challenge and LPS exposure once (-
19.8±4.9% compared to pre-Ova challenge, -0.2±1.9%) and twice (-19.1±10.6% 
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compared to pre-Ova challenge, -0.2±1.9%) also produced a bronchoconstriction to 
histamine at 0 minutes. These bronchoconstrictions continued to increase over the 
10 minutes. At 10 minutes post-histamine challenge in guinea-pigs exposed to LPS 
once the bronchoconstriction was -27.0±5.0% compared to pre-Ova, 0.9±3.3% and 
for LPS twice it was -41.1±7.0% compared to 7.3±2.7% (Figure 20).  
 
LPS co-administered and given 48 hours before Ova challenge significantly increased 
protein levels compared with guinea-pigs challenge with Ova and Ova and LPS co-
administered (4.2±0.6mg/ml compared to 2.0±0.3mg/ml and 2.2±0.3mg/ml 
respectively) (Figure 21).  
 
A trend for an increase in total cell numbers was seen when Ova and LPS were co-
administered, although this failed to reach significance. LPS co-administered with 
Ova and given 48 hours before significantly increased total cell numbers 
(20.9±0.9x106/ml compared to saline, 10.5±0.8x106/ml respectively). Neutrophils 
were increased in both groups exposed to LPS once and twice compared to saline 
treatment (4.0±0.9x106/ml, 7.4±0.5x106/ml compared with saline, 0.5±0.1x106/ml). 
All other cell types remained unchanged (Figure 22).  
 
Both single and 2 LPS exposures significantly increased the concentration of IL-8 
compared to saline pre-treatment and Ova challenge (11.4±1.1pg/mg, 
11.5±1.6pg/mg compared to 5.2±0.34pg/mg respectively). IL-13 and IL-17 levels 
were significantly increased in guinea-pigs challenged with Ova and exposed to 
saline (10.5±1.2ng/mg compared to 1.4±0.5ng/mg; 130.5±11.4pg/mg compared to 
61.8±3.2pg/mg respectively). LPS exposure did not significantly change IL-13 and IL-
17 levels compared with Ova alone (Figure 23).  
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Figure 24 shows lung sections stained with haematoxylin and eosin for general 
morphology of the bronchioles. Guinea-pigs challenged with Ova show increased 
inflammatory cell numbers in the peribronchiolar area. Treatment with LPS does not 
alter the inflammatory cell presence. Figure 25 presents the mean pathology scores 
for the number of inflammatory cells in the peribronchiolar area in these guinea-
pigs. Ovalbumin challenge alone significantly increases the mean pathology score 
compared to saline challenge (2.64.±0.34 compared to 0.58±0.19). A single exposure 
to LPS co-administered pre-Ova challenge and also in guinea-pigs exposure 48 hours 
pre-Ova challenge also significantly increases the mean pathology score (2.71±0.2, 
3.1±0.2 compared to saline challenge, 0.58±0.19 respectively) but not significantly 
more than Ova alone.  
 
Figure 26 shows lung sections stained with Alcian blue/ periodic acid Schiff to reveal 
the number of goblet cells in the airway epithelium. Guinea-pigs challenged with Ova 
show an increased number of goblet cells. Treatment with LPS further increases the 
number of goblet cells. Figure 27 presents the number of mucin associated-goblet 
cells per 10,000 pixels of the epithelium.  Ovalbumin challenge with a single saline 
exposure or LPS co-administrated with Ova increases the number of goblet cells, 
although not significantly. Treatment with LPS 48 pre-Ova and co-administered with 
Ova increases the number of goblet cells significantly compared to all other groups 
(974.4±98.8 compared to saline, 182.4±65.2, to Ova, 554±102.2 and to Sal/LPS+Ova, 
485.1±175.0). 
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Figure 17: The mean time-course values of sGaw in ovalbumin (Ova) sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 48 hours 
before Ova challenge and co-administered with Ova. The histogram represents the maximum bronchoconstriction values recorded during the early 
asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as 
mean±SEM percentage change from baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=5 (Saline/Ova), N=5 (Saline/LPS 
+Ova), N=6 (LPS/Ova+LPS).*significantly different from saline treatment p<0.05; performed with one-way analysis of variance followed by Bonferroni post-
test. 
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Figure 18: Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) in sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 48 hours 
before Ova challenge and co-administered with Ova. For the purpose of analysis only 
negative peaks were considered and all positive sGaw values were excluded. Total includes 
all negative peaks from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 
hours) and late asthmatic response (LAR) includes values from 6-12 hours. Area under the 
curve is expressed as %.hour. N=5 (Saline/Ova), N=5 (Saline/LPS +Ova), N=6 (LPS/Ova+LPS); 
performed with one-way analysis of variance followed by Bonferroni post-test. 
 
Figure 19: Analysis of the time taken for early asthmatic responses (EAR) to recover to 50% 
of peak bronchoconstriction values in guinea-pigs treated with either saline or 30μg/ml LPS 
for 1 hour, 48 hours before Ova challenge and co-administered with Ova. Results are 
expressed as mean±SEM; N=5 (Saline/Ova), N=5 (Saline/LPS +Ova), N=6 
(LPS/Ova+LPS).*significantly different from saline treatment p<0.05; performed with one-
way analysis of variance followed by Bonferroni post-test. 
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Figure 20: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5 LPM, 2 minutes, 1 minute drying 
period) in ovalbumin (Ova) sensitised guinea-pigs treated with either A) saline or 30μg/ml LPS for 1 hour, B) co-administered with Ova or C) 48 hours before 
Ova challenge and co-administered with Ova. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as 
mean±SEM percentage change from baseline.  A negative value represents a bronchoconstriction. N=5 (Saline/Ova), N=5 (Saline/LPS +Ova), N=6 
(LPS/Ova+LPS). **Significantly different from time paired pre-Ova challenge values p<0.01; *** p<0.001; performed with a two tailed T-test. 
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Figure 21: Total lavage fluid protein in ovalbumin (Ova) sensitised guinea-pigs treated with 
either saline or 30μg/ml LPS for 1 hour, 48 hours before Ova challenge and co-administered 
with Ova. Protein content was determined by BCA protein assay. Results are expressed as 
mean±SEM; N=5 (Saline/Ova), N=5 (Saline/LPS +Ova), N=6 (LPS/Ova+LPS). *Significantly 
different from saline treatment p<0.05; # significantly different from saline/LPS+Ova p<0.05; 
performed with one-way analysis of variance followed by Bonferroni post-test 
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Figure 22: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in the bronchoalveolar fluid of ovalbumin (Ova) sensitised guinea-pigs treated 
with either saline or 30μg/ml LPS for 1 hour, 48 hours before Ova challenge and co-
administered with Ova. Results are expressed as mean±SEM; N=5 (Saline/Ova), N=5 
(Saline/LPS +Ova), N=6 (LPS/Ova+LPS). *Significantly different from saline treatment p<0.05, 
** p<0.01; performed with one-way analysis of variance followed by Bonferroni post-test. 
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Figure 23: The concentration of A) IL-8 B) IL-13 C) IL-17 in the lungs of ovalbumin (Ova) 
sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 48 hours before 
Ova challenge and co-administered with Ova.  Results are expressed as mean±SEM; N=5 
(Saline/Ova), N=5 (Saline/LPS +Ova), N=6 (LPS/Ova+LPS). *Significantly different from 
sensitised/saline challenged guinea-pigs p<0.05, ** p<0.01; *** p<0.001; ^^^ significantly 
different from Sal/sal/Ova p<0.001. performed with one-way analysis of variance followed 
by Bonferroni post-test. 
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Figure 24: Bronchiolar changes in ovalbumin (Ova) sensitised guinea-pigs exposed to A) 
saline or B) Ova C) 30μg/ml LPS co-administered with Ova challenge D) 30μg/ml LPS 48 hours 
pre-Ova challenge and co-administered. L: lumen; ASM: airway smooth muscle; E: 
epithelium, IC: inflammatory cell. Stained with haematoxylin and eosin. Original 
magnification 100x (bar = 25 µm). 
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Figure 25: The mean pathology score of the peribronchiolar area in ovalbumin (Ova) 
sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 48 hours before 
Ova challenge and co-administered with Ova. Results are expressed as mean±SEM; N=6 
Sen/saline (sensitised, exposed to saline), (saline/saline+Ova), (saline/LPS+Ova), N=4 
(LPS/LPS+Ova). *** Significantly different from sensitised/saline treated group treatment 
p<0.001; performed with one-way analysis of variance followed by Bonferroni post-test.  
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Figure 26: Bronchiolar changes in ovalbumin (Ova) sensitised guinea-pigs exposed to A) 
saline or B) Ova C) 30μg/ml LPS co-administered with Ova challenge D) 30μg/ml LPS 48 hours 
pre-Ova challenge and co-administered; L: lumen; ASM: airway smooth muscle; E: 
epithelium; G: goblet cell; Stained with alcian blue/periodic acid Schiff stain. Original 
magnification 200x (bar = 50 µm). 
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Figure 27: The number of mucin–associated goblet cells per 10,000 epithelial pixels in 
ovalbumin (Ova) sensitised guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour, 
48 hours before Ova challenge and co-administered with Ova. Results are expressed as 
mean±SEM; N=6 Sen/saline (sensitised, exposed to saline), (saline/saline+Ova), 
(saline/LPS+Ova), N=4 (LPS/LPS+Ova). *** Significantly different from sensitised/saline 
treated group treatment p<0.001; ^ significantly different from Sal/Sal+Ova p<0.05; # 
significantly different from sal/LPS/Ova p<0.05; performed with one-way analysis of variance 
followed by Bonferroni post-test. 
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5.5.3 LPS EXPOSURE IN NON-SENSITISED GUINEA-PIGS 
Lung function was assessed for 12 hours after the 1st LPS exposure and found to not 
produce an airway response significantly different from saline (data not shown).  
 
Both saline and LPS challenged animals demonstrated an immediate 
bronchoconstriction which peaked 1 hour post-challenge. The magnitude of this 
bronchoconstriction was significantly higher in LPS challenged animals (-41.3±2.7% 
compared to saline, -22.5±4.5%). In both groups sGaw values returned to baseline by 
5 hours post-challenge. No further bronchoconstrictions were seen across the 12 
hours of measurements (Figure 28). LPS significantly increased the peak 
bronchoconstriction during 12 hours of lung function assessment compared to saline 
(-44.1±2.7% compared to -25.4±4.1%) No difference was seen at the 24 hour time 
point (Figure 28). LPS also produced a significant increase in area under the curve 
during this period (144.6±12.0%.hr compared to 75.4±20.8%.hr) (Figure 29).  
 
LPS significantly increased protein levels over saline (1.3±0.3mg/ml compared to 
0.5±0.05mg/ml) (Figure 30). Guinea-pigs challenged with saline demonstrated no 
change in response to histamine. Guinea-pigs challenged with LPS demonstrated an 
increased bronchoconstrictive response to histamine at 0 minutes (-14.1±3.8% 
compared to pre-LPS, -0.9±1.0%). This bronchoconstriction persisted until 10 
minutes post-histamine (-16.1±4.7% compared to pre-LPS, -1.0±2.5%) (Figure 31).  
 
LPS significantly increased total cells (26.0±6.1 x106/ml compared to saline, 
1.4±0.2x106/ml), macrophages (11.7±1.7x106/ml compared to 1.3±0.15x106/ml) and 
neutrophils (13.7±4.2x106/ml compared with 0.02±0.01x106/ml) (Figure 32).  
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LPS exposure significantly increased the amount of IL-8 in lungs (23.8±3.6pg/mg 
compared to saline non-detection, 0±0pg/mg respectively) (Figure 33).  
 
Figure 34 shows the lung sections stained with haematoxylin and eosin for general 
morphology of the bronchioles. Guinea-pigs exposed to LPS show increased 
inflammatory cell numbers in the peribronchiolar area. Figure 35 presents the mean 
pathology scores for the number of inflammatory cells in the peribronchiolar area in 
these guinea-pigs.  LPS exposure significantly increases the mean pathology score 
compared to saline exposure (2.5.±0.36 compared to 0.4±0.16).  
 
Figure 36 shows the lung sections stained with Alcian blue/ periodic acid Schiff to 
identifiy number of goblet cells in the airway epithelium. Guinea-pigs challenged 
with LPS show increased number of goblet cells. Figure 37 presents the number of 
mucin associated-goblet cells per 10,000 pixels of the epithelium.  LPS exposure 
significantly increases goblet cell numbers compared to saline (898.0±221.6 
compared to saline, 163.6±89.7). 
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Figure 28: The mean time-course values of sGaw in guinea-pigs treated with either saline or 30μg/ml LPS for 1 hour both 48 and 0 hours before lung 
function measurements. The histogram represents the maximum bronchoconstriction values recorded 0-12 hours and during the 24 hour reading. Mean 
changes in sGaw are expressed as mean±SEM percentage change from baseline prior to saline or LPS challenge. A negative value represents a 
bronchoconstriction. Results shown are after the second LPS or saline exposure. N=6 *significantly different from saline treatment p<0.05, ** p<0.01; 
performed with a two tailed T-test. 
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Figure 29: Total area under the curve analysis of sGaw values in guinea-pigs treated with 
either saline or 30μg/ml LPS for 1 hour both 48 and 0 hours before lung function 
measurements. For the purpose of analysis only negative peaks were considered and all 
positive sGaw values were excluded. Total includes all negative peaks from 0-12 hours. Area 
under the curve is expressed as %.hour. N=6 *significantly different from saline treatment 
p<0.05; performed with a two tailed T-test. 
 
 
Figure 30: Total lavage fluid protein of guinea-pigs treated with either saline or 30μg/ml LPS 
for 1 hour, 72 and 24 hours before lavage. Protein content was determined by BCA protein 
assay. N=6 *Significantly different from saline treatment p<0.05; performed with a two 
tailed T-test. 
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Figure 31: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5 LPM per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs treated with either A) saline or B) 30μg/ml LPS for 1 hour, 72 and 24 hours before final AHR assessment. 
Values were recorded 7 days pre- and 24 hours post-2nd LPS challenge. Mean changes in sGaw are expressed as mean±SEM percentage change from 
baseline.  A negative value represents a bronchoconstriction. N=6 *Significantly different from time paired pre-LPS challenge values p<0.05, ** p<0.01; 
performed with a two tailed T-test. 
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Figure 32: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs treated with saline or 30μg/ml LPS for 1 
hour, 72 and 24 hours before lavage. Results are expressed as mean±SEM; N=6 
***significantly different from saline treatment p<0.001; performed with a two tailed T-test. 
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Figure 33: The concentration of IL-8 in the lungs of guinea-pigs treated with saline or 
30μg/ml LPS for 1 hour, 72 and 24 hours before lavage. Results are expressed as mean±SEM; 
N=6 *significantly different from saline treatment p<0.05; performed with a two tailed T-
test. 
 
 
Figure 34: Bronchiolar changes in guinea-pigs treated with saline or 30μg/ml LPS for 1 hour, 
72 and 24 hours before lavage. L: lumen; ASM: airway smooth muscle; E: epithelium, IC: 
inflammatory cell. Stained with haematoxylin and eosin. Original magnification 100x (bar = 
25 µm). 
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Figure 35: The mean pathology score of the peribronchiolar area in guinea-pigs treated with 
saline or 30μg/ml LPS for 1 hour, 72 and 24 hours before lavage. Results are expressed as 
mean±SEM; N=6 *** significantly different from saline treatment p<0.001; performed with a 
two tailed T-test. 
 
 
 
Figure 36: Bronchiolar changes in guinea-pigs treated with saline or 30μg/ml LPS for 1 hour, 
72 and 24 hours before lavage. L: lumen; ASM: airway smooth muscle; E: epithelium; G: 
goblet cell; Stained with alcian blue/periodic acid Schiff stain Original magnification 200x 
(bar = 50 µm). 
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Figure 37: The number of mucin–associated goblet cells per 10,000 epithelial pixels in 
guinea-pigs treated with saline or 30μg/ml LPS for 1 hour, 72 and 24 hours before lavage. 
Results are expressed as mean±SEM; . Results are expressed as mean±SEM; N=6 
*significantly different from saline treatment p<0.05; performed with a two tailed T-test. 
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5.6 DISCUSSION 
LPS exposure has been shown to both attenuate and exacerbate responses to 
allergen in both humans and animal models. The range of different species, allergen 
sensitisation and challenge protocols, LPS dose and exposure timings in relation to 
allergen challenge in animal models probably account for these divergent responses.  
The experiments described in this chapter were performed to examine the effects of 
number and timing of LPS exposures on allergen-induced responses. The overall aim 
was to find a timing and number of LPS exposures that exacerbates allergen-induced 
responses as a model of asthma exacerbation. 
5.6.1 LUNG FUNCTION 
In the present study it was shown that LPS exposure 24 hours before allergen 
challenge significantly attenuates the early asthmatic response to ovalbumin. 
Contrastingly, when LPS was co-administered with ovalbumin there was no decrease 
in early phase response. A decrease in the immediate asthmatic response with LPS 
given 24 hours before allergen challenge has been demonstrated in both animal 
models and humans (Vannier et al, 1991; Sohy et al, 2006). The attenuation of the 
early asthmatic response may be due to effects on mast cells, which mediate early 
phase bronchoconstrictions via histamine and other granule product released. Mast 
cells respond to LPS via TLR4 on the cell membrane and become activated both in 
vitro (Masuda et al, 2002) and in vivo (Murakami et al, 2000). This activation results 
in a partial degranulation of stored histamine and decrease in the production of 
arachidonate acid metabolites such as LTC4 and TXA2, both of which are potent 
bronchoconstrictors (Vannier et al, 1991). Mast cells can take over 24 hours to fully 
recover from degranulation (Dvorak, 2005). Thus, the decrease in early phase 
bronchoconstriction to Ova could be due to insufficient time for mast cells to recover 
from LPS induced degranulation 24 hours before allergen challenge. The 48 hours 
between LPS exposure and allergen challenge in the Ova and LPS co-administration 
protocol likely gives mast cells sufficient time to recover from these effects.  
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 Early phase responses are not typically measured in allergen challenge 
models and so there are few studies on which to compare responses. Using an 
ovalbumin and LPS co-administration protocol, Tulic et al, (2002) demonstrated an 
increase in the time taken to reach peak early phase bronchoconstriction. No 
elongation in the early phase response was reported. This is in accordance with the 
current study where a single dose of LPS co-administered with ovalbumin challenge 
did not significantly prolong the early phase bronchoconstriction. The addition of a 
second LPS exposure 48 hours before co-administration with ovalbumin significantly 
lengthened the duration of the early phase. To the best of my knowledge no other 
study has shown this effect. Other changes in the early phase response have been 
shown in humans. A further reduction in FEV1 values after allergen was shown when 
co-administered with LPS (Boehlecke et al, 2003). Other studies in humans have 
failed to demonstrate this effect (Nightingale et al, 2000). In the latter study, the 
administration of salbutamol shortly before allergen challenge likely accounts for 
this difference.  
The elongation of the EAR seen in this study could be due to enhanced activation of 
mast cells by LPS. Mast cells mediate other LPS-induced exacerbation effects such as 
enhanced allergic inflammation (Murakami et al, 2000). Also, mast cells have been 
shown in vitro to demonstrate increased IgE induced cross-linking in the presence of 
a single dose of LPS (Masuda et al, 2002). In the current study an increase in the 
length of the EAR was only observed in guinea-pigs in the co-administration protocol 
exposed to 2 doses of LPS. In vivo it might be necessary for LPS priming before an 
enhance response can be produced. LPS exposure upregulates the expression of 
TLR4, the main receptor involved in LPS signalling in addition to downstream 
messengers (Lin et al, 2006; Hoogerwerf et al, 2010). Subsequent LPS exposure in 
cells with increased TLR-4 expression may mediate a larger response (Nigo et al, 
2006). LPS also primes airway neutrophils and macrophages for further exposures 
and the release of bronchoconstrictor substances either directly and indirectly 
(Reino et al, 2012; Hoogerwerf et al, 2010). This may also be the mechanism behind 
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the bronchoconstriction seen in guinea-pigs treated with LPS twice in the current 
study; although non-IgE mediated mast cell degranulation cannot be ruled out. The 
need for previous exposure to LPS to produce an increased bronchoconstrictor 
response is further highlighted by the results for LPS exposure on a non-allergic 
background. In the current study, a single LPS exposure does not cause a 
bronchoconstriction, whereas a second exposure does. LPS induced 
bronchoconstrictions have been observed in humans (Michel et al, 1989; Cavagna 
1969). This process has been associated with the release of platelet activating factor, 
a potent bronchoconstrictor (Rylander & Beijer, 1987). 
 This study did not demonstrate any significant effect of LPS on late phase 
bronchoconstrictions to allergen. A lack of effect on the late phase 
bronchoconstriction following LPS exposure has also been shown in humans (Sohy et 
al, 2006). However it is difficult to draw many comparisons with this study as it only 
examined LPS exposure 24 hours before allergen challenge and failed to 
demonstrate a change in inflammatory response. This may be due to the low dose of 
LPS used. A study by Tulic et al, (2002) reported decreased late phase responses in 
rats following allergen and LPS co-administration. However, this study did not 
actually measure late phase bronchoconstrictions and instead inferred ‘late phase 
response’ from AHR and inflammation.  As seen previously in chapter 3, dissociation 
between allergen responses can happen, making inferences difficult. Despite not 
having a significant effect on the late phase bronchoconstriction, the results suggest 
LPS may be having some effect on the late phase. A non-significant trend for an 
increase in the peak bronchoconstriction of the late phase with increasing number of 
LPS exposures in the co-administration protocol was observed. Even in the studies 
where the EAR was reduced by LPS, the response was prolonged with the EAR and 
LAR merging. Due to a lack of studies, especially in animal models examining ‘true’ 
late phase bronchoconstrictions it’s not possible to be certain of the effect of LPS on 
the late phase.  
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5.6.2 AIRWAYS HYPERRESPONSIVENESS 
The present study demonstrated that LPS has dichotomous effects on AHR 
depending on the timing of the exposure. When LPS exposure took place 24 hours 
before ovalbumin challenge there was decreased development of AHR. 2 exposures 
to LPS before Ova challenge completely abolished the development of AHR. 
Similarly, Komlosi et al, 2006 reported a decrease but not abolition of AHR when a 
single dose of LPS was given 24 hours before Ova challenge. Others have 
demonstrated no change in allergen-induced AHR with LPS exposure (Gerhold et al, 
2002). However, in this particular study AHR was measured 48 hours after the final 
Ova challenge, a time point at which AHR to Ova alone would be expected to have 
diminished (Evans, 2009). The decreased AHR in this study does not seem to be due 
to the airways already being constricted. No significant bronchoconstriction was 
present at 24 hour post-Ova challenge, the time of AHR assessment.  
LPS co-administered with Ova prolonged the bronchoconstrictor response to 
histamine. Several studies have demonstrated increases in AHR to allergen with LPS 
exposure. Delayre-Orthez et al, 2004 demonstrated an increase in AHR when repeat 
Ova challenges were co-administered with LPS. Rodriguez et al, (2003) showed that 
intra-nasal LPS immediately before Ova challenge prolongs the airway response to a 
bronchoconstrictor agent. This effect is only found when LPS is administered locally. 
LPS administered intravenously abolished the AHR after Ova challenge. Contrasting 
with the current study, LPS and allergen co-exposure has been shown to decrease 
AHR in rats (Tulic et al, 2002). However, this study also reported a decrease in 
inflammation suggesting that an alternative LPS response at this time point may 
have been triggered. Factors such as the species, dose and source of LPS and Ova 
protocol (the aforementioned study used ricin instead of alum as the adjuvant) may 
account for this discrepancy.  
The mechanism behind both the increased and decreased AHR observed in 
this study is unknown. AHR is often associated with increases in airway inflammation 
(Cockcroft & Davis, 2006). Supporting this is the observation in the present study 
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that an increase in AHR was seen alongside an increase in inflammation in guinea-
pigs co-administered LPS and Ova. Additionally, LPS alone induces AHR, 24 hours 
after LPS exposure alongside an increase in inflammation. This contrasts with Nevin 
& Broadley (2004) who demonstrated AHR only 1 hour after LPS exposure in guinea-
pigs. However, this study only used a single LPS exposure, whereas the present study 
used 2, possibly increasing the duration of LPS-induced AHR. This supported by the 
observation that 2 LPS challenges induce AHR which is still present at 4 hours post-
challenge, whereas with one it has dissipated (Toward & Broadley, 2001). 
Contrasting with the present study, LPS exposure 24 hours before Ova challenge has 
also been shown to increase inflammation but decrease AHR. Furthermore, the 
airway response to histamine was abolished with the addition of an exposure 72 
hours before Ova challenge. This is not the first study to demonstrate dissociation 
between AHR and inflammation. AHR has been demonstrated with limited 
inflammation (Delayre-Orthez et al, 2004) and less AHR in the presence of increased 
inflammation (Komlosi et al, 2006). This suggests the importance of other factors in 
the development of AHR. 
The nature of the inflammatory response may be a more important factor 
then the extent of it. In particular, neutrophil and macrophage activity may be an 
important factor in the development of AHR. LPS alone induces AHR in rats which 
correlate strongly with fluctuating levels of neutrophils (Pauwels et al, 1990). 
Neutrophils and macrophages release reactive oxygen species which cause epithelial 
damage and reduce the amount of enzymes such as diamine oxidase, important in 
breakdown of histamine (Folkerts & Nijkamp, 1998). This could extend the biological 
half-life of histamine, prolonging bronchoconstriction. In allergy, this may require a 
full allergen response to result in a worsening of AHR. The EAR and LAR are closely 
associated, the latter of which has been linked to the development of AHR 
(Hargreave et al, 1986). The observation that LPS did not increase AHR in pre-Ova 
LPS exposure groups, also not demonstrating a full EAR would support this. 
Alternatively, an increase in the production of nitric oxide may mediate increased 
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AHR. Nitric oxide levels and AHR both decrease in LPS binding protein deficient mice, 
which helps mediate LPS receptor binding (Stroheimer et al, 2001). However, an 
iNOS inhibitor effective on AHR to Ova alone, fails to reduce AHR in an Ova and LPS 
combination model questioning the role of this potential mechanism (Komlosi et al, 
2006). Regardless of the mechanism behind prolonged AHR, this study has clearly 
highlighted the temporal nature of LPS’s effect on functional responses. A study by 
Tulic et al, (2002) further demonstrates this; when LPS is administered 18 hours after 
allergen challenge it diminishes AHR. Thus it seems there is a key period around the 
time of allergen challenge where LPS will exacerbate AHR but given 18-42 pre- or 
post-allergen challenge will attenuate it. 
5.6.3 AIRWAY INFLAMMATION AND CYTOKINES 
Leukocyte infiltration in lavage fluid increased with the number of LPS exposures but 
was unaffected by the timing of LPS exposure. Airway inflammation assessed by an 
H&E scoring method did not reveal this increase in inflammation with LPS treatment. 
This is probably because H&E scoring methods lack the same fidelity as lavage based 
methods of assessment. They are mainly used to assess morphological changes. The 
increase in lavage fluid inflammation with different LPS timings is in accordance with 
other studies which suggest that the route of LPS administration (intra-venous vs 
intra-nasal/inhaled) and the exposure dose are more important factors in the 
inflammatory response. A high dose of LPS administered locally to the airways 
increases total cell counts in both mice and rats.  As in the present study, neutrophils 
were significantly increased (Murakami et al, 2006; Tulic et al, 2000). Unlike in the 
present study where no significant change in eosinophil was seen, an increase in 
eosinophils was also observed. This is similar to the situation in humans where 
neutrophil and/or eosinophils increase during asthma exacerbations (Ordonez et al, 
2000). The lack of an increase in eosinophils in the present study could be due to 
variation in the protocols employed, with the former study using multiple 
allergen/LPS challenges. This may increase Th2 lymphocyte responses which would 
favour increases in eosinophils. 
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High doses of LPS have also been shown to result in an overall decrease in 
inflammatory cells (Gerhold et al, 2002). Most of the decrease was in eosinophils; 
whether neutrophils increased is unknown as the researchers were unable to detect 
them. Making comparisons between the results of these in vivo studies is always 
problematic. It is difficult to extrapolate the dose of LPS that an animal actually 
receives from what is reported in the literature. The time of exposure, route and 
pharmacokinetic properties likely all vary.  
 Underlying the increase in neutrophils seen in the present study was an 
increase in the amount of IL-8 in the lung of guinea-pigs where LPS was co-
administered with Ova challenge. A similar increase was seen in guinea-pigs exposed 
to LPS twice. An increase in IL-8 with LPS treatment would be expected as LPS is 
known to be a potent inducer of the cytokine (Alexis et al, 2005). IL-8 is a key 
chemoattractant in the migration of neutrophils and unregulated by LPS (Kamochi et 
al, 1999). However, increases in neutrophilia were also seen in guinea-pigs treated 
with LPS 24 hours before Ova challenge but with no increase in IL-8. This is likely due 
to differences in the time point after LPS exposure that lungs were assessed. In the 
LPS co-administration groups, lungs were frozen 24 hours after final LPS exposure, 
whereas this was done 48 hours later In the 24 hour pre-Ova LPS exposure groups. 
IL-8 is a transient cytokine, not persistently increased over long time periods 
(Angrisano et al, 2010; Danahay et al, 1999). At the 48 compared to 24 hours post-
LPS exposure, IL-8 levels would be expected to be lower.  
 Increased IL-13 was seen in guinea-pigs challenged with Ova. Ova induces Th2 
lymphocyte responses which are characterised by increased levels of cytokines such 
as IL-4 and IL-13. LPS exposure did not further increase IL-13 levels in lung. This is in 
accordance with a study that also used a high dose of LPS (Murakami et al, 2006). 
Other studies have shown a decrease in IL-13 (Komlosi et al, 2006; Rodriguez et al, 
2003). No increase in IL-13 levels indicates that LPS exposure is not further 
promoting Th2 allergic responses. This is more characteristic of lower doses of LPS, 
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whereas high doses tend to favour Th1 proinflammatory responses with increased 
IL-8, IL-1β and GM-CSF (Boehlecke et al, 2003).  
IL-17 levels were increased in guinea-pigs exposed to LPS but not above that 
seen for Ova alone. The exception to this was in guinea-pigs exposed to a single dose 
of LPS 24 before Ova challenge. IL-17 is implicated in more severe forms of asthma 
and associated with increased neutrophils (Doe et al, 2010). Few studies examining 
the effect of LPS on IL-17 levels in allergic responses have been performed. One 
study using house dust mite as an allergen found that LPS increased IL-17 
concentrations (de Boer et al, 2013). This study used repeat allergen challenge and a 
non-Ova allergen which may account for difference with the present study. In 
addition, Doe et al, (2010) noted that IL-17 can be difficult to detect and only 
secreted in certain lung compartments. Thus using lung homogenate may not have 
been the best way to detect changes in IL-17 levels. Ideally lavage fluid would have 
been used but IL-17 levels were too low to be consistently detected. Therefore the 
effect of LPS on IL-17 levels requires further investigation. 
5.6.4 AIRWAY OEDEMA   
Airway oedema was observed to be significantly increased in guinea-pigs treated 
with LPS 48 hours pre- and co-administered with Ova challenge. This increase was 
also seen with 2 doses of LPS alone. This is characteristic of asthma exacerbations in 
humans (Hogg, 1997). LPS is well established at causing protein extravasation and 
oedema and has been shown to increase LPS binding protein levels, which may 
further amplify oedema (Dubin et al, 1996). An increase in airway oedema was not 
seen with a single dose of LPS co-administered. This indicates that 2 LPS exposures 
may be necessary to cause an increase in airway oedema. The lack of an increase in 
oedema in guinea-pigs treated with either 1 or 2 LPS exposures 24 hour pre- Ova 
challenge may be due to a failure to invoke the full allergic response. Alternatively, 
oedema levels may have decreased 48 hours after LPS challenge. 
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5.6.5 GOBLET CELL HYPERPLASIA/METAPLASIA 
Goblet cell numbers increased significantly with 2 doses of LPS in either exposure 
protocol used but not with a single dose of LPS. Goblet cell numbers also increased 
with 2 doses of LPS on a non-allergic background. Other studies have confirmed this 
result (Toward & Broadley, 2002). The largest increase in goblet cells was seen with 2 
LPS exposures in the Ova co-administration protocol. Importantly this was the 
protocol that also exacerbated other Ova-induced responses. Mucus secretion is one 
of the hallmarks of asthma exacerbations and is commonly seen in asthmatics that 
have died from status asthmaticus (Kuyper et al, 2003).  
5.6.6 GENERAL CONCLUSIONS 
This study has demonstrated the temporal relationship that LPS has on allergen 
challenge induced responses. It has shown that LPS exposure within 24 hours of 
allergen challenge diminishes functional responses, while increasing airway 
inflammation. It has also shown that LPS co-administered with allergen challenge is 
able to exacerbate functional and inflammatory responses to allergen challenge. 
From this study a model of asthma exacerbation demonstrating prolonged EAR, 
prolonged bronchoconstrictor response to histamine, increased airways 
inflammation, airway oedema and goblet cell hyperplasia has been developed. The 
sensitivity of this model to anti-asthma treatments will be investigated in the coming 
chapters.  
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6.1 INTRODUCTION 
6.1.1 INHALED CORTICOSTEROIDS 
Corticosteroids are a frontline therapy used in the treatment of asthma. Historically, 
when their ability to treat the symptoms of asthma were realised they were given 
systemically. However this caused extensive side effects including growth 
retardation and osteoporosis, so in the 1970s inhaled preparations were developed. 
Inhaled corticosteroids continued to be developed and many including budesonide, 
beclometasone and fluticasone propionate are still used in routine control of 
asthma. Inhaled corticosteroids have proven effective in providing symptomatic 
control, reducing exacerbations and preventing the development of irreversible 
airway remodelling (Barnes et al, 1998A). Corticosteroids are frequently used alone 
or in combination with other therapies such as theophylline, anti-leukotrienes and 
β2-adrenoceptor agonists. These medicines are all complimentary to corticosteroid 
therapy. β2-adrenoceptor agonists in particular are able to suppress early phase 
bronchoconstriction, one of the elements of asthma upon which corticosteroids 
have limited efficacy (Booij-Noord et al, 1971). 
6.1.2 EFFECT OF CORTICOSTEROIDS IN ASTHMA 
The effects of inhaled and systemic steroids are similar so will be discussed together. 
Corticosteroids have a wide range of actions on inflammatory cells, mediators, 
mucus secretion and AHR.  Eosinophils, a hallmark of allergic disease, are reduced 
following treatment with steroids. This reduction is partly due to the suppression of 
eosinophil accumulation by decreased chemoattractants, adhesion molecules and 
increased eosinophil apoptosis (Underwood et al, 1997; Meagher et al, 1996). 
Macrophages can secrete both pro- and anti-inflammatory mediators. Corticosteroid 
treatment suppresses pro-inflammatory and increases anti-inflammatory secretion 
of mediators such as IL-10 (John et al, 1998). Corticosteroids also reduced mast cell 
numbers but have little effect on mast cell degranulation (Belvisi, 2004). This 
accounts for their lack of effect on the early asthmatic response which is mast cell 
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mediated. Dendritic cells are reduced in number by corticosteroids, decreasing 
allergen presentation and dampening the immune response (Nelson et al, 1995). T-
lymphocyte activity is also blocked by corticosteroid treatment, resulting in a 
reduction in the secretion of Th2 cytokines such as IL-4, IL-5 and IL-13, which are 
important mediators in allergic disease (Krouwels et al, 1996). Epithelial cells are 
now recognised as an important source of inflammatory mediators including IL-8, 
CCL11 (eotaxin-1), GM-CSF, CCL4 (MIP-1α), CCL5 (RANTES) and nitric oxide. These 
are all decreased by corticosteroid treatment (Barnes et al, 1998a). Neutrophils are 
not commonly found in milder forms of asthma but can make up a significant portion 
of the airway inflammatory cell population in more severe and neutrophilic forms of 
the disease (Wenzel et al, 1999). Contrastingly with other inflammatory cell types, 
neutrophils are relatively unresponsive to corticosteroid and may even enhance their 
survival (Strickland et al, 2001). AHR to bronchoconstrictor agents is also reduced by 
corticosteroid treatment (Barnes, 1990). The late asthmatic response, seen in a 
majority of asthmatics is also reduced, likely because of corticosteroids anti-
inflammatory actions (Palmqvist et al, 2005). Mucus secretion is reduced by several 
mechanisms including indirect action from a reduction in inflammatory mediators, 
direct action on the mucosal glands and inhibition of the mucin genes MUC5A and 
MUC2 (Shimura et al, 1990; Kai et al, 1996). Airway oedema is decreased by direct 
genomic effects but also by extra-genomic effects such as vasoconstriction (Mendes 
et al, 2003). A simplified diagram of some of the main cellular effects of 
corticosteroids is shown in Figure 1. 
In addition to these desirable effects of corticosteroids many side effects are 
frequently encountered. Fewer side effects are encountered with inhaled than with 
oral corticosteroids due to lower systemic distribution (Wood et al, 1999). However, 
the incidence of side effects increases with higher inhaled doses, which are used in 
less corticosteroid-responsive asthma. Although rare with inhaled therapy, potential 
side effects include osteoporosis, cataracts, growth retardation in children and 
cardiovascular and gastrointestinal disturbances (Schäcke et al, 2002). Additional 
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side effects of inhaled steroids include hoarseness of voice, oral infections; 
particularly fungal and dysphonia due to laryngeal deposition (Barnes et al, 1998A).  
 
 
Figure 1: Simplified diagram of the major cellular effects of corticosteroids. 
6.1.3 MECHANISMS OF CORTICOSTEROID ACTION 
Corticosteroids pass readily through the plasma membrane and bind to the 
cytoplasmic glucocorticoid receptor (GR). Several splice variants of the GR exist 
including GR-α which binds to corticosteroids and GR-β which does not. Thus the 
effects of corticosteroids are through GR-α, although GR-β may have a role in 
corticosteroid insensitivity (Leung and Bloom, 2003; Strickland et al, 2001). The 
binding of a corticosteroid to the GR results in dissociation of molecular chaperones 
such as heat shock protein (hsp-90) and FK-binding protein, resulting in nuclear 
localisation of the GR-corticosteroid complex. Corticosteroids exert their anti-
inflammatory effects by several distinct mechanisms (Marwick et al, 2007). One 
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mechanism termed trans-activation increases the transcription of anti-inflammatory 
genes. Negative glucocorticoid response elements sites also exist which can suppress 
gene expression (Cis-repression) and likely mediate some of the side effects of 
steroids (Schäcke et al, 2002). Another anti-inflammatory effect of steroids is trans-
repression which suppresses pro-inflammatory gene transcription. These processes 
are believed to take place at different concentrations of corticosteroid. 
Corticosteroids can also modify proteins post-transcriptionally by decreasing the 
stability of mRNA (Barnes, 2006). 
6.1.3.1TRANS-ACTIVATION 
GR-corticosteroid complexes are able to dimerise at specific DNA sites called 
glucocorticoid response elements (GRE) in the promoter regions of corticosteroid-
responsive genes. This allows GR to interact with a variety of co-activator molecules 
such as GRIP-1, pCAF and CREB binding protein (CBP). These proteins have intrinsic 
histone acetyltransferase (HAT) activity and thus can induce histone acetylation, 
which unwinds DNA and increases gene transcription. Inflammatory genes activated 
by corticosteroids include IL-10, MAP kinase phosophatase-1 (MKP-1), CBP, annexin-
1 and the inhibitor of NF-κB (IκB). This is unlikely to be the main mechanism of 
corticosteroids as in vitro 100 fold higher concentrations then for trans-repression 
are required (Ito et al, 2000). Most of the side effect profile of steroids at high doses 
such as cataracts, osteoporosis, growth retardation, metabolic effects and fragility 
may be caused by trans-activation. This process is shown in Figure 2. 
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Figure 2: Transactivation of anti-inflammatory gene expression by corticosteroids. 
Corticosteroids pass through the cell membrane and bind to glucocorticoid receptors (GR) in 
the cytoplasm and translocate to the nucleus. In the nucleus they increase transcription by 
binding to glucocorticoid response elements (GRE) and interactions with co-activators such 
as pCAF, GRIP-1 and CBP, inducing histone acetylation and anti-inflammatory gene 
trascription. pCAF= p300 and p300-CBP associated factor;  CBP= cyclic AMP response 
element binding (CREB) binding protein;  GRIP-1= GR interacting protein-1. Diagram redrawn 
and adapted from Barnes, 2006. 
 
6.1.3.2 TRANS-REPRESSION 
Trans-repression is the major mechanism by which corticosteroids exert their anti-
inflammatory effect. GR monomers are able to form co-repressor complexes which 
in turn can inhibit activated transcription factors such as NF-κB and AP-1 via protein-
protein interaction. This prevents their natural HAT activity, suppressing pro-
inflammatory gene transcription (Glass & Ogawa, 2006). Corticosteroids can also 
recruit histone deacetylases (HDAC) which remove acetyl groups from histone 
protein, causing DNA to become less accessible for transcription (Ito et al, 2000). 
This process is shown in Figure 3. Other modifications such as phosphorylations, 
methylations and ubiquitinations are also important in corticosteroid gene 
suppression effects.  
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Figure 3:  Transrepression of activated inflammatory genes. Inflammatory stimuli such as IL-
1β and TNF-α stimulate an inflammatory cascade, which activates NF-κB. NF-κB translocates 
to the nucleus and forms a pro-inflammatory complex with co-activators such as pCAF and 
CBP. These activators have intrinsic HAT activity and acetylate histone proteins, increasing 
inflammatory gene transcription. Corticosteroids interfere with this process by binding to GR 
and translocating to the nucleus. In the nucleus they bind to co-activators, inhibiting HAT 
activity and also directly recruit HDAC-2. HDAC-2 deactylates histone proteins, suppressing 
gene transcription. NF-κB= nuclearfactor-kappaB; pCAF= p300 and p300-CBP associated 
factor; CBP= cyclic AMP response element binding (CREB) binding protein; HAT= histone 
acetyl transferase; HDAC= Histone deacetylase. Diagram redrawn adapted from Barnes, 
2006. 
6.1.4 INHALED CORTICOSTEROID INSENSITIVITY 
Resistance or insensitivity to corticosteroids exists in about 5% of the asthmatic 
population. Full corticosteroid resistance is rare and most patients lie on a spectrum 
of responsiveness (Szefler et al, 2002). Insensitivity to inhaled corticosteroids often 
results in higher doses being used which carry an increased risk of side effects 
(Schäcke et al, 2002). In patients completely unresponsive to inhaled corticosteroids, 
short bursts of oral corticosteroids are used to control symptoms (Chan et al, 1998). 
These are associated with extensive side effects and are therefore not desirable for 
long term control. Patients that are unresponsive to corticosteroid treatment are 
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more likely to have poorly controlled asthma and present considerable management 
and economic problems. 
Patients with corticosteroid insensitive asthma display increases in mast cells, 
macrophages and lymphocytes. Increased levels of ECP, IL-8 and MPO are also 
observed and correspond with increases in eosinophils and neutrophils (Jatakanon et 
al, 1999). There is considerable heterogeneity in the presence of these 2 cells 
between individuals, suggesting several sub-groups of patients may exist (Wenzel et 
al, 1999). Whether these differences are due to variability in individuals’ 
corticosteroid treatment is currently unknown. This is possible though as neutrophils 
are known to be less corticosteroid responsive then eosinophils (Strickland et al, 
2001). The presence of neutrophils in corticosteroid insensitive asthmatics has led to 
the suggestion that the activation of the innate immune system is critical in its 
development. In particular, activation of interferon and TLR4 pathways during viral 
and LPS/bacterial induced asthma exacerbations have been implicated (Yang et al, 
2009). Corticosteroid-insensitive asthmatics demonstrate inflammatory patterns 
characteristic of LPS activation, coinciding with high levels of LPS in lavage fluid 
(Goleva et al, 2008). Additionally, LPS induces neutrophilic inflammation which is 
unresponsive to inhaled corticosteroid treatment in healthy volunteers and 
asthmatics (Trapp et al, 1998; Michel et al, 2000). However, despite these 
observations the full relationship between LPS-induced asthma exacerbations and 
corticosteroid resistance remains to be fully characterised.  
 
6.1.5 MECHANISMS CORTICOSTEROID INSENSITIVITY 
Several mechanisms have been implicated in corticosteroid insensitive asthma. 
These include decreased GR expression, decreased affinity of ligands for GR, 
decreased ability of GR to bind DNA, increased expression of pro-inflammatory 
transcription factors and decreased expression and activity of co-repressor proteins. 
Cellular mechanisms including Th17 lymphocytes and neutrophils have also been 
Chapter 6 
 
221 
 
proposed. The potential mechanisms are shown in Figure 4. The importance of these 
mechanisms probably varies between patients. It is know that the presence of 
corticosteroid insensitivity in asthma is not associated with any abnormality of 
cortisol levels or Addison’s disease.  
6.1.5.1 GR BINDING  
A reduction in GR binding affinity to corticosteroids has been found in corticosteroid 
insensitive asthmatics. In most patients this defect was found to be reversible in vitro 
without the presence of IL-2 or IL-4 suggesting that the change is not intrinsic (Sher 
et al, 1994). One potential mechanism for this is increased expression of GR-β which 
can decrease the affinity of ligands for GR-α by the formation of hetrodimer 
complexes (Oakley et al, 1999). The combination of IL-2 and IL-4 or IL-13 alone 
increases the expression of GR-β but with no change in GR-α levels (Leung and 
Bloom, 2003). Increased expression of GR-β has been shown in macrophages of 
corticosteroid insensitive patients (Goleva et al, 2006). The high expression of GR-β 
in neutrophils, prevalent in corticosteroid insensitive asthma may also explain their 
insensitivity to steroids (Strickland et al, 2001). However, increased GR-β levels have 
not been found in all patients so may represent just one of many pathways that lead 
to corticosteroid insensitivity (Gagliardo et al, 2000; Butler et al, 2012). Other factors 
such as p38 MAPK and nitric oxide can also decrease GR activity, although the 
mechanism of this remains uncertain (Irusen et al, 2002; Galigniana et al, 1999).  
6.1.5.2 GR NUCLEAR TRANSLOCATION AND GRE BINDING 
Other groups of corticosteroid insensitive patients have shown decreased nuclear 
translocation of GR in human monocytes (Matthews et al, 2002). As with GR ligand 
affinity, p38 MAPK may also mediate this process (Irusen et al, 2002). The JAK-STAT 
pathway may also play a role in decreased nuclear translocation. Treatment of 
murine cells with IL-2 induced corticosteroid insensitivity which was reversed by a 
JAK3 inhibitor. The JAK3 inhibitor prevented GR and STAT5 binding, preventing 
nuclear translocation of GR (Goleva et al, 2002). However, Matthews et al, (2002) 
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demonstrated that in a separate group of patients nuclear translocation was normal 
but the ability of steroids to trans-activate certain genes was decreased.  
6.1.5.2 COFACTOR ASSOCIATION 
Corticosteroid insensitivity may also be due to an inability to repress pro-
inflammatory signalling. Both AP-1 and NF-κB are redox sensitive proteins which 
demonstrate increased activity with increasing oxidative burden, as seen in asthma 
exacerbations or severe chronic inflammation (Rahman & MacNee, 1998). Increased 
levels of AP-1 are observed in corticosteroid insensitive asthma and concordantly a 
reduction in the ability of steroids to repress its pro-inflammatory activity (Adcock et 
al, 1995). A decrease in the ability to recruit co-repressor proteins such as HDAC may 
also be important in corticosteroid insensitivity. Many patients demonstrate no 
decrease in nuclear translocation or corticosteroid side effects (mediated by trans-
activation) but decreased HDAC-2 function (Ito et al, 2006; Hew et al, 2006). The 
restoration of HDAC-2 activity by the drug theophylline restores corticosteroid 
sensitivity in alveolar macrophages ex vivo and in vivo (Ito et al, 2002; Ford et al, 
2010). Decreased HDAC-2 activity may be direct or indirect.  
Indirect routes include the PI3K/Akt pathway which is increased during oxidative 
stress. The PI3K-δ subtype is particularly important in the development of 
corticosteroid-insensitivity as mice without this protein are resistant to cigarette 
smoke-induced corticosteroid insensitivity (Marwick et al, 2009). Inhibition of this 
pathway by the PI3K inhibitor LY-294002 attenuates allergic inflammation, AHR and 
reverses corticosteroid resistance in mice (Barthel & Klotz, 2005). More selective 
inhibitors of PI3K-δ such as Nortriptyline have similar biological actions but lower 
incidence of toxic side-effects (Mercado et al, 2011). Directly, reactive oxygen 
species such as hydrogen peroxide and SIN-1 (a peroxynitrate generator) are able to 
reduce HDAC-2 activity and increased tyrosine nitiration of HDAC-2 (Ito et al, 2004). 
However, a recent study has called into question the importance of this mechanism 
in a majority of patients (Butler et al, 2012). 
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6.1.5.4 CELLULAR MECHANISMS 
Neutrophils are implicated in the development of corticosteroid insensitive asthma. 
Their survival is increased in severe asthma and apoptosis inhibited by corticosteroid 
treatment (Uddin et al, 2009; Cox, 1995). This is associated with high constitutive 
levels of GR-β in circulating neutrophils and decreased expression of GR-α upon 
entering the airway (Strickland et al, 2001; Plumb et al, 2012). This particular 
modification may make airway neutrophils especially insensitive to corticosteroid 
treatment. Continued exposure to neutrophil promoting factors may facilitate 
neutrophil tissue damage and further oxidative stress induced modifications to 
corticosteroid responsiveness (Leung & Bloom, 2003). 
Th17 cells and their cytokines have also been implicated in corticosteroid insensitive 
asthma. IL-17, a hallmark cytokine of Th17 responses is increased with neutrophilia 
in asthma (Bullens et al, 2006). Th17 cells are insensitive to corticosteroid both in 
vitro and in vivo. Additionally, Th17 cell transfer decreased responsiveness to 
corticosteroids in animals previously sensitive to their effects (Mckinley et al, 2008). 
Whether IL-17 represents a distinct pathway of corticosteroid insensitivity or can 
occur alongside the other potential mechanisms is unknown.  
 
Chapter 6 
 
224 
 
 
Figure 4: Diagram of the potential mechanisms of corticosteroid insensitivity in asthma.  
6.1.5 EFFECT OF INHALED CORTICOSTEROIDS IN ANIMAL MODELS  
Inhaled corticosteroids such as fluticasone propionate (FP) have a range of effects on 
animal models of asthma. Evans et al, (2012) demonstrated that inhaled FP abolishes 
the late asthmatic response but has no effect on the early asthmatic response in 
guinea-pigs. Coinciding with this was a suppression of AHR and a significant 
reduction in eosinophilia and lymphocytes. These effects in guinea-pigs have also 
been confirmed by other groups (Lawrence et al, 1998).  
Few groups have examined the effect of inhaled corticosteroids on asthma 
exacerbations. Animal models demonstrating partial insensitivity to inhaled 
corticosteroids have been developed. Ito et al, (2008) demonstrated that low level 
Ova challenge for 4 weeks followed by a large exacerbating dose can evoke partially 
inhaled corticosteroid insensitive inflammation and fully insensitive AHR in mice. 
This was associated with a decrease In HDAC-2 activity. Singam et al, (2006) 
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demonstrated similar results in mice using respiratory syncytial virus infection 
superimposed on allergen challenge. Inhaled FP did not reduce AHR, lymphocytes 
and neutrophils but did reduce eosinophils. Essilfie et al, (2012) demonstrated that H 
influenza before allergen sensitisation in mice increases neutrophilia and Th17 
lymphocyte responses but decreased AHR, eosinophilia, total cell counts and Th2 
cytokines. Treatment with a dose of intranasal dexamethasone, effective on Ova 
evoked responses alone does not reduce the H.influenza induced changes. Presently, 
no one has examined the effect of inhaled steroids in a model demonstrating 
exacerbation of functional and allergic responses to LPS.  
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6.2 HYPOTHESIS 
‘LPS exposure will decrease the inhaled corticosteroid sensitivity of functional and 
inflammatory responses in an acute ovalbumin model of asthma’ 
6.3 AIMS AND OBJECTIVES 
The aim of this chapter was to determine the sensitivity to the inhaled 
corticosteroid, fluticasone propionate, of functional and inflammatory responses in 
ovalbumin, LPS and ovalbumin and LPS models. The initial aim was to establish an 
inhaled fluticasone propionate dose which significantly attenuates the late asthmatic 
response, AHR and cellular inflammation in an ovalbumin model. The effective dose 
was then used to establish the corticosteroid sensitivity of these responses in LPS 
alone and ovalbumin and LPS combination models. The effect of inhaled fluticasone 
propionate on lavage fluid protein and lung cytokines was also established. Whether 
the timing of LPS exposure alters the corticosteroid sensitivity of responses was also 
assessed by comparing 2 ovalbumin and LPS models used in chapter 5. 
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6.4 METHODS 
Methods describing the measurement of lung function, AHR, airway oedema, airway 
inflammation and cytokine levels can be found in more detail in chapter 2.  
6.4.1 OVALBUMIN PROTOCOLS 
6.4.1.1 SENSITISATION 
Guinea-pigs (200-300g, Dunkin-Hartley, male) were sensitised by a bilateral intra-
peritoneal injection of a solution containing 150µg ovalbumin (Ova) and 100mg 
aluminium hydroxide (Al(OH)3) in normal saline on day 1, 4 and 7. 
 
6.4.1.2 ACUTE OVALBUMIN MODEL  
Guinea-pigs were exposed to inhaled Ova (0.03%) for 1 hour on day 21 in a Perspex 
container as described in section 6.4.1.2. The lung function response to Ova was 
assessed over 12 hours. The bronchoconstrictor response to 0.3mM histamine was 
assessed on day 15 and 22 as described in section 6.4.5. FP (0.05, 0.1, 0.5 and 
1mg/ml per day split into twice daily doses) was administered by inhalation in a 
Perspex chamber for 15 minutes, twice a day from day 16-21. On day 21 FP was 
administered 30 minutes pre- and 6 hours post-Ova challenge. A diagram of this 
protocol is shown in Figure 5. 
 
Figure 5: The acute ovalbumin (Ova) protocol. Guinea-pigs were challenged with inhaled Ova 
(0.03% on day 21). Fluticasone propionate (FP) was dosed twice daily for 6 days 
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6.4.1.3 LPS PRE-ACUTE OVALBUMIN EXPOSURE PROTOCOL 
Sensitised guinea-pigs were exposed to inhaled LPS (30μg/ml) 24 hours before Ova 
challenge for 1 hour in a Perspex box. On day 21 guinea-pigs were exposed to Ova 
(0.03%) for one hour. The bronchoconstrictor response to histamine was assessed on 
day 15 and day 22. FP (0.5mg/ml per day, split into twice daily doses) was 
administered by inhalation in a Perspex chamber for 15 minutes, from day 16-21. On 
day 20 and 21 FP was administered 30 minutes pre- and 6 hours post-Ova or LPS 
challenge. A diagram of this protocol is shown in Figure 6. 
 
Figure 6: Diagram of the pre-ovalbumin (Ova) challenge LPS exposure protocol. Guinea-pigs 
were challenged with LPS (30μg/ml) 24 hours pre-Ova exposure. Fluticasone propionate (FP) 
was dosed twice daily for 6 days 
 
6.4.1.4 ACUTE OVA AND LPS CO-EXPOSURE MODEL 
Sensitised guinea-pigs were exposed to inhaled LPS (30μg/ml) 48 hours before Ova 
challenge in an exposure chamber and both LPS (30μg/ml) and Ova (0.03%) co-
administered on day 21. The bronchoconstrictor response to histamine was assessed 
on day 15 and day 22. FP (0.5 or 1mg/ml per day, split into twice daily doses) was 
administered by inhalation in a Perspex chamber for 15 minutes, from day 16-21. On 
day 19 and 21 FP was administered 30 minutes pre- and 6 hours post-Ova or LPS 
challenge. A diagram of this protocol is shown in shown in Figure 7. 
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Figure 7: Diagram of the LPS and Ova co-exposure protocol. Guinea-pigs were exposed to 
LPS (30μg/ml) on day 19 and both Ova and LPS co-administered on day 21. Fluticasone 
propionate (FP) was dosed twice daily for 6 days 
 
6.4.2 LPS EXPOSURE PROTOCOL 
Non-sensitised guinea-pigs were exposed to LPS (30μg/ml) on day 5 and 7 of the 
protocol. The bronchoconstrictor response to histamine was assessed on day 1 and 
day 8. FP (0.5 or 1mg/ml per day, split into twice daily doses) was administered by 
inhalation in a Perspex chamber for 15 minutes, from day 2-7. On day 5 and 7 FP was 
administered 30 minutes pre- and 6 hours post-LPS challenge. A diagram of this 
protocol is shown in Figure 8 
 
Figure 8: Diagram of the LPS alone exposure protocol. Guinea-pigs were exposed to 30μg/ml 
of LPS on day 5 and 7. Fluticasone propionate (FP) was dosed twice daily for 6 days. 
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6.4.3 DRUG ADMINISTRATION 
FP was dissolved in ethanol (30%), DMSO (30%) and saline (40%) and nebulised for 
15 minutes into a Perspex exposure chamber using a DeVilbiss nebuliser. 
6.4.4 MEASUREMENT OF LUNG FUNCTION 
Lung function was measured by whole body plethysmography following final Ova, 
LPS or Ova /LPS exposure in all protocols. Lung function was recorded hourly for 12 
hours and every 15 minutes during the first hour of measurements. A final 
measurement was also taken 24 hours post-final challenge. All values were 
expressed as a percentage of the baseline reading, taken before the final challenge. 
A negative percentage change in baseline value represents a bronchoconstriction. In 
Ova protocols, early (0-6 hours) and late (6-12 hours) asthmatic responses were 
expressed as the peak bronchoconstriction during that period (displayed as a 
histogram next to a time course plot) and the area under the curve. The duration of 
the early phase was expressed as the time taken to recover to 50% of peak early 
phase bronchoconstriction values. In the LPS only protocol, lung function was 
measured for 12 hours after the second LPS exposure. The peak bronchoconstriction 
during this period was expressed on a histogram next to the time course plot.  
6.4.5 AIRWAYS HYPERRESPONSIVENESS ASSESSMENT. 
AHR was determined using whole body plethysmography. This was performed by 
measuring the bronchoconstrictor response to histamine before inhaled 
corticosteroid treatment and 24 hours post-final LPS, Ova, LPS or Ova challenge. 
Histamine was delivered as described in chapter 2. Lung function was measured just 
before histamine inhalation and at 0, 5 and 10 minutes post-histamine exposure. The 
peak bronchoconstriction during this period was expressed on a histogram.  
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6.4.6 ASSESSMENT OF AIRWAYS INFLAMMATION 
Following final histamine exposure guinea-pigs were sacrificed by an intra-peritoneal 
overdose of sodium pentobarbitone, the lungs excised and lavaged. Total and 
differential cell counts were then performed as described in chapter 2.  
6.4.7 QUANTIFICATION OF CYTOKINE LEVELS USING ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) 
Levels of IL-8, IL-17 and IL-13 were measured in diluted homogenised lung samples 
using ELISA supplied by R&D systems. Cytokine levels were adjusted for total lung 
protein and expressed as weight per mg of lung as described in section 2.2.3.2. 
6.4.8 ASSESSMENT OF AIRWAY OEDEMA 
Protein content in lavage fluid was determined as a measure of airway oedema by 
BCA protein assay as per the manufacturer’s instructions (Pierce protein biology).  
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6.5 RESULTS 
6.5.1 SENSITIVITY OF OVALBUMIN RESPONSES TO INHALED FLUTICASONE 
PROPIONATE 
Guinea-pigs treated with 0.05mg/ml FP (-68.9±3.3%), 0.1mg/ml FP (-71.7±2.9%) and 
vehicle (-69.4±7.5%) demonstrated an immediate bronchoconstriction. FP had no 
effect on the time course of the EAR. A further bronchoconstriction was observed in 
all groups between 6-12 hours including 0.05mg/ml FP at 8 hours (-17.2±5.7%), 
0.01mg/ml FP (-15.2±4.6%) and vehicle at 7 hours (-19.7±5.7%)  (Figure 9, time 
course. No significant change in peak EAR, LAR or 24 values were observed with 
0.05mg/ml and 0.1mg/ml FP treatment (Figure 9, histogram).  
 
Guinea-pigs treated with 0.5mg/ml FP (-59.0±4.6%), 1mg/ml FP (-67.9±2.3%) and 
vehicle (-69.4±7.5%) demonstrated an immediate bronchoconstriction. Treatment 
with FP did not significantly change the EAR time course. A further 
bronchoconstriction was observed in vehicle treated guinea-pigs between 6-12 
hours, at 7 hours the sGaw value was -19.7±5.7%. Guinea-pigs treated with 
0.5mg/ml or 1mg/ml FP demonstrated significantly smaller bronchoconstrictions 
than vehicle between 7 and 10 hours; at 7 hours sGaw values were 2.8±3.2% and -
1.3±2.8% respectively (Figure 10, time course). Peak EAR responses were not 
significantly changed by FP treatment. Peak LAR were significantly attenuated with 
0.5mg/ml and 0.1mg/ml FP (-10.2±1.9% and -8.6±2.4%) compared with vehicle (-
26.8±3.8%). No significant difference in sGaw values was observed 24 hours post-
Ova challenge (Figure 10, histogram) 
 
No significant difference in the total and EAR AUC were observed with FP treatment, 
although a non-significant trend for decreased EAR was observed with the 0.5 and 
1mg/ml FP. LAR area under the curve decreased in a dose-dependent manner with 
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FP. This reached significance in guinea-pigs treated with 0.5mg/ml FP (16.8±6.2%.hr 
compared to 72.3±10.5%.hr). Guinea-pigs treated with 1mg/ml FP demonstrated a 
trend for decreased LAR area but this did not reach significance (Figure 11).  
 
Vehicle treated guinea-pigs demonstrated a significant increase in the 
bronchoconstrictor response to histamine post-Ova compared to pre-Ova challenge 
(-25.7±5.6% compared to 3.4±3.3%). At 5 minutes post-histamine challenge, this 
bronchoconstriction was no longer significant compared to pre-challenge sGaw 
values (-6.8±5.0% compared to -2.3±1.9%). Guinea-pigs treated with 0.05mg/ml and 
0.1mg/ml FP demonstrated significant increases in the bronchoconstrictor responses 
to histamine post-Ova challenge (-21.4±7.5% at 5 minutes compared to pre-
challenge, 5.3±1.5%,; -14.8±3.8% at 0 minutes compared to pre-challenge -4.8±1.7%, 
respectively). Both these bronchoconstrictions returned to pre-challenge levels after 
10 minutes. Guinea-pigs treated with 0.5 or 1mg/ml FP demonstrated no 
bronchonstrictor response to histamine post-Ova compared to pre-challenge values. 
Figure 12F demonstrates the peak bronchoconstrictor response to histamine both 
pre- and post-Ova challenge. Vehicle, 0.05mg/ml FP and 0.1mg/ml FP treated 
animals demonstrated a significant increase in bronchonstrictor response to 
histamine post- compared to pre-Ova challenge (-21.4±6.3% compared to -1.7±3.8%; 
-18.9±4.1% compared to -6.7±1.8%; -28.5±8.1% compared to -4.7±2.8% respectively) 
(Figure 12).  
 
The total protein content in lavage fluid, of guinea-pigs challenged with Ova and 
treated with 0.05, 0.1, 0.5 or 1mg/ml FP or vehicle demonstrated a dose-dependent 
decrease with FP treatment but did significantly attenuate this response even at the 
highest FP dose, 1mg/ml (Figure 13).  
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0.05mg/ml FP treatment did not significantly reduce any cell type measured. Both 
0.5mg/ml and 1mg/ml FP significantly decreased total cell numbers, compared to 
vehicle (5.2±0.4x106/ml, 4.5±0.4x106/ml compared to 9.0±0.45x106/ml respectively). 
This decrease was further characterised as both a significant decrease in eosinophils 
(2.0±0.23x106/ml, 1.8±0.17x106/ml compared to 3.6±0.235x106/ml respectively) and 
macrophages (2.74±0.28x106/ml, 2.1±0.19x106/ml compared to 4.38±0.24x106/ml 
respectively). Macrophage numbers were also reduced in 0.1mg/ml FP treated group 
(3.07±0.34x106/ml). Lymphocytes demonstrated a significant dose-dependent 
decrease with increasing FP dose, for 0.5 and 1mg/ml FP it was 0.07±0.02x106/ml 
and 0.08±0.01x106/ml respectively, compared to vehicle (0.23±0.01x106/ml). 
Neutrophil numbers were unchanged from vehicle level in FP treatment groups 
(Figure 14).  
 
IL-13 levels, increased in Ova challenged and vehicle treated guinea-pigs 
(13.9±1.4ng/mg) compared to naïve (8.8±0.9ng/mg), decreased non-significantly 
with increasing FP dose. IL-17 levels were also elevated in vehicle groups 
(306.1±17.9pg/mg compared to 123.6±6.5) were not significantly reduced by FP in 
any group, although 0.5 and 1mg/ml FP did tend to produce lower IL-17 levels. IL-8 
was not detectable in samples and is not shown (Figure 15).  
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Figure 9: The mean time-course values of sGaw in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either inhaled fluticasone propionate 
(FP, 0.05mg/ml or 0.1mg/ml), split into twice daily doses. The histogram represents the maximum bronchoconstriction values recorded during the early 
asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as 
mean±SEM percentage change from baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=5 (Ova + vehicle), N=10 (Ova + 
0.05mg/ml FP), N=9 (Ova + 0.1mg/ml FP). *Significantly different from vehicle treatment p<0.05, performed with one-way analysis of variance followed by 
Dunnet’s post-test. 
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Figure 10: The mean time-course sGaw values in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either inhaled fluticasone propionate 
(FP, 0.5mg/ml or 1mg/ml), split into twice daily doses. The histogram represents the maximum bronchoconstriction values recorded during the early 
asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as 
mean±SEM percentage change from baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=5 (Ova + vehicle), N=9 (Ova + 
0.5mg/ml FP), N=6 (Ova + 1mg/ml FP). *Significantly different from vehicle treatment p<0.05, ** p<0.01; *** p<0.001; performed with one-way analysis of 
variance followed by Dunnet’s post-test.  
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Figure 11 Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) challenge in guinea-pigs treated with either inhaled vehicle or fluticasone propionate 
(FP; 0.05mg/ml, 0.1mg/ml, 0.5mg/ml or 1mg/ml) split into twice daily doses. For the 
purpose of analysis only negative peaks were considered and all positive sGaw values were 
excluded. Total includes all negative peaks from 0-12 hours, early asthmatic response (EAR) 
includes values from 0-6 hours and late asthmatic response (LAR) includes values from 6-12 
hours. Area under the curve is expressed as %.hour. N=5 (vehicle), N=10 (0.05mg/ml FP), 
N=9 (0.1mg/ml FP), N=9 (0.5mg/ml FP), N=6 (1mg/ml FP); *significantly different from 
vehicle treatment p<0.05; performed with one-way analysis of variance followed by 
Dunnet’s post-test. 
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Figure 12: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period,) in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either inhaled A) vehicle or fluticasone propionate 
(FP) (B) 0.05mg/ml, C) 0.1mg/ml, D) 0.5mg/ml or E) 1mg/ml split into twice daily doses. F) Represents the peak bronchoconstriction to histamine pre- and 
post-Ova challenge. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage 
change from baseline. A negative value represents a bronchoconstriction. N=5 (vehicle), N=10 (0.05mg/ml FP), N=9 (0.1mg/ml FP), N=9 (0.5mg/ml FP), N=6 
(1mg/ml FP). *Significantly different from time paired pre-Ova challenge values p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 13: Total lavage fluid protein in ovalbumin (Ova) sensitised and challenged guinea-
pigs treated with either inhaled vehicle or fluticasone propionate (FP) (0.05mg/ml, 
0.1mg/ml, 0.5mg/ml or 1mg/ml) split into twice daily doses. N=5 (naïve and vehicle), N=10 
(0.05mg/ml FP), N=9 (0.1mg/ml FP), N=9 (0.5mg/ml FP), N=6 (1mg/ml FP); performed with 
one-way analysis of variance followed by selected groups Bonferroni post-test. 
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Figure 14 The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in ovalbumin (Ova) sensitised and challenged guinea-pigs 
treated with vehicle or inhaled vehicle fluticasone propionate (FP) (0.05mg/ml, 0.1mg/ml, 
0.5mg/ml or 1mg/ml) split into twice daily doses. ^^ significantly different from naïve, 
p<0.01; ^^^ p<0.001; *significantly different from vehicle treatment p<0.05, ** p<0.01; *** 
p<0.001; N=5 (vehicle), N=10 (0.05mg/ml FP), N=9 (0.1mg/ml FP), N=9 (0.5mg/ml FP), N=6 
(1mg/ml FP); performed with one-way analysis of variance followed by selected groups 
Bonferroni post-test. 
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Figure 15: The concentration of A) IL-13 B) IL-17 in the lungs of ovalbumin (Ova) sensitised 
and challenged guinea-pigs treated with either inhaled vehicle fluticasone propionate (FP) 
(0.05mg/ml, 0.1mg/ml, 0.5mg/ml or 1mg/ml) split into twice daily doses. Results are 
expressed as mean±SEM; N=5 (vehicle), N=10 (0.05mg/ml FP), N=9 (0.1mg/ml FP), N=9 
(0.5mg/ml FP), N=6 (1mg/ml FP); ^ significantly different from naïve, p<0.05; ^^^ p<0.001 
performed with one-way analysis of variance followed by selected groups Bonferroni post-
test. 
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6.5.2 SENSITIVITY TO INHALED FLUTICASONE PROPIONATE OF ACUTE 
OVALBUMIN RESPONSES WITH LPS EXPOSURE 24 HOURS BEFORE  
Both vehicle and FP treated guinea-pigs demonstrated early phase responses 
peaking within the first hour (-35.2±8.0% and -29.8±4.5%, respectively, 30 minutes 
post-Ova). This bronchoconstriction began to return to baseline within the first 6 
hours and returned to baseline sGaw values by 12 hours. No significant difference in 
bronchoconstriction to Ova was observed at any time point in FP or vehicle treated 
guinea pigs. Figure 16 also represents the peak EAR, LAR and 24 sGaw values (Figure 
16, time course). No significant difference in peak early and late phase responses (-
22.0±3.9%, FP compared -20.3±2.8%, vehicle) was observed with FP treatment 
(Figure 16, histogram). No significant difference in the total, EAR and LAR area under 
the curve with FP treatment were observed (Figure 17).  
 
Vehicle treated guinea-pigs demonstrated a significant increase in the 
bronchoconstrictor response to histamine 0 minutes post-Ova challenge compared 
to the pre-challenge sGaw values (-19.3±7.5% and -0.04±0.9%). This 
bronchoconstriction returned to baseline by 10 minutes post-histamine challenge. In 
FP treated guinea-pigs, a significant bronchoconstriction to histamine was seen at 0 
minutes (-16.9±5.0% compared to -1.3±1.3%), 5 minutes (-19.0±4.1% compared to -
1.1±2.6%) and 10 minutes post-histamine challenge (-20.8±5.9% compared to -
2.9±1.4%) (Figure 18). Figure 18  also presents the peak bronchoconstriction to 
histamine exposure pre- and post- Ova challenge. Guinea-pigs treated with vehicle 
demonstrated a significant increase in the peak bronchoconstrictor response to 
histamine post-Ova challenge (-20.7±6.8%) compared to pre-Ova challenge 
(4.2±2.1%). Guinea pigs treated with FP also demonstrated a significant increase in 
the peak bronchonstrictor response to histamine post-Ova challenge (-27.9±5.1% 
compared to -5.2±1.3%). No significant difference between peak post-Ova 
bronchoconstrictions were found.  
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Total cell numbers, increased in Ova challenged and vehicle treated animals 
(14.1±0.8x106/ml compared to naïve, 1.5±0.05x106/ml were unchanged by FP 
treatment (15.5±2.7x106/ml). No change in eosinophils, macrophages and 
neutrophils cell population numbers were observed with FP treatment (Figure 19).  
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Figure 16: The mean time-course values of sGaw in ovalbumin (Ova) sensitised and challenged guinea pigs exposed to 30μg/ml LPS for 1 hour, 24 hours pre-
Ova challenge and treated with vehicle and fluticasone propionate (FP) (0.5mg/ml, split into 2 twice daily 15 minute inhalations). The histogram represents 
the maximum bronchoconstriction values recorded during the early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 
24 hours readings. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline prior to Ova challenge. A negative value 
represents a bronchoconstriction. A negative value represents a bronchoconstriction. N=6 (vehicle), N=9 (FP); performed with two tailed T-test. 
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Figure 17: Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) challenge in guinea-pigs exposed to 30μg/ml LPS for 1 hour, 24 hours pre-Ova 
challenge and treated with vehicle or fluticasone propionate (FP) (0.5mg/ml, split into 2 
twice daily 15 minute inhalations). For the purpose of analysis only negative peaks were 
considered and all positive sGaw values were excluded. Total includes all negative peaks 
from 0-12 hours, early asthmatic response (EAR) includes values from 0-6 hours and late 
asthmatic response (LAR) includes values from 6-12 hours. Area under the curve is expressed 
as %.hour. N=6 (vehicle), N=9 (FP); performed with two tailed T-test. 
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Figure 18: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs exposed to 30μg/ml LPS for 1 hour, 24 hours pre-Ova challenge and treated with A) vehicle or B) fluticasone 
propionate (FP) (0.5mg/ml, split into 2 twice daily 15 minute inhalations). D) represents the peak sGaw values pre- and post-Ova challenge. Values were 
recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative 
value represents a bronchoconstriction. N=6 (vehicle), N=9 (FP). *Significantly different from vehicle treatment p<0.05, ** p<0.01; *** p<0.001; performed 
with two tailed T-test. 
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Figure 19: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs exposed to 30μg/ml LPS for 1 hour, 24 
hours pre-Ova challenge and treated with vehicle or fluticasone propionate (FP) (0.5mg/ml, 
split into 2 twice daily 15 minute inhalations). N=6 (naïve and vehicle), N=9 (FP); 
^significantly different from naive p<0.05, ^^^ p<0.001; performed with one-way analysis of 
variance followed by selected groups Bonferroni post-test. 
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5.5.3 SENSITIVITY OF OVALBUMIN AND LPS CO-ADMINISTRATION PROTOCOL 
RESPONSES TO INHALED FLUTICASONE PROPIONATE 
Both vehicle and FP treated groups demonstrated EAR peaking in the first hour and 
returning to baseline values between 6-8 hours. No significant differences were 
observed between these groups. Vehicle and 0.5mg/ml FP treated guinea-pigs 
demonstrated a second delayed response peaking at 10 hours (-17.6±2.4% and -
18.9±5.1%, respectively). This response was reduced but not significantly attenuated 
in 1mg/ml FP treated guinea-pigs at the same time point (-2.6±5.4%) (Figure 20, time 
course). No difference in the peak EAR was observed between all treatment groups. 
Peak LAR demonstrated a trend for a decrease with 0.5 and 1mg/ml FP treatment 
but did not reach significance. (-28.0±6.0% and -15.3±3.7% compared to vehicle, -
34.6±6.8% respectively) No significant bronchoconstriction at the 24 hour reading 
was observed (Figure 20, histogram). No significant difference in total, EAR and LAR 
area under the curve were observed between all treatment groups (Figure 21). 0.5 
or 1mg/ml FP not did not significantly reduce the time taken for the early phase to 
return to 50% of peak bronchoconstriction (3.7±0.4h, 4.0±0.4h compared to vehicle, 
4.2±0.7h respectively) (Figure 22). 
 
Vehicle treated guinea-pigs produced an immediate non-significant increase in the 
bronchoconstrictor response to histamine, post-Ova challenge. The 
bronchoconstriction continued to increase at 5 (-28.1±8.2% compared to pre-Ova: -
1.8±3.3%) and 10 minutes (-34.7±8.5% compared to pre-Ova: -0.1±2.1%). 0.5 and 
1mg/ml FP treatment did not significantly alter this response with significant 
constrictions still present at 10 minutes (-34.2±8.3% compared to pre-Ova: -
0.1±2.0%; -31.7±11.8% compared to pre-Ova -4.5±1.9%, respectively) (Figure 23) 
Figure 23D also presents the peak bronchoconstriction to histamine pre- and post- 
Ova challenge. Guinea-pigs treated with vehicle, 0.5mg/ml FP and 1mg/ml FP 
demonstrated a significant increase in the peak bronchoconstriction to histamine 
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following Ova challenge (-33.3±4.5% compared to -9.4±7.1%; -40.2±9.0% compared 
to 6.1±1.6%; -41.2±10.6% compared to -9.9±2.0% respectively).  
 
Lavage protein levels, elevated in vehicle treated guinea-pigs (3.05±0.1mg/ml, 
compared to naïve, 0.5±0.05mg/ml) were significantly reduced by 0.5 and 1mg/ml FP 
(1.4±0.1mg/ml and 1.8±0.4mg/ml respectively) compared to vehicle (Figure 24).  
 
Total cells, increased in vehicle treated guinea pigs (21.6±1.3x106/ml, compared to 
naïve 1.4±0.2x106/ml) were not significantly reduced by 0.5 or 1mg/ml FP 
(21.6±1.3x106/ml, and 18.0±2.6x106/ml respectively). No specific cell population was 
reduced by FP treatment (Figure 25). 
 
IL-8 and IL-17 levels were significantly increased in Ova challenged and vehicle 
treated guinea-pigs compared to naïve animals (16.5±1.6ng/mg compared to 
undetectable; 183.4±36.4ng/mg compared to 61.2±3.2ng/mg, respectively). IL-8 and 
IL-17 were not reduced by FP treatment. IL-13 was significantly decreased by both 
0.5mg/ml FP and 1mg/ml (6.1±0.6ng/mg, 6.4±0.3ng/mg compared to vehicle, 
8.6±0.6ng/mg) (Figure 26). 
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Figure 20: The mean time-course values of sGaw in ovalbumin (Ova) challenged guinea-pigs exposed to 30μg/ml LPS for 1 hour, 48 hours before Ova 
challenge and co-administered with Ova and treated with fluticasone propionate (FP) (0.05mg/ml or 1mg/ml, split into 2 twice daily 15 inhalations,) or 
vehicle. The histogram represents the maximum bronchoconstriction values recorded during the early asthmatic response (EAR) (0-6 hours), late asthmatic 
response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline prior to Ova 
challenge. A negative value represents a bronchoconstriction. N=7 (vehicle), N=7 (0.5mg/ml FP), N=5 (1mg/ml FP; performed with one-way analysis of 
variance followed by Dunnet’s post-test. 
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Figure 21:  Area under the curve analysis of sGaw values over 12 hours in ovalbumin (Ova) 
challenged guinea-pigs exposed to 30μg/ml LPS for 1 hour, 48 hours before Ova challenge 
and co-administered with Ova and treated with fluticasone propionate (FP) (0.05mg/ml or 
1mg/ml, split into 2 twice daily 15 inhalations) or vehicle. For the purpose of analysis only 
negative peaks were considered and all positive sGaw values were excluded. Total includes 
all negative peaks from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 
hours and late asthmatic response (LAR) includes values from 6-12 hours. Area under the 
curve is expressed as %.hour. N=7 (vehicle), N=7 (0.5mg/ml FP), N=5 (1mg/ml FP); 
performed with one-way analysis of variance followed by Dunnet’s post-test. 
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Figure 22: Analysis of the time taken for early asthmatic responses (EAR) to recover to 50% 
of peak bronchoconstriction values in ovalbumin (Ova) challenged guinea-pigs exposed to 
30μg/ml LPS for 1 hour, 48 hours before Ova challenge and co-administered with Ova and 
treated with fluticasone propionate (FP) (0.05mg/ml or 1mg/ml, split into 2 twice daily 15 
inhalations) or vehicle. N=7 (vehicle), N=7 (0.5mg/ml FP), N=5 (1mg/ml FP); performed with 
one-way analysis of variance followed by Dunnet’s post-test. 
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Figure 23: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in ovalbumin (Ova) challenged guinea-pigs exposed to 30μg/ml LPS for 1 hour, 48 hours before Ova challenge and co-
administered with Ova and treated with A) vehicle or fluticasone propionate (FP) (B) 0.05mg/ml or C) 1mg/ml, split into 2 twice daily 15 inhalations). D) 
represents the peak sGaw values pre- and post-Ova challenge. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw 
are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=7 (vehicle), N=7 (0.5mg/ml FP), N=5 
(1mg/ml FP). *Significantly different from time paired pre-Ova challenge values p<0.05, ** p<0.01; *** p<0.001; performed with a two tailed T-test. 
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Figure 24: Total lavage fluid protein in ovalbumin (Ova) challenged guinea-pigs exposed to 
30μg/ml LPS for 1 hour, 48 hours before Ova challenge and co-administered with Ova and 
treated with fluticasone propionate (FP) (0.05mg/ml or 1mg/ml, split into 2 twice daily 15 
inhalations) or vehicle. Protein content was determined by BCA protein assay. N=6 (naïve), 
N=7 (vehicle), N=7 (0.5mg/ml FP), N=5 (1mg/ml FP). ^^^significantly different from naive 
p<0.001;*significantly different from vehicle treatment p<0.05, ** p<0.01; performed with 
one-way analysis of variance followed by selected groups Bonferroni post-test. 
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Figure 25: The total cell (A), macrophages (B), eosinophils (C), lymphocytes (D) and 
neutrophils (E) counts in bronchoalveolar fluid in ovalbumin (Ova) challenged guinea-pigs 
exposed to 30μg/ml LPS for 1 hour, 48 hours before Ova challenge and co-administered with 
Ova and treated with fluticasone propionate (FP) (0.05mg/ml or 1mg/ml, split into 2 twice 
daily 15 inhalations) or vehicle. N=6( naïve), N=7 (vehicle), N=7 (0.5mg/ml FP), N=5 (1mg/ml 
FP). ^significantly different from naive p<0.05, ^^^ p<0.001; performed with one-way 
analysis of variance followed by selected groups Bonferroni post-test. 
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Figure 26: The concentration of A) IL-8 B) IL-13 C) IL-17 in the lungs of ovalbumin (Ova) 
sensitised guinea-pigs exposed to 30μg/ml LPS for 1 hour, 48 hours before Ova challenge 
and co-administered with Ova and treated with fluticasone propionate (FP) (0.05mg/ml or 
1mg/ml, split into 2 twice daily 15 inhalations or vehicle. N=6 (naïve), N=7 (vehicle), N=7 
(0.5mg/ml FP), N=5 (1mg/ml FP). ^^significantly different from naive p<0.01, ^^^ p<0.001; 
*significantly different from vehicle treatment p<0.05, ** p<0.01; performed with one-way 
analysis of variance followed by selected groups Bonferroni post-test. 
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6.5.4 SENSITIVITY OF LPS RESPONSES TO INHALED FLUTICASONE PROPIONATE 
Both vehicle and FP treated groups showed a progressive increase in 
bronchoconstriction during the 1st hour post-LPS exposure, reaching its greatest 
extent at 3 hours (vehicle: -22.9±5.4%; 0.5mg/ml FP: -24.3±6.1%; 1mg/ml -
19.4±2.0%). The bronchoconstriction then dissipated and returned to near baseline 
sGaw levels by 5 hours (Figure 27, time course). Vehicle treated guinea pigs 
demonstrated a peak bronchoconstriction of -32.9±2.9% which was not significantly 
changed by FP treatment, despite a trend (0.5mg/ml: -28.9±4.4%; 1mg/ml -
24.6±3.8%). A small bronchoconstriction was observed at 24 hours in vehicle treated 
guinea-pigs and unaltered by FP treatment (Figure 27, histogram). FP treatment did 
not significantly change the area under the curve between 0-12 hours (Figure 28) 
 
In vehicle treated guinea-pigs a non-significant increase in the response to histamine 
was observed post-LPS challenge throughout the 10 minutes post-histamine 
challenge, reaching significance at 10 minutes (-16.5±1.9%) compared to pre-
challenge (-5.6±1.9 %). Guinea-pigs treated with 0.5mg/ml and 1mg/ml FP 
demonstrated non-significant increase in the bronchoconstrictor response to 
histamine following LPS exposure. In guinea-pigs treated with 1mg/ml FP this was 
significant at 5 minutes post-histamine (-16.2±3.4%) compared to pre-LPS (-
1.6±5.3%) (Figure 29). Figure 29D shows peak bronchoconstrictor responses pre- and 
post-LPS exposure. A significant increase in the peak bronchoconstrictor response to 
histamine was seen in vehicle treated guinea-pigs (-22.0±5.2% post-LPS, compared 
to pre-LPS -7.0±1.8%). Guinea-pigs treated with FP demonstrated a non-significant 
trend for an increase in the bronchoconstrictor response to histamine post-LPS. 
 
LPS increased protein levels in lavage fluid (1.9±0.3mg/ml, compared to naïve 
0.5±0.05mg/ml) which were not significantly reduced by FP treatment (0.5mg/ml: 
2.2±0.5mg/ml and 1mg/ml: 1.6±0.3mg/ml) (Figure 30).  
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Total cell numbers, increased in vehicle treated groups (22.5±2.3x106/ml compared 
to naïve, 1.4±0.2x106/ml) were not significantly reduced by treatment with 0.5 or 
1mg/ml FP (20.9±2.8x106 and 20.5±3.7x106/ml, respectively). Macrophages, 
eosinophils, lymphocytes and neutrophils were all significantly increased by LPS 
exposure but not significantly reduced by either dose of FP (Figure 31). 
 
IL-8 levels, increased in guinea-pigs challenged with Ova and treated with vehicle 
were not significantly reduced by either does of FP used (0.5mg/ml FP: 
21.9±1.4pg/ml: 1mg/mg FP: 29.5±6.4pg/mg and vehicle: 18.6±1.3pg/mg) (Figure 32).
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Figure 27: The mean time-course values of sGaw in guinea-pigs exposed to 30μg/ml LPS twice and treated with fluticasone propionate (FP, 0.5 or 1mg/ml) 
or vehicle. The histogram represents the maximum bronchoconstriction values recorded during the 0-12 hours and 24 hours readings. Mean changes in 
sGaw are expressed as mean±SEM percentage change from baseline prior LPS challenge. A negative value represents a bronchoconstriction. Results shown 
are after the second LPS exposure. N=6 (veh and 0.5mg/ml FP), N=4 1mg/ml FP; performed with one-way analysis of variance followed by Dunnet’s post-
test. 
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Figure 28: Total area under the curve analysis of sGaw values in guinea-pigs exposed to 
30μg/ml LPS twice and treated with fluticasone propionate (FP, 0.5 or 1mg/ml) or vehicle. 
For the purpose of analysis only negative peaks were considered and all positive sGaw 
values were excluded. Total includes all negative peaks from 0-12 hours. Area under the 
curve is expressed as %.hour. N=6 (veh and 0.5mg/ml FP), N=4 1mg/ml FP; performed with 
one-way analysis of variance followed by Dunnet’s post-test. 
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Figure 29: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs exposed to 30μg/ml LPS twice and treated with A) vehicle or fluticasone propionate (FP, B) 0.5 or C) 
1mg/ml). D) represents the peak sGaw values pre- and post-Ova challenge. Values were recorded 7 days pre- and 24 hours post-2nd LPS challenge. Mean 
changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=6 (veh and 0.5mg/ml 
FP), N=4 1mg/ml FP *Significantly different from time paired pre-LPS challenge values p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 30: Total lavage fluid protein in guinea-pigs exposed to 30μg/ml LPS twice and treated 
with fluticasone propionate (FP, 0.5 or 1mg/ml) or vehicle. Protein content was determined 
by BCA protein assay.  N=6 (Naïve, veh and 0.5mg/ml FP), N=4 1mg/ml FP; ^^^significantly 
different from naive p<0.001; performed with one-way analysis of variance followed by 
selected groups Bonferroni post-test. 
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Figure 31: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid in guinea-pigs exposed to 30μg/ml LPS twice and treated 
with fluticasone propionate (FP, 0.5 or 1mg/ml) or vehicle; N=6 (naïve, veh and 0.5mg/ml 
FP), N=4 1mg/ml FP ^significantly different from naive p<0.05; ^^^ p<0.001; performed with 
one-way analysis of variance followed by selected groups Bonferroni post-test. 
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Figure 32: The concentration of IL-8 in the lungs of guinea-pigs exposed to 30μg/ml LPS 
twice for 1 hour and treated with vehicle or fluticasone propionate (FP, 0.5 or 1mg/ml). 
Results are expressed as mean±SEM; N=6 (Naïve, veh and 0.5mg/ml FP), N=4 1mg/ml FP 
^^^significantly different from naive p<0.001; performed with one-way analysis of variance 
followed by selected groups Bonferroni post-test. 
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6.6 DISCUSSION 
Inhaled corticosteroids have wide ranging effects on both inflammatory and 
functional attributes of asthma. Initial work in this chapter established a dose of 
fluticasone propionate (FP) that significantly attenuated the LAR, AHR and cellular 
influx by dose-response curve. This dose was then used on 2 ovalbumin and LPS 
models developed in chapter 5. A higher dose of FP was also tried on the Ova and 
LPS combination model to assess the extent of inhaled corticosteroid insensitivity. 
Finally, these 2 doses of FP were used to assess the corticosteroid sensitivity of 
bronchoconstrictor and inflammatory responses in a double LPS exposure model. 
6.6.1 THE EFFECT OF INHALED FLUTICASONE PROPIONATE ON EARLY AND LATE 
ASTHMATIC RESPONSES 
In the current study it was shown that FP does not significantly affect the EAR in 
guinea-pigs challenged with Ova alone. The EAR in both humans and animal models 
has been shown to be insensitive to corticosteroids (Booij-Noord et al., 1971; Evans 
et al, 2012). This would be expected as the EAR is mainly mediated by mast cell 
degranulation and corticosteroids are not known to have any effect on this process. 
The prolonged EAR induced by LPS co-administered with ovalbumin was also found 
to be FP insensitive. This would suggest that the mechanisms that mediate the 
increased duration of the EAR are also insensitive to inhaled corticosteroid. Thus 
enhanced activation of mast cells or neutrophils by LPS may be the cause (Masuda et 
al, 2002; Reino et al, 2012). Neutrophils are known to be relatively corticosteroid 
insensitive, especially in the lung and have been implicated in the EAR (Plumb et al, 
2012). However, their levels do not increase until 3 hours post-allergen challenge, so 
neutrophils are not likely to be involved in the induction of the EAR but may be 
responsible for its elongation of it (Danahay et al, 1999). In the current study, LPS 
alone also induced a bronchoconstriction which developed slowly over 3 hours and 
was insensitive to inhaled FP. Similarly, the attenuated but prolonged EAR in guinea-
pigs exposed to LPS 24 hours before Ova challenge was also unresponsive to inhaled 
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FP. These both coincided with an increase in lavage fluid neutrophils 24 hours later, 
further suggesting the role of the neutrophil in elongated EARs.  
The LAR was attenuated with 0.5mg/ml inhaled FP in ovalbumin challenged guinea-
pigs. The LAR was not suppressed by the 5-fold lower dose of FP (0.1mg/ml), nor was 
there increased suppression at the 2-fold higher dose of 1mg/ml. This indicates that 
the LAR has a fairly steep dose-response relationship with inhaled FP. This is similar 
in humans where higher doses of inhaled corticosteroid do not provide increased 
clinical benefit above lower effective doses (Adam et al, 2001). The attenuation of 
the LAR by Inhaled FP would be expected as corticosteroids are able to suppress this 
response in both humans and animal models (Palmqvist et al, 2005; Evans et al, 
2012). The LAR has been linked to a range of inflammatory cells and mediators 
including lymphocytes, eosinophils and IL-5, all of which are suppressed by the wide 
ranging anti-inflammatory activity of corticosteroids (Belvisi, 2004).  
Contrasting with effects of inhaled FP on Ova alone, in guinea-pigs exposed to either 
of the Ova and LPS protocols, the LAR was not significantly decreased by 0.5mg/ml 
FP. This indicates that LPS exposure has decreased the sensitivity of the Ova induced 
LAR to inhaled FP. It also indicates that the development of corticosteroid 
insensitivity is not dependent on the presence of a full EAR. Guinea-pigs exposed to 
LPS 24 hours before Ova challenge, displayed an attenuated EAR, merging into a LAR 
which was not reduced by FP treatment. To examine the extent of inhaled FP 
insensitivity of the LAR in the Ova and LPS co-administration model, a higher dose of 
1mg/ml FP, effective on the LAR of Ova challenged guinea-pigs, was used. This dose 
of FP was not able to significantly attenuate the LAR but did demonstrate a trend for 
decreased sGaw values. This would suggest that the insensitivity to inhaled FP is due 
to a rightward shift in the dose response curve. Higher doses of FP were not tried 
due to issues with FP solubility.  
 
 
Chapter 6 
 
267 
 
6.6.2 THE EFFECT OF INHALED FLUTICASONE PROPIONATE ON AIRWAYS 
HYPERRESPONSIVENESS 
Inhaled FP (0.5 and 1mg/ml) significantly attenuated the development of AHR 
following Ova challenge. Contrastingly, the 2 lower doses of FP used did not suppress 
the development of AHR. This was an expected effect as inhaled corticosteroids are 
well known clinically to suppress the development of AHR (Palmqvist et al, 2005). In 
contrast, inhaled FP demonstrated only modest suppressive effects on AHR to LPS 
alone. Even at 1mg/ml FP AHR was not completely abolished. This may indicate that 
LPS-induced AHR is inherently insensitive to inhaled FP. Although the precise 
mechanisms of AHR are still unknown, a general link to inflammation has been made 
and more specifically eosinophils. Eosinophil granule release can cause epithelial 
damage, increasing the exposure of underlying nerves to bronchoconstrictor stimuli 
(Gleich et al, 1993; Laitinen et al, 1987). Regardless of the specific inflammatory 
mediators of AHR, corticosteroids broad anti-inflammatory action is likely to be 
responsible for the suppression of AHR.  
In contrast with the effectiveness of inhaled FP on Ova induced AHR, in guinea-pigs 
also exposed to LPS, 0.5mg/ml did not attenuate the development of AHR. In the 
case of guinea-pigs exposed to LPS 24 hours before Ova challenge, 0.5mg/ml FP 
actually potentiated the length of the bronchoconstrictor response to histamine 
compared to vehicle. Additionally, a higher dose of FP (1mg/ml) was also unable to 
suppress the development of AHR in Ova/LPS co-administration groups. The failure 
to suppress AHR would further suggest the development of insensitivity to this 
inhaled corticosteroid in the combined Ova and LPS model. It would also support the 
hypothesis that AHR in the model is mediated by inflammation. Differences in the 
inflammatory responses may account for the differing responsiveness of AHR to 
inhaled FP between Ova and Ova/LPS models. In particular, neutrophils, which are 
prominent in Ova and LPS models, have been implicated in the development of AHR 
(Essilfie et al, 2012; Ito et al, 2008). Additionally, neutrophils demonstrate increased 
survival in the presence of corticosteroids (Cox, 1995). This could explain why 
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inhaled FP potentiated AHR in guinea-pigs exposed to LPS 24 hours before Ova 
challenge. This could increase exposure to neutrophil granule products, increasing 
airway damage. However, a potentiation of AHR was not seen in LPS challenged 
guinea-pigs, also displaying increased neutrophilia indicating that this process is 
more complex and requires the presence of other factors induced by Ova. This is 
supported by Yang et al, (2009) who found that the development of corticosteroid-
resistant AHR is dependent on exposure to both Ova and LPS. It was also found that 
macrophage but not neutrophil depletion was able to prevent the development of 
AHR. This may indicate that macrophages are an important cell type in the 
development of corticosteroid resistant AHR. However, this study produced these 
effects on a Th1 inflammatory background, contrasting with the Th2 inflammatory 
background present in the current study. This may mean that different molecular 
pathways are involved in AHR, making it difficult to make comparisons. Overall, the 
lack of insensitivity of all inflammatory cells measured does not allow any 
conclusions as to which particular inflammatory cell is mediating these effects.  
6.6.3 THE EFFECT OF INHALED FLUTICASONE PROPIONATE ON AIRWAY 
INFLAMMATION AND CYTOKINES 
Inhaled FP reduced the total cells, macrophages and lymphocytes in lavage fluid in a 
dose-dependent manner in Ova challenged guinea-pigs. 0.5 and 1mg/ml FP reduced 
eosinophils significantly but 0.05 and 0.1mg/ml FP had no effect on numbers. This 
indicates a steep dose response effect of inhaled FP on eosinophilia. IL-13 a typical 
Th2 cytokine implicated in the development of AHR was also reduced. The 
effectiveness of inhaled FP in reducing Ova induced inflammation would be expected 
as corticosteroids are known to be potent suppressants of allergic inflammation 
(Belvisi, 2004).  
LPS responses have been shown to be less sensitive to single and multiple doses of 
inhaled corticosteroids (Trapp et al, 1998; Michel et al, 2000). These results were 
confirmed in the present study. Neither dose of FP was able to significantly reduce 
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LPS-induced increases in total cells, macrophages and neutrophils. IL-8, an important 
chemoattractant for neutrophils was also not reduced by inhaled FP treatment, 
indicating that this cytokine may be partly responsible for the continued presence of 
neutrophils even in the presence of FP. Whether the combination of Ova and LPS 
would result in inflammation that was inhaled corticosteroid insensitive was 
previously unknown. The present study showed that guinea-pigs exposed to LPS and 
Ova demonstrate no decrease in any cell type with 0.5mg/ml FP treatment, 
regardless of the timing of LPS exposure. Increasing the inhaled FP dose to 1mg/ml 
did not significantly decrease any cell type in the Ova and LPS co-administration 
model. However, a non-significant trend for a decrease was seen, further suggesting 
a rightward shift in corticosteroid dose-response effects. 
The mechanism behind insensitivity to inhaled FP in this study remains to be 
investigated. However, several hypotheses exist. Neutrophils are known to be less 
sensitive to corticosteroid treatment then other cell types, so inhaled FP not 
reducing neutrophils would be expected (Uddin et al, 2009). The observation that 
eosinophils, macrophages and lymphocytes are all not significantly decreased is less 
expected as these cells are typically corticosteroid sensitive. Essilfie et al, (2012) also 
demonstrated that H. Influenza can cause inhaled corticosteroid insensitivity in 
eosinophils and lymphocytes. This contrasts with the findings of Ito et al, (2008) who 
demonstrated that eosinophils and lymphocytes are both significantly decreased 
with inhaled FP, while neutrophils and AHR are unaffected in repeat, low level 
allergen challenge model. This suggests that more widespread corticosteroid 
insensitivity is evoked by the TLR4 pathway which is activated by LPS.  
Corticosteroid insensitivity in eosinophils, macrophages and lymphocytes in Ova and 
LPS challenged guinea-pigs may be as a result of the upregulation of GR-β. Increases 
in GR-β in macrophages, eosinophils and lymphocytes have been found in other 
allergic diseases (Hamilos et al, 2001). GR-β does not bind corticosteroids but can 
interfere with GR-α binding at DNA sites, as well as forming transcriptionally less 
active heterodimers with GR-α (Oakley et al, 1999). Thus, an increase in GR-β would 
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make cells less sensitive to corticosteroids. Alternatively, mechanisms such as a 
decrease in HDAC-2 as a result of increased AP-1 and NF-κB signalling, activation of 
the PI3K/Akt pathway and decreased HDAC-2 activity could all be involved. Pro-
inflammatory signalling and the oxidative burden of the lungs increase during an 
asthma exacerbation which activates these pathways and decreases corticosteroid 
activity (Ito et al, 2004). 
Interestingly, IL-13 levels were decreased despite there not being a significant 
decrease in any of the inflammatory cells measured. This may indicate that other cell 
types e.g. epithelial cells, not measured are producing IL-13 and are being 
suppressed by corticosteroids (Temann et al, 2007). Alternatively, a decrease in Th2 
lymphocytes which secrete IL-13 may be masked by the corticosteroid insensitivity of 
other lymphocyte subpopulations. In the present study although no significant 
decrease in lymphocytes was seen, there is a trend for decreasing numbers with 
increasing FP dose. Analysis of the sensitivity of different lymphocyte populations 
may find that Th2 cells are still corticosteroids sensitive, as is typically reported (Yang 
et al, 2009).  
IL-17 levels in the lung were unaffected by inhaled FP treatment in Ova challenged 
guinea-pigs. Similarly, FP did not significantly decrease IL-17 levels in LPS and Ova 
challenged guinea-pigs. This is in accordance with studies that have shown IL-17 
responses to be corticosteroid insensitive (Mckinley et al, 2008). This has led to the 
suggestion that IL-17 and Th17 cells, a major source of IL-17 may have a role in 
corticosteroid insensitivity. As IL-17 levels did not increase with the addition of LPS 
to Ova (data shown in chapter 5) it seems unlikely that IL-17 is mediating 
corticosteroid-insensitivity in this model. However, other cytokines such as IL-17F 
and IL-22 have been implicated in Th17 responses. These cytokines along with Th17 
cell numbers are unknown in the present study meaning its not possible to fully rule 
out a role of IL-17 in the inhaled FP insensitivity observed.  
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6.6.4 THE EFFECT OF INHALED FLUTICASONE PROPIONATE ON AIRWAY 
OEDEMA 
Total protein levels in lavage fluid, an indicator of airway oedema decreased with FP 
treatment (although not significantly) in Ova challenged guinea-pigs. They were also 
decreased in Ova and LPS challenged guinea-pigs indicating that although this model 
demonstrates corticosteroid insensitivity, not all corticosteroid effects are reduced. 
This also indicates that results seen in this model are not due to impaired delivery of 
inhaled FP. This reduction in total lavage fluid protein levels may be due to the 
vasoconstrictive effects of corticosteroids (Mendes et al, 2003). This is thought to be 
by decreased uptake of noradrenaline at sympathetic synapses, potentiating 
noradrenaline’s action at α1 adrenoreceptors (Wanner et al, 2004). Contrastingly, 
guinea-pigs exposed to LPS demonstrated no reduction in total lavage fluid protein 
levels with inhaled FP. A lack of corticosteroid effect on plasma extravasation has 
been demonstrated before with systemic corticosteroids (O'Leary et al, 1996). The 
reason behind a lack of corticosteroid effect on LPS induced increases in lavage fluid 
protein levels is unknown.  
6.6.5 GENERAL CONCLUSIONS 
This study has demonstrated that the LAR, AHR, airway inflammation and airway 
oedema induced by Ova alone is sensitive to inhaled FP. Moreover, it has been 
shown that exposure to LPS and Ova together decreases the response of the LAR, 
AHR and airway inflammation to inhaled FP. The timing of LPS exposure (24 hours 
pre- vs 48 hours pre-Ova and co-administered with Ova) does not affect the 
development of inhaled corticosteroid insensitivity. LPS alone was shown to produce 
a bronchoconstriction, inflammation and airway oedema which is also insensitive to 
inhaled FP. Whether a systemically administered corticosteroid will have the same 
effect is unknown and will be investigated in the following chapter.  
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CHAPTER 7 
The Effect Of Systemic Dexamethasone On 
Functional And Inflammatory Responses 
To Ovalbumin And LPS  
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 7.1 INTRODUCTION 
7.1.1 SYSTEMIC CORTICOSTEROIDS 
Systemic corticosteroids are used as last resort therapy in patients who do not 
achieve symptomatic control with high dose inhaled corticosteroids, long acting β2-
adrenoreceptor agonists or alternative therapies. Systemic corticosteroids such as 
prednisone and dexamethasone are given orally while hydrocortisone is generally 
given by intravenous injection. Side effects with systemic corticosteroids are 
extensive and include osteoporosis, cataracts, various cardiovascular and 
gastrointestinal disturbances and growth retardation in children (Schäcke et al, 
2002). For this reason, systemic corticosteroids are only used in short bursts (1-2 
weeks). Oral corticosteroids are indicated in the treatment of asthma exacerbations 
whereas intravenous therapy is used in acute asthma, with patients displaying <30% 
of predicted lung function and not responsive to a β2-adrenoreceptor agonist (Chan 
et al, 1998). Their biological action and mechanisms are similar to inhaled 
corticosteroids. A description of these can be found in chapter 6. Systemic 
corticosteroids do have the added effect of suppressing bone marrow 
haematopoiesis (Mao et al, 2004). This decreases the maturation of inflammatory 
progenitor cells, especially eosinophils. Corticosteroids do this by suppressing CCL11 
(eotaxin-1) and IL-5 induced differentiation of CD34+ cells into eosinophils (Ben et al, 
2008). Inhaled corticosteroids can also suppress bone marrow inflammatory cell 
maturation but probably only with sustained treatment and higher doses (Wood et 
al, 1999; Shen et al, 2002).  
7.1.2 SYSTEMIC CORTICOSTEROID RESISTANCE 
A description of proposed mechanisms of corticosteroid insensitivity can be found in 
chapter 6. Clinically, a patient is defined as fully corticosteroid resistant if they 
demonstrate a failure to increase FEV1 more than >15% after 14 days of prednisone 
treatment, despite demonstrating the same increase with a β2 agonist. Although 
insensitivity to corticosteroids is reported to exist in about 5% of the asthmatic 
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population, full resistance to systemic corticosteroids is rare (Szefler et al, 2002). The 
development of full corticosteroid resistance is associated with longer disease 
duration, increased airway inflammation and more frequent exacerbations 
(Bumbacea et al, 2004). This suggests that repeated asthma exacerbations on a 
chronic inflammatory background can progressively increase corticosteroid 
insensitivity in an individual. Asthma exacerbations, although not particularly 
sensitive to inhaled corticosteroids seem to retain some sensitivity to systemic 
corticosteroids. Matsuse et al, 2012 reported that patients with virally induced 
asthma exacerbations demonstrate reduced time to clear symptoms with oral 
corticosteroid treatment. However, this study did not use any measures to assess 
improvement so it is not possible to know what aspects of the asthma exacerbation 
responded to corticosteroid therapy. A recent study by Hodgson et al, (2012) 
suggests that inhaled corticosteroid-insensitive patients with eosinophilic or mixed 
granulocytic airway inflammation retain sensitivity to systemic corticosteroid 
treatment. Oral prednisone treatment increased lung function and decreased 
eosinophil numbers. LPS induced inflammatory responses also seem to retain some 
sensitivity to systemic corticosteroid, despite not displaying any towards inhaled 
corticosteroids (Trapp et al, 1998).  
7.1.3 THE EFFECT OF SYSTEMIC CORTICOSTEROIDS IN ANIMAL MODELS 
Systemic corticosteroids such as dexamethasone have been shown to attenuate the 
LAR, AHR and inflammation in a guinea-pig Ova model (Toward & Broadley, 2004). 
Asthma exacerbation models have differing sensitivity to systemic corticosteroids 
depending on the nature of the exacerbation. Latent adenovirus infection in 
combination with Ova sensitisation and challenge results in systemic corticosteroid 
resistant eosinophils and sensitive lymphocyte subpopulations (Yamada et al, 2000). 
Contrastingly, combined Ova and LPS induced inflammation is sensitive and AHR 
insensitive to treatment with systemic dexamethasone in mice (Komlosi et al, 2006). 
LPS responses without the presence of Ova seem to be sensitive to systemic 
dexamethasone. Single or multiple LPS exposures cause systemic corticosteroid 
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sensitive airway inflammation and goblet cell hyperplasia, but insensitive lung 
function (O’leary et al 1996; Toward & Broadley 2002). The effect of systemic 
corticosteroid on early and late asthmatic responses has not been investigated in a 
model of asthma exacerbation. Moreover, a comparison between the sensitivity of 
asthma exacerbation models to inhaled and systemic corticosteroid has not been 
made.  
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7.2 HYPOTHESIS 
‘LPS exposure will decrease the systemic corticosteroid sensitivity of functional and 
inflammatory responses in an acute ovalbumin model of asthma’ 
 
7.3 AIMS AND OBJECTIVES 
The aim of this chapter will be to determine the systemic corticosteroid sensitivity of 
functional and inflammatory responses to ovalbumin, LPS and combined ovalbumin 
and LPS models. Initially a dose of systemic dexamethasone which reduces the LAR, 
AHR and airways inflammation after Ova challenge was established. The sensitivity 
of LPS and ovalbumin and LPS responses to this dose of systemic dexamethasone 
was also tested. The effect of systemic dexamethasone on cytokines and lavage fluid 
protein was also established.  
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7.4 METHODS 
Methods describing the measurement of lung function, AHR, airway oedema, airway 
inflammation, cytokine levels and can be found in more detail in chapter 2.  
7.4.1 OVALBUMIN PROTOCOLS 
7.4.1.1 SENSITISATION 
Guinea-pigs (200-300g, Dunkin-Hartley, male) were sensitised by a bilateral intra-
peritoneal injection of a solution containing 150µg Ovalbumin (Ova) and 100mg 
aluminium hydroxide (Al(OH)3) in normal saline on day 1, 4 and 7. 
 
7.4.1.2 ACUTE OVALBUMIN MODEL  
Sensitised guinea-pigs were exposed to inhaled Ova (0.03%) for 1 hour on day 21 in a 
Perspex container as described in section 7.4.1.2. The lung function response to Ova 
was assessed over 12 hours. The bronchoconstrictor response to 0.3mM histamine 
was assessed on day 15 and 22 as described in section 7.4.5. Dexamethasone (5, 10 
or 20mg/kg) was given by intraperitoneal injections, daily from day 16-21. On day 21, 
dexamethasone was administered 30 minutes pre-Ova challenge. A diagram of this 
protocol is shown Figure 1. 
 
Figure 1: The acute Ovalbumin (Ova) protocol. Guinea-pigs were challenged with inhaled 
Ova (0.03% on day 21). Dexamethasone was administered once a day by intraperitoneal 
injection.    
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7.4.1.3 ACUTE OVA AND LPS CO-EXPOSURE MODEL 
Sensitised guinea-pigs were exposed to inhaled LPS (30μg/ml) 48 hours before Ova 
challenge in an exposure chamber and both LPS (30μg/ml) and Ova (0.03%) co-
administered on day 21. The bronchoconstrictor response to histamine was assessed 
on day 15 and day 22. Dexamethasone (5, 10 or 20mg/kg) was given by 
intraperitoneal injections, daily from day 16-21. On day 21, dexamethasone was 
administered 30 minutes pre-Ova challenge. A diagram of this protocol is shown in 
shown in Figure 2. 
 
 
Figure 2: Diagram of the LPS and Ova co-exposure protocol. Guinea-pigs were exposed to 
LPS (30μg/ml) on day 19 and both Ova and LPS co-administered on day 21. Dexamethasone 
was administered once a day by intraperitoneal injection.    
7.4.2 LPS EXPOSURE PROTOCOL  
Non-sensitised guinea-pigs were exposed to LPS (30μg/ml) on day 5 and 7 of the 
protocol. The bronchoconstrictor response to histamine was assessed on day 1 and 
day 8. Dexamethasone (5, 10 or 20mg/kg) was given by intraperitoneal injections, 
daily from day 16-21. On day 5 and 7, dexamethasone was administered 30 minutes 
pre-LPS challenge. A diagram of this protocol is shown in Figure 3. 
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Figure 3: Diagram of the LPS alone exposure protocol. Guinea-pigs were exposed to 30μg/ml 
of LPS on day 5 and 7. Dexamethasone was administered once a day by intra peritoneal 
injection.    
7.4.3 DRUG ADMINISTRATION 
Dexamethasone was dissolved in 25% DMSO and 75% saline and administered by a 
bilateral intraperitoneal injection. 
7.4.4 MEASUREMENT OF LUNG FUNCTION 
Lung function was measured by whole body plethysmography following final Ova, 
LPS or combined Ova and LPS exposure in all protocols. Lung function was recorded 
hourly for 12 hours and every 15 minutes during the first hour of measurements. A 
final measurement was also taken 24 hours post-final challenge. All values were 
expressed as a percentage of the baseline reading, taken before the final challenge. 
A negative percentage change in baseline value represents a bronchoconstriction. In 
Ova protocols, early (0-6 hours) and late (6-12 hours) asthmatic responses were 
expressed as the peak bronchoconstriction during that period (displayed as a 
histogram next to a time course plot) and area under the curve. The duration of the 
early phase was expressed as the time taken to recover to 50% of peak early phase 
bronchoconstriction values.  In the LPS only protocol lung function was measured for 
12 hours after the second LPS exposure. The peak bronchoconstriction during this 
period was expressed on a histogram next to the time course plot.  
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7.4.5 AIRWAYS HYPER-RESPONSIVENESS ASSESSMENT. 
AHR was determined using whole body plethysmography. This was performed by 
measuring the bronchoconstrictor response to histamine before inhaled 
corticosteroid treatment and 24 hours post-final LPS, Ova, LPS or Ova challenge. 
Histamine was delivered as described in chapter 2. Lung function was measured just 
before histamine inhalation and at 0, 5 and 10 minutes post-histamine exposure. The 
peak bronchoconstriction during this period was expressed on a histogram.  
7.4.6 ASSESSMENT OF AIRWAYS INFLAMMATION 
Following final histamine exposure guinea-pigs were sacrificed by an intra-peritoneal 
overdose of sodium pentobarbitone, the lungs excised and lavaged. Total and 
differential cell counts were then performed as described in chapter 2.  
7.4.7 QUANTIFICATION OF CYTOKINE LEVELS USING ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) 
Levels of IL-8, IL-17 and IL-13 were measured in diluted homogenised lung samples 
using ELISA supplied by R&D systems. Cytokine levels were adjusted for total lung 
protein and expressed as weight per mg of lung as described in section 2.2.3.2. 
7.4.8 ASSESSMENT OF AIRWAY OEDEMA 
Protein content in lavage fluid was determined as a measure of airway oedema by 
BCA protein assay as per the manufacturer’s instructions (Pierce protein biology).  
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7.5 RESULTS 
7.5.1 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON ACUTE OVALBUMIN 
RESPONSES 
Vehicle treated guinea-pigs displayed an immediate bronchoconstriction to Ova at 0 
minutes (-74.4±1.5%) which returned to baseline sGaw values by 6 hours. Guinea-
pigs treated with 5mg/kg dexamethasone also displayed an immediate 
bronchoconstriction to Ova (-66.0±5.5%) and significantly less of a 
bronchoconstriction then vehicle at 45 minutes (-32.8±3.2% and -58.7±2.7% 
respectively). 10mg/kg dexamethasone treated guinea-pigs consistently 
demonstrated less of a bronchoconstriction to Ova during the first 4 hours, at 1 hour 
it was (-33.6±3.3%) compared to vehicle (-56.7±4.3%) and at 2 hours it was (-
20.8±4.3%) compared to vehicle (-51.9±3.8%). 20mg/kg dexamethasone did not 
significantly alter the early phase response to Ova. Vehicle treated guinea-pigs 
demonstrated a second, delayed response at 7 hours (-21.4±2.2%), which was 
unchanged by 5mg/kg dexamethasone but significantly attenuated by both 10 and 
20mg/kg dexamethasone (-3.1±3.5% and 2.0±4.0% respectively). sGaw values 
returned to baseline levels in all groups by 12 hours (Figure 4, time course).  
Dexamethasone treatment did not significantly alter the peak EAR compared 
to vehicle. 20 but not 5 and 10mg/kg dexamethasone significantly reduced the peak 
LAR (-10.2±1.7%, -21.4±7.4% and -21.3±2.0% respectively) compared to vehicle (-
22.6±1.9%). No significant differences between the 24 hour sGaw values were found 
(Figure 4, histogram). The total area under the curve (AUC) was significantly reduced 
by 5, 10 and 20mg/kg dexamethasone (187.6±22.9%.hr, 177.4±17.8%.hr and 
194.1±28.4%.hr respectively) compared to vehicle (316.6±28.3%.hr). Early asthmatic 
response AUC was significantly decreased by 10mg/kg dexamethasone 
(139.1±12.4%.hr) compared to vehicle (248.6±19.7%.hr). 5 and 20mg/kg 
dexamethasone did not significantly reduce the early asthmatic response AUC. Late 
asthmatic response AUC was significantly attenuated by 5, 10 and 20mg/kg 
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dexamethasone (20.7±6.5%.hr, 39.5±9.6%.hr and 11.8±3.5%.hr respectively) 
compared to vehicle (68.1±12.9%.hr) (Figure 5). 
 
In vehicle treated guinea-pigs histamine produced a significant increase in 
bronchoconstrictor response to histamine post-Ova challenge (-20.3±3.7%) 
compared to pre-Ova (-0.02±5.2%). At 5 and 10 minutes, the bronchoconstriction 
was still significantly increased over pre-Ova values (-23.7±3.4% compared to pre-
Ova, -2.8±5.9%; -23.3±2.9% compared to pre-Ova, -0.2±1.9%, respectively). 
Treatment with 5, 10 and 20mg/kg dexamethasone reduced the bronchoconstrictor 
response to histamine, with no significant difference between pre and post-Ova 
responses (Figure 6). The peak bronchoconstrictor response to histamine was 
significantly increased in guinea-pigs treated with vehicle post-Ova treatment (-
21.0±4.8%) compared to pre-Ova (-4.9±3.3%). All doses of dexamethasone 
significantly decreased this response (Figure 6). 
 
Guinea-pigs challenged with Ova and treated with vehicle demonstrated a significant 
increase in protein (1.74±0.1mg/ml) compared to naïve levels (0.4±0.01mg/ml). 10 
and 20 but not 5mg/kg dexamethasone significantly reduced protein levels 
(1.2±0.2mg/ml, 1.1±0.2mg/ml and 1.7±0.2mg/ml respectively) (Figure 7) 
 
Total cell numbers were increased in Ova challenged and vehicle treated guinea-pigs 
(8.6±0.5x106/ml) compared to naïve 1.4±0.2x106/ml). Dexamethasone reduced total 
cell numbers in a dose-dependent manner; 20mg/kg dexamethasone significantly 
decreased total cell numbers (5.6±0.5x106/ml). Macrophages were also significantly 
decreased by 20mg/kg dexamethasone (2.9±0.3x106/ml compared to vehicle, 
4.0±0.3x106/ml). Eosinophils were significantly reduced by both 10 and 20mg/kg 
dexamethasone (2.2±0.5x106/ml and 2.3±0.3x106/ml compared to vehicle, 
4.3±0.5x106/ml). Additionally 10mg/kg dexamethasone significantly decreased 
Chapter 7 
 
283 
 
lymphocyte numbers (0.03±0.01x106 compared to vehicle 0.8±0.02x106). A non 
significant trend for decreased neutrophils with increasing dexamethasone dose was 
also observed (Figure 8).  
 
IL-13 levels were significantly increased in Ova challenged and vehicle treated 
guinea-pigs (13.9±1.14ng/ml) compared to naïve (9.8±0.6ng/mg). IL-13 was 
significantly decreased by treatment with 5, 10 and 20mg/kg dexamethasone 
compared to vehicle (10.2±0.42ng/mg, 10.1±0.8ng/ml and 10.0±0.6ng/ml 
respectively). IL-17 levels were also increased in Ova challenged and vehicle treated 
guinea-pigs (143.5±6.5pg/mg) compared to naïve (112±5.0pg/mg). IL-17 levels were 
decreased by dexamethasone treatment in a dose-dependent manner. With 5, 10 
and 20mg/kg dexamethasone IL-17 levels were 107.6±5.7pg/mg, 103.0±4.0pg/mg 
and 98.2±6.1pg/mg respectively. IL-8 was not detectable in samples and is not 
shown (Figure 9). 
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Figure 4: The mean time-course values of sGaw in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either intra-peritoneal vehicle or 
dexamethasone (Dex, 5mg/kg, 10mg/kg and 20mg/kg) dosed daily for 6 days. The histogram represents the maximum bronchoconstriction values recorded 
during the early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are 
expressed as mean±SEM percentage change from baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=6 (vehicle), N=4 
(Dex 5mg/kg), N=6 (Dex 10mg/kg), N=7 (Dex 20mg/kg). *Dex 10mg/kg significantly different from vehicle treatment p<0.05, ** p<0.01; ^^ Dex 20mg/kg 
significantly from vehicle treatment p<0.01; # Dex 5mg/kg significantly different from vehicle treatment p<0.05 performed with one-way analysis of 
variance followed by Bonferroni post-test. 
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Figure 5: Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) challenge in sensitised guinea-pigs treated with either intra-peritoneal vehicle or 
dexamethasone (Dex, 5mg/kg, 10mg/kg and 20mg/kg) dosed daily for 6 days. For the 
purpose of analysis only negative peaks were considered and all positive sGaw values were 
excluded. Total includes all negative peaks from 0-12 hours, early asthmatic response (EAR) 
includes values from 0-6 hours and late asthmatic response (LAR) includes values from 6-12 
hours. Area under the curve is expressed as %.hour N=6 (vehicle), N=4 (Dex 5mg/kg), N=6 
(Dex 10mg/kg), N=7 (Dex 20mg/kg).*significantly different from vehicle treatment p<0.05, 
** p<0.01; performed with one-way analysis of variance followed by Dunnet’s post-test.
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Figure 6: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 
2minutes, 1 minute drying period) in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either A) intra-peritoneal vehicle or 
dexamethasone (B) 5mg/kg C) 10mg/kg D) 20mg/kg) dosed daily for 6 days. E) Represents the peak the bronchoconstriction pre- and post-Ova following 
histamine challenge. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage 
change from baseline. A negative value represents a bronchoconstriction. N=6 (vehicle), N=4 (Dex 5mg/kg), N=6 (Dex 10mg/kg), N=7 (Dex 20mg/kg). 
***significantly different from vehicle treatment p<0.001; performed with performed with a two tailed T-test. 
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Figure 7: Total lavage fluid protein in ovalbumin (Ova) sensitised and challenged guinea-pigs 
treated with either intra-peritoneal vehicle or dexamethasone (Dex, 5mg/kg, 10mg/kg and 
20mg/kg) dosed daily for 6 days. Protein content was determined by BCA protein assay. N=6 
(vehicle), N=4 (Dex 5mg/kg), N=6 (Dex 10mg/kg), N=7 (Dex 20mg/kg).*significantly different 
from vehicle treatment p<0.05, ** p<0.01; ^^^significantly different from naïve, p<0.001; 
performed with one-way analysis of variance followed by selected groups Bonferroni post-
test. 
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Figure 8: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil (E) 
counts in bronchoalveolar fluid in ovalbumin (Ova) sensitised and challenged guinea-pigs 
treated with intra-peritoneal vehicle or dexamethasone (Dex, 5mg/kg, 10mg/kg and 
20mg/kg) dosed daily for 6 days. N=6 (vehicle), N=4 (Dex 5mg/kg), N=6 (Dex 10mg/kg), N=7 
(Dex 20mg/kg).*significantly different from vehicle treatment p<0.05, ** p<0.01; ^^^ 
significantly different from naive p<0.001; performed with one-way analysis of variance 
followed by selected groups Bonferroni post-test. 
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Figure 9: The concentration of A) IL-13 B) IL-17 in the lungs of ovalbumin (Ova) sensitised 
and challenged guinea-pigs treated with intra-peritoneal vehicle or dexamethasone (Dex, 
5mg/kg, 10mg/kg and 20mg/kg) dosed daily for 6 days. N=6 (vehicle), N=4 (Dex 5mg/kg), 
N=6 (Dex 10mg/kg), N=7 (Dex 20mg/kg).*significantly different from vehicle treatment 
p<0.05, ** p<0.01; *** p<0.001; ^^ significantly different from naive p<0.01; performed with 
one-way analysis of variance followed by selected groups Bonferroni post-test. 
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7.5.2 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON ACUTE OVALBUMIN AND 
LPS CO-EXPOSURE RESPONSES 
Ova challenged and vehicle treated guinea-pigs demonstrated an immediate 
bronchoconstriction to Ova at 0 minutes (-54.3±6.6%) which did not return to 
baseline sGaw values until 7 hours. Dexamethasone (20mg/kg) treated animals also 
demonstrated an immediate bronchoconstriction (-46.1±11.2%). During the first 6 
hours following Ova exposure, dexamethasone treated animals demonstrated 
significantly less of a bronchoconstriction than vehicle, including at 3 (-15.4±10.0% 
compared to -55.6±4.6%) 4 (-7.9±8.8% compared to -41.9±5.2%) and 5 hours (-
11.5±8.2% compared to -35.1±3.4%). Vehicle treated guinea-pigs displayed a late 
asthmatic response at 9 hours (-21.9±9.9%) which was not significantly reduced by 
dexamethasone treatment (-9.0±9.7%) (Figure 10, time course). No difference in the 
peak early or late phase responses was observed between vehicle and 
dexamethasone treatment groups (Figure 10, histogram). The area under the curve 
for early phase responses was significantly reduced by dexamethasone treatment 
(208.0±59.3%.hr compared to vehicle, 357.6±44.0%.hr). No significant difference in 
late phase area under the curve was observed (Figure 11). Intra-peritoneal 
dexamethasone (20mg/kg) significantly increased the recovery from early asthmatic 
response bronchoconstriction (2.1±0.5h compared to 4.8±0.5h respectively) (Figure 
12).   
 
Vehicle treated guinea-pigs demonstrated an immediate increase in the 
bronchoconstrictor response to histamine, post-Ova challenge (-34.8±5.8% 
compared to pre-Ova, -2.0±1.3%). This bronchoconstriction continued to increase 
over 10 minutes. At 10 minutes it was -43.2±5.1% compared to pre-challenge, -
6.9±3.1%. Treatment with 20mg/kg dexamethasone did not significantly attenuate 
the development of airways-hyperresponsiveness. At 5 and 10 minutes the 
bronchoconstriction to histamine post-Ova challenge was -36.0±12.3% compared to 
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pre-Ova, -3.9±4.1%; -35.3±9.9% compared to pre-Ova, -1.1±2.6% respectively) 
although the immediate response to histamine was attenuated (Figure 13). The peak 
bronchoconstriction to histamine increased post-Ova/LPS challenge in both vehicle (-
43.2±5.1% compared to pre-Ova, -7.0±5.1%) and dexamethasone (-36.0±12.3% 
compared to pre-Ova, -6.3±1.8%).  
 
Lavage fluid protein levels, increased in vehicle treated guinea-pigs (2.4±0.4mg/ml) 
compared to naïve (0.4±0.1). Lavage fluid protein levels were reduced in 
dexamethasone (20mg/kg) treated guinea pigs, nearly back to naïve levels 
(0.7±0.2mf/ml) (Figure 14).  
 
Total cell numbers, increased In Ova/LPS challenged guinea-pigs (25.8±1.6x106/ml) 
compared to naïve (1.4±0.2x106/ml), were significantly reduced by dexamethasone 
(20mg/kg) treatment (11.2±1.2x106/ml). All cell types measured were reduced by 
dexamethasone treatment including macrophages (5.5±0.5x106/ml compared to 
vehicle 10.5±0.8x106/ml), eosinophils (2.4±0.7x106/ml compared to vehicle 
8.2±1.2x106/ml), lymphocytes (0.1±0.04x106/ml compared to vehicle 
0.6±0.2x106/ml) and neutrophils (3.2±0.8x106/ml compared to vehicle 
6.8±0.8x106/ml) (Figure 15).  
 
IL-8, IL-13 and IL-17 levels were significantly elevated in Ova/LPS challenged and 
vehicle treated guinea-pigs (45±7.3pg/mg, 16.9±1.0ng/mg and 105.6±19.8pg/mg, 
respectively) compared to naïve (not detectable, 8.7±2.9ng/mg and not detectable 
respectively). None of these cytokines were significantly reduced by dexamethasone 
treatment (Figure 16).  
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Figure 10: The mean time-course values of sGaw in ovalbumin (Ova) and LPS challenged guinea-pigs treated with intra-peritoneal vehicle or dexamethasone 
(Dex, 20mg/kg) dosed daily for 6 days. The histogram represents the maximum bronchoconstriction values recorded during the early asthmatic response 
(EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as mean±SEM percentage 
change from baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=5 (vehicle), N=6 (Dex) *significantly different from 
vehicle treatment p<0.05, ** p<0.01; performed with a two tailed T-test. 
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Figure 11: Area under the curve analysis of sGaw values over 12 in ovalbumin (Ova) and LPS 
challenged guinea-pigs treated with intra-peritoneal vehicle or dexamethasone (Dex, 
20mg/kg) dosed daily for 6 days. For the purpose of analysis only negative peaks were 
considered and all positive sGaw values were excluded. Total includes all negative peaks 
from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 hours and late 
asthmatic response (LAR) includes values from 6-12 hours. Area under the curve is expressed 
as %.hour. N=5 (vehicle), N=6 (Dex) *significantly different from vehicle treatment p<0.05; 
performed with a two tailed T-test. 
 
Figure 12: Analysis of the time taken for early asthmatic responses (EAR) to recover to 50% 
of peak bronchoconstriction values in ovalbumin (Ova) and LPS challenged guinea-pigs 
treated with intra-peritoneal vehicle or dexamethasone (Dex, 20mg/kg) dosed daily for 6 
days. N=5 (vehicle), N=6 (Dex) **significantly different from vehicle treatment p<0.01; 
performed with a two tailed T-test. 
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Figure 13: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in ovalbumin (Ova) and LPS challenged guinea-pigs treated with intra-peritoneal A) vehicle or B) dexamethasone (Dex, 
20mg/kg) dosed daily for 6 days. C) Represents the peak the bronchoconstriction pre- and post-Ova following histamine challenge. Values were recorded 7 
days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline.  A negative value 
represents a bronchoconstriction. N=5 (vehicle), N=6 (Dex) **significantly different from time paired pre-Ova challenge values p<0.01; *** p<0.001; 
performed with a two tailed T-test. 
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Figure 14: Total lavage fluid protein in ovalbumin (Ova) and LPS challenged guinea-pigs 
treated with intra-peritoneal vehicle or dexamethasone (Dex, 20mg/kg) dosed daily for 6 
days. Protein content was determined by BCA protein assay. N=5 (vehicle), N=6 (Dex) 
**significantly different from vehicle treatment p<0.01; ^^^significantly different from 
naïve, p<0.001; performed with one-way analysis of variance followed by selected groups 
Bonferroni post-test. 
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Figure 15: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid of ovalbumin (Ova) and LPS challenged guinea-pigs 
treated with intra-peritoneal vehicle or dexamethasone (Dex, 20mg/kg) dosed daily for 6 
days. N=5 (vehicle), N=6 (Dex) *significantly different from vehicle treatment p<0.05,; *** 
p<0.001; ^^^significantly different from naïve, p<0.001; performed with one-way analysis of 
variance followed by selected groups Bonferroni post-test. 
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Figure 16: The concentration of A) IL-8 B) IL-13 C) IL-17 in the lungs of ovalbumin (Ova) 
sensitised guinea-pigs treated with intra-peritoneal vehicle or dexamethasone (Dex, 
20mg/kg) dosed daily for 6 days. N=5 (vehicle), N=6 (Dex) ^significantly different from naive 
p<0.05, ^^^ p<0.001; performed with one-way analysis of variance followed by selected 
groups Bonferroni post-test. 
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8.5.3 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON LPS EXPOSURE 
RESPONSES 
Vehicle treated animals demonstrated a progressive increase in bronchoconstriction 
during the 1st hour post-LPS exposure, reaching its peak at 3 hours (-36.0±3.5%). 
Dexamethasone (20mg/kg) significantly attenuated the LPS induced 
bronchoconstriction during this time period. At 1 hour the bronchoconstriction was -
9.5±7.1% compared to vehicle -31.8±2.8%, 2 hours -7.9±5.1% compared to vehicle, -
29.1±3.4% and 3 hours -7.8±5.9% compared to -36.0±3.5%. In vehicle treated 
animals the bronchoconstriction returned to baseline sGaw levels at 5 hours. No 
further significant difference between vehicle and dexamethasone treated groups 
was seen (Figure 17, time course). Vehicle treated guinea pigs demonstrated a peak 
constriction between 0-12 hours of -38.5±3.2% which was significantly reduced by 
dexamethasone treatment (-17.6±5.6%) (Figure 17, histogram). Dexamethasone 
treatment significantly reduced the area under the curve between 0-12 hours 
compared to vehicle (212.6±34.1%.hr compared to 93.0±30.4%.hr) (Figure 18).  
 
LPS increased protein levels in lavage fluid (1.5±0.1mg/ml) compared with naïve 
(0.5±0.05mg/ml) was significantly reduced by dexamethasone (20mg/kg) treatment 
to near naïve levels (0.6±0.1mg/ml and 0.5±0.1mg/ml respectively) (Figure 19).  
 
Vehicle treated guinea-pigs demonstrated a significant increase in the 
bronchoconstrictor response at 0 minutes to histamine post-LPS exposure (-
15.8±3.1%) compared to pre-LPS (-2.1±3.5%). At 5 minutes post-histamine challenge 
a significant bronchoconstriction was still present (-12.3±2.3%) compared to pre-LPS 
(5.6±2.4%). The bronchoconstriction was no longer significant at 10 minutes. 
Dexamethasone treated guinea-pigs also displayed no increase in bronchoconstrictor 
response to histamine (Figure 20). LPS challenged and vehicle treated guinea pigs 
also demonstrated an increase in the peak bronchoconstriction to histamine (-
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16.5±2.7%) compared to pre-LPS (-7.4±1.7%). Dexamethasone treated guinea-pigs 
demonstrated no change in peak bronchoconstriction.  
 
LPS increased total cell numbers (19.4±0.8x106/ml) compared to naïve 
(1.1±00.2x106/ml) and were significantly reduced by treatment with dexamethasone 
(13.5±0.9x106/ml). This decrease corresponded with a decrease in the number of 
eosinophils and neutrophils (0.1±0.02x106/ml compared with vehicle, 
0.6±0.2x106/ml; 5.5±0.7x106/ml compared with vehicle, 10.5±0.4x106/ml). All other 
cell types remained unchanged by dexamethasone treatment (Figure 21).  
 
IL-8 levels increased in vehicle treated guinea–pigs (190.8±34.4pg/mg) compared to 
naïve (not detectable) and was significantly reduced by treatment with 
dexamethasone (91.4±15.8pg/mg) (Figure 22). 
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Figure 17: The mean time-course values of sGaw in guinea-pigs exposed to LPS twice and treated with an intra-peritoneal injection of vehicle or 20mg/kg 
dexamethasone, dosed daily for 6 days. The histogram represents the maximum bronchoconstriction values recorded during 0-12 hours and 24 hours 
readings. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline prior LPS challenge. A negative value represents a 
bronchoconstriction. Results shown are after the second LPS exposure. N=6 *significantly different from vehicle treatment p<0.05, ** p<0.01; performed 
with a two tailed T-test. 
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Figure 18: Total area under the curve analysis of sGaw values in guinea-pigs exposed to LPS 
twice and treated with an intra-peritoneal injection of vehicle or 20mg/kg dexamethasone, 
dosed daily for 6 days.  For the purpose of analysis only negative peaks were considered and 
all positive sGaw values were excluded. Total includes all negative peaks from 0-12 hours. 
Area under the curve is expressed as %.hour. N=6 ***significantly different from vehicle 
treatment p<0.001; performed with a two tailed T-test. 
 
 
Figure 19: Total lavage fluid in guinea-pigs exposed to LPS twice and treated with an intra-
peritoneal injection of vehicle or 20mg/kg dexamethasone, dosed daily for 6 days. Protein 
content was determined by BCA protein assay.  N=6 ***significantly different from vehicle 
treatment  p<0.001; ^^^ significantly different from naive p<0.001; performed with one-way 
analysis of variance followed by selected groups Bonferroni post-test.  
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Figure 20: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period,) in guinea-pigs exposed to LPS twice and treated with an intra-peritoneal injection of A) vehicle or B) 20mg/kg 
dexamethasone, dosed daily for 6 days. C) Represents the peak the bronchoconstriction pre- and post-Ova following histamine challenge. Values were 
recorded 7 days pre- and 24 hours post-Ova challenge.  Mean changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative 
value represents a bronchoconstriction. N=6 *significantly different from time paired pre-LPS challenge values p<0.05; *** p<0.001; performed with a two 
tailed T-test. 
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Figure 21: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar in guinea-pigs exposed to LPS twice and treated with an intra-
peritoneal injection of vehicle or 20mg/kg dexamethasone, dosed daily for 6 days. N=6 
***significantly different from vehicle treatment p<0.001; ^significantly different from 
naïve, p<0.05; ^^^ p<0.001; performed with one-way analysis of variance followed by 
selected groups Bonferroni post-test. 
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Figure 22: The concentration of IL-8 in the lungs of guinea-pigs exposed to LPS twice and 
treated with an intra-peritoneal injection of vehicle or 20mg/kg dexamethasone, dosed daily 
for 6 days. N=6 *significantly different from vehicle treatment p<0.05, ^^^ significantly 
different from naive p<0.001; performed with one-way analysis of variance followed by 
selected groups Bonferroni post-test. 
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7.6 DISCUSSION 
Initially, a dose of systemic dexamethasone which reduced the LAR, AHR and airway 
inflammation induced by Ova alone was sought. This dose was then used to test the 
systemic corticosteroid sensitivity of the Ova and LPS exacerbation model developed 
in chapter 5. The sensitivity of LPS induced responses to this same dose was also 
investigated.  
7.6.1 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON EARLY AND LATE 
ASTHMATIC RESPONSES 
Systemic dexamethasone demonstrated some effect on the EAR. The peak of the 
EAR was not affected by any dose of systemic dexamethasone but the area under 
the curve during this time period was reduced. In the case of 10mg/kg 
dexamethasone this was a statistically significant reduction. This indicates that 
systemic dexamethasone can reduce the duration of the EAR. This effect of 
dexamethasone is supported by a study by Toward & Broadley, 2004, who also 
demonstrated that systemically administered dexamethasone reduces the length of 
the EAR. This response coincided with a reduction in lavage fluid histamine levels 
and increased nitric oxide 1 hour after allergen challenge. This indicates that a 
reduction in histamine release from mast cells and increased nitric oxide production 
may mediate this effect in the present study. This is further supported by the 
observation that L-NAME, a nitric oxide synthase inhibitor increases the duration of 
the EAR (Schuiling et al, 1998).    
Systemic dexamethasone also reduced the prolonged EAR in Ova and LPS challenged 
guinea-pigs. This may suggest that the EAR in Ova/LPS groups consists of separate 
systemic corticosteroid sensitive and insensitive components. This could be 
mediated by the selective decrease in mast cells and histamine release. James et al, 
(2012) recently demonstrated that inhaled corticosteroids can selectively decrease 
epithelial and smooth muscle mast cells but not sub mucosal mast cells. A similar 
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selective decrease in the mast cells with a systemic corticosteroid may account for a 
decrease in the prolonged EAR in Ova/LPS groups. The reduction could also be due 
to a decrease in neutrophils in lavage fluid. Systemic dexamethasone treatment in 
LPS exposed guinea-pigs also decreased LPS-induced bronchoconstrictions and 
neutrophil numbers. Neutrophils increase during the EAR and can release 
bronchoconstrictive substances (Danahay et al, 1995; Reino et al, 2012). However, 
sensitivity to systemic corticosteroid of LPS-induced bronchoconstrictions and 
neutrophils has not been shown in all studies. Lefort et al, (2001) demonstrated that 
LPS-induced bronchoconstrictions were systemic corticosteroid insensitive while 
lavage neutrophils were not. However, no decrease in neutrophil numbers was 
found in the airway structure with histological assessment, not making it possible to 
rule out the role of neutrophils. Instead this study suggested that macrophages may 
be the mediators of immediate bronchoconstrictions to LPS. However, in the present 
study macrophage numbers were not reduced with systemic dexamethasone 
treatment not supporting this conclusion. The reasons for this disparity are unclear, 
but differences in the LPS exposure protocol and the use of C57BL/6 mice may 
account for this.  
 The LAR was reduced in a dose-dependent manner; being significantly 
attenuated by the highest dose of dexamethasone (20mg/kg) used in Ova challenged 
guinea-pigs. The ability of systemic dexamethasone to reduce the LAR is well 
established (Toward & Broadley, 2004). In contrast, systemic dexamethasone did not 
significantly reduce the LAR in Ova and LPS challenged guinea-pigs. This is slightly 
surprising as the LAR is linked to the presence of airway inflammation but in the 
current study inflammation is reduced by dexamethasone treatment (Yoshida et al, 
2005; Gauvreau et al, 2000). However, the specific component of the inflammatory 
response that promotes the LAR is unknown and consequently dissociation has been 
observed in several animal models (Smith & Broadley, 2007). Additionally, despite 
the reduction in airway inflammations by systemic dexamethasone, the absolute 
number of cells found in lavage fluid is still high (10 million total). Thus the reduction 
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in airway inflammation may not be sufficient to suppress the LAR. The observation 
that IL-13 levels, typically corticosteroid sensitive are not reduced by systemic 
dexamethasone would suggest these remaining cells are still actively secreting 
mediators.  
7.6.2 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON AIRWAYS 
HYPERRESPONSIVENESS 
All doses of systemic dexamethasone reduced the development of AHR following 
Ova challenge. This confirms the results of previous studies from this laboratory in 
guinea-pigs (Toward & Broadley, 2004; Smith & Broadley, 2010). Systemic 
dexamethasone (20mg/kg) also reduced LPS-induced AHR at 24 hours. This confirms 
that the AHR suppressive effects of systemic dexamethasone at 1 hour extend to the 
24 hour time point (Toward & Broadley, 2001). 
In contrast, even the highest dose (20mg/kg) of systemic dexamethasone did not 
significantly reduce the development of AHR in guinea-pigs exposed to Ova and LPS. 
This result is supported by a study by Komlosi et al, (2006) who also found that Ova 
and LPS induced systemic corticosteroid insensitive AHR. Although AHR is generally 
associated with inflammation, in the present study total and differential cell counts 
are all reduced by systemic dexamethasone in Ova/LPS animals. This suggests that 
the reduction in inflammation is not sufficient to completely abolish the 
development of AHR in these animals. In support of this is the observation that 
although inflammation is reduced by systemic dexamethasone treatment, cell 
numbers are still significantly higher than naïve levels. Thus neutrophils and 
macrophages may still be active and releasing mediators which cause epithelial 
damage. The damage may increase the access and prevent the breakdown of 
bronchoconstrictive substances such as exogenous histamine. Some mediators such 
as IFN-γ and IL-13 are also directly implicated in AHR (Cockcroft & Davis, 2006; Yang 
et al, 2009). In the current study, IL-13 levels are not significantly reduced by 
systemic dexamethasone in Ova/LPS challenged guinea-pigs. However, IL-13 is 
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unlikely to be the main mediator of the prolonged bronchoconstrictor response in 
this model since levels do not increase over those in Ova challenged guinea-pigs 
7.6.3 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON AIRWAY INFLAMMATION 
AND CYTOKINES 
Systemic dexamethasone reduced the total number of lavage cells in a dose-
dependent manner in Ova challenged guinea-pigs. Eosinophils, macrophages and 
lymphocytes were all reduced by the highest dose (20mg/kg) of systemic 
dexamethasone. This confirms the findings of Toward & Broadley, (2004) and Smith 
& Broadley, (2010) who also used systemic dexamethasone in a guinea-pig allergen 
challenge model. Total and differential cells were also reduced by systemic 
dexamethasone in Ova and LPS challenged guinea-pigs, indicating that the 
inflammation in this model is sensitive to systemic corticosteroids. This confirms the 
findings of Komlosi et al, (2006) who also demonstrated significant decreases in 
these cell populations with systemic dexamethasone in mice. IL-13 was significantly 
reduced by systemic dexamethasone in both Ova and Ova and LPS groups. 
Contrastingly, in the present study IL-13 levels were only decreased in Ova but not 
Ova/LPS challenged groups. The reason for this difference is unknown but species 
differences, protocols and the medium used to assess IL-13 (lavage fluid vs lung) may 
account for the difference. 
The reason inflammation is sensitive to systemic corticosteroid in the Ova and LPS 
model is likely to be due to the compartmentalisation of corticosteroid insensitivity 
in the lung. Also, systemic corticosteroids have additional biological effects over 
inhaled corticosteroids. Systemic corticosteroids work not only by reducing 
inflammation in the lungs but also by suppressing bone marrow derived 
haemopoietic cells (Mao et al, 2004; Ben et al, 2008). Since LPS is administered by 
inhalation to the lungs the main corticosteroid insensitivity inducing effects are likely 
localised to this region of the body.  Although systemic exposure to LPS from 
inhalation is also likely, the levels of exposure will be lower than that of the lung. At 
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higher doses or increased numbers of LPS exposures, corticosteroid insensitivity may 
become more generalised in the body. Goleva et al, (2008) showed that in vitro 
prolonged exposure to LPS reduces the effect of dexamethasone on human 
monocytes. In vivo a high dose of intranasal LPS in mice can cause systemic 
corticosteroids insensitivity (Lefort et al, 2001). This contrasts with the current study 
where fewer and lower doses of LPS induced inflammation that was sensitive to 
systemic dexamethasone.  
Neutrophils have different sensitivity to corticosteroids in the systemic 
circulation and the lungs. Although neutrophils in the lung are relatively 
corticosteroid insensitive due to decreased expression of GR-α, in the blood they 
demonstrate increased expression of GR-α, rendering them sensitive to suppression 
by corticosteroids (Plumb et al, 2012). This may account for the decrease in 
neutrophils with systemic dexamethasone in Ova/LPS and LPS challenged guinea-
pigs. Systemic administration of corticosteroids suppresses neutrophil recruitment to 
the lung because of high circulating levels of the drug (Ben et al, 2008). However, 
blood neutrophils are still relatively insensitive to corticosteroids, probably 
explaining why systemic dexamethasone does not completely eliminate them. Lung 
neutrophils in conditions of high oxidative stress may become even more 
corticosteroid insensitive by decreasing the activity of HDAC-2 and increasing GR-β 
(Hamilos et al, 2001; Ito et al, 2004). Thus the elevated neutrophil numbers still 
present in Ova and LPS challenged guinea-pigs may represent a distinct 
corticosteroid insensitive lung neutrophil population. This population may be 
supported by the increased levels of IL-8 in the lungs, which are not suppressed by 
systemic dexamethasone. IL-17 levels in lung were unaffected by systemic 
dexamethasone treatment in Ova and LPS but decreased in Ova challenged groups. 
This indicates that IL-17-based responses have become less responsive to systemic 
corticosteroid treatment. This may be as a result of IL-17 responses being localised 
to the lung, where cells secreting IL-17 are less corticosteroid sensitive with Ova and 
LPS exposure.  
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7.6.4 THE EFFECT OF SYSTEMIC DEXAMETHASONE ON AIRWAY OEDEMA 
Systemic dexamethasone significantly decreased total lavage fluid protein levels in 
guinea-pigs challenged with Ova, LPS/Ova and LPS. The decrease in total protein 
levels correlated with decreases in inflammation which may indicate that these 
effects are due to decreased levels of pro-inflammatory mediators. However, 
corticosteroids are known to have extra-genomic effects such as vasoconstriction so 
these effects are likely to also be important (Mendes et al, 2003).  
7.6.5 GENERAL CONCLUSIONS 
This study has demonstrated that Ova induced LAR, AHR, airway inflammation, lung 
cytokines and lavage fluid protein levels are sensitive to systemic dexamethasone. 
Exposure to LPS reduces the effect of systemic dexamethasone on the LAR, AHR and 
cytokines. However, the elongated EAR, inflammatory cell influx and lavage protein 
levels are still sensitive to systemic dexamethasone. These results demonstrate that 
the Ova and LPS model may be clinically relevant. Patients who are insensitive to 
inhaled corticosteroids frequently demonstrate some sensitivity to systemic 
corticosteroids (Hodgson et al, 2012; Massuse et al, 2012). To fully confirm inhaled 
corticosteroid insensitivity in this model, the next chapter will use dexamethasone as 
an inhaled preparation.  
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CHAPTER 8 
The Effect Of Inhaled Dexamethasone On 
Functional And Inflammatory Responses 
To Ovalbumin And LPS 
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8.1 INTRODUCTION 
For a description of the use of inhaled corticosteroids, corticosteroid insensitivity 
and their mechanism please refer to Chapter 6.1. 
8.1.1 CONFIRMATION OF INHALED CORTICOSTEROID INSENSITIVITY 
Following on from the results of chapter 6 and 7, this chapter aimed to confirm that 
insensitivity to inhaled corticosteroids in the Ova and LPS combination model was 
not specific to just FP. Therefore dexamethasone, having been shown to be 
systemically active in reducing functional and allergic responses in the Ova and LPS 
combination model was given as an inhalation. Dexamethasone is normally 
administered systemically but a few studies have given it as an intranasal 
preparation and found that it reduces AHR, airway inflammation and Th2 cytokines 
(Essilfie et al, 2012). Only one previous study in animals has administered 
dexamethasone as an inhalation (Jungsuwadee et al, 2004). This study found that 
inhaled dexamethasone in mice was also effective at reducing Ova-induced AHR and 
airway inflammation. To find an effective dose at reducing these parameters and the 
EAR, LAR and oedema induced by Ova alone, several doses were initially 
investigated.  
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8.2 HYPOTHESIS 
‘LPS exposure will decrease the sensitivity of functional and inflammatory responses 
to inhaled dexamethasone in an ovalbumin model of asthma’ 
8.3 AIMS AND OBJECTIVES 
The aim of this chapter was to establish whether LPS decreases the sensitivity of 
Ova-induced functional and inflammatory responses to inhaled dexamethasone. 
Initially a dose of inhaled dexamethasone effective at reducing the LAR, AHR and 
airway inflammation by Ova alone was established. This dose was then tested in the 
LPS and Ova/LPS models. 
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8.4 METHODS 
Methods describing the measurement of lung function, AHR, airway oedema, airway 
inflammation and cytokine levels can be found in more detail in chapter 2.  
8.4.1 OVALBUMIN PROTOCOLS 
8.4.1.1 SENSITISATION 
Guinea-pigs (200-300g, Dunkin-Hartley, male) were sensitised by a bilateral intra-
peritoneal injection of a solution containing 150µg ovalbumin (Ova) and 100mg 
aluminium hydroxide (Al(OH)3) in normal saline on day 1, 4 and 7. 
 
8.4.1.23 ACUTE OVALBUMIN MODEL  
Sensitised guinea-pigs were exposed to inhaled Ova (0.03%) for 1 hour on day 21 in a 
Perspex container as described in section 8.4.1.2. The lung function response to Ova 
was assessed over 12 hours. The bronchoconstrictor response to 0.3mM histamine 
was accessed on day 15 and 22 as described in section 8.4.5. Dexamethasone was 
administered by inhalation in a Perspex chamber for 15 minutes, once a day from 
day 16-21. On day 21, dexamethasone was administered 30 minutes pre-Ova 
challenge. A diagram of this protocol is shown in shown in Figure 1. 
 
Figure 1: The acute ovalbumin (Ova) protocol. Guinea-pigs were challenged with inhaled Ova 
(0.03% on day 21). Dexamethasone (Dex) was dosed daily for 6 days.  
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8.4.1.3 ACUTE OVA AND LPS CO-EXPOSURE MODEL 
Sensitised guinea-pigs were exposed to inhaled LPS (30μg/ml) 48 hours before Ova 
challenge in an exposure chamber and both LPS (30μg/ml) and Ova (0.03%) co-
administered on day 21. The bronchoconstrictor response to histamine was assessed 
on day 15 and day 22. Dexamethasone was administered by inhalation in a Perspex 
chamber for 15 minutes, once a day from day 16-21. On day 21, dexamethasone was 
administered 30 minutes pre-Ova challenge. A diagram of this protocol is shown in 
shown in Figure 2. 
 
 
Figure 2 Diagram of the LPS and Ova co-exposure protocol. Guinea-pigs were exposed to LPS 
(30μg/ml) on day 19 and both Ova and LPS co-administered on day 21. Dexamethasone 
(Dex) was dosed daily for 6 days. 
 
8.4.2 LPS EXPOSURE PROTOCOL 
Non-sensitised guinea-pigs were exposed to LPS (30μg/ml) on days 5 and 7 of the 
protocol. The bronchoconstrictor response to histamine was assessed on day 1 and 
day 8. Figure 3 shows a diagram of this protocol. Dexamethasone was administered 
by inhalation in a Perspex chamber for 15 minutes, once a day from day 2-7. On day 
7,  dexamethasone was administered 30 minutes pre-LPS challenge. A diagram of 
this protocol is shown in Figure 2. 
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Figure 3: Diagram of the LPS alone exposure protocol. Guinea-pigs were exposed to 30μg/ml 
of LPS on day 5 and 7. Dexamethasone (Dex) was dosed daily for 6 days. 
8.4.3 DRUG ADMINISTRATION 
Dexamethasone was dissolved in 25% DMSO and 75% saline and administered as an 
inhalation for 15 minutes in a Perspex exposure chamber using a DeVilbiss nebuliser. 
8.4.4 MEASUREMENT OF LUNG FUNCTION 
Lung function was measured by whole body plethysmography following final Ova, 
LPS or Ova/LPS exposure in all protocols. Lung function was recorded hourly for 12 
hours and every 15 minutes during the first hour of measurements. A final 
measurement was also taken 24 hours post-final challenge. All values were 
expressed as a percentage of the baseline reading, taken before the final challenge. 
A negative percentage change in baseline value represents a bronchoconstriction. In 
Ova protocols, early (0-6 hours) and late (6-12 hours) asthmatic responses were 
expressed as the peak bronchoconstriction during that period (displayed as a 
histogram next to a time course plot) and area under the curve. The duration of the 
early phase was expressed as the time taken to recover to 50% of peak early phase 
bronchoconstriction values.  In the LPS only protocol, lung function was measured 
for 12 hours after the second LPS exposure. The peak bronchoconstriction during 
this period was expressed on a histogram next to the time course plot.  
1          2          3          4          5 6          7          8
Histamine 
inhalation & 
BAL
Histamine 
inhalation
Inhaled LPSLPS and Inhaled 
Steroid Protocol 
Vehicle/inhaled 
Steroid 
Chapter 8 
 
317 
 
8.4.5 AIRWAYS HYPERRESPONSIVENESS ASSESSMENT. 
AHR was determined using whole body plethysmography. This was performed by 
measuring the bronchoconstrictor response to histamine before inhaled 
corticosteroid treatment and 24 hours post-final LPS, Ova, LPS or Ova challenge. 
Histamine was delivered as described in chapter 2. Lung function was measured just 
before histamine inhalation and at 0, 5 and 10 minutes post-histamine exposure. The 
peak bronchoconstriction during this period was expressed on a histogram.  
6.4.6 ASSESSMENT OF AIRWAYS INFLAMMATION 
Following final histamine exposure guinea-pigs were sacrificed by an intra-peritoneal 
overdose of sodium pentobarbitone, the lungs excised and lavaged. Total and 
differential cell counts were then performed as described in chapter 2.  
8.4.7 QUANTIFICATION OF CYTOKINE LEVELS USING ENZYME-LINKED 
IMMUNOSORBENT ASSAY (ELISA) 
Levels of IL-8, IL-17 and IL-13 were measured in diluted homogenised lung samples 
using ELISA supplied by R&D systems. Cytokine levels were adjusted for total lung 
protein and expressed as weight per mg of lung as described in section 2.2.3.2. 
8.4.8 ASSESSMENT OF AIRWAY OEDEMA 
Protein content in lavage fluid was determined as a measure of airway oedema by 
BCA protein assay as per the manufacturer’s instructions (Pierce protein biology).  
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8.5 RESULTS 
8.5.1 THE EFFECT OF INHALED DEXAMETHASONE ON ACUTE OVALBUMIN  
Inhaled vehicle (25% DMSO/75% saline) treated animals demonstrated an 
immediate bronchoconstriction to Ova at 0 minutes (-70.2±2.7%). This was 
attenuated in guinea-pigs treated with 20mg/ml but not 4mg/ml dexamethasone (-
57.7±3.6% and -72.8±2.7%, respectively). Animals treated with 20mg/ml 
dexamethasone demonstrated significantly less of a bronchoconstriction than 
vehicle during the first hour of readings, at 1 hour the sGaw value was -34.0±5.1% 
compared to vehicle, -56.2±5.4%. This was also the case at 3 hours (-26.1±5.8%) 
compared to vehicle (-46.5±5.5%). Both vehicle and dexamethasone treated group’s 
early phase bronchoconstrictions returned to baseline sGaw values by 6 hours. Both 
vehicle and 4mg/ml dexamethasone treated animals demonstrated late asthmatic 
responses between 7-10 hours (-18.3±3.7% and -18.7±2.6% respectively). No clear 
LAR was seen in 20mg/ml treated animals during this period (-6.2±3.5%) (Figure 4, 
time course).  
Vehicle treated guinea-pigs demonstrated a peak EAR of -70.8±2.6%, unchanged by 
4mg/ml dexamethasone (-73.2±2.7%) but significantly attenuated by 20mg/ml 
dexamethasone (-57.9±3.6%). Late asthmatic response in animals treated with 
4mg/ml dexamethasone were unchanged from vehicle (-21.3±2.6 compared to -
23.3±2.6%) but were significantly reduced by 20mg/ml dexamethasone (-11.1±2.0%). 
No significant differences between sGaw values at 24 hours were observed (Figure 4, 
histogram). 4mg/ml dexamethasone did not significantly reduce the total or early 
asthmatic response area under the curve compared to vehicle. 20mg/ml 
dexamethasone significantly reduced both total (169.2±31.9%.hr compared to 
vehicle, 302.1±32.1%.hr) and EAR area (145.5±25.9%.hr compared to vehicle, 
235.9±24.4%.hr). LAR area was reduced by 20mg/ml dexamethasone but not 
significantly (Figure 5). 
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Vehicle treated guinea-pigs demonstrated a significant increase in the 
bronchoconstrictor response to histamine post-Ova compared to pre-Ova challenge 
(-17.1±6.2% compared to 0.3±2.9%). At 5 minutes post-histamine challenge, sGaw 
values began to return to pre-challenge values (-12.3±4.5% compared to 8.2±2.4%). 
At 10 minutes the bronchoconstriction was still significant (-11.4±4.2% compared to 
pre-challenge, 6.8±4.0%). Guinea pigs treated with both 4 and 20 mg/ml 
dexamethasone demonstrated no significant change in histamine bronchoconstrictor 
response post-Ova challenge (Figure 6).  
 
Lavage fluid protein levels increased following Ova challenge and vehicle treatment 
(2.6±0.5mg/ml) and was reduced non-significantly by both 4 and 20mg/ml 
dexamethasone treatment (1.5±0.3mg/ml and 1.7±0.2mg/ml respectively) (Figure 7).  
 
Ova challenge with vehicle treatment increased total (9.1±1.1x106/ml) compared to 
naïve (1.4±0.2x106/ml) and differential cell counts. Guinea-pigs treated with 
dexamethasone or vehicle. Both 4 and 20mg/ml dexamethasone treatment 
significantly reduced total cell numbers compared to vehicle (6.1±0.7x106/ml and 
5.3±0.3x106/ml). Both 4 and 20mg/ml dexamethasone also significantly reduced 
eosinophil numbers (2.1±0.3x106/ml, 1.8±0.2x106/ml compared to vehicle, 
4.1±0.8x106/ml respectively). Additionally, 20mg/ml dexamethasone significantly 
reduced macrophage cell numbers compared to vehicle levels (3.1±0.3x106/ml 
compared to 4.8±0.4x106/ml). 4 but not 20mg/ml dexamethasone significantly 
reduced neutrophil numbers compared to vehicle (0.2±0.1x106/ml compared with 
0.5±0.1x106/ml respectively) (Figure 7). 
 
IL-13 levels, increased in Ova challenged and vehicle treated guinea-pigs (32.0±5.0%) 
compared to naïve (2.8±0.8ng/mg), demonstrated a non-significant trend for a 
decrease with increasing dose of dexamethasone. IL-17 levels were also increased in 
vehicle treated animals (106.6±17.7pg/mg) compared to naïve (41.9±15.4pg/mg) 
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and decreased non-significantly by dexamethasone, IL-8 was not detectable and is 
not shown (Figure 9).  
 
Chapter 8 
 
321 
 
 
Figure 4: The mean time-course values of sGaw in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either inhaled vehicle or 
dexamethasone (Dex, 4mg/ml or 20mg/ml), dosed daily for 6 days. The histogram represents the maximum bronchoconstriction values recorded during the 
early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as 
mean±SEM percentage change from baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=6 *significantly different from 
vehicle treatment p<0.05, ** p<0.01; performed with one-way analysis of variance followed by Dunnet’s post-test. 
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Figure 5: Area under the curve analysis of sGaw values over 12 hours following ovalbumin 
(Ova) challenge in guinea-pigs treated with either inhaled vehicle or dexamethasone (Dex, 
4mg/ml or 20mg/ml), dosed daily for 6 days. For the purpose of analysis only negative peaks 
were considered and all positive sGaw values were excluded. Total includes all negative 
peaks from 0-12 hours, early asthmatic response (EAR) includes values from 0-6 hours and 
late asthmatic response (LAR) includes values from 6-12 hours. Area under the curve is 
expressed as %.hour. N=6 *significantly different from vehicle treatment p<0.05; performed 
with one-way analysis of variance followed by Dunnet’s post-test. 
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Figure 6: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in ovalbumin (Ova) sensitised and challenged guinea-pigs treated with either inhaled A) vehicle (B) 4mg/ml 
dexamethasone (Dex)  C) 20mg/ml dexamethasone dosed daily for 6 days. D) Represents the peak the bronchoconstriction pre- and post-Ova following 
histamine challenge. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage 
change from baseline. A negative value represents a bronchoconstriction. N=6, *Significantly different from time paired pre-Ova challenge values p<0.05, 
** p<0.01; performed with a two tailed T-test. 
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Figure 7: Total lavage fluid protein in ovalbumin (Ova) sensitised and challenged guinea-pigs 
treated with either inhaled vehicle or dexamethasone (Dex, 4mg/ml or 20mg/ml), dosed 
daily for 6 days. ^^^significantly different from naïve p<0.001; N=6, performed with one-way 
analysis of variance followed by selected groups Bonferroni post-test 
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Figure 8: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil (E) 
counts in bronchoalveolar fluid in ovalbumin (Ova) sensitised and challenged guinea-pigs 
treated with either inhaled vehicle or dexamethasone (Dex, 4mg/ml or 20mg/ml), dosed 
daily for 6 days. N=6 *significantly different from vehicle treatment p<0.05, ** p<0.01; 
^^significantly different from naïve p<0.01; ^^^ p<0.001; performed with one-way analysis 
of variance followed by selected groups Bonferroni post-test 
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Figure 9: The concentration of A) IL-13 B) IL-17 in the lungs of ovalbumin (Ova) sensitised 
and challenged guinea-pigs treated with either inhaled vehicle or dexamethasone (Dex, 
4mg/ml or 20mg/ml), dosed daily for 6 days, N=6 ^^significantly different from naive p<0.01; 
performed with one-way analysis of variance followed by selected groups Bonferroni post-
test. 
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7.5.6 THE EFFECT OF INHALED DEXAMETHASONE ON ACUTE OVALBUMIN AND 
LPS CO-EXPOSURE. 
Vehicle treated guinea-pigs demonstrated an immediate bronchoconstriction to 
Ova/LPS at 0 minutes (-50.6±4.9%) which returned to baseline sGaw values at 6 
hours. Dexamethasone (20mg/ml) treated animals also demonstrated an immediate 
bronchoconstriction (-55.5±2.2%). During the first hour following Ova exposure, 
dexamethasone treated animals demonstrated significantly more of a 
bronchoconstriction then vehicle, including at 15 (-61.8±3.1% compared to -
48.3±3.1%), 30 (-61.1±2.8% compared to -46.9±4.2%) and 45 minutes (-57.2±3.1% 
compared to -47.2±2.8%). Vehicle treated guinea-pigs displayed a late asthmatic 
response from 7 hours (-18.2±5.9%) which was not significantly reduced by 
dexamethasone treatment (-15.0±2.6%). No significant difference in LAR responses 
was seen from 8-12 hours (Figure 10, time course). No difference in the peak early or 
late phase responses was observed between vehicle and dexamethasone treatment 
groups (Figure 10, histogram). No significant difference in total, early phase, late 
phase area under the curve was observed (Figure 11). Inhaled dexamethasone 
treatment did not significantly change the length of the early phase 
bronchoconstriction (2.9±02h) compared to vehicle (3.8±0.9h) (Figure 12). 
 
Vehicle treated guinea-pigs demonstrated an immediate increase in the 
bronchoconstrictor response to histamine, post-Ova/LPS challenge but this was not 
significant. This bronchoconstriction continued to increase and at 5 minutes was 
significant compared to pre-Ova challenge sGaw values (-17.7±6.0%) compared to 
pre-challenge (-3.1±1.2%). By 10 minutes post-histamine challenge the 
bronchoconstriction was -30.2±10.2% compared to pre-Ova, -0.2±2.1%. Treatment 
with dexamethasone (20mg/ml) did not significantly attenuate the development of 
airway hyperresponsiveness. At 0 minutes the bronchoconstriction to histamine was 
significantly increased (-13.0±4.6%) compared to pre-Ova (-2.0±1.3%). This 
bronchoconstriction continued to increase and at 5 and 10 minutes the 
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bronchoconstriction to histamine post-Ova challenge was -20.5±4.3% compared to 
pre-Ova, -4.1±2.8% and -23.3±5.0% compared to pre-Ova, -4.0±2.4% respectively 
(Figure 13).  
 
Protein levels were increased in vehicle treated guinea-pigs (1.6±0.3mg/ml) 
compared to naïve (0.4±0.06mg/ml). Protein levels were significantly reduced in 
dexamethasone treated guinea pigs, (0.8±0.1mg/ml) (Figure 14).  
 
Total cell numbers were significantly increased in Ova/LPS challenged and vehicle 
treated guinea-pigs (18.2±1.0x106/ml) compared to naïve (1.4±0.2x106/ml). 
Dexamethasone treatment significantly increased total cell numbers 
(21.3±0.8x106/ml). Correspondingly, macrophage numbers were also increased by 
dexamethasone treatment (10.5±0.4x106/ml compared to vehicle 8.6±0.5x106/ml). 
Dexamethasone treatment did not significantly decrease eosinophils, lymphocytes 
and neutrophils (Figure 15).  
 
IL-8, IL-13 and IL-17 levels increased in Ova/LPS challenged and vehicle treated 
guinea-pigs. IL-8, IL-13 and IL-17 levels were not significantly reduced by 
dexamethasone treatment (Figure 16).  
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Figure 10: The mean time-course values of sGaw in ovalbumin (Ova) and LPS challenged guinea-pigs treated with inhaled vehicle or dexamethasone (Dex, 
20mg/ml) dosed daily for 6 days. The histogram represents the maximum bronchoconstriction values recorded during the early asthmatic response (EAR) 
(0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are expressed as mean±SEM percentage change from 
baseline prior to Ova challenge. A negative value represents a bronchoconstriction. N=6 *significantly different from vehicle treatment p<0.05; performed 
with a two tailed T-test. 
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Figure 11: Area under the curve analysis of sGaw values over 12 in ovalbumin (Ova) and LPS 
challenged guinea-pigs treated with inhaled vehicle or dexamethasone (Dex, 20mg/ml) 
dosed daily for 6 days. For the purpose of analysis only negative peaks were considered and 
all positive sGaw values were excluded. Total includes all negative peaks from 0-24 hours, 
early asthmatic response (EAR) includes values from 0-6 hours and late asthmatic response 
(LAR) includes values from 6-12 hours. Area under the curve is expressed as %.hour. N=6 
performed with a two tailed T-test. 
 
 
Figure 12: Analysis of the time taken for early asthmatic responses (EAR) to recover to 50% 
of peak bronchoconstriction values in ovalbumin (Ova) and LPS challenged guinea-pigs 
treated with inhaled vehicle or dexamethasone (Dex, 20mg/ml) dosed daily for 6 days. N=6; 
performed with a two tailed T-test. 
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Figure 13: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in ovalbumin (Ova) and LPS challenged guinea-pigs treated with inhaled vehicle or dexamethasone (Dex, 20mg/ml) dosed 
daily for 6 days. Values were recorded 7 days pre- and 24 hours post-Ova challenge. Mean changes in sGaw are expressed as mean±SEM percentage change 
from baseline. A negative value represents a bronchoconstriction. N=6 *significantly different from time paired pre-Ova challenge values p<0.05, ** p<0.01; 
performed with a two tailed T-test. 
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Figure 14: Total lavage fluid protein in ovalbumin (Ova) and LPS challenged guinea-pigs 
treated with inhaled vehicle or dexamethasone (Dex, 20mg/ml) dosed daily for 6 days. 
Protein content was determined by BCA protein assay. N=6 *significantly different from 
vehicle treatment p<0.05, ^^^significantly different from naïve, p<0.001; performed with 
one-way analysis of variance followed by selected groups Bonferroni post-test. 
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Figure 15: The total cell (A), macrophage (B), eosinophil (C), lymphocyte (D) and neutrophil 
(E) counts in bronchoalveolar fluid of ovalbumin (Ova) and LPS challenged guinea-pigs 
treated with inhaled vehicle or dexamethasone (Dex, 20mg/ml) dosed daily for 6 days. N=6 
*significantly different from vehicle treatment p<0.05; ^^^significantly different from naive 
p<0.001; performed with one-way analysis of variance followed by selected groups 
Bonferroni post-test. 
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Figure 16: The concentration of A) IL-8 B) IL-13 C) IL-17 in the lungs of ovalbumin (Ova) 
sensitised guinea-pigs treated with inhaled vehicle or dexamethasone (Dex, 20mg/ml) dosed 
daily for 6 days. N=6 ^^^significantly different from naive p<0.001; performed with one-way 
analysis of variance followed by selected groups Bonferroni post-test. 
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7.5.7 THE EFFECT OF INHALED DEXAMETHASONE ON LPS EXPOSURE. 
Both vehicle and dexamethasone (20mg/ml) treated animals demonstrated a 
progressively increasing bronchoconstriction during the 1st hour post-LPS exposure, 
reaching its peaking at 3 hours (vehicle: -20.1±6.0%; dexamethasone:  -19.8±5.5%). 
The bronchoconstrictions then dissipated and returned to near baseline levels by 7 
hours. Figure 17 also presents the mean peak bronchoconstrictions between 0-12 
hours and at 24 hours. Vehicle treated guinea pigs demonstrated a peak 
bronchoconstriction of -30.8±4.0% which was not significantly changed by 
dexamethasone treatment (-26.0±5.5%) (Figure 17, time course). Dexamethasone 
treatment did not significantly change the area under the curve between 0-12 hours 
(Figure 18).  
 
In Ova challenged and vehicle treated guinea-pigs a significant increase in the 
response to histamine was observed post-LPS challenge (-21.9±5.4% compared to 
pre-challenge: -1.6±1.8%). A significant increase in histamine response was also 
present at 10 minutes (-18.5±5.2% compared to pre-challenge: -4.6±2.3%). Guinea-
pigs treated with dexamethasone demonstrated a bronchoconstriction to histamine 
at 0 minutes following LPS exposure (-5.7±1.6%) compared to pre-LPS (2.7±3.0%). At 
10 minutes a significant bronchoconstriction was still present (-9.4±2.8%) compared 
to pre-LPS (3.9±2.8%). Dexamethasone treatment significantly reduced the peak 
bronchoconstriction to histamine post-LPS challenge (-11.1±2.8%) compared to 
vehicle (-26.3±3.8%) (Figure 19).  
 
LPS increased protein levels in lavage fluid (1.7±0.1mg/ml) compared to naïve 
(0.5±0.05mg/ml), which were not significantly reduced by dexamethasone treatment 
(1.3±0.2mg/ml) (Figure 20).  
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LPS increased total cell numbers (18.9±1.0x106/ml) compared to naïve 
(1.4±0.2x106/ml). These were not significantly reduced by treatment with 
dexamethasone (20mg/ml) (20.5±1.6x106/ml). Macrophages, eosinophils, 
lymphocytes and neutrophils were all increased by LPS exposure but not significantly 
reduced by dexamethasone (Figure 21).  
 
IL-8 levels were increased in Ova challenged and vehicle treated guinea-pigs 
(85.0±14.7pg/mg) compared to naïve (undetectable) and were not significantly 
reduced by dexamethasone (20mg/ml) treatment (Figure 22).  
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Figure 17:  The mean time-course values of sGaw in guinea-pigs exposed to LPS twice and treated with inhaled vehicle or 20mg/ml dexamethasone, dosed 
daily for 6 days. The histogram represents the maximum bronchoconstriction values recorded during 0-12 hours and 24 hours readings. Mean changes in 
sGaw are expressed as mean±SEM percentage change from baseline prior LPS challenge. A negative value represents a bronchoconstriction. Results shown 
are after the second LPS exposure. N=6; performed with a two tailed T-test. 
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Figure 18: Total area under the curve analysis of sGaw values in guinea-pigs exposed to LPS 
twice and treated with inhaled vehicle or 20mg/ml dexamethasone, dosed daily for 6 days.  
For the purpose of analysis only negative peaks were considered and all positive sGaw 
values were excluded. Total includes all negative peaks from 0-12 hours. Area under the 
curve is expressed as %.hour. N=6; performed with a two tailed T-test. 
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Figure 19: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 10% duty cycles and 0.5LPM flow per chamber over 2 
minutes, 1 minute drying period) in guinea-pigs exposed to LPS twice and treated with inhaled vehicle or 20mg/ml dexamethasone, dosed daily for 6 days. 
C) Represents the peak the bronchoconstriction pre- and post-Ova following histamine challenge. Values were recorded 7 days pre- and 24 hours post-Ova 
challenge. Mean changes in sGaw are expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction. N=6 
*Significantly different from time paired pre-LPS challenge values p<0.05, ** p<0.01; # significantly different from post-LPS + veh; A & B) performed with a 
two tailed T-test.; C) performed with one-way analysis of variance followed by selected groups Bonferroni post-test. 
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Figure 20: Total lavage fluid protein in guinea-pigs exposed to LPS twice and treated with 
inhaled vehicle or 20mg/ml dexamethasone, dosed daily for 6 days. Protein content was 
determined by BCA protein assay. N=6 ^^^significantly different from naïve, p<0.001; 
performed with one-way analysis of variance followed by selected groups Bonferroni post-
test. 
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Figure 21: The total cell (A), macrophages (B), eosinophils (C), lymphocytes (D) and 
neutrophils (E) counts in bronchoalveolar fluid in guinea-pigs exposed to LPS twice and 
treated with inhaled vehicle or 20mg/ml dexamethasone, dosed daily for 6 days.  N=6 
^^^significantly different from naïve, p<0.001; performed with one-way analysis of variance 
followed by selected groups Bonferroni post-test. 
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Figure 22: The concentration of IL-8 in the lungs of guinea-pigs exposed to LPS twice and 
treated with inhaled vehicle or 20mg/ml dexamethasone, dosed daily for 6 days. N=6 
^^^significantly different from naïve p<0.001; performed with one-way analysis of variance 
followed by selected groups Bonferroni post-test. 
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8.5 DISCUSSION 
8.5.1 THE EFFECT OF INHALED DEXAMETHASONE ON OVALBUMIN, LPS AND 
OVALBUMIN AND LPS INDUCED RESPONSES. 
Dose-response assessment of inhaled dexamethasone’s effect on Ova responses 
revealed that 20mg/ml was an effective dose at decreasing the LAR, AHR, total cells, 
macrophages, eosinophils and lavage fluid protein levels, as inhaled FP (0.5 and 
1mg/ml) did in chapter 6. Also like inhaled FP, inhaled dexamethasone demonstrated 
a trend for a reduction in lymphocytes and IL-13 levels. Unlike inhaled FP, IL-17 levels 
were also decreased, although non-significantly. These results confirm the sensitivity 
of Ova induced responses to inhaled corticosteroid and the report in the literature 
by Jungsuwadee et al, (2004). The effects of inhaled dexamethasone on LPS alone 
were also similar to inhaled FP. Inhaled dexamethasone did not reduce the 
immediate bronchoconstriction to LPS, total and differential cells and lavage fluid 
protein. Similar to inhaled FP, inhaled dexamethasone also reduced but did not 
abolish AHR 24 hours after the second LPS exposure. This indicates that inhaled LPS 
responses in the airways are insensitive to inhaled corticosteroids. 
In the combined Ova /LPS challenged groups, inhaled dexamethasone did not reduce 
the prolonged EAR, LAR and AHR, confirming the results from chapter 6. However 
lavage fluid protein levels were also decreased indicating that this was not due to 
drug delivery issues. Unlike inhaled FP which did not change total and differential 
cell counts, dexamethasone increased total cells and macrophages. Additionally, 
although IL-13 levels demonstrated a trend for a reduction with inhaled 
dexamethasone, they were not significantly reduced as in inhaled FP groups. This 
may be due to the issues of using the lung to assess cytokine changes. Levels may be 
higher or lower in different regions of the lung. Although the part of the lung that 
was homogenised was standardised, discrepancies are possible. These results 
confirm that 2 inhaled LPS exposures decrease the inhaled corticosteroid sensitivity 
of Ova induced functional and allergic responses. In the LPS alone challenged groups, 
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Inhaled dexamethasone did not reduce the bronchoconstriction, inflammation or 
lavage fluid protein levels. Thus these results confirm the lack of sensitivity of LPS 
responses to inhaled corticosteroids.  
These results suggest that the induction of inhaled corticosteroid insensitivity in Ova 
and LPS challenged guinea-pigs may be due to the inherent inhaled corticosteroid 
insensitivity of LPS responses. However, the insensitivity of responses such as the 
LAR and eosinophilia suggests that on an allergic background LPS renders allergic 
responses also insensitive, suggesting a synergistic effect. This study revealed some 
slight differences in the effect of inhaled FP and dexamethasone on Ova and LPS 
responses. The most interesting finding was that total cells and more specifically 
macrophages increased with inhaled dexamethasone treatment. This increase in 
macrophages could represent an as yet unidentified pro-survival effect of 
corticosteroids on macrophages in conditions of increased oxidative and nitric stress. 
Neutrophils are known to demonstrate this effect in the presence of corticosteroid. 
Strickland et al, (2001) observed decreased neutrophil apoptosis due to upregulation 
of GR-β in the presence of dexamethasone in vitro. Why this effect was not seen 
with inhaled FP is unknown but it may represent a dose related effect. The dose of 
FP used in this thesis was close to the threshold for suppression of the LAR, AHR and 
airway inflammation whereas the dose of inhaled dexamethasone was fairly high. 
Alternatively, this may be due to differences in the pharmadynamic and 
pharmacokinetic properties of inhaled corticosteroids. Differences in the GR 
receptor binding affinity, particle size, bioavailability, pulmonary residence size, 
systemic availability and excretion could account for the differences in the effects 
between inhaled FP and inhaled dexamethasone (Derendorf et al, 2006; Schaaf et al, 
2005). Further studies are required to explore the mechanisms behind this effect in 
macrophages.  
 
  
  
Chapter 9 General Discussion 
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9.1 MAIN AIMS 
Exacerbations of asthma are a serious economic and social burden, accounting for the 
majority of asthma hospitalisations and deaths. Currently they are poorly treated due to 
their decreased responsiveness to frontline inhaled corticosteroid therapy. In the long 
term consistent asthma exacerbations can lead to a more severe form of disease, 
refractory to even oral corticosteroid treatment. There is currently a need for animal 
models to identify targets and develop novel therapeutics. Most models of asthma 
exacerbation only examine inflammatory components of asthma and ignore the 
functional changes in the lungs. This is important since inflammatory and functional 
parameters in these models can be dissociated (Smith & Broadley, 2007). Moreover, 
differences in the sensitivity to inhaled and systemic corticosteroids in these models 
have not been assessed. Clinically this is important as patients who are insensitive to 
inhaled corticosteroids demonstrate some responsiveness to systemic corticosteroids 
(Hodgson et al, 2012). The main aim of this thesis was to create a model of asthma 
displaying an exacerbation of functional and allergic responses. The second aim was to 
establish the corticosteroid sensitivity of this model in comparison to a standard model 
of asthma. The parameters that were assessed were early and late asthmatic responses 
(EAR & LAR, respectively), airway hyperresponsiveness (AHR), cellular inflammation, 
lung and lavage fluid cytokines, lavage fluid protein and goblet cell hyperplasia. 
9.2 OUTCOMES 
9.2.1 MODEL OF ASTHMA  
At the start of the program of work the established Ova sensitisation and challenge 
model was found to no longer induce a LAR or AHR (Evans et al, 2012). By cumulative 
modifications to the sensitisation and challenge protocols, these responses together 
with the EAR and cellular influx were established. AHR to histamine was re-established 
by increasing the Ova challenge dose 3-fold. The LAR was re-established by increasing 
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the amount of Ova and number of sensitisation injections from 2 to 3 and either 
increasing aluminium hydroxide sensitisation dose or increasing the length of time 
between Ova sensitisation and challenge. The latter protocol was better tolerated and 
was used in all subsequent chapters. Thus, following modification this Ova model 
demonstrated an EAR, LAR, AHR and eosinophilic airway inflammation. These studies 
demonstrated that full functional and allergic responses can be restored by increasing 
the severity of both sensitisation and challenge procedures. The reasons behind the 
decreased response to the ovalbumin protocol are unknown but not believed to be 
related to seasonal effects, infection or changes in environment or transportation (Wiley 
& Evans, 2009).  
9.2.2 ASTHMA EXACERBATION MODELS 
Viral infection is an important cause of asthma exacerbations in humans (Johnston et al, 
1995). The effects of parainfluenza-3 (PIV-3) alone and in combination with ovalbumin 
challenge were established. Initially, PIV-3 induced AHR to histamine, airway 
inflammation and oedema. However, this response was not consistent with repeat 
experiments, coinciding with decreased viral titres in lavage fluid. PIV-3 inoculation in 
Ova sensitised and challenged guinea-pigs showed no change in early or late asthmatic 
responses or total inflammation, with small increases in eosinophilia and AHR to 
histamine. This result was not consistent with Broadley et al, (2008), who demonstrated 
that PIV-3 caused merging of the EAR and LAR and increased total inflammation 
(especially neutrophils). The unreliability of PIV-3 effects in guinea-pigs led to the 
investigation of the TLR-3 agonist, poly I:C as a potential alternative exacerbating agent. 
TLR-3 activates similar pathways to viral infection. However, poly I:C did not induce AHR 
to histamine, airway inflammation or oedema so was not further investigated.  
LPS is also important in asthma exacerbations and the development of corticosteroid 
insensitivity (Goleva et al, 2008). Two LPS exposures induced a bronchoconstriction, 
immediately following the 2nd exposure, increased airway inflammation and oedema, 
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goblet cell hyperplasia and a small increase in AHR. In combination with Ova it increased 
the duration of the EAR, prolonged the bronchoconstrictor response to histamine and 
increased total cells, neutrophils, macrophages, goblet cells and IL-8 levels. This effect 
was found to be dependent on the timing of LPS exposure. The aforementioned effects 
were only found when the second LPS exposure was co-administered with Ova 
challenge. LPS exposure 24 hours before Ova challenge decreased the EAR and AHR, 
while increasing airway inflammation and goblet cell numbers. The temporal differences 
in the effect of LPS may be due to its ability to activate mast cells, causing degranulation 
(Masuda et al, 2002). Since the production of new granules may take over 24 hours, 
mast cells challenged with allergen within this period may not be able to fully respond 
to allergen challenge (Dvorak, 2005). 
9.2.3 CORTICOSTEROID SENSITIVITY 
The dose-response effects of corticosteroids on Ova induced responses were 
determined to establish effective doses at reducing the LAR, AHR, airway inflammation 
and oedema. Inhaled fluticasone propionate (Fp), inhaled dexamethasone and 
systemically administered dexamethasone all attenuated the development of the LAR, 
AHR, airway inflammation, lung IL-13 levels and oedema induced by ovalbumin. In 
contrast, responses to combined Ova and LPS challenge were found to be insensitive to 
inhaled Fp. No decrease in the prolonged EAR, LAR, prolonged bronchoconstrictor 
response to histamine and cellular inflammation was seen. Inhaled Fp was still effective 
at decreasing lavage fluid protein levels and IL-13. These results were confirmed by the 
use of inhaled dexamethasone, indicating that LPS reduces the sensitivity of Ova 
responses to inhaled corticosteroids. However, the combined Ova and LPS-induced 
responses were found to be partially sensitive to systemically administered 
dexamethasone. Systemic dexamethasone reduced airway inflammation (including 
neutrophils), the prolonged EAR and lavage fluid protein but not AHR, the LAR and 
Chapter 9 
 
  349 
cytokine levels. Responses to LPS alone were also found to be insensitive to inhaled 
corticosteroids but fully sensitive to systemic dexamethasone.  
These results indicate that corticosteroid insensitivity in asthma may be a localised 
phenomenon and that the route of corticosteroid administration can alter the sensitivity 
of asthma exacerbation responses. This is important as many studies have assumed that 
corticosteroids always have the same effect regardless of the route of administration. A 
good example of this is in the discussion of Trapp et al, (1998), where the researchers 
comment on their results being contrary to O’leary et al, (1996), despite the former 
using the inhaled route and the latter systemic.  
Inhaled corticosteroids mainly act by suppressing asthmatic responses directly in the 
lung due to their poor systemic bioavailability (Wood et al, 1999; Shen et al, 2002). 
Systemic corticosteroids also work locally in the lungs but due to their systemic 
distribution can also suppress bone marrow derived hemopoietic cells, which are 
recruited to the lung in asthma (Mao et al, 2004; Ben et al, 2008). During asthma 
exacerbations, asthmatic responses are less sensitive to corticosteroids due to a range 
of modifications to proteins responsible for mediating the effects of these drugs. The 
corticosteroid insensitivity inducing effects of asthma exacerbations are likely to be local 
to the site of the exacerbation i.e. the lungs. Therefore, inhaled corticosteroids which 
act mainly in the lungs are unable to reduce asthmatic responses during an 
exacerbation, whereas systemic corticosteroids which can act via the lungs, blood and 
bone marrow are still partially effective. 
A particular problem in asthma exacerbations is the large increase in neutrophils 
commonly observed. Neutrophils by their very nature are less corticosteroid sensitive 
than other inflammatory cell types (Strickland et al, 2001). However, their response to 
corticosteroid seems to differ depending on their location within the body. Neutrophils 
in the blood are more sensitive than in the lung due to differences in glucocorticoid 
receptors (Plumb et al, 2012). Therefore, the large increase in lung neutrophils during 
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asthma exacerbations may represent an inherently inhaled corticosteroid insensitive 
population. On the other hand, systemic corticosteroids can suppress neutrophil 
recruitment before sequestering to the lungs. However, since not all neutrophils are 
prevented from lung recruitment, those that make it into the airways may undergo 
extensive neutrophil degranulation. This may increase the oxidative/nitric stress of the 
lungs, in turn modifying the expression of proteins important in corticosteroid effects in 
a range of cells (Goleva et al, 2006; Ito et al, 2004; Hamilos et al, 2001). This may also 
account for the persistence of functional effects such as AHR despite reductions in 
inflammation seen with systemic dexamethasone.  
The development of steroid insensitivity may represent an evolutionary mechanism to 
locally suppress the effects of endogenous corticosteroids during periods of short term 
immune activation i.e. during a chronic bacterial infection. However, during chronic 
bombardment by antigens, especially in the modern world this process may in the long 
term be counter-productive. Unchecked inflammation can cause excessive damage to 
the afflicted site, leading to processes such as airway remodelling, which cause 
permanent airflow obstruction.  
9.3 EXPERIMENTAL LIMITATIONS 
The use of animal models in the research of what is almost an exclusively human disease 
has been criticised (Holmes et al, 2011). However, the use of animals in asthma research 
is not a problem as long as it is remembered that they cannot replicate the full human 
disease, which is the extensive product of interacting genetic and environmental factors. 
Instead animal models offer the opportunity to model and examine certain aspects of 
asthma such as the late asthmatic responses and inflammation. They are 
complementary to studies examining the underlying causes of asthma in humans. 
However, the use of animals is not without drawbacks. The guinea-pig has several 
disadvantages including IgG mediated type 1 hypersensitivity reactions and axonal 
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reflexes not present in humans. However, their benefits outweigh their disadvantages, 
especially in comparison to the more commonly used mouse. 
The systemic route of allergen sensitisation in ovalbumin models is often criticised. 
Humans are probably sensitised to allergen via the respiratory mucosa which in theory 
could lead to differences in immune response. Since the development of asthma is 
complex and not understood it is very difficult to fully replicate this process.  
Additionally, no study to compare the difference between models using the systemic 
and inhaled route has been conducted. The use of adjuvants such as aluminium 
hydroxide has also been criticised as they may alter the mechanism of allergen 
sensitisation. Ova protocols which do not use a separate adjuvant do exist but generally 
take longer to achieve sensitisation or are not able to fully reproduce functional 
responses e.g. the LAR (Hessel et al, 1997; Dale et al, 2012). Additionally, these 
protocols contain quantities of LPS, which acts as an adjuvant and has been shown to be 
critical for Ova sensitisation (Eisenbarth et al, 2002). Other allergens now used in 
models such as Aspergillus fumigatus and house dust mite also contain substances such 
as LPS and proteases which act as adjutants (Canning & Chou, 2008; Cates et al, 2007). 
Instead the nature of the adjuvant may be a more important factor (Matzinger, 1994). 
The use of aluminium hydroxide with Ova alters the nature of allergen responses (Nakae 
et al, 2007). This is important to bear in mind when making comparisons between 
animal models and humans.  
One other drawback of the models used throughout this thesis is their acute nature. 
Acute models tend to only use a single allergen challenge, with no pre-existing 
background of inflammation. Since asthma exacerbations likely occur on a background 
of chronic inflammation, the model employed in this thesis probably does not fully 
reflect the situation in humans. However, the model does still demonstrate many 
features of asthma such as an EAR, LAR, AHR and airway inflammation. Thus the acute 
model used still represents a good starting point for the investigation of asthma 
exacerbations and for early trials of novel drug therapy.  
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9.4 FURTHER WORK 
There are many opportunities for further work from this thesis. Some of these 
suggestions were originally planned to be included in this thesis but due to time and 
financial constraints they were unable to be completed. Some studies are very difficult 
to perform in guinea-pigs due to a scarcity of molecular tools. Ideally a full assessment 
of all the models used in this thesis would be made using PCR/gene array technology 
which would allow for an unbiased assessment of molecular changes. 
Further investigation of the temporal effects of LPS on allergen-induced responses is 
warranted. It would be interesting to investigate whether the decrease in the EAR seen 
with LPS delivered 24 hours before allergen exposure is due to partial mast cell 
degranulation. Microscopic investigation of mast cells after LPS exposure and 
measurement of histamine following allergen challenge may be able to help determine 
this (Vannier et al, 1991). Additionally, although airway inflammation still increases in 
these guinea-pigs the nature of the inflammatory response may be different. The use of 
FACS to identify lymphocyte subpopulations and immunohistochemistry could help 
achieve this, although such techniques are difficult with guinea-pigs due to a lack of 
available reagents. Further characterisation of the exacerbating effects of LPS on allergic 
inflammation would also be of interest; specifically the mechanisms behind the 
prolonged bronchoconstrictor response to histamine. This process may be mediated by 
decreased levels of diamine oxidase, which breaks down histamine or by increased nitric 
oxide (Stroheimer et al, 2001).  Whether this effect is non-specific to the spasmogen 
would also be of interest. The use of alternative bronchoconstrictive agents such as 
methacholine could help investigate this. The use of an iNOS inhibitors could help 
determine this. A determination of neutrophil and eosinophil activity by elastase and 
EPO may also determine whether changes in the activity of these cells are involved.  
The mechanisms that mediate inhaled corticosteroid insensitivity in the Ova and LPS 
combination model require further investigation. Many mechanisms have been 
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proposed to mediate this process including decreased GR-α, increased GR-β, decreased 
activity of HDAC-2 and increased PI3K activity (Leung & Bloom, 2003). The levels/activity 
of these proteins could be measured using ELISA assays and western blotting. These 
effects may be localised to specific cell populations, making it necessary to use 
immunohistochemistry and cell isolation techniques. Gross assessment of lung levels 
may give a false picture as to the importance of any mechanism. Additionally, a 
comparison of the activity of these proteins in airway cells with those in the circulation 
may explain the differing sensitivity of the Ova and LPS models sensitivity to inhaled and 
systemic corticosteroids. The use of drugs such as curcumin (HDAC-2 activator) and 
nortriptyline (PI3K inhibitor) could also help determine the mechanisms of 
corticosteroid insensitivity.  
The importance of neutrophils in corticosteroid insensitivity also requires further 
investigation. Neutrophils are known to be less corticosteroid sensitive than other 
inflammatory cells and are also present in other corticosteroids insensitive lung diseases 
such as COPD (Strickland et al, 2001). The use of a pharmacological agent such as 
vinblastine, which depletes neutrophils in bone marrow would be useful for this. Finally 
a proper determination of the effect of inhaled and systemic corticosteroids on bone 
marrow in the models used in this thesis is warranted. Measurement of the plasma 
concentrations of circulating corticosteroid, as well as activity on bone marrow 
haematopoiesis would allow this.  
Further studies could also assess the effect of LPS on airway responses in a chronic 
model of asthma. These models reflect the chronic nature of inflammation in humans 
and would allow for the assessment of the effect of LPS on a pre-existing inflammatory 
background. Chronic models also demonstrate airway remodelling which would allow 
for the long term assessment of the effect of repeat exacerbations on this process 
(Evans et al, 2012). Differences in corticosteroid insensitivity between acute and chronic 
models could also be assessed. Additionally, whether corticosteroid insensitivity 
resolves after a period of time or is permanent is unknown. Allowing a period of 
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resolution of Ova and LPS challenge before starting corticosteroid treatment would 
allow this. 
9.5 CONCLUSIONS AND CLINICAL RELEVANCE 
LPS inhalation exacerbates Ova-induced functional and inflammatory responses, 
decreasing their sensitivity to inhaled and partially to systemic corticosteroids. Clinically, 
LPS is a relevant agent for asthma exacerbations and corticosteroid insensitivity as it’s 
found ubiquitously in the environment (Hunt et al, 1994; Goleva et al, 2008). The 
observation that responses in an asthma exacerbation model are nearly fully insensitive 
to inhaled corticosteroid is important. Clinically, asthmatic patients are less sensitive to 
inhaled corticosteroids during an asthma exacerbation and in more severe forms of the 
disease (in't Veen et al, 1999; Hodgson et al, 2012). However, they often show some 
clinical benefit with oral corticosteroids, which act systemically (Matsuse et al, 2012; 
Hodgson et al, 2012). Reflecting this, the asthma exacerbation model demonstrated 
some sensitivity to a systemic corticosteroid. Further work is required to better 
characterise this animal model and understand its applicability to asthma. None the less, 
this model may be useful as a preclinical model for investigating mechanisms and 
developing novel drugs for asthma exacerbations and corticosteroid-resistant asthma.  
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A1.1 EQUIPMENT 
Cannula - Bio-Med healthcare, India 
Capillary tube - Roche, Switzerland 
Cell culture flasks - Fisher Scientific UK, Loughborough, UK. 
Centrifuge (Mistral 3000) - Mistral, UK. 
Cold Plate - Fisher Scientific UK, Loughborough, UK. 
Coverslip - Fisher Scientific UK, Loughborough, UK. 
Digital Camera (Leica DC500) - Leica Microsystems, Germany 
ELISA Plates - Sigma, Poole, UK. 
Exposure Chamber - Buxco Research Systems, Winchester, UK. 
Glass Slides - Surgipath Europe Ltd, Peterborough, UK. 
Histology Cassettes - Surgipath Europe Ltd, Peterborough, UK. 
Microscope (Olympia BH-2) - Olympus, London, UK. 
Microscope (Leica DMRAZ) - Leica Microsystems, Germany 
Microtome - Mistral, UK. 
Neubauer Haemocytometer - Supe-rior, Marienfeld, Germany. 
Nuclease free tubes - Invitrogen, USA 
Polysine slides - Thermo Scientific, UK 
Cyclegene thermo cycler - Technene, Staffordshire, UK 
Thermo light cycler - Roche, Switzerland 
Tissue homogeniser - Precellys, UK 
Tissue homogeniser tubes - Precellys, UK  
Wax Dispenser - Fisher Scientific UK, Loughborough, UK. 
Whole Body Plethysmograph (complete set up) - Buxco Research Systems, Winchester, UK. 
Wright Nebuliser (Pulmostar) - Sunrise Medical Ltd., Wollaston, UK.  
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A1.2 MATERIALS 
Acetic acid - Sigma, Poole, UK. 
Alcian blue powder - Sigma, Poole, UK. 
Aluminium ammonium sulphate - Fisher Scientific UK, Loughborough, UK. 
Aluminium hydroxide - Sigma, Poole, UK. 
Aprotinin - Sigma, Poole, UK. 
Aqueous acetic acid - Sigma, Poole, UK. 
BCA protein assay Kit - Pierce protein biology, Thermo Scientific, UK 
BCA protein assay chemical A 
BCA protein assay chemical B 
BCA protein assay standard 
BSC-1 cells - European collection animal cell culture (ECACC) 
BSC-1 cell culture reagents 
 EMEM - Invitrogen, USA 
Glutamine - Sigma, Poole, UK. 
Non-essential amino acids - Sigma, Poole, UK. 
Foetal bovine serum - Sigma, Poole, UK. 
cDNA primers - Primer design Ltd 
Chloroform - Sigma, Poole, UK. 
Chloral hydrate - Fisher Scientific UK, Loughborough, UK. 
Citric acid - Sigma, Poole, UK. 
Cytokine assay reagents (Capture and detection Ab, protein standard (Duoset) - R&D 
systems, UK  
Cytokine assay diluent - R&D systems, UK 
Cytokine assay TMB substrate solutions A & - R&D systems, UK 
Cytokine assay Stepavidin-HRP - R&D systems, UK  
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Dexamethasone 21-phosphate salt - Sigma, Poole, UK. 
Dimethyl sulfoxide - Sigma, Poole, UK. 
EGTA disodium salt - Sigma, Poole, UK. 
Eosin - Surgipath Europe Ltd, Peterborough, UK. 
Ethanol - Sigma, Poole, UK. 
Fluticasone propionate - Sigma, Poole, UK. 
Formaldehyde - Fisher Scientific UK, Loughborough, UK. 
Guinea Pigs - Harlan, UK and Charles River, Germany 
Haematoxylin - Fisher scientific, UK 
Histamine - Sigma, Poole, UK. 
Histoclear - Fisher scientific, UK 
Histomount - Fisher scientific, UK 
Hydrochloric acid - Sigma, Poole, UK. 
Leishman’s Powder - Sigma, Poole, UK. 
Leupeptin - Sigma, Poole, UK. 
Lipopolysaccharide from E. coli - Sigma, Poole, UK. 
Magnesium sulphate - Fisher Scientific UK, Loughborough, UK. 
Mayer’s haematoxylin - Surgipath Europe Ltd, Peterborough, UK. 
Mepyramine - Sigma, Poole, UK. 
Methanol - Fisher Scientific UK, Loughborough, UK. 
Ovalbumin - VWR International Ltd., Leicestershire, UK. 
Paraffin wax - Surgipath Europe Ltd, Peterborough, UK. 
Periodic acid - Surgipath Europe Ltd, Peterborough, UK. 
PMSF - Sigma, Poole, UK. 
Phenylarsine oxide - Sigma, Poole, UK. 
Picric acid - Sigma, Poole, UK. 
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Potassium alum - Fisher Scientific UK, Loughborough, UK. 
Saline tablets - Fisher Scientific UK, Loughborough, UK.  
Schiff’s reagent - Surgipath Europe Ltd, Peterborough, UK. 
Sirius red - Sigma, Poole, UK. 
Sodium bicarbonate - Fisher Scientific UK, Loughborough, UK. 
Sodium chloride - Sigma, Poole, UK. 
Sodium Fluoride - Sigma, Poole, UK. 
Sodium iodate - Fisher Scientific UK, Loughborough, UK. 
Sodium molybdate - Sigma, Poole, UK. 
Sodium pentobarbitone (Euthatal) - Cardiff University, UK 
NaVO4 - Sigma, Poole, UK. 
Sulphuric acid - Sigma, Poole, UK. 
Superscript first-strand synthesis system kit - Invitrogen, USA 
Triton x - Sigma, Poole, UK. 
Trizma base - Sigma, Poole, UK. 
Tween 20 - Sigma, Poole, UK. 
Viral ribonucleic acid isolation kit - Roche, Switzerland 
Contains: Proteinase K - (reconstituted in 5ml Elution buffer) 
Poly A - (reconstituted in 500µl Elution buffer)  
Binding buffer - premade 
Inhibitor removal buffer - (reconstituted in 20ml ethanol) 
Wash buffer - (reconstituted in 40ml ethanol) 
Elution buffer - (Nuclease-free, sterile, double distilled water).  
All made up as per the manufactures instructions 
Light cycler TaqMan master kit (contains master mix) - Roche, Switzerland 
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A1.3 SOLUTIONS MADE 
Alcian blue- 
 1g Alcian blue powder  
 100ml 3% acetic acid 
BCA protein assay working reagent -Pierce protein biology, Thermo scientific, UK 
50 parts BCA protein assay chemical A 
1 part BCA protein assay chemical B 
Leishman’s solution - 0.5% w/v Leishman’s powder in 100% methanol 
Lipopolysaccharide - Made up in normal saline 
Lysis buffer -  
Component A - 50mM Trizma base, 5mM EGTA disodium salt, 150mM NaCl, 1% 
Triton and 100ml DH2O. 
Component B - 0.4mM NaVO4, 50mM NaF, 1mM PMSF, 20μM Phenylarsine oxide, 
10mM Sodium molybdate, 10μg/ml Leupeptin, 10μg/ml Aprotinin in lysis buffer component 
A.  
Mayer’s haematoxylin - 
 1g haematoxylin, 50g Aluminium ammonium sulphate and 0.2g sodium iodate 
dissolved in 1L distilled water with warming. 1g citric acid and 50g chloral hydrate added, 
the solution boiled for 5 minutes, cooled then filtered.  
Normal saline - 1 saline tablet per 100ml of dH2O 
Ovalbumin - made up in normal saline 
Phosphate buffered saline - 1 PBS tablet to 100µl dH20 
Phosphate buffered saline-tween 20 - 25µl tween 20 in 500ml of PBS. 
Scotts tap water - 20g sodium bicarbonate, 3.5g magnesium sulphate, 1 distilled water. 
Sirius red stain - (pH 8-9)- 2g Direct Red 80, 180ml Distilled water, 200ml 100% ethanol.                        
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A1.4 COMPUTER PROGRAMS 
Data acquisition - Fine point software, Buxco 
GraphPad Instat 3 - GraphPad  software, Inc., La Jolla, CA, USA.  
GraphPad Prism 5 - GraphPad software, Inc., La Jolla, CA, USA. 
ImageJ - National Institute of Health - http://rsbweb.nih.gov/ij/index.html  
Microsoft Excel - Microsoft corporation 
Leica QWin software - Leica Microsystems, Germany 
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A2.1 THE MEASUREMENT OF SGAW 
 
Specific airway conductance (sGaw) is derived from the changes in volume between animal 
body and plethysmograph chamber that occur as a result of ventilation. Flow based whole 
body plethysmograph chambers such as the one used in the present thesis are divided into 
nasal and thoracic components. The plethysmograph chamber measures the difference 
between the rate of change in nasal flow and thoracic displacement. The volume and rate of 
these flows is affected by both conditioning and resistance.   
To minimise the effect of conditioning, a reading is taken at the end of inspiration, where 
conditioning (which is equal to flow) is zero as there is no flow at this point.  
At this point box pressure is proportional to  
Resistance (R) x thoracic gas volume (TGV) x Difference in flow (dF) x difference 
in time (dt) 
The negative pressure in lungs during inspiration pulls air into the lungs against airway 
resistance so 
Negative pressure of the lungs (Palv) = R x F  
The rate of pressure change (dPb/dt) may also be expressed as  
TGV x dPalv/dt at the flow zero crossings.  
Additionally, when there is zero flow dF/dt is generally large as there is a delay in transition 
between inspiratory to expiratory thoracic flow.  
Thus, when there is zero flow the resistance component of the plethysmograph signal 
dominates, despite conditioning being a large component for the rest of the waveform.  
During a bronchoconstriction the nasal flow lags behind the thoracic flow (Figure 1). When 
conditioning is low as when there is zero flow the time delay between the 2 flows is related 
to specific airway resistance (sRaw) and sGaw. The reciprocal of Raw, airway conductance 
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(Gaw), is considered a better measurement of airway function as it accounts for change in 
lung tissue tension and transpulmonary pressure. 
Gaw = 1/ Raw 
sGaw = Gaw/TGV 
 
Figure 1- Waveform trace showing nasal and thoracic flows during a bronchoconstrictions 
 
Adapted from Lamask, (2005). 
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A3.1 IL-4 
 
GUINEA PIG SEQUENCE 
1 MGLVPQLTVI LFCLLACASA VVRGCNHHTL QEIIQHLNTL SREKSPCAEL LVTDVFADPQ 
61 GPASGDLCTA ATVLHHTAYL RGPQSCPNRE GDPLYPSVLR QVFRNLRSMA QSNCPVSELR 
121 QTTLKDFLEN LKRIMQKRYS KCRR 
 
HUMAN SEQUENCE 
 GENE ID: 3565 IL4 | interleukin 4 [Homo sapiens] 
 
Score = 88.6 bits (218),  Expect = 2e-20, Method: Compositional matrix adjust. 
Identities = 68/153 (44%), Positives = 89/153 (58%), Gaps = 13/153 (8%) 
 
Query  1    MGLVPQLTVILFCLLACASAVVRG--CNHHTLQEIIQHLNTLSREKSPCAELLVTDVFAD  58 
            MGL  QL   LF LLACA   V G  C+  TLQEII+ LN+L+ +K+ C EL VTD+FA  
Sbjct  1    MGLTSQLLPPLFFLLACAGNFVHGHKCDI-TLQEIIKTLNSLTEQKTLCTELTVTDIFAA  59 
 
Query  59   PQGPASGD-LCTAATVL-----HHTAYLR--GPQSCPNREGDPLYPSVLRQVFRNLRSMA  110 
             +     +  C AATVL     HH    R  G  +        L   +L+++ RNL  +A 
Sbjct  60   SKNTTEKETFCRAATVLRQFYSHHEKDTRCLGATAQQFHRHKQLIR-LLKRLDRNLWGLA  118 
 
Query  111  QSN-CPVSELRQTTLKDFLENLKRIMQKRYSKC  142 
              N CPV E  Q+TL++FLE LK IM+++YSKC 
Sbjct  119  GLNSCPVKEANQSTLENFLERLKTIMREKYSKC  151 
 
MOUSE SEQUENCE 
GENE ID: 16189 Il4 | interleukin 4 [Mus musculus] 
 
 Score = 85.9 bits (211),  Expect = 1e-19, Method: Compositional matrix adjust. 
 Identities = 53/142 (37%), Positives = 77/142 (54%), Gaps = 4/142 (3%) 
 
Query  1    MGLVPQLTVILFCLLACASAVVRGCNHHTLQEIIQHLNTLSREKSPCAELLVTDVFADPQ  60 
            MGL PQL VIL   L C  + + GC+ + L+EII  LN ++ E +PC E+ V +V    + 
Sbjct  1    MGLNPQLVVILLFFLECTRSHIHGCDKNHLREIIGILNEVTGEGTPCXEMDVPNVLTATK  60 
 
Query  61   GPASGDL-CTAATVLHHTAYLRGPQSCPNREGDPLYPSVLRQVFRNLRSMAQS-NCPVSE  118 
                 +L C A+ VL       G   C  +    L    L+++FR  R +  S +C ++E 
Sbjct  61   NTTESELVCRASKVLRIFYLKHGKTPCLKKNSSVLME--LQRLFRAFRCLDSSISCTMNE  118 
 
Query  119  LRQTTLKDFLENLKRIMQKRYS  140 
             +  +LKDFLE+LK IMQ  YS 
Sbjct  119  SKSXSLKDFLESLKSIMQMDYS  140 
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A3.2 IL-5 
 
GUINEA PIG SEQUENCE 
1 MRVLLQLGLL ALGAVCVCAI PKQSATLRAL VRETLTLLST HRTLLKGNET LRISVPAHKN 
61 HQLCIEEIFQ GIDTLKNQTT QGEALATLFQ NLSLIKKHID LQKQKCGEER RRVKQFLDYL 
121 QEFLAVINTE WTIEG 
  
HUMAN SEQUENCE 
interleukin 5 (colony-stimulating factor, eosinophil) [Homo sapiens]  
 
 Score =  174 bits (440),  Expect = 1e-54, Method: Compositional matrix adjust. 
 Identities = 87/119 (73%), Positives = 96/119 (81%), Gaps = 1/119 (1%) 
 
Query  17   VCAIPKQSATLRALVRETLTLLSTHRTLLKGNETLRISVPAHKNHQLCIEEIFQGIDTLK  76 
            V AIP +  T  ALV+ETL LLSTHRTLL  NETLRI VP HKNHQLC EEIFQGI TL+ 
Sbjct  17   VYAIPTEIPT-SALVKETLALLSTHRTLLIANETLRIPVPVHKNHQLCTEEIFQGIGTLE  75 
 
Query  77   NQTTQGEALATLFQNLSLIKKHIDLQKQKCGEERRRVKQFLDYLQEFLAVINTEWTIEG  135 
            +QT QG  +  LF+NLSLIKK+ID QK+KCGEERRRV QFLDYLQEFL V+NTEW IE  
Sbjct  76   SQTVQGGTVERLFKNLSLIKKYIDGQKKKCGEERRRVNQFLDYLQEFLGVMNTEWIIES  134 
 
CAT SEQUENCE 
interleukin 5 (colony-stimulating factor, eosinophil) 
[Felis catus] 
 
Score = 165 bits (418),  Expect = 3e-51, Method: Compositional matrix 
adjust. 
Identities = 84/119 (71%), Positives = 93/119 (78%), Gaps = 1/119 (1%) 
 
Query  17   VCAIPKQSATLRALVRETLTLLSTHRTLLKGNETLRISVPAHKNHQLCIEEIFQGIDTLK  76 
            V AI  QS   R LV ETL LLSTHRTLL G+  L I  P H NHQLCIEE+FQGIDTLK 
Sbjct  17   VSAIAVQSPMNR-LVAETLALLSTHRTLLIGDGNLMIPTPEHNNHQLCIEEVFQGIDTLK  75 
 
Query  77   NQTTQGEALATLFQNLSLIKKHIDLQKQKCGEERRRVKQFLDYLQEFLAVINTEWTIEG  135 
            N+T  G+A+  LF+NLSLIK+HID QK+KCG ER RVK+FLDYLQ FL VINTEWTIEG 
Sbjct  76   NRTVPGDAVEKLFRNLSLIKEHIDRQKKKCGGERWRVKKFLDYLQVFLGVINTEWTIEG  134 
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A3.3 INTERFERON GAMMA 
 
GUINEA PIG SEQUENCE 
 
1 MKYTSSILAL QFCIILSFSS YYCQSRFTNE IRILKNYFNA DNSDVGDNGT LFVGILKNCQ 
61 EESERKIFQS QIVSFYFKLF EKHFTDNQTV QNSMNTIKEQ IITKFFKDNS SNKVQAFKNL 
121 IQISVNDEHV QRQAIIELKK VIDDLSPNQR KRRRTQMLFQ SRRASK 
 
HORSE SEQUENCE 
 
Score =  191 bits (484),  Expect = 3e-60, Method: Compositional matrix adjust. 
 Identities = 101/166 (61%), Positives = 125/166 (75%), Gaps = 4/166 (2%) 
 
Query  1    MKYTSSILALQFCIILSFSSYYCQSRFTNEIRILKNYFNADNSDVGDNGTLFVGILKNCQ  60 
            MKYTS ILA Q C IL  S+YYCQ+ F  EI  LK YFNA N DVGD G LF+ ILKN + 
Sbjct  1    MKYTSFILAFQLCAILGSSTYYCQAAFFKEIENLKEYFNASNPDVGDGGPLFLDILKNWK  60 
 
Query  61   EESERKIFQSQIVSFYFKLFEKHFTDNQTVQNSMNTIKEQIITKFFKDNSSNKVQAFKNL  120 
            E+S++KI QSQIVSFYFKLFE +  DNQ +Q SM+TIKE +  KFF ++S++K++ F+ L 
Sbjct  61   EDSDKKIIQSQIVSFYFKLFE-NLKDNQVIQKSMDTIKEDLFVKFF-NSSTSKLEDFQKL  118 
 
Query  121  IQISVNDEHVQRQAIIELKKVIDDLSP--NQRKRRRTQMLFQSRRA  164 
            IQI VND  VQR+AI EL KV++DLSP  N RKR+R+Q  F+ RRA 
Sbjct  119  IQIPVNDLKVQRKAISELIKVMNDLSPKANLRKRKRSQNPFRGRRA  164 
 
HUMAN SEQUENCE 
 
GENE ID: 3458 IFNG | interferon, gamma [Homo sapiens] (Over 100 PubMed links) 
 
 Score =  175 bits (443),  Expect = 5e-54, Method: Compositional matrix adjust. 
 Identities = 96/168 (57%), Positives = 119/168 (71%), Gaps = 4/168 (2%) 
 
Query  1    MKYTSSILALQFCIILSFSSYYCQSRFTNEIRILKNYFNADNSDVGDNGTLFVGILKNCQ  60 
            MKYTS ILA Q CI+L     YCQ  +  E   LK YFNA +SDV DNGTLF+GILKN + 
Sbjct  1    MKYTSYILAFQXCIVLGSLGCYCQDPYVKEAENLKKYFNAGHSDVADNGTLFLGILKNWK  60 
 
Query  61   EESERKIFQSQIVSFYFKLFEKHFTDNQTVQNSMNTIKEQIITKFFKDNSSNKVQAFKNL  120 
            EES+RKI QSQIVSFYFKLF K+F D+Q++Q S+ TIKE +  KFF  N   K   F+ L 
Sbjct  61   EESDRKIMQSQIVSFYFKLF-KNFKDDQSIQKSVETIKEDMNVKFFNSNKK-KRDDFEKL  118 
 
Query  121  IQISVNDEHVQRQAIIELKKVIDDLSPNQR--KRRRTQMLFQSRRASK  166 
               SV D +VQR+AI EL +V+ +LSP  +  KR+R+QMLF+ RRAS+ 
Sbjct  119  TNYSVTDLNVQRKAIHELIQVMAELSPAAKTGKRKRSQMLFRGRRASQ  166 
Appendix 3 
 
398 
 
A3.4 IL-10 
 
GUINEA PIG SEQUENCE 
1 MPSSALLCCL VLLAGVKASQ GTNTQSEDSC AHFPAGLPHM LRELRAAFGR VKTFFQTQDQ 
61 LDNVLLNKSL LEDFKGYLGC QALSEMIQFY LVEVMPKAEN HDPDIKEHVS SLGEKLKTLR 
121 LRLRRCHRFL PCENKSKAVE QVKNTFNKLQ EKGVYKAMSE FDIFINYIEA YMTRKLTN 
 
MOUSE SEQUENCE 
 
GENE ID: 16153 Il10 | interleukin 10 [Mus musculus] (Over 100 PubMed links) 
 
 Score =  303 bits (777),  Expect = 1e-104, Method: Compositional matrix adjust. 
 Identities = 150/178 (84%), Positives = 163/178 (92%), Gaps = 0/178 (0%) 
 
Query  1    MPGSALLCCLALLAGVKASQGTNTQSEDSCAHFPAGLPHMLRELRAAFGRVKTFFQTQDQ  60 
            MPGSALLCCL LL G++ S+G  ++ +++C HFP G  HML ELR AF +VKTFFQT+DQ 
Sbjct  1    MPGSALLCCLLLLTGMRISRGQYSREDNNCTHFPVGQSHMLLELRTAFSQVKTFFQTKDQ  60 
 
Query  61   LDNVLLNKSLLEDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLR  120 
            LDN+LL  SL++DFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLR 
Sbjct  61   LDNILLTDSLMQDFKGYLGCQALSEMIQFYLVEVMPQAEKHGPEIKEHLNSLGEKLKTLR  120 
 
Query  121  MRLRRCHRFLPCENKSKAVEQVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS  178 
            MRLRRCHRFLPCENKSKAVEQVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS 
Sbjct  121  MRLRRCHRFLPCENKSKAVEQVKSDFNKLQDQGVYKAMNEFDIFINCIEAYMMIKMKS  178 
 
A3.5 IL-12 P70 (P40 & P35) 
 
GUINEA PIG P40 SUBUNIT SEQUENCE 
 
1   MCHRQLISSW LSLVLLASPL LAMWELKKDV YVVELDWHTD APGETVVLTC NTAEEDGITW 
61  TSDRKSDILG SGKTLTIQVK EFEDAGGYTC HKGGEVLSRS QLLLHKKEDE IWSTDILKEQ 
121 KGSNGKTFLK CEARSYSGRF TCWWLTAFGT DVKFSVKGSR GSSDPSGVTC GEAERVSGDN 
181 QEYKYSVECQ EDSACPTAEE SLPIEVVVDA IHKFKYENYT SSFYIRDIIK PDPPKNLQLK 
241 PSVNSQQVEV SWEYPDTWST PHSYFSLTFL VQTHGKNKNR REKKYELFTD KTSATVSCHK 
301 ISKVEVRARD RYYSSSWSEW ASVSCSEVSV SR 
 
HUMAN P40 SUBUNIT SEQUENCE 
 
gb|AAA59938.1|  natural killer cell stimulatory factor [Homo sapiens] 
Length=328 
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 GENE ID: 3593 IL12B | interleukin 12B (natural killer cell stimulatory factor 
2, cytotoxic lymphocyte maturation factor 2, p40) [Homo sapiens] 
(Over 100 PubMed links) 
 
 Score =  512 bits (1319),  Expect = 0.0, Method: Compositional matrix adjust. 
 Identities = 258/330 (78%), Positives = 283/330 (86%), Gaps = 6/330 (2%) 
 
Query  1    MCHRQLISSWLSLVLLASPLLAMWELKKDVYVVELDWHTDAPGETVVLTCNTAEEDGITW  60 
            MCH+QL+ SW SLV LASPL+A+WELKKDVYVVELDW+ DAPGE VVLTC+T EEDGITW 
Sbjct  1    MCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITW  60 
 
Query  61   TSDRKSDILGSGKTLTIQVKEFEDAGGYTCHKGGEVLSRSQLLLHKKEDEIWSTDILKEQ  120 
            T D+ S++LGSGKTLTIQVKEF DAG YTCHKGGEVLS S LLLHKKED IWSTDILK+Q 
Sbjct  61   TLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQ  120 
 
Query  121  KGSNGKTFLKCEARSYSGRFTCWWLTAFGTDVKFSVKGSRGSSDPSGVTCG----EAERV  176 
            K    KTFL+CEA++YSGRFTCWWLT   TD+ FSVK SRGSSDP GVTCG     AERV 
Sbjct  121  KEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERV  180 
 
Query  177  SGDNQEYKYSVECQEDSACPTAEESLPIEVVVDAIHKFKYENYTSSFYIRDIIKPDPPKN  236 
             GDN+EY+YSVECQEDSACP AEESLPIEV+VDA+HK KYENYTSSF+IRDIIKPDPP N 
Sbjct  181  RGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPNN  240 
 
Query  237  LQLKPSVNSQQVEVSWEYPDTWSTPHSYFSLTFLVQTHGKNKNRREKKYELFTDKTSATV  296 
            LQLKP  NS+QVEVSWEYPDTWSTPHSYFSLTF VQ  GK+K  REKK  +FTDKTSATV 
Sbjct  241  LQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSK--REKKDRVFTDKTSATV  298 
 
Query  297  SCHKISKVEVRARDRYYSSSWSEWASVSCS  326 
             C K + + VRA+DRYYSSSWSEWASV CS 
Sbjct  299  ICRKNASISVRAQDRYYSSSWSEWASVPCS  328 
 
MOUSE SEQUENCE 
 
 
 gb|AAF22556.1|AF128215_1  interleukin 12b p40 subunit [Mus musculus] 
Length=335 
 
 GENE ID: 16160 Il12b | interleukin 12b [Mus musculus] (Over 100 PubMed links) 
 
 Score =  396 bits (1017),  Expect = 4e-136, Method: Compositional matrix adjust. 
 Identities = 208/336 (62%), Positives = 249/336 (74%), Gaps = 16/336 (5%) 
 
Query  1    MCHRQLISSWLSLVLLASPLLAMWELKKDVYVVELDWHTDAPGETVVLTCNTAEEDGITW  60 
            MC ++L  SW ++VLL SPL+AMWEL+KDVYVVE+DW  DAPGETV LTC+T EED ITW 
Sbjct  1    MCPQKLTISWFAIVLLVSPLMAMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITW  60 
 
Query  61   TSDRKSDILGSGKTLTIQVKEFEDAGGYTCHKGGEVLSRSQLLLHKKEDEIWSTDILKEQ  120 
            TSD++  ++GSGKTLTI VKEF DAG YTCHKGGE LS S LLLHKKE+ IWST+ILK   
Sbjct  61   TSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNF  120 
 
Query  121  KGSNGKTFLKCEARSYSGRFTCWWLTAFGTDVKFSVKGSRGSSDPSGVTCG----EAERV  176 
            K    KTFLKCEA +YSGRFTC WL     D+KF++K S  S D   VTCG     AE+V 
Sbjct  121  K---NKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGTASLSAEKV  177 
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Query  177  SGDNQEY-KYSVECQEDSACPTAEESLPIEVVVDAIHKFKYENYTSSFYIRDIIKPDPPK  235 
            + D ++Y KYSV CQED  CPTAEE+LPIE+ ++A  + KYENY++SF+IRDIIKPDPPK 
Sbjct  178  TLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPK  237 
 
Query  236  NLQLKPSVNSQQVEVSWEYPDTWSTPHSYFSLTFLVQTHGKNKNRR------EKKYELFT  289 
            NLQ+KP  NS QVEVSWEYPD+WSTPHSYFSL F V+   K +  +       +K  L   
Sbjct  238  NLQMKPLKNS-QVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGALLV  296 
 
Query  290  DKTSATVSCHKISKVEVRARDRYYSSSWSEWASVSC  325 
            +KTS  V C K   V V+A+DRYY+SS S+WA V C 
Sbjct  297  EKTSTEVQC-KGGNVCVQAQDRYYNSSCSKWACVPC  331 
 
 
GUINEA PIG IL-12 P35 SUBUNIT 
 
1 MSPLRKCLLL TSLVLLVSCS LARNLPRASP APVTEPVQCF NHSQTLLRAV NSELHKAIQM 
61 LAVYSCTPEE IDHEDITKDK TSTVKACVPL ELVKNESCLA SGHISFTTNG SCLASGKTSF 
121 MMALCLNSIY EDLKLYQLEF KNMNAQLLMD PQRQIFLDQN MLSAIDELIQ ALNGSDVTVP 
181 QKLSLEEPDF YKIKMKLCIL LHAFRIRAVT IDRVMSYLTS S 
 
HUMAN SEQUENCE 
gb|AAA35694.1| cytotoxic lymphocyte maturation factor 35 kDa subunit [Homo sapiens] 
Length=219 
 
 GENE ID: 3592 IL12A | interleukin 12A (natural killer cell stimulatory factor 
1, cytotoxic lymphocyte maturation factor 1, p35) [Homo sapiens] 
(Over 100 PubMed links) 
 
 Score =  305 bits (780),  Expect = 1e-108, Method: Compositional matrix adjust. 
 Identities = 153/202 (76%), Positives = 169/202 (84%), Gaps = 2/202 (1%) 
 
Query  20   SLARNLPRASPAPVTEPVQCFNHSQTLLRAVNSELHKAIQMLAVYSCTPEEIDHEDITKD  79 
            SLARNLP A+P P   P  C +HSQ LLRAV++ L KA Q L  Y CT EEIDHEDITKD 
Sbjct  20   SLARNLPVATPDPGMFP--CLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKD  77 
 
Query  80   KTSTVKACVPLELVKNESCLASGHISFTTNGSCLASGKTSFMMALCLNSIYEDLKLYQLE  139 
            KTSTV+AC+PLEL KNESCL S   SF TNGSCLAS KTSFMMALCL+SIYEDLK+YQ+E 
Sbjct  78   KTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVE  137 
 
Query  140  FKNMNAQLLMDPQRQIFLDQNMLSAIDELIQALNGSDVTVPQKLSLEEPDFYKIKMKLCI  199 
            FK MNA+LLMDP+RQIFLDQNML+ IDEL+QALN +  TVPQK SLEEPDFYK K+KLCI 
Sbjct  138  FKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCI  197 
 
Query  200  LLHAFRIRAVTIDRVMSYLTSS  221 
            LLHAFRIRAVTIDRV SYL +S 
Sbjct  198  LLHAFRIRAVTIDRVTSYLNAS  219 
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MOUSE SEQUENCE 
 
gb|AAF22552.1|AF128211_1 interleukin 12a [Mus musculus] 
Length=116 
 
 GENE ID: 16159 Il12a | interleukin 12a [Mus musculus] (Over 100 PubMed links) 
 
 Score = 87.4 bits (215),  Expect = 1e-24, Method: Compositional matrix adjust. 
 Identities = 41/77 (53%), Positives = 55/77 (71%), Gaps = 0/77 (0%) 
 
Query  32   PVTEPVQCFNHSQTLLRAVNSELHKAIQMLAVYSCTPEEIDHEDITKDKTSTVKACVPLE  91 
            PV+ P +C + S+ LL+  +  +  A + L  YSCT E+IDHEDIT+D+TST+K C+PLE 
Sbjct  26   PVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLE  85 
 
Query  92   LVKNESCLASGHISFTT  108 
            L KNESCLA+   S TT 
Sbjct  86   LHKNESCLATRETSSTT  102 
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A3.6 IL-17 (IL-17A) 
 
GUINEA PIG SEQUENCE: PREDICTED 
 1 MVIKVDQEKS KSIVGVRAEE KIIGSLQSLQ RAPSWKGTRS PYAFPPTART FRSLLLLSLM 
 61 ATVKAGIPIP RNPGCPTATE GKNFLQNVKL NLSIFNPLTQ NVNSRRSSDY YKRSTSPWTL 
121 HRNENPNRYP PVIWEAECRY SGCVNAAGKE DHHVSSVPIQ QEILVLQREP QNCPLSFRLE 
181 KMKVTVGCTC VTPIVRHVG 
 
HUMAN SEQUENCE 
 
ref|XP_003474811.1| PREDICTED: interleukin-17A-like [Cavia porcellus] 
Length=199 
 
 GENE ID: 100735572 LOC100735572 | interleukin-17A-like [Cavia porcellus] 
 
 Score =  205 bits (521),  Expect = 1e-65, Method: Compositional matrix adjust. 
 Identities = 102/146 (70%), Positives = 118/146 (81%), Gaps = 2/146 (1%) 
 
Query  12   LLLLSLEAIVKAGITIPRNPGCPNS-EDKNFPRTVMVNLNIHNRNT-NTNPKRSSDYYNR  69 
            LLLLSL A VKAGI IPRNPGCP + E KNF + V +NL+I N  T N N +RSSDYY R 
Sbjct  54   LLLLSLMATVKAGIPIPRNPGCPTATEGKNFLQNVKLNLSIFNPLTQNVNSRRSSDYYKR  113 
 
Query  70   STSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHC  129 
            STSPW LHRNE+P RYP VIWEA+CR+ GC+NA G  D+H++SVPIQQEILVL+REP +C 
Sbjct  114  STSPWTLHRNENPNRYPPVIWEAECRYSGCVNAAGKEDHHVSSVPIQQEILVLQREPQNC  173 
 
Query  130  PNSFRLEKILVSVGCTCVTPIVHHVA  155 
            P SFRLEK+ V+VGCTCVTPIV HV  
Sbjct  174  PLSFRLEKMKVTVGCTCVTPIVRHVG  199 
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A3.7 IL-13 
 
GUINEA PIG SEQUENCE- PREDICTED 
 
1 MAFWVTVVLA LACLGGLTAP GPVPVSSTVA VSIKELLGEL VNITQDQKTP LCNSSMVWSV 
61 NLTAGLWYCA ARESLINVSN CSALQRTQKI LSGLCQHKAS AGVSSLRSPD TKIEVAEFVK 
121 KLRIHVQCLY RHGKFH 
 
HUMAN SEQUENCE 
ref|XP_003464584.1|  PREDICTED: interleukin-13-like [Cavia porcellus] 
Length=136 
 GENE ID: 100720118 LOC100720118 | interleukin-13-like [Cavia porcellus] 
 
 Score =  171 bits (433),  Expect = 3e-53, Method: Compositional matrix adjust. 
 Identities = 85/137 (62%), Positives = 108/137 (79%), Gaps = 6/137 (4%) 
 
Query  1    MALLLTTVIALTCLGGFASPGPVPPST----ALRELIEELVNITQNQKAPLCNGSMVWSI  56 
            MA  +T V+AL CLGG  +PGPVP S+    +++EL+ ELVNITQ+QK PLCN SMVWS+ 
Sbjct  1    MAFWVTVVLALACLGGLTAPGPVPVSSTVAVSIKELLGELVNITQDQKTPLCNSSMVWSV  60 
 
Query  57   NLTAGM-YCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFV  115 
            NLTAG+ YCAA ESLINVS CSA+++TQ++LSG C HK SAG  SSL   DTKIEVA+FV 
Sbjct  61   NLTAGLWYCAARESLINVSNCSALQRTQKILSGLCQHKASAG-VSSLRSPDTKIEVAEFV  119 
 
Query  116  KDLLLHLKKLFREGQFN  132 
            K L +H++ L+R G+F+ 
Sbjct  120  KKLRIHVQCLYRHGKFH  136 
 
MOUSE SEQUENCE 
ref|XP_003464584.1|  PREDICTED: interleukin-13-like [Cavia porcellus] 
Length=136 
 GENE ID: 100720118 LOC100720118 | interleukin-13-like [Cavia porcellus] 
 
 Score =  167 bits (424),  Expect = 4e-52, Method: Compositional matrix adjust. 
 Identities = 86/135 (64%), Positives = 103/135 (76%), Gaps = 4/135 (3%) 
 
Query  1    MALWVTAVLALACLGGLAAPGPVPRSVSLPLTLKELIEELSNITQDQ-TPLCNGSMVWSV  59 
            MA WVT VLALACLGGL APGPVP S ++ +++KEL+ EL NITQDQ TPLCN SMVWSV 
Sbjct  1    MAFWVTVVLALACLGGLTAPGPVPVSSTVAVSIKELLGELVNITQDQKTPLCNSSMVWSV  60 
 
Query  60   DLAAG-GFCVALDSLTNISNCNAIYRTQRILHGLCNRKAPTTVSSL--PDTKIEVAHFIT  116 
            +L AG  +C A +SL N+SNC+A+ RTQ+IL GLC  KA   VSSL  PDTKIEVA F+  
Sbjct  61   NLTAGLWYCAARESLINVSNCSALQRTQKILSGLCQHKASAGVSSLRSPDTKIEVAEFVK  120 
 
Query  117  KLLSYTKQLFRHGPF  131 
            KL  + + L+RHG F 
Sbjct  121  KLRIHVQCLYRHGKF  135 
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A4.1 PROTOCOL 5 
Sensitisation: 3 intra-peritoneal injections of 150µg Ova and 100mg Al(OH)3 in 1ml 
(protocol 4) or in 2ml (protocol 5) of saline 
Ova challenge:  0.03% Ova 
In both guinea-pig groups Ova challenge a significant bronchoconstriction was 
observed immediately (-60.7±4.1% and –61.0±5.5%, protocol 4 and 5 respectively). 
No significant difference was seen in the time course. No significant 
bronchoconstrictions were observed during the expected time of the LAR (6-12 
hours) (Figure 1, time course). No significant difference in peak bronchoconstriction 
was seen during the EAR and LAR (Figure 1, histogram). No difference was observed 
between the two groups at total, EAR and LAR time points (Figure 2).  
In guinea-pigs sensitised by protocol 5 there was a significant bronchoconstriction 
immediately following histamine challenge when compared to the sGaw values 
measured prior to Ova challenge (-34.2±18.4% compared to 6.1±7.3%). At 5 minutes 
post-histamine exposure sGaw values were not significantly different from pre-Ova 
challenge values. No significant difference in post-Ova response to histamine was 
found between the 2 groups (Figure 3).  
No significant difference in total or differential cell counts was observed (Figure 4). 
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Figure 1: the mean time-course values of sGaw in guinea-pigs sensitised with 3 injections of either 1ml (protocol 4) or 2mls (protocol 5) of a suspension of 
150ug ova and 100mg aluminium hydroxide and challenged with 0.03% Ova. The histogram represents the maximum bronchoconstriction values recorded 
during baseline, early asthmatic response (EAR) (0-6 hours), late asthmatic response (LAR) (6-12 hours) and 24 hours readings. Mean changes in sGaw are 
expressed as mean±SEM percentage change from baseline. A negative value represents a bronchoconstriction.  N=5; performed with a two tailed t-test. 
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Figure 2: Area under the curve analysis of the bronchoconstrictor response of guinea-pigs sensitised 
with 3 injections of either 1ml (protocol 4) or 2mls (protocol 5) of a suspension of 150ug Ova and 
100mg aluminium hydroxide and challenged with 0.03% Ova. For the purpose of analysis only 
negative peaks were considered and all positive sGaw values were excluded. Total includes all 
negative peaks from 0-24 hours, early asthmatic response (EAR) includes values from 0-6 hours and 
late asthmatic response (LAR) includes values from 6-12 hours. Area under the curve is measured in 
%.hour.  N=5; performed with a two tailed T-test. 
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Figure 3: Response of the airways to nebulised histamine delivered in a plethysmograph (0.3mM, 
10% duty cycles per camber over 2 minutes, 1 minute drying period, 0.5LPM flow per chamber) in 
guinea-pigs sensitised with 3 injections of either 1ml (protocol 4) or 2mls (protocol 5) of a 
suspension of 150ug Ova and 100mg aluminium hydroxide and challenged with 0.03% Ova. Values 
were recorded 24 hours before Ova challenge and at 24 hours post-Ova challenge. Mean changes in 
sGaw are expressed as mean±SEM percentage change from baseline. A negative value represents a 
bronchoconstriction. N=5; **significantly different from time paired pre-Ova challenge values 
p<0.01; performed with a two tailed T-test. 
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Figure 4: The total cell (A), macrophages (B), eosinophils (C), lymphocytes (D) and neutrophils (E) 
counts in bronchoalveolar fluid in guinea-pigs sensitised with 3 injections of either 1ml (protocol 4) 
or 2mls (protocol 5) of a suspension of 150ug Ova and 100mg aluminium hydroxide and challenged 
with 0.03% Ova. N=5; *; performed with a two tailed T-test. 
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